Commonwealth of Australia Gazette

No. GN 32, Wednesday, 9 December 1987

Published by the Australian Government Publishing Service, Canberra

GOVERNMENT NOTICES

CONTENTS

The date of publication of this *Gazette* is 10 December 1987.

VARIATION TO ADVERTISING RATES FOR SPECIAL GAZETTES

The advertising rates for Special *Gazettes* will change as from 1 January 1988. The charge will be the same as that applied to publishing notices in the Government Notices *Gazette* PLUS a set fee of $100.00 to cover the production costs.

For further information contact the Gazette Officer (062) 95 4657.

15067/87 Cat. No. 87 5790 1

N.N.—8741651

GENERAL INFORMATION

IMPORTANT COPYRIGHT NOTICE

Government Notices issues, published each Wednesday, containing all legislation, proclamations, special information and government departments notices and are sold at $4.95 each or on subscription of $205.00 (50 issues), $102.50 (25 issues) or $50.00 (12 issues).

NOTICES FOR PUBLICATION and related correspondence should be addressed to:

Gazette Officer, Australian Government Publishing Service, G.P.O. Box 4007, Canberra, A.C.T. 2601 telephone (062) 95 4656

or lodged at AGPS, Government Printing Office Building, Wentworth Avenue, Kingston. Notices are accepted for publication in the next available issue, unless otherwise specified.

Except where a standard form is used, all notices for publication must have a covering instruction setting out requirements. A typewritten original or good copies are to be provided, wherever possible double-spaced, with a margin surrounding the typewritten matter. Copy is to be confined to one side of the paper, sheets are to be of uniform size (preferably A4), numbered consecutively and fastened securely together. Dates, proper names and signatures particularly are to be shown clearly.

Copy will be returned unpublished if not submitted in accordance with these requirements.

CLOSING TIMES. Notices for publication should be lodged at AGPS, Government Printing Office Building, unless otherwise specified, by the following times (except at holiday periods for which special advice of earlier closing times will be given).

Government Notices Gazette all copy: Friday at 10.00 a.m. in the week before publication.

PRIVATE NOTICES

The rates of charge and conditions applying to acceptance of copy for private notices are as follows:

(a) minimum charge up to 125 words $35.00;

(b) each 25 words (or part thereof) thereafter $4.70.

Remittances must be forwarded with a copy of the notice for publication unless prior credit approval has been granted for account customers. Account customers are reminded that payment is due immediately on presentation of invoice. Should payment not be received within twenty-eight days of the invoice date, credit privileges will be withdrawn.

Notices received without payment or from account customers whose credit privileges have been withdrawn will be returned unpublished.

SUBSCRIPTIONS are payable in advance and are accepted for a maximum period of one year. All subscriptions are on a firm basis and refunds for cancellations will not be given. Rates include surface postage in Australia and overseas. Other carriage rates are available on application.

AVAILABILITY. The *Gazette* may be purchased by mail from:

Mail Order Sales, Australian Government Publishing Service, G.P.O. Box 84, Canberra, A.C.T. 2601

or over the counter from Commonwealth Government Bookshops at:

Adelaide:	12 Pirie Street tel. (08) 212 3646
Brisbane:	294 Adelaide Street tel. (07) 229 6822
Canberra:	70 Alinga Street tel. (062) 47 7211
Hobart:	162 Macquarie Street tel. (002) 23 7151
Melbourne:	347 Swanston Street tel. (03) 663 3010
Perth:	200 St George's Terrace tel. (09) 322 4737
Sydney:	120 Clarence Street tel. (02) 29 1940

Commonwealth Acts and Statutory Rules, Australian Capital Territory Ordinances and Regulations, and other Commonwealth Government publications may also be purchased at these addresses.

ALL REMITTANCES should be made payable to : Collector of Public Moneys, Australian Government Publishing Service.

OTHER ISSUES OF THE GAZETTE

Public Service issues contain notices concerning administrative matters, including examinations, vacancies, transfers and promotions within the Australian Public Service and the Services of the Australian Postal Commission, Australian Telecommunications Commission, Commonwealth Teaching Service and Defence Force appointments etc. These issues are published weekly at 10.30 a.m. on Thursday, and sold at $7.95 each plus postage or on subscription of $350.00 (50 issues), $175.00 (25 issues) or $84.00 (12 issues).

Business issues, published each Tuesday, containing Notices under the Co-operative Companies and Securities Scheme, Bankruptcy Act and Private Notices and sold at $3.95 each or on subscription of $180.00 (50 issues), $90.00 (25 issues) or $44.00 (12 issues).

Special issues include notices which require urgent publication. All costs associated with producing Specials will be borne by the responsible department or authority. A limited number of Special *Gazettes* will be made available for sale from the Commonwealth Government Bookshop, Canberra, on the day of publication. General distribution of these notices will be by their inclusion in the next published issue of the Government Notices *Gazette* or Business *Gazette* as well as in the next published issue of the series of the *Gazette* in which the notice would normally have been published.

Tariff concessions issues contain notices of tariff concessions proposed, granted or revoked in accordance with the provisions of Part XVA of the *Customs Act 1901*. These issues are published each Wednesday and are sold at $1.95 plus postage or on subscription only at $80.00 for 50 issues including surface postage.

Periodic issues contain lengthy notices of a non-urgent nature, including the following: certificates of Australian citizenship; registered tax agents; authorised celebrants; unclaimed deposits and moneys; Australian Public Service conditions of entry and advancement; appointments to the Australian Public Service; holders of import licences and tariff quotas. Issues are made at irregular intervals as required, at individual prices according to size. Advice of availability is given in the Government Notices, Business and Public Service issues immediately following the day of publication. Periodic issues are not available on subscription, but standing orders are accepted for all selected issues.

Purchasing and Disposals issues of the *Gazette* provide information on Commonwealth purchases and disposals and other matters of general interest to persons buying from or selling to the Commonwealth. These issues are published each Wednesday and sold at $2.95 plus postage or on subscription of $140.00 including postage for 50 issues.

Index issues contain references to entries in the Government Notices issues and entries in the Orders in Council, Notices under the Superannuation Act, Notices under the Public Service Act, and Determinations under the Public Service Act sections of the Public Service issues. Index issues are published quarterly, are available over the counter from Commonwealth Government Bookshops and are supplied without charge to annual subscribers to the Government Notices issues.

Variation of closing times

CHRISTMAS/NEW YEAR PERIOD

Commonwealth of Australia Gazette

The last regular *Gazette* for 1987 will be the Public Service issue to be published on 24 December 1987 with normal closing times. There will be no regular issues of the *Gazette* on 29 December 1987, 30 December 1987, 31 December 1987, 5 January 1988, 6 January 1988 and 7 January 1988.

The Government Notices Gazette of 13 January will have normal closing times:

Friday, 8 January 1988, at 10.00 a.m.

Departments are requested to note the dates upon which regular issues will not appear and to make every effort to avoid the need for SPECIAL ISSUES during the holiday period by making arrangements for all necessary administrative and executive material to be gazetted by Tuesday, 22 December 1987. Where possible, all other material should be held over until the first regular issue of 1988.

N.N.—8741652

ISSUE OF PERIODIC GAZETTES

The following Periodic issues of the *Gazette* have been published.

Copies may be purchased from Commonwealth Government Bookshops or by mail (plus postage) from the relevant address given on the front page of this *Gazette*.

Gazette number	*Date of publication*	*Subject*
P1	6.1.87	Customs Act 1901—Prohibited exports, certain goods
P2	20.2.87	Wildlife Protection (Regulation of Exports and Imports) Act 1982
P3	20.2.87	Wildlife Protection (Regulation of Exports and Imports) Act 1982
P4	18.2.87	National Memorials Ordinance 1928—Street Nomenclature
P5	9.3.87	Wildlife Protection (Regulation of Exports and Imports) Act 1982
P6	3.3.87	Tariff Quotas—Transfers of quota allocations
P7	6.3.87	Tariff Quotas—List of Holders
P8	12.3.87	Tariff Quotas—Textiles, clothing and footwear—allocation of residual
P9	12.3.87	Tariff Quotas—Import licences—issued under the Customs (Import Licensing)
P10	17.3.87	Tariff Quotas—1986—Special allocations—list of holders
P11	15.5.87	National Memorials Ordinance 1928—Street Nomenclature
P12	30.3.87	States Grants (Petroleum Products) Act 1965
P13	27.5.87	Wildlife Protection (Regulation of Exports and Imports) Act 1982
P14	13.4.87	Tariff Quotas—Second allocation of tender quota for motor vehicles under the 1985 four period scheme.
P15	7.4.87	Australian Code for the Transport of Dangerous Goods by Road and Rail
P16	29.5.87	Wildlife Protection (Regulation of Exports and Imports) Act 1982
P17	14.5.87	Draft Code of Practice for the Safe Removal of Asbestos
P18	19.6.87	Film Censorship Board
P19	1.7.87	Survey Practice Directions 1987
P20	26.6.87	Wildlife Protection (Regulation of Exports and Imports) Act 1982
P21	10.7.87	Tariff Quotas—Goods including handicrafts
P22	13.7.87	Import Licences—For used, second-hand or disposals; earthmoving, construction and materials handling machinery and equipment
P23	31.7.87	Notice of Amendment to the Petroleum Products Subsidy Scheme
P24	3.8.87	Publications Classified under the A.C.T. Classification of Publications Ordinance 1983
P26	14.8.87	Wildlife Protection (Regulation of Exports and Imports) Act 1982
P27	27.8.87	National Health and Medical Research Council Food Standards Code
P28	12.8.87	Tariff Quotas—Goods Falling Within Base Quota Categories
P29	27.8.87	Wildlife Protection (Regulation of Exports and Imports) Act 1982
P30	28.8.87	Tariff Quotas—Developing Country Allocations—July 1987–June 1988
P31	1.9.87	Tariff Quotas—Base Quotas Allocations—Cheese—1 June 1987 to 19 August 1987
P32	1.9.87	Customs (Import Licensing) Regulations
P33	11.9.87	Wildlife Protection (Regulation of Exports and Imports) Act 1982
P35	9.11.87	Wildlife Protection (Regulation of Exports and Imports) Act 1982

N.N.—8741653

Special Information

NOTICES UNDER THE INDEPENDENT AIR FARES COMMITTEE ACT 1981

Operator and reference	*Section of Act*	*Date notified*

Determination

NORFOLK AIRLINES (B8/87) — 16 — 25.11.87

Determination of the following one-way economy air fares effective from 1 December 1987:

	$		$
Brisbane–Lord Howe Is.	215.00	Lord Howe Is.–Norfolk Is.	277.00
–Norfolk Is.	309.00	Sydney–Lord Howe Is.	263.50
Coolangatta–Lord Howe Is.	189.00	Newcastle–Lord Howe Is.	263.50

Increase in fares of 1.6 per cent approved to reflect increased costs of landing charges and wages.

Determination and decision

AIR CENTRAL EYRE P/L (NF14 AND D165/87) — 15 and 17 (4) — 25.11.87

Determination of the following one-way economy air fares:

Wudinna–Adelaide	$87	Cleve–Adelaide	$74

and approval of the following discount return fares under specified conditions as proposed by the operator:

Wudinna–Adelaide	$168	Cleve–Adelaide	$142

All fares are effective from 1 December 1987.

Discount fares approved on basis of estimates provided by the operator that they will generate additional traffic and improve profitability.

Decisions

STAYWOOD AIR (D156/87) — 17 (4) — 20.11.87

Approval to offer from 23 November 1987 a one-way standby fare of $35 for travel Warrnambool–Melbourne under specified conditions as proposed by the operator.

Approved on basis of estimates provided by the operator that the discount fare will generate additional traffic and improve profitability.

ANSETT AIRLINES OF AUSTRALIA (D157/87)
ANSETT W.A. (D158/87), ANSETT N.T. (D159/87), AIR N.S.W. (D160/87) — 17 (4) — 25.11.87

Approval for the above operators to offer the 'See Australia' fare at 30 per cent off the normal economy air fare for sale only in conjunction with international economy class promotional fares to Australia, available from 25 November 1987 until 31 March 1988 under specified conditions as proposed by the operator.

Approved on basis of estimates provided by the operators that the discount fare will generate additional traffic and improve profitability.

AUSTRALIAN AIR CHARTERERS P/L
trading as AUS-AIR (D162/87) — 17 (4) — 25.11.87

Approval of backloading return discount fares available from 21 December 1987 to 28 January 1988 on the following routes under specified conditions as proposed by the operator.

King Is.–Moorabbin–King Is.	$100
Smithton–Moorabbin–Smithton	$120

Approved on basis of estimates provided by the operator that the discount fares will generate additional traffic and improve profitability.

NOTICE OF CREATION OF STATUTORY LIEN IN RESPECT OF CERTAIN AIRCRAFT

Notice is hereby given that pursuant to section 5B (4) of the *Air Navigation (Charges) Act 1952*, a Statutory Lien has been vested in the Commonwealth in respect of each of the aircraft described hereunder.

Lien No.	*Date and time created (EDST)*	*Description and registration*	*Payable by*
00423	26 November 1987, 4.24 p.m.	Piper PA31, VH-CFE	Regent Air Services Pty Ltd, 83 Cohn Street, Kewdale, W.A. 6105
00424	26 November 1987, 4.29 p.m.	Beech 95, VH-RLS	Maroomba Pty Ltd, 17 Hellenic Road, Rolleystone, W.A. 6111
00425	26 November 1987, 4.33 p.m.	Beech 58, VH-ADB	Wilson Aviation Pty Ltd, P.O. Box 578, Mascot, N.S.W. 2020
00426	26 November 1987, 4.42 p.m.	Cessna 421C, VH-CMR	Central Murchison Pty Ltd, P.O. Box 7467, Cloisters Square, Perth, W.A. 6000
00427	26 November 1987, 4.45 p.m.	Cessna 310R, VH-PSI	As above
00248	26 November 1987, 4.50 p.m.	Beech 58, VH-MLX	The Broughton Group, Fauntelroy Avenue, Perth Airport, W.A. 6104
00437	27 November 1987, 9.16 a.m.	Piper PA31, VH-ITF	As above

Lien No.	*Date and time created (EDST)*	*Description and registration*	*Payable by*
00438	27 November 1987, 9.20 a.m.	Beech 95, VH-IHM	As above
00429	27 November 1987, 8.39 a.m.	Bell B205, VH-NST	Mivipe Pty Ltd, V.R.D. Station, via Katherine, N.T. 5771
00431	27 November 1987, 8.48 a.m.	Bell 205A-1, VH-HLH	As above
00436	27 November 1987, 9.13 a.m.	Sikorsky S-76A, VH-CPH	As above

Dated this 3rd day of December 1987.

K. L. CLAYTON
Registrar of Statutory Liens

NOTICE OF CREATION OF STATUTORY LIEN IN RESPECT OF CERTAIN AIRCRAFT

Notice is hereby given that pursuant to section 5B (4) of the *Air Navigation (Charges) Act 1952*, a Statutory Lien has been vested in the Commonwealth in respect of each of the aircraft described hereunder.

Lien No.	*Date and time created (EDST)*	*Description and registration*	*Payable by*
00430	27 November 1987, 8.44 a.m.	Mitsubishi MU-2B-25, VH-MUO	Great Western Aviation Pty Ltd, Unit 3/431 Great Eastern Highway, Redcliffe, W.A. 6104
00432	27 November 1987, 8.58 a.m.	Cessna 500, VH-OIL	Corporate Air Services (W.A.) Pty Ltd, 3/132 Epsom Avenue, Belmont, W.A. 6104
00433	27 November 1987, 9.02 a.m.	Cessna 421C, VH-USH	As above
00434	27 November 1987, 9.05 a.m.	Beech 58, VH-EPJ	Mr B. Baldwin, 6 Ashton Road, Leeming, W.A. 6155
00435	27 November 1987, 9.09 a.m.	Cessna 340, VH-CPB	Boomerang Air Services, Lot 5, Parker Street, Parkerville, W.A. 6553
00439	27 November 1987, 9.24 a.m.	Beech 95-B55, VH-ABT	Xanthippus Pty Ltd, 140 Canning Highway, South Perth, W.A. 6157
00440	2 December 1987, 2.02 p.m.	Bell 47G5A, VH-BHR	Helimuster Pty Ltd, Victoria River Downs Station, via Katherine, N.T. 5771
00441	2 December 1987, 2.08 p.m.	Cessna U206F, VH-CJG	As above
00442	2 December 1987, 2.11 p.m.	Bell 47G-3B1, VH-CSE	As above
00443	2 December 1987, 2.14 p.m.	Bell 47G-3B1, VH-CSM	As above
00444	2 December 1987, 2.16 p.m.	Bell 47G-3B1, VH-HMI	As above

Dated this 3rd day of December 1987.

K. L. CLAYTON
Registrar of Statutory Liens

NOTICE OF CREATION OF STATUTORY LIEN IN RESPECT OF CERTAIN AIRCRAFT

Notice is hereby given that pursuant to section 5B (4) of the *Air Navigation (Charges) Act 1952*, a Statutory Lien has been vested in the Commonwealth in respect of each of the aircraft described hereunder.

Lien No.	*Date and time created (EDST)*	*Description and registration*	*Payable by*
00445	2 December 1987, 2.19 p.m.	Bell 47G-4A, VH-HMJ	Helimuster Pty Ltd, Victoria River Downs Station via Katherine, N.T. 5771
00446	2 December 1987, 2.21 p.m.	Bell 47G-3B1, VH-HMU	As above
00447	2 December 1987, 2.24 p.m.	Aero Commander 500A, VH-IOE	As above
00448	2 December 1987, 2.27 p.m.	Bell 47G-3B-KH4, VH-JWC	As above
00449	2 December 1987, 2.30 p.m.	Cessna A188B/A1, VH-JWD	As above
00450	2 December 1987, 2.53 p.m.	Bell 47G-3B1, VH-MQU	As above
00451	2 December 1987, 2.59 p.m.	Pitts S2A, VH-PAS	As above
00452	2 December 1987, 3.01 p.m.	Bell 47G5, VH-SJA	As above
00453	2 December 1987, 3.04 p.m.	Bell 47G-3B2, VH-SUC	As above
00454	2 December 1987, 3.05 p.m.	Beech 58, VH-TWO	As above
00455	2 December 1987, 3.08 p.m.	Bell 47G-3B1, VH-UTY	As above
00456	2 December 1987, 3.10 p.m.	Pitts S2A, VH-WEB	As above
00457	2 December 1987, 3.12 p.m.	Bell 47G-3B1, VH-WHF	As above
00458	2 December 1987, 3.17 p.m.	CA25 "Winjeel", VH-WHZ	As above
00459	2 December 1987, 4.40 p.m.	Bell 47G-3B-KH4, VH-JWB	As above

Dated this 3rd day of December 1987.

K. L. CLAYTON
Registrar of Statutory Liens

NOTICE OF CREATION OF STATUTORY LIEN IN RESPECT OF CERTAIN AIRCRAFT

Notice is hereby given that pursuant to section 5B (4) of the *Air Navigation (Charges) Act 1952*, a Statutory Lien has been vested in the Commonwealth in respect of each of the aircraft described hereunder.

Lien No.	*Date and time created (EDST)*	*Description and registration*	*Payable by*
00460	3 December 1987, 8.45 a.m.	Bell 47G5, VH-CSJ	J. V. Weymouth, Victoria River Downs Station via Katherine, N.T. 5771
00461	3 December 1987, 8.49 a.m.	Bell 47-3B1, VH-CSW	As above
00462	3 December 1987, 8.51 a.m.	PA32-300, VH-PWF	As above
00463	3 December 1987, 8.54 a.m.	Aero Commander 500S, VH-SDI	As above
00464	3 December 1987, 9.04 a.m.	Cessna 310R, VH-JVO	Biltoft Holdings Pty Ltd, Suite 8/431, Great Eastern Highway, Redcliffe, W.A. 6104
00465	3 December 1987, 9.08 a.m.	Beech 95-C55, VH-KXK	Western Courier Service 131 Claisebrook Road, East Perth, W.A. 6000
00466	3 December 1987, 9.12 a.m.	Piper PA31-350, VH-TWU	As above
00467	3 December 1987, 9.17 a.m.	Cessna 210L, VH-DFS	Zip Air Freight, Suite 8/431, Great Eastern Highway, Redcliffe, W.A. 6104
00468	3 December 1987, 9.22 a.m.	Cessna 210M, VH-SMC	As above

NOTICE OF CESSATION OF STATUTORY LIEN IN RESPECT OF CERTAIN AIRCRAFT

Notice is hereby given that pursuant to section 5B (12) of the *Air Navigation (Charges) Act 1952*, a Statutory Lien vested in the Commonwealth ceased to have effect in respect of each of the aircraft described hereunder.

Lien No.	*Description and registration mark*	*Date on which the Lien ceased to have effect*
00355	Cessna R172K, VH-DRM	20 November 1987

Dated this 3rd day of December 1987.

K. L. CLAYTON
Registrar of Statutory Liens

AUSTRALIAN CODE FOR THE TRANSPORT OF DANGEROUS GOODS BY ROAD AND RAIL (ADG CODE)

COMMONWEALTH OF AUSTRALIA GAZETTE No. P 15 OF 7 APRIL 1987

Corrigenda No. 2

A number of typographical errors have been noted in the ADG Code since its publication. The necessary corrections are specified below.

1st Corrigenda— in part (2) amend telephone no. for Victoria and prefix to facsimile no. for South Australia to read '(03) 651 0011' and '(08)' respectively

p. 19— amend 'AS1534' and 'AS1829' to read 'AS2906' and 'AS2380.7' respectively (amend all references to these standards throughout Code accordingly)

p. 25— amend heading for sub-section 2.6 to read 'Assignment of Correct Shipping Name and UN Number to Mixtures and Unlisted Substances'

p. 31— amend 'Packaging Group 1' in heading to Table 3.1 (a) to read 'Packaging Group I'

p. 38— in 2nd column of Table 3.3 amend '5' in illustrations of Class 5.1 and 5.2 labels to read '5.1' and '5.2' respectively

p. 42— amend 'Section 1' page heading to read 'Section 3'

p. 48— in 4th column of Table 5.1 amend '5M3' to read '5M2'
in 5.5 (a) delete'/'

p. 49— in 5.5.1 (c) (ii) delete '.' after '1.2' and insert '; or'

p. 61— insert the following after entry 'K9.2.....45L':
'Series K10—Plastics Bags and Liners

K10.1a	NA	NA Bag	New Plastic	100 kg'

p. 62— in 5.8.9.1 amend '5.8.4.17' to read '5.8.9.17'

p. 63— in 2nd column entries for packaging methods P1a and P2a amend 'receptable' to read 'receptacle'

p. 66— in table to 5.9.5.10 amend 'K10.1' at bottom of 3rd Column to read 'K11.1'

p. 71— in 6.3.1 amend '6.6' to read '6.8'

p. 72— in Table 6.1 amend 'Liquified' to read 'Liquefied'

p. 86— in second line of 8.4.2 amend 'tranport' to read 'transport'

p. 127— in Col. 2 entry for grouped UN2796/2797 amend 'BATTERY FLUID, CORROSIVE with storage battery' to read 'BATTERY FLUID, ACID OR BATTERY FLUID, ALKALI, with storage battery'.

p. 158— in Col. 3 entry for UN1013 amend '2.1' to read '2.2'

p. 217— in Col. 3 and Col. 4 entries for UN1993 (lfp) insert '3.1' and delete '3.1' respectively

p. 219— in Col. 2 entry for UN1778 amend 'FLUOROSILICIC' to read 'FLUOSILICIC'

p. 228— in Col. 8 entries for UN1011, 1969, 1012, 1055, 1027, 2044, 1964, 1978, 1077, 1075 and 1965 insert 'RT2' under '5.9.2'

p. 232— in entry for UN1791, insert '°' after 'III' in Col. 7 and immediately before 'Packaging group III' in Col. 9

p. 272— in Col. 8 entry for UN1263 (1fp) add '5.9.3'

p. 288— in Col. 2 entry for UN2214 delete 'dust or powder; molten liquid,'

p. 319— relocate complete entry for UN2813 to appear after '2242 SUBERENE SEE—CYCLOHEPTENE'

pp 368-370— in Col. 3 entries for methods E1, E9 and E12 amend '(5N1)' entry against Bags, paper, waterproof to read '(5M2)'

pp 368-374— in Col. 3 amend all entries identified with the type designators 1A2, 1A2A or 1A2B to read 'steel, removable head (1A2)'

p. 381— in Col. 1 entry for 'BOOSTERS, WITH DETONATOR' amend '0255' to read '0225'

p. 382— in col. 3 entry for UN0348 amend '1.4' to read '1.4F'

— in Col. 3 and Col. 4 entries for UN0048 amend '1.4S' and 'E116' to read '1.1D' and 'E118' respectively. Delete Col. 3 and Col. 4 entries on next line

— in Col. 1, Col. 3 and Col. 4 for 'CASES, CARTRIDGE, EMPTY WITH PRIMER' add '0055', '1.4S' and 'E116' respectively

p. 383— in Col. 2 entry for UN0226 amend 'OCTOGENE' to read 'OCTOGEN'

— in Col. 2 entry for UN0391 amend "OXTOGENE' to read 'OCTOGEN'

— in Col. 1, Col. 3 and Col. 4 for 'DETONATORS FOR AMMUNITION' add '0366', '1.4S' and 'E128' respectively

p. 384— in Col. 1 amend '0041' to read '0401'

p. 386— in Col. 2 amend 'GRENADES, ILLUMINATING SEE—GRENADES, PRACTICE HAND OR RIFLE' to read 'GRENADES, ILLUMINATING SEE—AMMUNITION, ILLUMINATING'

p. 388— in Col. 2 amend 'OCTOGENE SEE—OCTOLITE' to read 'OCTOGEN—CYCLOTETRAMETHYLENE—TETRANITRAMINE'

p. 390— delete entries '0319', '0320', 0376' and associated entries in Col. 2, Col. 3 and Col. 4

— relocate complete entry for 0155 to p. 391 after entry for UN0215

Proclamation

QUARANTINE PROCLAMATION No. 111P

Commonwealth of Australia
N. M. STEPHEN
Governor-General

By His Excellency the Governor-General of the Commonwealth of Australia

I, SIR NINIAN MARTIN STEPHEN, the Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council under section 13 of the *Quarantine Act 1908*, hereby prohibit the importation into the Cocos Islands of:

(a) citrus seeds;

(b) coconuts;

(c) fresh fruit;

(d) vegetables;

(e) rooted plants and all living plant material used for vegetative propagation other than seeds that are not citrus seeds; and

(f) soil;

from any country other than Australia unless:

(g) the Director of Animal and Plant Quarantine, or a person authorised by him or her, having regard to any documents furnished to him or her and to the circumstances of the case, approves, by instrument, of that importation; and

(h) that instrument is produced to a quarantine officer at the port of entry into the Cocos Islands.

(L.S.) Given under my Hand and the Great Seal of Australia on 25 November 1987.

By His Excellency's Command,
PETER MORRIS
Minister of State for Resources

GOD SAVE THE QUEEN!

N.N.—8741719

Legislation

Acts of Parliament assented to

IT IS HEREBY NOTIFIED, for general information, that His Excellency the Governor-General, in the name of Her Majesty, assented, on 26 November 1987 to the undermentioned Acts passed by the Senate and the House of Representatives in Parliament assembled, viz.:

No. 109 of 1987—An Act to amend the *Income Tax Act 1986*, and for related purposes. (*Income Tax Amendment Act (No. 2) 1987*).

No. 110 of 1987—An Act to amend the *Medicare Levy Act 1986*, and for related purposes. (*Medicare Levy Amendment Act 1987*).

A. R. BROWNING
Clerk of the House of Representatives

N.N.—8741720

IT IS HEREBY NOTIFIED, for general information, that His Excellency the Governor-General, in the name of Her Majesty, assented, on 30 November 1987 to the undermentioned Act passed by the Senate and the House of Representatives in Parliament assembled, viz.:

No. 111 of 1987—An Act to appropriate certain sums out of the Consolidated Revenue Fund for certain expenditure, in relation to the Parliamentary Departments, in respect of the year ending on 30 June 1988. (*Appropriation (Parliamentary Departments) Act 1987-88*).

A. R. BROWNING
Clerk of the House of Representatives

N.N.—8741721

Orders

PRIMARY INDUSTRIES AND ENERGY

NOTIFICATION OF THE MAKING OF ORDERS UNDER THE MEAT INSPECTION (ORDERS) REGULATIONS

Notice is hereby given that the undermentioned orders under the Meat Inspection (Orders) Regulations have been made. Copies of the orders can be obtained from the Australian Government Publishing Service Bookshop at 70 Alinga Street, Canberra, A.C.T. 2601 or by Mail from:

Mail Order Sales, Australian Government Publishing Service, G.P.O. Box 84, Canberra, A.C.T. 2601

Number of orders	*Description of orders*
6 of 1987	Meat Inspection (Northern Territory) Orders (Amendment)

N.N.—8741722

Government Departments

Administrative Services

THE MANUFACTURING GROCERS' EMPLOYEES' FEDERATION OF AUSTRALIA

Conciliation and Arbitration Act 1904

NOTICE OF BALLOT IN RESPECT OF A PROPOSED AMALGAMATION

Notice is hereby given that a secret ballot by postal voting of the members of the Manufacturing Grocers' Employees' Federation of Australia who are entitled to vote in the ballot is to be conducted on the question whether those members approve the proposed amalgamation of that organisation with the following organisation namely, The Federated Millers' and Mill Employees' Association of Australasia.

A copy of the scheme for the proposed amalgamation will be sent to members entitled to vote in the ballot.

The commencing date of the ballot is 10 March 1988.

The closing date of the ballot is Thursday, 31 March 1988.

Dated this 8th day of December 1987.

MICHAEL E. SMALL

Conducting ballot under section 158K of the *Conciliation and Arbitration Act 1904*

Australian Electoral Commission, Industrial Elections Branch, 399 Lonsdale Street, Melbourne Vic. 3000. P.O. Box 768G, Melbourne 3001. Telephone (03) 604 4337

THE FEDERATED MILLERS' AND MILL EMPLOYEES' ASSOCIATION OF AUSTRALASIA

Conciliation and Arbitration Act 1904

NOTICE OF BALLOT IN RESPECT OF A PROPOSED AMALGAMATION

Notice is hereby given that a secret ballot by postal voting of the members of the Federated Millers' and Mill Employees' Association of Australasia who are entitled to vote in the ballot is to be conducted on the question whether those members approve the proposed amalgamation of that organisation with the following organisation namely, The Manufacturing Grocers' Employees' Federation of Australia.

A copy of the scheme for the proposed amalgamation will be sent to members entitled to vote in the ballot.

The commencing date of the ballot is 10 March 1988.

The closing date of the ballot is Thursday, 31 March 1988.

Dated this 8th day of December 1987.

MICHAEL E. SMALL

Conducting ballot under section 158K of the *Conciliation and Arbitration Act 1904*

Australian Electoral Commission, Industrial Elections Branch, 399 Lonsdale Street, Melbourne Vic. 3000. P.O. Box 768G, Melbourne 3001. Telephone (03) 604 4337

Note: In lieu of notification appearing in *Gazette* GN 30 of 25.11.87.

N.N.—8741761

The Arts, Sport, the Environment, Tourism and Territories

TERRITORY OF CHRISTMAS ISLAND

Foreign Judgments (Reciprocal Enforcement) Ordinance 1977

NOTICE OF COMMENCEMENT

I, JOHN JOSEPH BROWN, Minister of State for The Arts, Sport, the Environment, Tourism and Territories, pursuant to sub-section 2 (1) of the *Foreign Judgments (Reciprocal Enforcement) Ordinance 1977* fix 28 October 1987 as the date on which the provisions of that Ordinance, other than section 3, shall come into operation.

Dated this 22nd day of October 1987.

JOHN BROWN

Minister of State
for the Arts, Sport, the Environment,
Tourism and Territories

Note: In lieu of notification appearing in *Gazette* GN 26 of 28.10.87

N.N.—8741723

NOTICE OF APPLICATION RECEIVED UNDER THE ENVIRONMENT PROTECTION (SEA DUMPING) ACT 1981

Pursuant to section 25 of *Environment Protection (Sea Dumping) Act 1981*, notice is given that an application was made on 21 September 1987 by the Administrator of the Cocos (Keeling) Islands for approval to dump at sea some 60 assorted car, truck, plant and equipment bodies.

Copies of the application may be obtained from the Department of The Arts, Sport, the Environment, Tourism and Territories, G.P.O. Box 787, Canberra, A.C.T. 2601 or by telephoning F. Ziolkowski (062) 46 637.

NELSON QUINN

First Assistant Secretary
Environment Contaminants
and Co-ordination Division

Dated this 25th day of November 1987.

N.N.—8741724

NOTICE OF APPLICATION RECEIVED UNDER THE ENVIRONMENT PROTECTION (SEA DUMPING) ACT 1981

Pursuant to section 25 of the *Environment Protection (Sea Dumping) Act 1981*, notice is given that an application was made on 18 September 1987 by Department of Administrative Services, Construction Group, P.O. Box 157, Alexandria, N.S.W. 2015, for approval to dump at sea up to 2 500 cubic metres of dredged material from the entrance to the Captain Cook Dry Dock, Garden Island, Sydney.

Copies of the application may be obtained from the Department of The Arts, Sport, the Environment, Tourism and Territories, G.P.O. Box 787, Canberra, A.C.T. 2601 or may be inspected at the office of the Department of Administrative Services, Construction Group, Stokes Avenue, Alexandria, N.S.W. 2015 by arrangement with K. Dawson by telephoning (02) 359 3341.

NELSON QUINN
First Assistant Secretary
Environment Contaminants
and Co-ordination Division

N.N.—8741725

COMMONWEALTH OF AUSTRALIA

Environment Protection (Nuclear Codes) Act 1978

NOTIFICATION OF THE MAKING OF AN ORDER

Notice is hereby given that on 18 November 1987, pursuant to sub-section 9 (1) of the *Environment Protection (Nuclear Codes) Act 1978*, the Governor-General made an order approving the Code of Practice on Radiation Protection in the Mining and Milling of Radioactive Ores (1987). Copies of the order can be purchased from:

Director
Air, Noise and Nuclear Section
Environment Co-ordination Branch
Department of The Arts, Sport, the Environment, Tourism and Territories
Room 114, First Floor
Colonial Mutual Building
Corner Marcus Clarke Street and University Avenue
Canberra City, A.C.T.

Postal address:
G.P.O. Box 787
Canberra, A.C.T., 2601

Contact officer for inquiries is B. T. Garton (062) 46 7356

N.N.—8741726

DEPARTMENT OF THE ARTS, SPORT, THE ENVIRONMENT, TOURISM AND TERRITORIES

Environment Protection (Impact of Proposals) Act 1974

NOTICE OF DIRECTION REQUIRING A PUBLIC ENVIRONMENT REPORT

Pursuant to paragraph 3.4 of the Administrative Procedures under the Act, notice is hereby given that the Minister for The Environment and the Arts, on 23 November 1987, directed the preparation of a public environment report in relation to a proposal by Hamilton Island Enterprises Pty Ltd to install a fixed walkway and associated tourist facilities at Hardy Reef or a nearby reef in the Great Barrier Reef Marine Park.

N.N.—8741727

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER WILLIAM KENNA, being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of Donald Thomas McCauley and Jennifer Dulcie McCauley ('the Applicant') carrying on the profession, trade, occupation or calling of carpet overlocker ('the business') on Block 13, Section 43, Division of Higgins, known as 17 Kinsella Street, Higgins ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

(1) that this approval will remain valid only while the Applicant continues to be a bona side resident of the land;

(2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;

(3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the National Capital Development Commission and the Building Controller;

(4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the City Area Leases Ordinance unless otherwise stipulated in this Instrument;

(5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;

(6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land;

(7) that the Applicant will not employ any assistants for the purpose of conducting or carrying on the business on the land without the prior approval of the Minister;

(8) that only the garage be used for the conduct of the business;

(9) that the business will only be conducted on the land between the hours of 12.00 noon and 5.00 p.m. Mondays and Fridays and 9.00 a.m. and 5.00 p.m. Thursdays and Saturdays only;

(10) that this approval will terminate on the thirty-first day of January 1989 or on such earlier date as the Minister determines in accordance with condition 11;

(11) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 27th day of November 1987.

P. KENNA
Delegate of the Minister of State
for The Arts, Sport, the Environment,
Tourism and Territories

N.N.—8741728

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER WILLIAM KENNA, being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of Elaine June Wise ('the Applicant') carrying on the profession, trade, occupation or

calling of signwriter ('the business') on Block 18, Section 84, Division of Charnwood known as 40 Jauncey Court, Charnwood ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

(1) that this approval will remain valid only while the Applicant continues to be a bona fide resident of the land;

(2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;

(3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the National Capital Development Commission and the Building Controller;

(4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the City Area Leases Ordinance unless otherwise stipulated in this Instrument;

(5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;

(6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land;

(7) that the Applicant will not employ any assistants for the purpose of conducting or carrying on the business on the land without the prior approval of the Minister;

(8) that only one room in the house be used for the conduct of the business;

(9) that the business will only be conducted on the land between the hours of 9.00 a.m. and 3.00 p.m. Monday to Friday;

(10) that the Applicant will conduct the business strictly by appointment;

(11) that this approval will terminate on the thirty-first day of December 1988 or on such earlier date as the Minister determines in accordance with condition 12;

(12) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 24th day of November 1987.

P. KENNA

Delegate of the Minister of State
for The Arts, Sport, the Environment,
Tourism and Territories

N.N.—8741729

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER WILLIAM KENNA, being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of Rosalind Jean Mandy Cramer and Peter John Cramer ('the Applicant') carrying on the profession, trade, occupation or calling of tapestry and fine needle work suppliers ('the business') on Block 14, Section 434, Division of Kambah, known as 12 Samson Place, Kambah ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

(1) that this approval will remain valid only while the Applicant continues to be a bona fide resident of the land;

(2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;

(3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the National Capital Development Commission and the Building Controller;

(4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the City Area Leases Ordinance unless otherwise stipulated in this Instrument;

(5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;

(6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land;

(7) that the Applicants will not employ any assistants for the purpose of conducting or carrying on the business on the land without the prior approval of the Minister;

(8) that the business shall only be conducted between the hours of 10.00 a.m. and 5.30 p.m. Saturdays, Sundays and public holidays;

(9) that this approval only relates to the selling of needle work supplies and demonstration of needle work techniques by the Applicant;

(10) that this approval will terminate on the thirty-first day of June 1988 or on such earlier date as the Minister determines in accordance with condition 11;

(11) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 27th day of November 1987.

P. KENNA

Delegate of the Minister of State
for The Arts, Sport, the Environment,
Tourism and Territories

N.N.—8741730

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER WILLIAM KENNA, being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of Russell James Wombey ('the Applicant') carrying on the profession, trade, occupation or calling of architect ('the business') on Block 5, Section 171, Division of Kambah known as 76 Crozier Circuit, Kambah ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

(1) that this approval will remain valid only while the Applicant continues to be a bona fide resident of the land;

(2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;

(3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the National Capital Development Commission and the Building Controller;

(4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the City Area Leases Ordinance unless otherwise stipulated in this Instrument;

(5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;

(6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land;

(7) that the Applicant will not employ more than one assistant for the purpose of conducting or carrying on the business on the land without the prior approval of the Minister;

(8) that only one room in the house be used for the conduct of the business;

(9) that the business will only be conducted on the land between the hours of 9.00 a.m. and 5.00 p.m. Monday to Friday;

(10) that the Applicant will conduct the business strictly by appointment;

(11) that this approval will terminate on the thirty-first day of December 1988 or on such earlier date as the Minister determines in accordance with condition 12;

(12) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 27th day of November 1987.

P. KENNA
Delegate of the Minister of State
for The Arts, Sport, the Environment,
Tourism and Territories

N.N.—8741731

SURVEYORS BOARD OF THE AUSTRALIAN CAPITAL TERRITORY

Surveyors Ordinance 1967

GAZETTAL OF REGISTERED SURVEYORS

The undermentioned has been registered as a surveyor under Section 17 of the *Surveyors Ordinance 1967.*

Registration Number	*Date of registration*	*Name*	*Address*
297	19 November 1987	Vincent John Morgan	Prospect County Council Building, cnr Henry and Station Streets, Penrith, N.S.W. 2750

J. W. SLEEP
Chairman

N.N.—8741732

AUSTRALIAN CAPITAL TERRITORY

Health Professions Boards (Elections) Ordinance 1980

ELECTION FOR NURSES BOARD OF THE A.C.T.

DECLARATION OF SUCCESSFUL CANDIDATES IN ACCORDANCE WITH SECTION 25 (1) (a)

I, ROGER DAVID RANKIN, being the officer for the time being occupying an office, the occupant of which has been appointed by the Electoral Commissioner to be the Returning Officer for the purposes of an election of four members of the Nurses Board of the A.C.T., declare the following registered practitioners named as having been nominated as candidates in the *Commonwealth of Australia Gazette* No. GN 23, 7.10.87 to be duly elected.

Louise Elizabeth Muir
3 Dry Street
Curtin, A.C.T. 2605

Anne McQueen
7 Yate Gardens
Rivett, A.C.T. 2611

Judith Robson
14 Hargrave Street
Scullin, A.C.T. 2614

Yvonne Anne Sangster
9 Oliff Place
Farrer, A.C.T. 2607

ROGER RANKIN
Returning Officer

N.N.—8741733

AUSTRALIAN CAPITAL TERRITORY

Health Professions Boards (Election) Ordinance 1980

ELECTION FOR OPTOMETRISTS BOARD OF THE A.C.T.

DECLARATION OF SUCCESSFUL CANDIDATES IN ACCORDANCE WITH SECTION 12 (1) (a)

I, ROGER DAVID RANKIN, being the officer for the time being occupying an office, the occupant of which has been appointed by the Electoral Commissioner to be the Returning Officer for the purposes of an election of one (1) member of the Optometrists Board of the A.C.T., declare the following registered practitioner to be duly elected.

Leon John Evans
Tasman House
Hobart Place
Canberra City, A.C.T. 2601

ROGER RANKIN
Returning Officer

N.N.—8741734

AUSTRALIAN CAPITAL TERRITORY HEALTH AUTHORITY

PHYSIOTHERAPISTS BOARD OF THE AUSTRALIAN CAPITAL TERRITORY

ELECTION OF DEPUTY CHAIRMAN OF THE BOARD

Pursuant to paragraph 6 (2) (b) of the *Health Professions Boards (Procedures) Ordinance 1981*, it is hereby notified that Patricia Levick was on 20 November 1987, elected by the Physiotherapists Board to be Deputy Chairman of the Board for twelve months from and including 20 November 1987.

Dated this twenty-seventh day of November 1987.

J. J. RILEY
Chairman of the Board

N.N.—8741735

COMMONWEALTH OF AUSTRALIA

Wildlife Protection (Regulation of Exports and Imports) Act 1982

Section 11

DECLARATION OF AN APPROVED INSTITUTION

I, JOHN DERRICK OVINGTON, the Designated Authority under sub-section 18 (1) of the *Wildlife Protection (Regulation of Exports and Imports) Act 1982*, in pursuance of sub-section 11 (1) of that Act, hereby declare the organisation specified in column 2 of the Schedule, in an item in the Schedule, to be an approved institution in relation to the class, or classes, of specimens specified in Column 3 of the Schedule in that item.

Dated this third day of December 1987.

J. D. OVINGTON
Designated Authority

SCHEDULE

Column 1	*Column 2*	*Column 3*
Item	*Name and country of approved institution*	*Approved class, or classes, of specimens*
1.	Animal Holding Facility First Floor, Services Block, Department of Obstetrics and Gynaecology, Royal Melbourne Hospital, Parkville, Vic. 3052	*Callithrix jacchus*

N.N.—8741736

Attorney-General

APPOINTMENT OF AN ADDITIONAL JUDGE OF THE SUPREME COURT OF THE AUSTRALIAN CAPITAL TERRITORY

I, SIR NINIAN MARTIN STEPHEN, a member of Her Majesty's Most Honourable Privy Council, Knight of the Order of Australia, Knight Grand Cross of The Most Distinguished Order of Saint Michael and Saint George, Knight Grand Cross of The Royal Victorian Order, Knight Commander of The Most Excellent Order of the British Empire and Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council and pursuant to sub-section 7 (2) of the *Australian Capital Territory Supreme Court Act 1933*, hereby appoint the Honourable Michael Leader Foster, a Judge of the Federal Court of Australia, to be an additional Judge of the Supreme Court of the Australian Capital Territory.

(L.S.) GIVEN under my Hand and the Great Seal of Australia on 25 November 1987.

N. M. STEPHEN
Governor-General

By His Excellency's Command,
LIONEL BOWEN
Attorney-General
(Ex. Min. No. 111)

N.N.—8741737

FILM CENSORSHIP BOARD

WEEK ENDING 18 SEPTEMBER 1987

Classifications assigned to films for sale/hire

Australian Capital Territory Classification of Publications Ordinance 1983.

An explanatory key to reasons for classifying non-'G' films appears hereunder:

	Frequency		*Explicitness/Intensity*			*Purpose*	
	Infrequent	*Frequent*	*Low*	*Medium*	*High*	*Justified*	*Gratuitous*
S (Sex)	i	f	l	m	h	j	g
V (Violence)	i	f	l	m	h	j	g
L (Language)	i	f	l	m	h	j	g
O (Other)							

***Films Board of Review Decision
**Code reasons unavailable for films originally classified before 1972.

Title	*Producer*	*Country*	*Submitted length (mins)*	*Applicant*	*Reason for decision*
G—Suitable for general exhibition					
Asterix in Britain	Y. Piel	France	79	Filmpac	
Big Bird in China	D. Liu	U.S.A.	80	Roadshow Home Video	

Title	*Producer*	*Country*	*Submitted length (mins)*	*Applicant*	*Reason for decision*
Big Bird Storytime	J. Stone	U.S.A.	30	Roadshow Home Video	
Black Cannon Incident	XI'AN Film Studio	China	99	Ronin Films	
Care Bears Adventure in Wonderland	M. Hirsh	Canada	75	Virgin Video Australia	
Christmas Eve on Sesame Street	D. Singer	U.S.A.	58	Roadshow Home Video	
Don't Eat the Pictures	L. Simon/A. Sherman/T. Geiss	U.S.A.	50	Roadshow Home Video	
Elvis '56	A. & S. Raymond	U.S.A.	60	Virgin Video Australia	
Getting Ready for School	J. Stone	U.S.A.	30	Roadshow Home Video	
Gulliver's Travels	M. Fleischer	U.S.A.	76	Communications & Entertainment	
Kaboodle Series 1 (Episodes 12, 2 & 3)	ACFT Prods	Australia	80	CBS/Fox Video	
Kaboodle Series 2 (Episodes 4 & 5)	ACFT Prods	Australia	55	CBS/Fox Video	
Kaboodle Series 3 (Episodes 6 & 7)	ACFT Prods	Australia	55	CBS/Fox Video	
Kaboodle Series 4 (Episodes 8 & 9)	ACFT Prods	Australia	55	CBS/Fox Video	
Kaboodle Series 5 (Episodes 10 & 11)	ACFT Prods	Australia	55	CBS/Fox Video	
Kaboodle Series 6 (Episodes 1 & 13)	ACFT Prods	Australia	55	CBS/Fox Video	
Learning to Add & Subtract	J. Stone	U.S.A.	30	Roadshow Home Video	
Sing Along	J. Stone	U.S.A.	30	Roadshow Home Video	
Tom Corbett Space Cadet (said to be Vol. 1)	Rockhill Prods	U.S.A.	87	Communications & Entertainment	
Untitled (said to be Sir Michael Tippett)	K. Price	U.K.	26	Catersons	
Winfield State of Origin Story—Part 2 '86 and '87	Not shown	Australia	120	TVC Productions	
PG—Parental guidance required for those under 15					
Dracula Sovereign of the Damned	Harmony Gold Ltd	Japan	90	Outland Promotions	O (adult concepts) V (f-l-g)
Good Morning Babylon	G. E. Negri	U.S.A.	117	Communications & Entertainment	O (adult concepts)
Living Daylights, The	A. Broccoli/M. Wilson	U.K.	130	United International Pictures	V (f-l-j)
Sticks of Death (A.K.A. Arnis—The Stick of Death)	Consolidated Prods	U.S.A.	90	Video Excellence	V (i-l-g)
Vincent	T. Llewellyn-Jones	Australia	99	Roadshow Home Video	O (adult concepts)
M—Mature (not recommended for viewing by persons under 15)					
Battle in the Antilles (A.K.A. Burn)	A. Grimaldi	Italy	109	Delta Home Video	V (f-m-j)
Burnin' Love	M. Gruskoff	U.S.A.	87	Filmpac	O (sexual allusions)
Die Screaming Marianne	P. Walker	U.S.A.	99	Video Excellence	V (i-m-g)
Friends	L. Gilbert	U.K.	96	CIC-Taft Video	S (i-m-j) O (adult concepts)
Friends and Enemies	T. Zubrycki	Australia	89	Ronin Films	L (i-m-j)
Jaws the Revenge	J. Sargent	U.S.A.	90	United International Pictures	V (i-m-g)
Killing Cars	M. Krebs	West Germany	94	Filmpac	L (f-m-j) V (f-m-j) O (sexual allusions)

Title	*Producer*	*Country*	*Submitted length (mins)*	*Applicant*	*Reason for decision*
La Bamba	T. Hackford/B. Borden	U.S.A.	107	Fox Columbia Film Distributors	L (i-m-g) O (drug use)
Lost Boys, The	H. Bernhard	U.S.A.	97	Warner Home Video	V (i-m-j) O (horror)
Loyalties	W. Johnston/R. Lillie	Canada	98	Filmpac	O (adult concepts) L (i-m-g) V (i-m-j)
Mona Lisa	P. Cassavetti/S. Woolley	U.K.	104	Hoyts Distribution	L (f-m-j) V (i-m-j) O (adult concepts)
Predator	L. Gordon/J. Silver/ J. Davis	U.S.A.	106	Fox Columbia Film Distributors	V (f-m-g) L (i-m-g)
Revenge of the Nerds II: Nerds in Paradise	Field/Cort/Bart	U.S.A.	89	Fox Columbia Film Distributors	O (drug use, Sexual allusions)
Summer School	G. Shapiro/H. West	U.S.A.	97	United International Pictures	L (i-m-g) V (i-m-j)
Those Dear Departed	P. Emanuel	Australia	92	Roadshow Home Video	L (i-m-g) O (adult concepts)
Those Dear Departed (Edited Version)	P. Emanuel	Australia	88	Roadshow Home Video	L (i-m-g) O (adult concepts)
R—Restricted (not to be sold or hired or delivered to minors or displayed in a public place unless container bears prescribed markings)					
Dirty Mind of Young Sally, The (Edited Version)	Buckalew	U.S.A.	64	Variety Video	S (f-m-g)
Every Woman has a Fantasy Part III (Edited Version)	R. Lynn	U.S.A.	79	Fourteenth Mandolin	S (f-m-g)
Frightmare	P. Walker	U.K.	88	Video Excellence	O (horror)
Game, Sex & Match (Edited Version)	Not shown	France	73	Palace Home Video	L (f-m-g) S (f-m-g)
Hellraiser	C. Figg	U.S.A.	91	Roadshow Home Video	V (f-m-g) O (horror)
Sex Star Search (Edited Version)	Hollywood Confidential	U.S.A.	62	Fourteenth Mandolin	S (f-m-g)
X—Extra-restricted (not to be sold or hired or delivered to minors or displayed except in a restricted publications area and bearing prescribed markings)					
All For His Ladies	Plum Production	U.S.A.	90	Capital Duplicators	S (f-h-g)
Center Spread Girls	H. Lime	U.S.A.	85	South Australia Police	S (i-h-g)
Dirty Harriet	P. Ross/C. Williams	U.S.A.	78	Victoria Police	S (f-h-g)
Frisky Business	A. Berry	U.S.A.	74	Victoria Police	S (f-h-g)
Getting Lucky	P. Vatelli	U.S.A.	73	N.S.W. Police	S (f-h-g)
Kissin' Cousins	L. Burton	U.S.A.	82	Victoria Police	S (f-h-g)
Lady by Night	D. Ferrara	U.S.A.	87	Victoria Police	S (f-h-g)
Little Bit O' Honey, A	J. Malibu	U.S.A.	79	Victoria Police	S (f-h-g)
New Wave Hookers	G. Dark	U.S.A.	77	N.S.W. Police	S (f-h-g)
Sex Star Search	Hollywood Confidential	U.S.A.	68	Fourteenth Mandolin	S (f-h-g)
Shave Tail	B. Seven	U.S.A.	72	N.S.W. Police	S (f-h-g)
Star is Porn, A	M. Kaplan	U.S.A.	81	Victoria Police	S (f-h-g)
Summer Camp Girls	H. Lime	U.S.A.	80	N.S.W. Police	S (f-h-g)
Untitled (said to be Explicit)	Variety Video	U.S.A.	59	N.S.W. Police	S (f-h-g)
Wild Orgies	Phase II	U.S.A.	92	N.S.W. Police	S (f-h-g)
Wild Orgies	Phase II	U.S.A.	75	N.S.W. Police	S (f-h-g)
Wizard of Ahh's	Electric Hollywood	U.S.A.	73	Victoria Police	S (f-h-g)
Working It Out	J. Williams	U.S.A.	72	Victoria Police	S (f-h-g)
Refused not to be offered for sale or hire					
Debbie Does Dallas—Part II	J. Clarke	U.S.A.	77	N.S.W. Pollice	O (gratuitous sexual violence)

FILM CENSORSHIP BOARD

WEEK ENDING 23 OCTOBER 1987

Classifications assigned to films for sale/hire pursuant to the *Australian Capital Territory Classification of Publications Ordinance 1983.*

An explanatory key to reasons for classifying non-'G' films appears hereunder:

	Frequency		*Explicitness/Intensity*			*Purpose*	
	Infrequent	*Frequent*	*Low*	*Medium*	*High*	*Justified*	*Gratuitous*
S (Sex)	i	f	l	m	h	j	g
V (Violence)	i	f	l	m	h	j	g
L (Language)	i	f	l	m	h	j	g
O (Other)							

***Films Board of Review decision

**Code reasons unavailable for films originally classified before 1972.

Title	*Producer*	*Country*	*Submitted length (mins)*	*Applicant*	*Reason for decision*
G—Suitable for general exhibition					
Ambush at Masai/ Leopard, A Darkness in the Grass	H. Miles	U.K.	80	Polygram Video	
Best of Wimbledon the Young Champions, The	J. Vigar	U.K.	90	Polygram Video	
Cricket in Australia	J. Egan	Australia	50	Festival Records	
Dot Goes to Hollywood	Y. Gross	Australia	73	Yoram Gross Film Studios	
Ewoks—Volume 1	Hirsh/Loubert/Smith	Taiwan/ U.S.A.	90	CBS/Fox Video	
Ewoks—Volume 2	M. Hirsh/P. Loubert/ C. Smith	Taiwan/ U.S.A.	85	CBS/Fox Video	
Ewoks—Volume 3	M. Hirsh/P. Loubert/ C. Smith	Taiwan/ U.S.A.	85	CBS/Fox Video	
Ewoks—Volume 4	M. Hirsh/P. Loubert/ C. Smith	Taiwan/ U.S.A.	85	CBS/Fox Video	
Ewoks—Volume 5	M. Hirsh/P. Loubert/ C. Smith	Taiwan/ U.S.A.	85	CBS/Fox Video	
Ewoks—Volume 6	M. Hirsh/P. Loubert/ C. Smith	Taiwan/ U.S.A.	85	CBS/Fox Video	
G. I. Joe	D. Jurwich	U.S.A.	94	Golden Press	
Link-up Diary	D. MacDougall	Australia	84	Ronin Films	
Mask—Homeward Bound/Challenge of the Masters/Cliff Hanger/Race Against Time	J. Chalopin/A. Heyward/T. Katayama	U.S.A.	84	Golden Press	
Mask—Where Eagles Dare/Demolition Duel To The Death	Chalopin/Heyward	U.S.A.	43	Golden Press	
Mediterranean Cookery Vol. 1	C. Brigstocke	U.K.	90	Polygram Video	
Mediterranean Cookery Vol. 2	C. Brigstocke	U.K.	90	Polygram Video	
Meerkats United/The Impossible Bird	H. Miles	U.K.	55	Polygram Video	
Rock 'N Gold	C. Braverman	U.S.A.	31	Roadshow Home Video	
Rugby Football Union Coaching Video	A. Davie	U.K.	104	Polygram Video	
Ski Right	Sportsimaging	U.S.A.	84	Australian Ski Federation	
Snakes and Ladders	T. Fitzsimons/M. Goldman	Australia	57	Ronin Films	
Star Wars Droids—The Adventures of R2D2 and C3PO Volume 3	M. Hirsh/P. Loubert/ C. Smith	Taiwan	90	CBS/Fox Video	
Star Wars Droids—The Adventures of R2D2 and C3PO, Volume 2	M. Hirsh/P. Loubert/ C. Smith	Taiwan	90	CBS/Fox Video	

Title	*Producer*	*Country*	*Submitted length (mins)*	*Applicant*	*Reason for decision*
Star Wars Droids—The Adventures of R2D2 and C3PO, Volume 1	M. Hirsh/P. Loubert/C. Smith	Taiwan	88	CBS/Fox Video	
Star Wars Droids—The Adventures of R2D2 and C3PO—The Great Heep	M. Hirsh/P. Loubert/C. Smith	Taiwan	47	CBS/Fox Video	
Superbout Series, Vol. 25, Curry vs Starling	Not shown	U.S.A.	60	Polygram Video	
Superbout Series, Vol. 26, Duran vs De Jesus	Not shown	U.S.A.	60	Polygram Video	
Superbout Series, Vol. 27, Weaver vs Coetzee	Not shown	U.S.A.	70	Polygram Video	
Superbout Series, Vol. 28, Lopez vs Ayala	Not shown	U.S.A.	55	Polygram Video	
Swing Out Sister . . . And Why Not	Phonogram Records	U.K.	17	Polygram Video	
You Can't Take It With You	Columbia Pictures	U.S.A.	127	RCA/Columbia Pictures/Hoyts Video	
Zip-A-Dee-Doo-Dah	P. Savenick/H. Arends	U.S.A.	26	Roadshow Home Video	
'PG'—Parental guidance required for those under 15					
Back to the Beach	F. Mancuso	U.S.A.	90	United International Pictures	O (adult concepts) L (i-l-g)
Batteries Not Included	R. Schwary	U.S.A.	109	United International Pictures	L (i-l-g)
Ernest Goes to Camp	S. Williams	U.S.A.	91	Roadshow Home Video	V (i-l-g)
Good Neighbour Sam	D. Swift	U.S.A.	130	RCA/Columbia Pictures/Hoyts Video	**
Grass Is Greener, The	S. Donen	U.K.	105	Crystal Screen Entertainment	**
Hunchback of Notre Dame, The	N. Rosemont	U.K.	102	RCA/Columbia Pictures/Hoyts Video	V (i-l-j) O (adult concepts)
I've Heard the Mermaids Singing	P. Rozema/A. Raffe	Canada	83	Palace Home Video	O (adult concepts) L (i-l-j)
In a Lonely Place	R. Lord	U.S.A.	94	RCA/Columbia Pictures/Hoyts Video	**
Incredible Sarah, The	H. Strauss	U.S.A.	105	Roadshow Home Video	O (adult concepts)
Innerspace	M. Finnell	U.S.A.	119	Warner Home Video	L (i-l-g) V (i-l-g) O (sexual allusions)
James Dean	W. Bast/J. Forbes	U.S.A.	99	Roadshow Home Video	O (adult concepts)
Lionheart	S. O'Toole/T. Shire	Hungary	101	Roadshow Home Video	V (i-l-j)
Masters of the Universe	M. Golan/Y. Globus	U.S.A.	105	Hoyts Distribution	V (f-l-g) L (i-l-g)
North Shore	W. Finnegan	U.S.A.	95	United International Pictures	V (i-m-j) L (i-l-g)
Sirocco	R. Lord	U.S.A.	98	RCA/Columbia Pictures/Hoyts Video	**
Superman IV—The Quest for Peace	M. Golan/Y. Globus	U.S.A./U.K.	92	Hoyts Distribution	V (i-m-j)
Taking Care of Yourself—Breast Self Examination (BSE)	Westmead Hospital/N.S.W. Cancer Council	Australia	13	Director Audio Visual Services	O (adult theme)
Time Guardian, The	N. Wilkinson/R. Lagetti	Australia	87	Filmpac	V (f-l-g) L (f-l-g)

Title	*Producer*	*Country*	*Submitted length (mins)*	*Applicant*	*Reason for decision*
M—Mature (not recommended for viewing by persons under 15)					
Bates Motel	K. Topolsky	U.S.A.	91	CIC-Taft Video	O (adult concepts)
Believers, The	J. Schlesinger/M. Childers/B. Camhe	U.S.A.	110	RCA/Columbia Pictures/Hoyts Video	V (i-m-j) L(i-m-j) O (occult themes)
Big Town, The	M. Ransohoff	U.S.A.	110	Hoyts Distribution	S (i-m-g) V (i-m-j)
Dancing In The Dark	A. Kramreither	Canada	98	Seven Keys Video	O (adult theme) S (i-m-j)
Everlasting Secret Family, The	M. Thornhill	Australia	90	Filmpac	O (adult concepts)
Fallen Angel	L. Hunter/A. Blasdel-Goddard	U.S.A.	112	RCA/Columbia Pictures/Hoyts Video	O (adult concepts)
Georgy Girl	R. Goldston	U.K.	110	RCA/Columbia Pictures/Hoyts Video	**
Hello Mary Lou Prom Night II	P. Simpson	Canada	96	Roadshow Home Video	O (horror) V (i-m-g) S (i-m-g) L (i-m-g)
Indian Summer	L. Hardie-Brown/M. Swindale	U.K./India	97	Taft Hardie Group	S (i-m-g)
Malone	L. Fuchs	U.S.A.	92	RCA/Columbia Pictures/Hoyts Video	V (f-m-g) L (i-m-g)
Running From The Guns	G. Burrows	Australia	87	Hoyts Distribution	V (i-m-g) L (i-m-g)
Streets Of Gold	J. Roth/H. Ufland	U.S.A.	92	Outland Promotions	L (i-m-g) V (i-m-j)
Warm Nights On A Slow Moving Train	R. Dimsey/P. Juillet	Australia	90	Filmpac	O (drug use/ adult concepts) S (i-m-j)
Whatever Happened To Baby Jane?	R. Aldrich	U.S.A.	128	Corporate Video	O (adult theme) V (i-m-j)
Who's That Girl	R. Heller/B. Williams	U.S.A.	93	Warner Home Video	O (anti-social behaviour)
R—Restricted (not to be sold or hired or delivered to minors or displayed in a public place unless container bears prescribed markings)					
1988 Playboy Video Playmate Calendar	M. Trikilis	U.S.A.	62	Palace Home Video	O (exploitative nudity)
Debbie Does Dallas (Edited Version)	J. Clark	U.S.A.	79	Fourteenth Mandolin	S (f-m-g)
Eclipse Of Reason	C. Warren	U.S.A.	26	Right To Life Association (N.S.W.)	O (adult concepts, explicit surgical procedures)
Playboy Presents Ribald Classics	R. Hughes/M. Trikilis/W. Kronick	U.S.A.	58	Palace Home Video	S (f-m-g)
X Extra-Restricted (not to be sold or hired or delivered to minors or displayed except in a restricted publications area and bearing prescribed markings)					
Bizarre X/Handfick Anal Orgasmus	Not shown	West Germany	51	N.S.W..Police	S (f-h-g)
Confessions	C. Ludwig	U.S.A.	68	Victoria Police	S (f-h-g)
Debbie Does Dallas	J. Clark	U.S.A.	80	Fourteenth Mandolin	S (f-h-g)
Dirty Lilly	Not shown	U.S.A.	65	N.S.W. Police	S (f-h-g)
Erotic Aerobics	A. Robbins	U.S.A.	79	N.S.W. Police	S (f-h-g)
Extremes	Filmvest Corp	U.S.A.	68	N.S.W. Police	S (f-h-g)
Physical	J. Blackthorn	U.S.A.	80	Victoria Police	S (f-h-g)
Power of Nicole, The	Not shown	U.S.A.	78	N.S.W. Police	S (f-h-g)
Rikki Blake Starring in a Gourmet Quickie/Heather Wayne Starring in a Gourmet Quickie	Gourmet Video	U.S.A.	60	Capital Duplicators	S (f-h-g)

Title	*Producer*	*Country*	*Submitted length (mins)*	*Applicant*	*Reason for decision*
RX For Sex	C. Farmer	U.S.A.	69	N.S.W. Police	S (f-h-g)
Shauna Grant 2 Starring in a Gourmet Quickie/ Monique Perry Starring in a Gourmet Quickie	Gourmet Video	U.S.A.	59	Capital Duplicators	S (f-h-g)
Swedish Erotica Vol. 48	Caballero Control Corp	U.S.A.	58	Victoria Police	S (f-h-g)
Swedish Erotica Vol. 50	Caballero Control Corp	U.S.A.	35	Victoria Police	S (f-h-g)
Sweet Dominance	Gourmet Video Collection	U.S.A.	60	N.S.W. Police	S (f-h-g) O (mild bondage)
Untitled (said to be Swedish Erotica No. 503/No. 504)	Cabellero/Swedish Erotica	U.S.A.	114	Victoria Police	S (f-h-g)
Yamahama Mama	TGA/Excalibur	U.S.A.	55	N.S.W. Police	S (f-h-g)
REFUSED Not to be offered for sale or hire					
Pretty Peaches	A. De Renzy	U.S.A.	87	N.S.W. Police	O (gratuitous sexual violence)

FILM CENSORSHIP BOARD

WEEK ENDING 30 OCTOBER 1987

Classifications assigned to films for sale/hire pursuant to the *Australian Capital Territory Classification of Publications Ordinance 1983*

An explanatory key to reasons for classifying non-'G' films appears hereunder:

	Frequency		*Explicitness/Intensity*			*Purpose*	
	Infrequent	*Frequent*	*Low*	*Medium*	*High*	*Justified*	*Gratuitous*
S (Sex)	i	f	l	m	h	j	g
V (Violence)	i	f	l	m	h	j	g
L (Language)	i	f	l	m	h	j	g
O (Other)							

*** Films Board of Review decision.
** Code reasons unavailable for films originally classified before 1972.

Title	*Producer*	*Country*	*Submitted length (mins)*	*Applicant*	*Reason for decision*
G Suitable for general exhibition					
AC/DC	Not shown	Australia	40	EMI Records Australia	
Baseball Bunch—Fielding, The	R. Domich/J. Shapiro/G. Cohen	U.S.A.	54	Roadshow Home Video	
Baseball Bunch—Hitting, The	J. Shapiro/R. Domich/G. Cohen	U.S.A.	51	Roadshow Home Video	
Baseball Bunch—Pitching, The	R. Domich/J. Shapiro/G. Cohen	U.S.A.	58	Roadshow Home Video	
BMX Freestyle	M. Sembellow/M. Hudson	U.S.A.	30	K5 International Pty Ltd	
Cross Country Skiing—The Ultimate Fitness Sport	R. Brown	U.S.A.	88	Australian Ski Federation	
Dr Who—Death to the Daleks	B. Letts	U.K.	91	Polygram Video	
Dream Cars	Westwood Prods	U.S.A.	30	K5 International Pty Ltd	
Last Oasis, The	P. Martic/Z. Sulovic	Yugoslavia/ U.S.A.	83	Hoyts Distribution	
Leslie Chazins Introduction to Low Impact Aerobics	R. Diercks	U.S.A.	30	K5 International Pty Ltd	
Lord Howe—The Fisherman's Island	Pilgrim International	Australia	55	Polygram Video	
Marilyn Monroe Beyond the Legend	S. Winter/G. Feldman	U.S.A.	60	PolyGram MusicVideo	

Title	*Producer*	*Country*	*Submitted length (mins)*	*Applicant*	*Reason for decision*
Murray River Quest (Edited version)	P. McKay	Australia	60	c/- Arbor Productions	
Offshore Sportfishing—A Fishermans' World with Ron Calcutt—Sportfishing Tournament—Fishing Frontiers	Pilgrim Int	Australia	90	PolyGram MusicVideo	
Porsche	Amour Prods	U.S.A.	30	K5 International Pty Ltd	
Scouts	M. Murphy	U.S.A.	56	Festival Records	
Ski with Klammer	M. Boney	U.K.	88	Australian Ski Federation	
South Sydney—Pride of the League	G. McNeice/G. Deans	Australia	88	S.C.T.V./South Sydney Rugby League	
Space Challenge	Select Merchandise	U.S.A.	13	Yared Perry Paton	
Super Car Showdown	Armour Prods	U.S.A.	30	K5 International Pty Ltd	
Visions of War—Birth of The Bomb	P. Batty	U.K.	50	Catersons	
Visions of War—Search for the Super	P. Batty	U.K.	50	Catersons	
Visions of War—Superspy	P. Batty	U.K.	50	Catersons	
PG—Parental Guidance required for those under 15					
Brothers by Choice	S. McLean/L. Clark	Canada	101	Virgin Video Australia	V (i-l-g) O (drug references)
Connection, The	A. D'Antoni	U.S.A.	73	CBS/Fox Video	V (i-l-j)
Deadline	Universal	U.S.A.	89	CIC-Taft Video	L (i-l-g) V (i-l-j)
LBJ The Early Years	J. Brice/S. Saxon Brice	U.S.A.	182	Virgin Video Australia	V (i-l-j) L (i-l-g)
Max Headroom Vol. 1	P. Wagg/B. Frankish	U.S.A.	96	RCA Columbia Pictures/Hoyts Video	V (i-m-g) O (adult concepts)
Night of the Grizzly, The	B. Dunne	U.S.A.	98	CIC-Taft Video	V (i-l-g)
Return of Sherlock Holmes, The	N. Gillott	U.S.A.	91	CBS/Fox Video	V (i-m-j) O (adult concepts)
Visions of War—Battle for Cassino	P. Batty	U.K.	50	Catersons	O (graphic war footage)
Visions of War—Battle for Dien Bien Phu	P. Batty	U.K.	50	Catersons	O (graphic war footage)
Visions of War—Battle for the Bulge	P. Batty	U.K.	50	Catersons	O (graphic war footage)
Visions of War—Battle for Warsaw	P. Batty	U.K.	50	Catersons	O (graphic war footage)
Visions of War—Operation Barbarossa	P. Batty	U.K.	50	Catersons	O (graphic war footage)
M—Mature (not recommended for viewing by persons under 15)					
Private Eye	S. Brazil	U.S.A.	103	CIC-Taft Video	V (i-m-j) S (i-m-j)
Treasure of the Moon Goddess	G. Green	U.S.A.	91	Roadshow Home Video	V (i-m-g)
Wisdom	B. Williams	U.S.A.	105	Corporate Video	V (i-m-g) L (i-m-g)
X Extra-Restricted (not to be sold or hired or delivered to minors or displayed except in a restricted publications area and bearing prescribed markings)					
Big Bad Bertha II	Unique Video	U.S.A.	60	N.S.W. Police	S (f-h-g)
Bondage Debut	Leetime Video Prod	Australia	56	Australian Federal Police	O (mild bondage)

Title	*Producer*	*Country*	*Submitted length (mins)*	*Applicant*	*Reason for decision*
Diplomat Films Present Bizarre Life/ Diplomat Films Present Bizarre Life Pain Master	Not shown	West Germany	22	Australian Federal Police	S (f-h-g)
Fantasy of 'M'	Dinos Blue Movie Video	West Germany	59	Australian Federal Police	S (f-h-g) O (mild sexual fetish)
Gold Diggers	R. Emmis	U.S.A.	80	Fourteenth Mandolin	S (f-h-g)
Gold Diggers(Edited version)	R. Emmis	U.S.A.	80	Fourteenth Mandolin	S (i-h-g)
Interlude	Zorro	U.S.A.	53	Australian Federal Police	O (mild sexual fetish) S (i-h-g)
Just For Me	Variety Video	U.S.A.	63	N.S.W. Police	S (f-h-g)
Leather Games V1220	Wara Films	West Germany	70	Australian Federal Police	S (f-h-g)
N.Y. Babes	B. Hollander	U.S.A.	69	N.S.W. Police	S (f-h-g)
Ring's Privat	Dino Blue Movie Video	West Germany	50	Australian Federal Police	S (f-m-g) O (mild sexual fetish)
Slave Training	Bizarre Video Productions	U.S.A.	52	Australian Federal Police	O (mild sexual fetish)
TGA Excalibur 4— Blazing Redheads	TGA Video	U.S.A.	60	N.S.W. Police	S (f-h-g)
Untitled (said to be Kinky Couples)	Not shown	U.S.A.	60	Australian Federal Police	O (mild sexual fetish)
REFUSED Not to be offered for sale or hire					
Bitter Sweet Revenge	B. Behr	U.S.A.	55	Australian Federal Police	O (gratuitous sexual violence)
Bizarre Life—Torture of the Slaves	Not shown	West Germany	21	Australian Federal Police	O (gratuitous sexual violence)
Bondage Classics 4	HOM	U.S.A.	39	Australian Federal Police	O (gratuitous sexual violence)
Chained	Erotic Video Co.	U.S.A.	70	Australian Federal Police	O (gratuitous sexual violence)
Club De Sade	Golden Geissel Video Prods	West Germany	24	Australian Federal Police	O (gratuitous sexual violence)
Judi's B & D Slave School	D. Majors	U.S.A.	53	Australian Federal Police	O (gratuitous sexual violence)
Sweet Nightmares	B. Behr	U.S.A.	55	Australian Federal Police	O (gratuitous sexual violence)
Untitled (said to be Bizarre Bondage †2)	Bizarre Video Productions	U.S.A.	41	Australian Federal Police	O (gratuitous sexual violence)
Untitled (said to be Bondage Fantasies)	Not shown	U.S.A.	48	Australian Federal Police	O (gratuitous sexual violence)
Untitled (said to be Roped and Raped)	Not shown	West Germany	26	Australian Federal Police	O (gratuitous sexual violence)
Untitled (said to be Spanking—Knickers Up, Knickers Down)	Not shown	U.K.	28	Australian Federal Police	O (gratuitous sexual violence)

FILM CENSORSHIP BOARD

WEEK ENDING 6 NOVEMBER 1987

Classifications assigned to films for sale/hire pursuant to the *Australian Capital Territory Classification of Publications Ordinance 1983*

An explanatory key to reasons for classifying non-'G' films appears hereunder:

	Frequency		*Explicitness/Intensity*			*Purpose*	
	Infrequent	*Frequent*	*Low*	*Medium*	*High*	*Justified*	*Gratuitous*
S (Sex)	i	f	l	m	h	j	g
V (Violence)	i	f	l	m	h	j	g
L (Language)	i	f	l	m	h	j	g
O (Other)							

*** Films Board of Review decision.
** Code reasons unavailable for films originally classified before 1972.

Title	*Producer*	*Country*	*Submitted length (mins)*	*Applicant*	*Reason for decision*
PG—Parental Guidance required for those under 15					
From Noon Till Three	M. Frankovich/ W. Self	U.S.A.	95	Corporate Video	L (i-l-j) O (sexual allusions)
Great Northfield Minnesota Raid, The	Universal/Robertson & Associates	U.S.A.	90	CIC-Taft Video	V (i-m-j) O (sexual allusions)
Urgent—Man Wanted (said to be Title not shown in English)	Not shown in English	Greece	99	Pegasus Video Distributions	O (adult concepts)
M—Mature (not recommended for viewing by persons under 15)					
Firehouse	J. Ingvordsen/ S. Kaman	U.S.A.	86	Virgin Video Australia	L (i-m-g) O (nudity, sexual allusions)
X—Extra-Restricted (not to be sold or hired or delivered to minors or displayed except in a restricted publications area and bearing prescribed markings)					
All for his Ladies	Plum Productions	U.S.A.	90	Victoria Police	S (f-h-g)
Every Inch a lady	J. Amero/L. Amero	U.S.A.	75	NSW Police	S (f-h-g)
Naughty Girls Need Love Too	S. Winters	U.S.A.	90	Victoria Police	S (f-h-g)
Night Moves	J. Blackthorn	U.S.A.	72	NSW Police	S (f-h-g)
Pain by Lana	B. Behr	U.S.A.	58	Australian Federal Police	O (mild sexual fetish)
Up 'n' Coming	G. Daniels	U.S.A.	80	NSW Police	S (f-h-g)
REFUSED Not to be offered for sale or hire					
Inferno Bizarre	Scandia Film/Orbis Film	West Germany	60	Australian Federal Police	O (coprophilia)

FILM CENSORSHIP OCTOBER 1987

Films examined in terms of the Customs (Cinematograph Films) Regulations and States' film censorship legislation are listed below.

An explanatory key to reasons for classifying non-'G' films appears hereunder:

	Frequency		*Explicitness/Intensity*			*Purpose*	
	Infrequent	*Frequent*	*Low*	*Medium*	*High*	*Justified*	*Gratuitous*
S (Sex)	i	f	l	m	h	j	g
V (Violence)	i	f	l	m	h	j	g
L (Language)	i	f	l	m	h	j	g
O (Other)							

*** Films Board of Review decision

Title	*Producer*	*Country*	*Submitted length (m)*	*Applicant*	*Reason for decision*
FILMS REGISTERED WITHOUT DELETIONS					
For general exhibition—"G"—Suitable for all ages					
How The West Was Lost (16mm)	H. Williams/ D. Noakes	Australia	778.87	Australian Film Commission	

Title	*Producer*	*Country*	*Submitted length (mins)*	*Applicant*	*Reason for decision*
Last Train to Tansui (16mm)	Not shown	Taiwan	1 086.03	Chinese Cultural Centre	
Parental guidance—"PG"—Parental guidance recommended for children under 15 years					
Love and Sword (16mm)	Not shown	Taiwan	987.30	Chinese Cultural Centre	V (f-l-g) L (i-l-g)
Made in Heaven	R. Gideon/B. Evans/ D. Blocker	U.S.A.	2 715.57	Village Roadshow Corporation	S (i-l-j) L (i-l-g)
My Grandfather (16mm)	Ke Jiunn-Shyong	Taiwan	921.48	Chinese Cultural Centre	O (adult concepts)
Nice Girls Don't Explode	D. Curtis/J. Wells	U.S.A.	2 194.40	Village Roadshow Corporation	O (sexual allusions)
Rite of Passage (also known as *Dust In The Wind*)	Central Motion Pictures	Taiwan	2 880.00	Chinese Cultural Centre	O (adult concepts L (i-l-g)
Time to Live and The Time to Die, The	Central Motion Pictures	Taiwan	3 648.19	Ronin Films	O (adult concepts)
Trouble Couples	R. Wing/A. Tam	Hong Kong	2 386.41	Chinatown Cinema	L (i-l-g) O (adult concepts)
For mature audience—"M"—Recommended as suitable for persons 15 years and over					
Association des Malfaiteurs	C. Zidi	France	2 852.72	Filmpac Holdings	L (i-m-j) O (sexual allusions)
Barfly	B. Schroeder/F. Ross/ T. Luddy	U.S.A.	2 660.71	Hoyts Distribution	O (alcohol abuse) V (i-m-j) L (f-m-g)
Bellman & True	M. Wearing/ C. Neame	U.K.	3 319.00	Communications and Entertainment	L (i-m-j) V (i-m-j) O (adult concepts)
Best Seller	C. De Haven	U.S.A.	2 523.56	Village Roadshow Corporation	V (i-m-g) L (i-m-g) O (adult concepts)
For Mature Audience—"M"—Recommended as suitable for persons 15 years and over—continued					
Cherry 2000	E. Pressman/ C. Chubb	U.S.A.	2 688.14	Village Roadshow Corporation	V (i-m-g) L (i-m-g) O (sexual allusions)
Death in the Family, A (16mm)	J. Wallace	New Zealand	526.56	Ronin Films	O (adult theme)
Des Teufels Paradise	V. Tschechowa/V. Glowna/B. Arnold	West Germany	2 550.99	Communications and Entertainment	S (i-m-j) V (i-m-j)
Easy Money	D. Poon	Hong Kong	2 633.28	Chinatown Cinema	V (i-m-j) O (adult concepts)
Five Corners	F. Murray/T. Bill	U.K.	2 578.42	Communications and Entertainment	V (i-m-j) L (i-m-j)
Julia and Julia	RAI Radiotelevisione Italiana	Italy	2 688.14	Hoyts Distribution	S (i-m-j) V (i-m-j)
Lady in Black	D. Shek	Hong Kong	2 550.99	Chinatown Cinema	O (adult concepts) V (i-m-g)
Man on Fire	A. Millchan	Italy/France	2 441.27	Communications and Entertainment	V (f-m-g) L (i-m-g)
Pick-up Artist, The	D. MacLeod	U.S.A.	2 221.83	Fox Columbia Film Distributors	O (sexual allusions)
Private Life	R. Tang	Hong Kong	2 441.27	Kwang Tai Mok	O (adult concepts) V (i-m-g)
Scenes from the Goldmines	D. Eisenberg	U.S.A.	2 852.72	Filmpac Holdings	L (f-m-g) O (drug use)
Sherman's March (16mm)	R. McElwee	U.S.A.	733.26	AFI Distribution	L (i-m-g)
Slam Dance	R. Harvey/B. Opper	U.S.A./U.K.	2 715.57	Hoyts Distribution	V (i-m-j) L(i-m-g) O (adult concepts)

Title	*Producer*	*Country*	*Submitted length (m)*	*Applicant*	*Reason for decision*
Someone to Watch Over Me	T. De Ganay/ H. Schneider	U.S.A.	2 825.29	Fox Columbia Film Distributors	V (i-m-j) L (i-m-g)
White Water Summer	M. Tarlov	U.S.A./New	2 386.41	Fox Columbia Film Distributors	L (i-m-g) V (i-m-g)
With Love to the Person Next to Me (16 mm)	J. Cruthers	Australia	1 042.00	Australian Film Institute	O (adult concepts) L (f-m-g)
For Restricted Exhibition—"R"—Persons 2 years of age and over, and under 18 years of age, are not admitted					
Lady Beware	L. Taylor-Mortorff/ T. Scotti	U.S.A.	2 962.44	Village Roadshow Corporation	O (concept of sexual menace) V (i-m-g)
Principal, The	T. Brodek	U.S.A.	2 935.01	Fox Columbia Film Distributors	L (f-m-g) V (i-m-g)
Retribution	G. Magar	U.S.A.	2 989.87	Hoyts Distribution	V (i-m-g)
Take Care—Your Majesty!	Run Run Shaw Bros.	Hong Kong	2 358.98	Chinatown Cinema	S (i-m-g) O (exploitative nudity)

Films Registered with Deletions

Nil

Films Refused Registration

Nil

Films Board of Review

Decision Reviewed:

Decision of the Board:

FILM CENSORSHIP BOARD

Australian Capital Territory Classification of Publications Ordinance 1983

CLASSIFICATIONS ASSIGNED TO FILMS FOR SALE/HIRE

WEEK ENDING 13 NOVEMBER 1987

An explanatory key to reasons for classifying non-'G' films appears hereunder:

	Frequency		*Explicitness/Intensity*			*Purpose*	
	Infrequent	*Frequent*	*Low*	*Medium*	*High*	*Justified*	*Gratuitous*
S (Sex)	i	f	l	m	h	j	g
V (Violence)	i	f	l	m	h	j	g
L (Language)	i	f	l	m	h	j	g
O (Other)							

*** Films Board of Review Decision

** Code reasons unavailable for films originally classified before 1972.

Title	*Producer*	*Country*	*Submitted length (mins)*	*Applicant*	*Reason for decision*
G—Suitable for general exhibition					
Australian Touring Car Championship—1987	ATN-7 Sports/Atlab Australia	Australia	90	Atlab	
Body & Soul	P. Deamer	Australia	34	WEA Records	
Chelsea Flower Show 1987	R. Day	U.K.	59	Catersons	
Elmchanted Forest, The	D. Hreljanovic	Yugoslavia/ U.S.A.	82	Macro Entertainment	
Garfield	J. Davies	U.S.A.	90	Crystal Screen Entertainment	
Happy Birthday N.S.W.	E.V.S. Group	Australia	14	Roadshow Home Video	
Hobo's Christmas, A	P. Freeman	U.S.A.	93	Roadshow Home Video	
James Hardie 1000 Highlights 1987	ATN-7 Sports/Atlab Australia	Australia	60	Atlab	
Silverhawks—The Origin Story	L. Dannacher	U.S.A./Japan	103	Roadshow Home Video	

Title	*Producer*	*Country*	*Submitted length (mins)*	*Applicant*	*Reason for decision*
PG—Parental Guidance required for those under 15					
Dolly Video	P. Fox	Australia	43	Kizim	O (adult concepts)
Don't be the Last to Know	A. Ziegler	Australia	46	Film Australia	O (adult concepts, drug education)
Grace Kelly the American Princess	G. Feldman/ S. Winter	U.S.A.	58	PolyGram MusicVideo	V (i-m-j)
Let's Talk about Sex	B. Huber	Australia	58	Catersons	O (sex education)
Nightside	A. Beaton	U.S.A.	68	CIC-Taft Video	V (i-l-j) O (adult concepts)
Overdrawn at the Memory Bank	R. Lantos/S. Roth	U.S.A.	84	Roadshow Home Video	O (adult concepts) V (i-l-j)
Star Trek the Next Generation—'Encounter at Farpoint'	Paramount Pictures Corporation	U.S.A.	92	CIC-Taft Video	O (adult concepts)
M—Mature (not recommended for viewing by persons under 15)					
American Way, The	L. Keller/P. Cowan	U.S.A.	104	RCA/Columbia Pictures/Hoyts Video	L (f-m-g) O (drug use, adult concepts)
Born a Ninja	J. Lai/B. Chan	Hong Kong/ U.S.A.	88	Delta Video	V (i-m-g)
Crime Story	E. Zavada	U.S.A.	89	Roadshow Home Video	V (f-m-g)
Dead of Winter	J. Bloomgarden/ M. Shmuger	U.S.A.	97	Communications & Entertainment	V (i-m-j)
Eclipse of Reason	C. Warren	U.S.A.	26	Right to Life Association (NSW)	***
Geek!	M. Sweeney	U.S.A.	82	Seven Keys Video	V (i-m-g) O (nudity)
Ghostriders	J. Desmarais/ A. Stewart/ T. Callaway	U.S.A.	85	Macro Entertainment	V (i-m-g) L (i-m-g)
Mayflower Madam	R. Halmi	U.S.A.	88	Communications & Entertainment	O (adult theme, sexual allusions)
Ninja Terminator	J. Lai/B. Chan	Japan	89	Delta Video	V (f-m-g) S (i-m-g)
Ordinary Heroes	I. Barmak	U.S.A.	88	Outland Promotions	L (i-m-g)
Population One	B. Daalder	U.S.A.	79	Seven Keys Video	O (adult concepts)
Remember Me	P. Juillet	Australia	93	Taft Hardie Group	S (i-m-g) V (i-m-g)
Shapeup	J. Frade	U.S.A.	89	RCA/Columbia Pictures/Hoyts Video	L (i-m-g) O (nudity, sexual allusions)
Steppenwolf	M. Fishman/ R. Herland	U.S.A.	105	Virgin Video Australia	O (adult concepts)
Valour of War, The (also known as Hornet's Nest)	S. Canter	U.S.A./Italy	105	Macro Entertainment	V (i-m-j) O (adult concepts)
R—Restricted (not to be sold or hired or delivered to minors or displayed in a public place unless container bears prescribed markings)					
Baby Face (edited version)	A. De Renzy	U.S.A.	56	Victoria Police	S (f-m-g)
Berserker	J. Rivera	U.S.A.	82	Virgin Video Australia	S (i-m-g) V (i-m-g)
Deep Throat II (edited version)	J. Edwards/ B. Dawson	U.S.A.	58	Capital Duplicators	S (f-m-g)
Devil's Playground/Oh Those Nurses	R. Teegee/ C. Williams	U.S.A.	78	Victoria Police	S (f-m-g)
Double Penetration (edited version)	M. Curtis	U.S.A.	65	Fourteenth Mandolin	S (f-m-g)

Title	Producer	Country	Submitted length (mins)	Applicant	Reason for decision
Goodbye Scarlet	H. Winters	U.S.A.	68	Victoria Police	S (f-m-g)
Hard Ticket to Hawaii	A. Sidaris	U.S.A.	92	RCA/Columbia Pictures/Hoyts Video	O (exploitative nudity) V (i-m-g)
Her Wicked Ways (edited version)	J. Lewis	U.S.A.	70	Victoria Police	S (f-m-g)
Ice Cream Tuesday's Lover Volume One (edited version)	Producers Concepts	U.S.A.	73	Fourteenth Mandolin	S (f-m-g)
Lust on the Orient Express (edited version)	T. McDonald	U.S.A.	85	Victoria Police	S (f-m-g)
Marauders	M. Savage	Australia	75	Paul Harrington	V (i-m-g) L (f-m-g)
Megaboobs	Electric Video	U.K.	56	Video Ray	O (exploitative nudity)
Monique	M. Style	U.K.	91	Victoria Police	S (i-m-g)
Oh Those Nurses/ Devil's Playground	C. Williams/ R. Teegee	U.S.A.	78	Victoria Police	S (f-m-g)
Talk Dirty To Me Part 4 (edited version)	J. Ross	U.S.A.	53	Victoria Police	S (f-m-g)
Thoroughly Amorous Amy	A. Linn/ K. Montgomery	U.S.A.	56	Victoria Police	S (f-m-g)
Trashy Lady (edited version)	D. Andrews	U.S.A.	72	Victoria Police	S (f-m-g)
Up Up and Away	B. Bouschard	U.S.A.	60	Victoria Police	S (f-m-g)
X—Extra-restricted (not to be sold or hired or delivered to minors or displayed except in a restricted publications area and bearing prescribed markings)					
Debbie Does Dallas III (The Final Chapter)	J. Clark	U.S.A.	72	N.S.W. Police	S (f-h-g)
Educating Wanda	Santa Fe Production	U.S.A.	57	N.S.W. Police	S (f-h-g)
Love Slaves	D. Goldstein	U.S.A.	88	Australian Federal Police	S (f-h-g)

N.N.—8740339

Industrial Relations

Conciliation and Arbitration Act 1904

Principal Registry
Nauru House
80 Collins Street
Melbourne, Vic. 3000

NOTICE OF APPLICATION FOR THE REGISTRATION OF AN ASSOCIATION OF EMPLOYERS

(R No. 238 of 1987)

NOTICE is given that application has been made to me under the *Conciliation and Arbitration Act 1904* for the registration of an association called the Association of Consulting Architects—Australia as an organization of employers in or in connection with the industry of the practice of Architecture.

Any organization registered under the Conciliation and Arbitration Act or any person interested who desires to object to the application may do so by lodging with me a notice of objection in the prescribed form and a statutory declaration in support thereof within thirty-five (35) days after the publication of this advertisement and by serving on the applicant (whose address for service is: C/- Phillips Fox, Solicitors, 461 Bourke Street, Melbourne, Australia 3000) within seven (7) days after the notice of objection has been lodged, copies of the notice of objection and statutory declaration so lodged.

JOHN McMAHON
Industrial Registrar

Community Services and Health

COMMONWEALTH OF AUSTRALIA

Health Insurance Act 1973

ORDER UNDER SUB-SECTION 6 (1)

I, NEAL BLEWETT, the Minister of State for Community Services and Health, in pursuance of sub-section 6 (1) of the *Health Insurance Act 1973* hereby declare that every person included in the following class of persons, namely those persons visiting Australia as members of a foreign contingent to the 16th World Scout Jamboree, being a person who, but for sub-section 6 (1) of that Act, would not be an eligible person for the purposes of that Act, shall be treated as being an eligible person for the purposes of that Act for the period 8 December 1987 to 20 January 1988 inclusive.

Dated this 10th day of November 1987.

NEAL BLEWETT
Minister of State
for Community Services and Health

N.N.—8741738

COMMONWEALTH OF AUSTRALIA

Health Insurance Act 1973

ORDER UNDER SUB-SECTION 6 (1)

I, NEAL BLEWETT, the Minister of State for Community Services and Health, in pursuance of sub-section 6 (1) of the *Health Insurance Act 1973* hereby declare that every person included in the following class of persons, namely those persons visiting Australia as a delegate or official observer to the 31st World Scout Conference being a person who, but for sub-section 6 (1) of that Act, would not be an eligible person for the purpose of that Act, shall be treated as being an eligible person for the purposes of that Act for the period 9 January to 17 January 1988 inclusive.

Dated this 10th day of November 1987.

NEAL BLEWETT
Minister of State
for Community Services and Health

N.N.—8741739

COMMONWEALTH OF AUSTRALIA

National Health Act 1953

PHARMACEUTICAL BENEFITS

DETERMINATION UNDER SUB-SECTION 84C (7)

I, JOHN STEWART DEEBLE, Acting First Assistant Secretary, Health Benefits Division, Department of Community Services and Health and Delegate of the Minister of State for Community Services and Health, pursuant to sub-section 84C (7) of the *National Health Act 1953*, hereby make the following Determination:

1. This Determination shall come into operation on the first day of December 1987.
2. The Determination under section 84C of the National Health Act made on 1 November 1986 with effect from 1 November 1986, as amended, is, in this Determination, referred to as the Principal Determination.
3. Sub-paragraphs 10 (a), 10 (b) and 10 (c) of the Principal Determination are amended by omitting '$0.58' (wherever occurring) and substituting '$0.59'.
4. Sub-paragraphs 10 (a), 10 (c), 20 (d), 38 (c) and 38 (d) of the Principal Determination are amended by omitting '$0.84' (wherever occurring) and substituting '$0.85'.

Dated this 1st day of December 1987.

J. S. DEEBLE
Acting First Assistant Secretary
Health Benefits Division
Delegate of the Minister of State
for Community Services and Health

N.N.—8741740

COMMONWEALTH OF AUSTRALIA

National Health Act 1953

PHARMACEUTICAL BENEFITS DETERMINATION UNDER SECTION 93

I, JOHN STEWART DEEBLE, Acting First Assistant Secretary, Health Benefits Division, Department of Community Services and Health and Delegate of the Minister of State for Community Services and Health, pursuant to section 93 of the *National Health Act 1953*, hereby make the following Determination:

1. This Determination shall come into operation on the first day of December 1987.
2. The Determination under section 93 of the National Health Act made on 25 March 1987 with effect from 1 April 1987 is hereby revoked.
3. The pharmaceutical benefits referred to in this Determination shall be those contained in the Schedule to this Determination.
4. A medical practitioner is authorised for the purpose of section 93 of the Act to supply any of the pharmaceutical benefits obtained by the medical practitioner, or by another medical practitioner for whom the first-named medical practitioner is temporarily acting as a locum, in pursuance of this Determination.
5. Subject to this Determination, the maximum quantity or number or units of a pharmaceutical benefit that may be obtained by a medical practitioner in any one month for the purpose of section 93 of the Act is the number or quantity specified in the Schedule to this Determination in relation to the pharmaceutical benefit.
6. Where a medical practitioner has obtained a pharmaceutical benefit for the purpose of section 93 of the Act, that medical practitioner is not entitled to obtain a further quantity or number of units of that pharmaceutical benefit for that purpose whilst in possession of a quantity or number of units of the pharmaceutical benefit obtained by the medical practitioner equal to or greater than the maximum quantity or number of units allowed for the pharamaceutical benefit by paragraph 5.
7. A medical practitioner is not entitled to obtain a pharamaceutical benefit for the purpose of section 93 of the Act more often than twice in any two months.

THE SCHEDULE

Name of Pharmaceutical Benefit	*Form (strength, type, size etc.)*	*Maximum quantity*
Adrenaline Injection B.P.	Adrenaline, 1 in 1 000, 1 mL	5
Aminophylline Injection B.P.	Ampoule, 250 mg per 10 mL	5
Atropine Sulphate Injection B.P.	Ampoule, 600 micrograms in 1 mL	5
Chlorpromazine Injection B.P. or	Ampoule, 50 mg in 2 mL	10
Haloperidol B.P.	Injection, 5 mg in 1 mL amp	10
Diazepam Injection B.P.	10 mg in 2mL	5
Digoxin Injection B.P.	Ampoule, 500 micrograms in 2 mL	5
Diphtheria and Tetanus Vaccine, Adsorbed B.P.	Injection, 0.5 mL amp	10
Diphtheria and Tetanus Vaccine, Adsorbed B.P., Diluted	Injection, 0.5 mL amp	10
Ergometrine Injection B.P.	Ampoule, 250 micrograms in 1 mL	5
Erythromycin Ethyl Succinate B.P.	Injection, 100 mg (base) in 2 mL	5
Frusemide Injection B.P.	Ampoule, 20 mg in 2 mL	5

Name of Pharmaceutical Benefit	*Form (strength, type, size etc.)*	*Maximum quantity*
Glucose Intravenous Infusion B.P.	Ampoule, 5 g in 10 mL	5
Heparin Injection B.P. (sodium salt)	Ampoule, 5 000 units per 1 mL	5
or		
Heparin Injection B.P. (sodium salt)	Ampoule, 25 000 units per 5 mL	5
Hydrocortisone Sodium Succinate B.P.	Injection set containing equivalent of 100 mg hydrocortisone and 2 mL solvent	2
or		
Hydrocortisone Sodium Succinate B.P.	Injection set containing equivalent of 250 mg hydrocortisone and 2 mL solvent	1
or		
Dexamethasone Sodium Phosphate B.P.	Injection, 1 mL amp containing equivalent of 4 mg dexamethasone phosphate	5
Lignocaine Hydrochloride B.P.	Injection, 100 mg in 5 mL	4
or		
Lignocaine Hydrochloride Injection B.P.	Syringe, disposable, 300 mg in 3 mL	1
Metoclopramide Injection B.P.	Ampoule, 10 mg in 2 mL	10
or		
Prochlorperazine Edisylate	Injection, 12.5 mg in 1 mL	10
or		
Prochlorperazine Injection B.P.	Ampoule, 12.5 mg in 1 mL	10
or		
Thiethylperazine Malate	Injection, 6.5 mg (base) in 1 mL amp	10
Morphine Sulphate Injection B.P.	Ampoule, 15 mg in 1 mL	5
or		
Morphine Sulphate Injection B.P.	Ampoule, 30 mg in 1 mL	5
Naloxone Hydrochloride	Injection, 2 mg in 5 mL disposable injection set	2
Pethidine Injection B.P.	Ampoule, 100 mg in 2 mL	5
Procaine Penicillin Injection B.P.	Syringe, disposable, 1.5 g	10
Promethazine Hydrochloride Injection B.P.	Ampoule, 50 mg in 2 mL	10
Terbutaline Sulphate B.P.	Injection, 100 micrograms in 1 mL amp	5
or		
Terbutaline Sulphate B.P.	Injection, 500 micrograms in 1 mL amp	5
Tetanus Vaccine, Adsorbed B.P.	Injection, 0.5 mL amp	10
Verapamil Hydrochloride Injection B.P.	Ampoule, 5 mg in 2 mL	5

Dated this 1st day of December 1987.

J. S. DEEBLE
Acting First Assistant Secretary
Health Benefits Division
Delegate of the Minister of State
for Community Services and Health

N.N.—8741741

COMMONWEALTH OF AUSTRALIA

National Health Act 1953

PHARMACEUTICAL BENEFITS DETERMINATION UNDER SUB-SECTION 84C (4A)

I, JOHN STEWART DEEBLE, Acting First Assistant Secretary, Health Benefits Division, Department of Community Services and Health and Delegate of the Minister of State for Community Services and Health, pursuant to sub-section 84C (4A) of the *National Health Act 1953*, hereby make the following Determination:

1. This Determination will come into operation on 1 December 1987.
2. The Determination under sub-section 84C (4A) of the National Health Act made on 26 June 1987 with effect from 1 July 1987 is hereby revoked.
3. Sub-paragraph 84C (4) (e) (ii) of the National Health Act does not apply in relation to any of the pharmaceutical benefits contained in the Schedule to this Determination.

THE SCHEDULE

List of benefits to which the requirement set out in sub-paragraph 84C (4) 9e) (ii) of the Act does not apply

Pharmaceutical Benefit	*Form (strength, type, size, etc.)*
Codeine Phosphate Tablets B.P.	30 mg
Dexamphetamine Tablets B.P.	5 mg
Ergotamine Tartrate B.P. with Caffeine B.P.	Suppositories, compound, 6 (Tasmania only)
Methadone Injection B.P.	Ampoule, 10 mg in 1 mL
Methadone Tablets B.P.	5 mg
	10 mg
Morphine Sulphate B.P. with Tacrine Hydrochloride	Tablet, 30 mg-15 mg
Morphine Sulphate Injection B.P.	Ampoule, 10 mg in 1 mL
	Ampoule, 15 mg in 1 mL
	Ampoule, 30 mg in 1 mL

Pharmaceutical Benefit	*Form (strength, type, size, etc.)*
Morphine Sulphate Tablets B.P.	30 mg
Oxycodone Hydrochloride	Tablet, 5 mg
Oxycodone Pectinate	Suppositories, 30 mg (base), 12
Papaveretum B.P.C. 1973	Ampoule, 20 mg in 1 mL
Papaveretum B.P.C. with Hyoscine Hydrobromide B.P.	Ampoule, 20 mg-400 micrograms in 1 mL
Pethidine Injection B.P.	Ampoule, 50 mg in 1 mL
	Ampoule, 100 mg in 2 mL
Pethidine Tablets B.P.	50 mg

Dated this 1st day of December 1987.

J. S. DEEBLE
Acting First Assistant Secretary
Health Benefits Division
Delegate of the Minister of State for
Community Services and Health

N.N.—8741742

COMMONWEALTH OF AUSTRALIA

Health Insurance Act 1973

STATEMENT UNDER SECTION 106AA

On the twenty-eighth day of April 1986 I, Neal Blewett, Minister of State for Community Services and Health, made a Determination under section 106 of the *Health Insurance Act 1973*, (the Act) in respect of Dr Keith Reye of Morris Street, Gin Gin, Queensland.

Particulars of determination

A copy of the initial Determination is at Attachment A. This Determination was varied by an Order on Review of the Medical Services Review Tribunal, which substituted the following amounts for those specified in the original Determination:

Payable to	*Amount*
	$
Commonwealth of Australia	7 537.50
Medibank Private	968.55
Medical Benefits Fund of Australia Ltd	2 306.45

The Tribunal affirmed the Determination that Dr Reye be counselled.

Reasons for determination

The initial Determination was made by me on the basis of a report made under section 104 of the Act by the Medical Services Committee of Inquiry for the State of Queensland after its inquiry into the practice of Dr Reye.

The Committee was of the opinion that in respect of the patients under reference, certain of the services were excessive, in that they were not reasonably necessary for the adequate medical care of the patients concerned. The Committee arrived at this opinion by referring to the information before it and bringing to bear the knowledge and experience of its members.

Comments

The Government is seriously concerned by the practice of doctors like Dr Reye who provide services which are not reasonably necessary for the adequate medical care of the patients concerned. Excessive services are a drain on public funds and every effort is being made to reduce the magnitude of the problem.

Dated this 26th day of August 1987.

NEAL BLEWETT
Minister of State
for Community Services and Health

N.N.—8741743

COMMONWEALTH OF AUSTRALIA

Health Insurance Act 1973

DETERMINATION UNDER SECTION 106

WHEREAS

(a) The Medical Services Committee of Inquiry for the State of Queensland established under sub-section 80 (1) of the *Health Insurance Act 1973*, has inquired into the matter of the rendering of professional services by Keith Reye, a legally qualified medical practitioner of Morris Street, Gin Gin, in that State, referred to the Committee under section 82 of the Act;

(b) the said Committee, after having conducted a hearing into the abovementioned matter pursuant to section 94 of the Act, has reported to the Minister, under section 104 of the Act, and has expressed the opinion that the services identified in its report and which were rendered by the said Keith Reye were excessive services within the meaning of paragraph 79 (1B) (a) of the Act;

(c) medical benefits within the meaning of paragraph 79 (1B) (d) of the Act in respect of the abovementioned services have been paid to the said Keith Reye or have been paid or are payable to another person or persons;

(d) section 134 (1) of the *Health Legislation Amendment Act 1983* continued the operation of paragraph 79 (1B) (d) in relation to any matter arising out of, or relevant to, the rendering of a professional service or a medical service before 1 February 1984 notwithstanding the omission of that paragraph by section 51 of the Act;

(e) Medicare benefits within the meaning of sub-section 3 (1) of the Act in respect of the abovementioned services have been paid or are payable to the said Keith Reye;

(f) the services in respect of 31 patients included in the reference to the Committee were rendered before 1 February 1984;

(g) the services in respect of 1 patient included in the reference to the Committee were rendered on or after 1 February 1984;

(h) the said Committee has made recommendations pursuant to paragraphs 105 (2) (ca), 105 (2) (e) and 105 (2) (f) of the Act; and

(i) sub-section 106 (1) of the Act provides that the Minister may make a determination in writing in accordance with the said Committee's recommendations.

Now therefore I, NEAL BLEWETT, Minister of State for Health, hereby determine that, in accordance with the said Committee's recommendations:

(i) under paragraph 105 (2) (ca) of the Act, the said Keith Reye be counselled;

(ii) under paragraph 105 (2) (e) of the Act, the amount of Medicare benefits referred to in (e) herein specified at (iv) hereunder, cease to be payable;

(iii) under paragraph 105 (2) (f) of the Act, the amount of medical benefits referred to in paragraph (c) herein be payable by the said Keithy Reye in the case of an amount of medical benefits paid or payable by the Commonwealth of Australia, to the Commonwealth of Australia, or in the case of an amount of medical benefits paid or payable by a registered organisation, to that organisation, the total amounts of medical benefits so payable by the said Keith Reye being as specified hereunder:

Payable to	*Amount*
	$
Commonwealth of Australia	7 570.90
Medibank Private	985.25
Medical Benefits Fund of Australia Ltd	2 306.45
Total	10 862.60

(iv) Amount of Medicare benefit ceasing to be payable: $408.90.

Dated this 28th day of April 1986.

NEAL BLEWETT
Minister of State for Health

N.N.—8741744

COMMONWEALTH OF AUSTRALIA

Health Insurance Act 1973

APPROVAL UNDER SUBSECTION 23DB(1)

I, NEAL BLEWETT, Minister of State for Community Services and Health, pursuant to subsection 23DB(1) of the *Health Insurance Act 1973*, hereby approve the form of undertaking set out in the Schedule to be the form of undertaking to be given by persons who are seeking to become approved pathology practitioners, with effect from 28 May 1987.

Dated this 26th day of November 1987.

NEAL BLEWETT
Minister of State
for Community Services and Health

SCHEDULE

COMMONWEALTH OF AUSTRALIA

HEALTH INSURANCE ACT 1973

APPROVED PATHOLOGY PRACTITIONER UNDERTAKING

For the purposes of section 23DC of the Health Insurance Act 1973, I,

_____
(FULL NAME)

of _____

_____
(ADDRESS FOR CORRESPONDENCE)

a medical practitioner who wishes to become an approved pathology practitioner, hereby give the following undertaking to the Minister for Health for and on behalf of the Commonwealth of Australia.

Dated

_____
(SIGNATURE OF APPLICANT)

In the presence of: _____ (signature)

_____ (full name)

_____ (address)

_____

APPROVED PATHOLOGY PRACTITIONER UNDERTAKING

CONTENTS

PART 1 - PERSONAL SUPERVISION

1. Subject to clause 2, I undertake that where a service is rendered on my behalf, I will accept personal responsibility for the rendering of that service under the following conditions of personal supervision -

(a) Where a service is rendered on my behalf, I must usually be physically available in the laboratory during the rendering of that service.

(b) I may be absent from the laboratory for brief periods where the absence is due to illness or other personal exigency, or involves activities which, in accordance with normal and accepted practice, relate to the provision of services by that laboratory. If such an absence occurs, and it does not exceed 7 consecutive days, then I will be regarded as continuing to personally supervise the rendering of services.

(c) Where I am absent from the laboratory for more than 7 consecutive days, I must arrange for another approved pathology practitioner to personally supervise the rendering of services in the laboratory which would otherwise be rendered by me or on my behalf. Where such an arrangement is made, then I will be regarded as continuing to personally supervise the rendering of services.

(d) For the purposes of the Health Insurance Act, services will not be regarded as being rendered by me or on my behalf during any absence, for any reason, which occurs after I have already been absent for a total of 14 working days in a calendar month.

(e) If a service is being rendered on my behalf outside the normal hours of operation of the laboratory, I must be able to be contacted at the time that the service is being rendered by the person who is rendering the service. If required, I must be able to be physically present at the laboratory during the rendering of the service.

(f) If a service is being rendered on my behalf by a person who is not;-

(i) a medical practitioner;

(ii) a scientist; or

(iii) a person having special qualifications or skills relevant to the service being rendered;

and no person in the above groups is physically present in the laboratory, I must be physically present and closely supervise the rendering of the service.

(g) I accept responsibility for taking all reasonable steps to ensure that in regard to services rendered by me or on my behalf:-

(i) all persons who render services are adequately trained;

(ii) all services which are to be rendered in the laboratory are allocated to persons with appropriate qualifications and experience to render the services;

(iii) the methods and procedures in operation in the laboratory for the purpose of rendering services are in accordance with proper and correct practices;

(iv) for services rendered, proper quality control methods are established and reviewed to ensure their reliability and effectiveness; and

(v) results of services and tests rendered are accurately recorded and reported.

2. Where services are to be rendered on my behalf in a laboratory -

(a) where the Minister has declared, by notice in writing, that the laboratory is located in an isolated area (as defined in the principles for the approval of premises as an accredited pathology laboratory), or that the nature of the service would preclude it from being rendered by another approved pathology practitioner; or

(b) which is in category 3 or 4 of the categories of accreditation and which is located in an area in which the personal supervision of pathology services is substantially restricted by reason of its distance or remoteness from a laboratory in which the requirements of personal supervision in clause 1 can be met;

I undertake to take all reasonable measures to ensure that the service is rendered under the supervision of the person designated in the category of accreditation of that laboratory to supervise the rendering of the service.

3. I understand that, in relation to a laboratory which is specified in paragraph 2(b), the provisions of clause 2 will only apply for a period of 12 months after the commencement of section 23DB of the Health Insurance Act, and that after that time the provisions of clause 1 will apply to me.

PART 2 - AGREEMENTS AND ARRANGEMENTS

4. Where services are rendered by me or on my behalf in an accredited pathology laboratory, and I am not the proprietor, or a proprietor, of that laboratory, I undertake:-

   (a) that I will not render services in that laboratory unless I have made a written agreement with the proprietor, or proprietors, of that laboratory which does not prevent me from complying fully with this undertaking and which specifies:-

      (i) the basis of the remuneration of myself and the proprietor, or proprietors, of the laboratory arising out of services rendered by me or on my behalf; and

      (ii) the agreement in respect of the use by me or on my behalf of the laboratory, staff, equipment and other facilities, goods or services provided by the proprietor or proprietors;

   (b) that I will not make any agreement of any type with a proprietor who is an approved pathology authority which would be inconsistent with, or would prevent that authority from discharging, the responsibilities contained in the undertaking given by the authority and accepted by the Minister; and

   (c) that I will not make any agreement of any type with the proprietor, or a proprietor, of the laboratory that provides any inducement, by way of financial or other benefit, or that provides for any disadvantage to me, in order to encourage me to render excessive services for the purpose of attracting the payment of medicare benefit.

PART 3 - MULTIPLE PATHOLOGY SERVICES

5. I undertake to render, or have rendered on my behalf, or to request, two or more services in relation to one person so as to cause the least possible financial imposition on the Commonwealth. I also undertake not to enter into any arrangement, or engage in any conduct, which will have the result of increasing the least possible financial imposition on the Commonwealth in relation to two or more services rendered in relation to one person.

6. Under clause 5 I undertake to render services, or to have them rendered on my behalf, in a manner which ensures that the medicare benefit payable in relation to the services is the minimum amount payable in the circumstances.

7. If, in relation to two or more services rendered by me or on my behalf in relation to one person I am aware that:-

(a) a request or requests for those services could reasonably be made solely to me and solely on the one day; or

(b) I could reasonably determine on the one day those services to be necessary; or

(c) I receive a request or requests for those services, and I could reasonably render them without the need to make a request or requests to any other approved pathology practitioner to render one or more of those services,

then I undertake to issue an account or receipt for fees, or make an agreement under section 20A of the Health Insurance Act, or cause or permit any person to issue an account or receipt for fees as if whichever of those circumstances is relevant had actually taken place.

PART 4 - EXCESSIVE PATHOLOGY SERVICES

8. I undertake that I will take all reasonable measures to avoid the provision of excessive pathology services.

PART 5 - ACCOUNTS, RECEIPTS AND ASSIGNMENT OF MEDICARE BENEFIT

9. I undertake that I will not:-

(a) issue an account or receipt for fees, or make an agreement under section 20A of the Health Insurance Act; or

(b) knowingly cause or permit any person to issue an account or receipt for fees,

in relation to a service rendered by me or on my behalf unless -

(c) I have personally rendered the service or personally supervised the rendering of the service; and

(d) the service is either:-

(i) a pathologist - determinable service which I have determined to be necessary; or

(ii) rendered pursuant to an unambiguous request or confirmation of request validly made to me for the rendering of the service and which is capable of interpretation in terms of

generally-accepted medical terminology or are in accordance with abbreviations listed in the Medicare Benefits Schedule Book; and

(e) the service was rendered using a specimen which permitted an accurate result to be obtained; and

(f) the service is rendered in an accredited pathology laboratory; and

(g) I have complied with the instructions, restrictions and limitations which apply in relation to groups of tests or services which are set out in the Medicare Benefits Schedule Book; and

(h) the account or receipt includes all particulars required to be provided by sub-section 19(6) of the Health Insurance Act.

10. I undertake that I will not issue an account or receipt for fees, or make an agreement under section 20A of the Health Insurance Act, that would permit a person to claim a medicare benefit when I am aware, or could reasonably be expected to be aware, that no medicare benefit is payable in relation to a procedure that has been performed by me or on my behalf because of:-

(a) the nature of the procedure; or

(b) the clinical circumstances in which the procedure is performed,

and I also undertake that if I am requested to perform such a procedure, I shall inform the patient that no medicare benefit is payable.

PART 6 - ADVERTISING

11. I undertake:-

(a) that I will not make any statement, as advertising or in any other form; and

(b) that I will take all reasonable measures to prevent any other person from making any statement, as advertising or in any other form,

explaining or referring to the services which may be rendered by me or on my behalf where the sole or main purpose of such a statement is to promote the requesting of excessive pathology services from any accredited pathology laboratory in which services are rendered by me or on my behalf.

12. I undertake:-

(a) that I will not publish, provide, distribute or make available any document; and

(b) that I will take all reasonable measures to prevent any other person from publishing, providing, distributing or making available any document,

which contains, provides or invites the supply of a pathology request form unless that document has been submitted to, and approved by, the Health Insurance Commission.

PART 7 - SUPPLY OF INFORMATION

13. I undertake that if any of the following circumstances takes place, or if I am aware that any of the following circumstances will take place, I will notify the Minister of the circumstance within 28 days of it taking place or my becoming aware that it will take place (whichever comes first):-

(a) there is a change in my name;

(b) there is a change in the address which I have given at the front of this undertaking;

(c) there is a change in my registration or licensing as a medical practitioner;

(d) there is a change in the name or address of any accredited pathology laboratory where services are, or will be, rendered by me or on my behalf;

(e) I begin, or intend to begin, to render services, or have then rendered on my behalf, under a business arrangement by which a relevant person will derive, or can reasonally be expected to derive, a financial benefit;

(f) I begin, or intend to begin, to render services, or have them rendered on my behalf, as the employee of a relevant person; or

(g) I enter into a position to control a company which is an approved pathology authority, and that approved pathology authority is a relevant person.

14. I undertake that if an officer makes a written request to me to provide any information, specified in the request, on any matter relevant to the acceptance or the continuation of the acceptance of this undertaking, or of any previous pathology undertaking which I have given, then I will provide that information in writing not later than 28 days after the day on which I received the request.

PART 8 - OFFENCES

15. A relevant offence, in relation to this undertaking, is:-

    (a) an offence against sub-section 23DP(1), 23DP(3), 128A(1), 128A(2), 128B(1). 128B(2), 129(2A), 129AA(1), 129AAA(1), 129AAA(2), 129AAA(3) or 129AAA(4) of the Health Insurance Act; or

    (b) an offence against section 6, 7 or 7A or paragraph 86(1)(a) of the Crimes Act 1914, provided that that offence relates to an offence specified in sub-clause 15(a) of this undertaking.

    Copies of those provisions are attached.

16. I undertake not to take any action that would constitute a relevant offence.

PART 9 - PERSONS ACTING ON MY BEHALF

17. Where a person acts on my behalf, or on behalf of a partnership or a body corporate of which I am a partner, member, director or other official or employee:-

    (a) whether by way of a contract of employment or otherwise; and

    (b) in relation to a matter in relation to which this undertaking is given,

    I undertake that I will take all reasonable measures to ensure that that person acts, in relation to that matter, as if that person had given this undertaking in respect of that matter.

PART 10 - NOTICES

18. I understand that by undertaking to accept the conditions imposed by this undertaking in relation to the giving of notices, the following conditions will apply:-

    (a) the Minister, or an officer, will give me any notice, request or other communication required by or for the purposes of this undertaking:-

        (i) in writing (including the use of telex, facsimile or similar methods);

        (ii) signed by the Minister or the officer (personally or by reproduction); and

(iii) delivered or posted to the address which I have given at the front of this undertaking (or any subsequent address notified under sub-clause 13(b));

(b) I will give the Minister, or an officer, any notice, request or other communication required by or for the purposes of this undertaking:-

(i) in writing (including the use of telex, facsimile or similar methods);

(ii) signed by me or on my behalf (for which I will accept personal responsibility), personally or by reproduction; and

(iii) delivered or posted to the Office of the Medical Director, Health Insurance Commission, at its postal address in the Australian Capital Territory; and

(c) unless the contrary is proved, any notice, request or other communication required by or for the purposes of this undertaking:-

(i) from the Minister, from an officer or from me; and

(ii) which is prepared, addressed and posted in accordance with sub-clause 18(a) or 18(b),

will be presumed to have been received by the addressee at the time at which it would have been delivered in the normal course of the postal service.

19. I undertake that I will accept the conditions imposed by this undertaking in relation to the giving of notices.

PART 11 - DEFINITIONS

20. In this undertaking:-

(a) "officer" means:-

(i) an officer of the Department of Health;

(ii) a member of the Health Insurance Commission; or

(iii) a member of the staff of the Health Insurance Commission who is engaged pursuant to sub-section 28(1) of the Health Insurance Commission Act 1973;

(b) "relevant person" means:-

(i) a practitioner who has been disqualified or otherwise barred from practice; or

(ii) any person who has been convicted of a relevant offence specified in clause 15;

(c) "service" means a pathology service to which an item in the pathology services table relates, and in respect of which medicare benefit has become, or may become, payable; and

(d) "the Minister" means the Minister of State of the Commonwealth for the time being administering the Health Insurance Act 1973, and includes any Minister of State of the Commonwealth authorised to act for or on behalf of the Minister.

N.N.—8741745

COMMONWEALTH OF AUSTRALIA

Health Insurance Act 1973

APPROVAL UNDER SUB-SECTION 23DB (1)

I, NEAL BLEWETT, Minister of State for Community Services and Health, pursuant to sub-section 23DB (1) of the *Health Insurance Act 1973*, hereby approve the form of undertaking set out in the Schedule to be the form of undertaking to be given by persons who are seeking to become approved pathology authorities, with effect from 28 May 1987.

Dated this 26th day of November 1987.

NEAL BLEWETT
Minister of State
for Community Services and Health

SCHEDULE

COMMONWEALTH OF AUSTRALIA

HEALTH INSURANCE ACT 1973

APPROVED PATHOLOGY AUTHORITY UNDERTAKING

PLEASE COMPLETE THIS SECTION IF YOU ARE SEEKING APPROVAL ON BEHALF OF YOURSELF ONLY, AND PLEASE ATTACH A LIST OF THE LABORATORIES COVERED BY THIS APPLICATION

For the purposes of section 23DB of the Health Insurance Act 1973, I, _____
(FULL NAME)

of _____

_____
(ADDRESS FOR CORRESPONDENCE)

a person who is seeking to become an approved pathology authority (referred to as "the authority') hereby give the following undertaking to the Minister for Health for and on behalf of the Commonwealth of Australia.

Dated

_____
(SIGNATURE OF APPLICANT)

In the presence of: _____
(SIGNATURE OF WITNESS PERSONALLY KNOWN TO THE APPLICANT)

_____
(FULL NAME)

_____
(ADDRESS)

_____

COMMONWEALTH OF AUSTRALIA

HEALTH INSURANCE ACT 1973

APPROVED PATHOLOGY AUTHORITY UNDERTAKING

PLEASE COMPLETE THIS SECTION IF YOU ARE SEEKING APPROVAL ON BEHALF OF A BODY CORPORATE, AND PLEASE ATTACH A LIST OF THE LABORATORIES COVERED BY THIS APPLICATION

THIS SECTION IS TO BE COMPLETED BY 2 OFFICERS OR OFFICE HOLDERS OF THE BODY CORPORATE

For the purposes of section 23DF of the Health Insurance Act 1973, we

_____

and _____
(FULL NAMES)

being properly authorised to represent and act on behalf of

_____
(NAME OF BODY CORPORATE INCLUDING TRADING NAME)

_____

_____
(ADDRESS FOR CORRESPONDENCE)

a body corporate which is seeking to become an approved pathology authority (referred to as "the authority") hereby give, on behalf of the body corporate, the following undertaking to the Minister for Health for and on behalf of the Commonwealth of Australia.

Dated

_____

_____
(SIGNATURES OF REPRESENTATIVES)

(SEAL OF THE BODY CORPORATE)

COMMONWEALTH OF AUSTRALIA

HEALTH INSURANCE ACT 1973

APPROVED PATHOLOGY AUTHORITY UNDERTAKING

COMPLETE THIS SECTION IF YOU ARE SEEKING APPROVAL ON BEHALF OF A STATE OF TERRITORY GOVERNMENT OR OTHER PUBLIC BODY, AND PLEASE ATTACH A LIST OF THE LABORATORIES COVERED BY THIS APPLICATION

THIS SECTION IS TO BE COMPLETED BY THE RELEVANT MINISTER, THE RELEVANT DEPARTMENT HEAD OR A PERSON AUTHORISED BY EITHER OF THOSE PERSONS

For the purposes of section 23DF of the Health Insurance Act 1973, I,

_____
(FULL NAME)

of _____
(ADDRESS)

being _____
(POSITION)

on behalf of _____
(STATE, TERRITORY OR OTHER PUBLIC BODY)

a State, Territory or public body which is seeking to become on approved pathology authority (referred to as "the authority") hereby give, on behalf of that State, Territory or public body, the following undertaking to the Minister for Health for and on behalf of the Commonwealth of Australia

Dated

_____
(SIGNATURE OF REPRESENTATIVE)

In the presence of: _____
(SIGNATURE OF WITNESS)

_____
(FULL NAME)

_____
(POSITION)

COMMONWEALTH OF AUSTRALIA

HEALTH INSURANCE ACT 1973

APPROVED PATHOLOGY AUTHORITY UNDERTAKING

PLEASE COMPLETE THIS SECTION IF YOU ARE SEEKING APPROVAL AS A PARTNERSHIP, AND PLEASE ATTACH A LIST OF THE LABORATORIES COVERED BY THIS APPLICATION

For the purposes of section 23DF of the Health Insurance Act 1973, we

_____

_____

_____

_____

(FULL NAMES)

being partners in

_____

(NAME OF PARTNERSHIP)

which is seeking to become an approved pathology authority (referred to as "the authority"), hereby give the following undertaking to the Minister for Health for and on behalf of the Commonwealth of Australia.

Dated

_____

_____

_____

_____

(SIGNATURES OF PARTNERS)

APPROVED PATHOLOGY AUTHORITY UNDERTAKING

CONTENTS

PART 1 - AGREEMENTS AND ARRANGEMENTS

1 Where-

(a) the authority is the proprietor, or a proprietor, of an accredited pathology laboratory or laboratories; and

(b) services are to be rendered in that laboratory by or on behalf of an approved pathology practitioner,

the authority undertakes -

(c) that it will not cause or permit any service to be rendered in that laboratory by or on behalf of that approved pathology practitioner unless it has made a written agreement with the approved pathology practitioner which does not prevent the authority from complying fully with this undertaking and which specifies -

(i) the basis of the remuneration of the authority and the approved pathology practitioner arising out of services rendered by or on behalf of the approved pathology practitioner; and

(ii) the agreement in respect of the use by or on behalf of the approved pathology practitioner of the laboratory, staff, equipment and other facilities, goods or services provided by the authority;

(d) that it will not make any agreement of any type with the approved pathology practitioner which would be inconsistent with, or would prevent the approved pathology practitioner from discharging, the responsibilities contained in the undertaking given by the approved pathology practitioner and accepted by the Minister; and

(e) that it will not make any agreement of any type with the approved pathology practitioner or any other person that provides any inducement, by way of financial or other benefit, or that provides for any disadvantage to the approved pathology practitioner, in order to encourage the approved practitioner to render excessive services for the purpose of attracting the payment of medicare benefit.

PART 2 - RENDERING OF PATHOLOGY SERVICES

2 The authority undertakes that it will not cause or permit a service to be rendered in a laboratory unless the conditions specified in sub-section 16A(2) and sub-section 16A(3) of the Health Insurance Act, being those conditions that must be satisfied before medicare benefit would be payable in respect of that service, are satisfied in respect of that service, and the authority undertakes that it will specifically ensure that -

(a) the service is rendered -

(i) by an approved pathology practitioner (who is not a disqualified practitioner in relation to a service); or

(ii) under the personal supervision of an approved pathology practitioner (who is not a disqualified practitioner in relation to a service) who exercises a reasonable level of personal control over the rendering of the service, and who accepts personal responsibility for the rendering of the service;

(b) the service is either -

(i) a pathologist - determinable service which the approved pathology practitioner has determined to be necessary; or

(ii) rendered pursuant to an unambiguous request or confirmation of a request validly made to the approved pathology practitioner for the rendering of the service and which is capable of interpretation in terms of generally-accepted medical terminology or are in accordance with abbreviations listed in the Medicare Benefits Schedule Book; and

(c) the service is rendered in an accredited pathology laboratory.

PART 3 - MULTIPLE PATHOLOGY SERVICES

3 The authority undertakes to cause an employed practitioner to render, or have rendered on his or her behalf, two or more services in relation to one person so as to cause the least possible financial imposition on the Commonwealth. The authority also undertakes not to enter into any arrangement, or engage in any conduct, which will have the result of increasing the least possible financial imposition on the Commonwealth in relation to two or more services rendered in relation to one person.

4 Under clause 3, the authority undertakes to cause an employed practitioner to render services, or have them rendered, in a manner which ensures that the medicare benefit payable in respect of those services is the minimum amount payable in the circumstances.

5 If, in relation to two or more services rendered in relation to one person, the authority is aware that - -

(a) a request or requests for those services could reasonably be made solely to the employed practitioner and solely on the one day; or

(b) the employed practitioner could reasonably determine, on the one day, those services to be necessary; or

(c) the employed practitioner receives a request or requests for those services, and the employed practitioner could reasonably render them without the need to make a request or requests to any other approved pathology practitioner to render one or more of those services,

then the authority undertakes to cause an account or receipt for fees to be issued, or an agreement under section 20A of the Health Insurance Act to be made, as if whichever of those circumstances is relevant had actually taken place.

PART 4 - EXCESSIVE PATHOLOGY SERVICES

6 The authority undertakes that it will take all reasonable measures to avoid the provision of excessive pathology services.

PART 5 - ACCOUNTS, RECEIPTS AND ASSIGNMENT OF MEDICARE BENEFIT IN RELATION TO EMPLOYED PRACTITIONERS

7 The authority undertakes that it will not cause or permit any person to issue an account or a receipt for fees, or make an agreement under section 20A of the Health Insurance Act, in relation to a service rendered by or on behalf of an employed practitioner unless -

(a) the employed practitioner has personally rendered or personally supervised the rendering of the service;

(b) the service is either -

(i) a pathologist - determinable service which the employed practitioner has determined to be necessary; or

(ii) rendered pursuant to an unambiguous request or confirmation of a request validly made to the

employed practitioner for the rendering of the service and which is capable of interpretation in terms of generally-accepted medical terminology or are in accordance with abbreviations listed in the Medicare Benefits Schedule Book; and

(c) the service was rendered using a specimen which permitted an accurate result to be obtained;

(d) the service is rendered in an accredited pathology laboratory;

(e) the employed practitioner has complied with the instructions, restrictions and limitations which apply in relation to groups of tests or services which are set out in the Medicare Benefits Schedule Book; and

(f) the account or receipt includes all particulars required to be provided by sub-section 19(6) of the Health Insurance Act.

8 The authority undertakes that it will not cause or permit any person to issue an account or receipt for fees, or make an agreement under section 20A of the Health Insurance Act, that would permit a person to claim a medicare benefit when the authority, or any person acting on behalf of the authority is aware, or could reasonably be expected to be aware, that no medicare benefit is payable in relation to a procedure that has been performed by or an behalf of an employed practitioner because of -

(a) the nature of the procedure; or

(b) the clinical circumstances in which the procedure is performed,

and the authority also undertakes that it will take all reasonable measures to cause patients to be informed that no medicare benefit is payable in relation to such procedures.

PART 6 - ACCOUNTS FOR SERVICES RENDERED BY EMPLOYED PRACTITIONERS

9 The authority undertakes that where a service has been rendered by or on behalf of an employed practitioner or a partner, the authority will not cause or permit -

(a) an account for fees in relation to that service to be issued;

(b) a receipt for fees in relation to that service to be given;

(c) an agreement in accordance with section 20A of the Health Insurance Act in relation to medicare benefit payable in relation to that service to be made; or

(d) an assignment in accordance with section 20A of the Health Insurance Act in relation to medicare benefit payable in relation to that service to be accepted,

except by or on behalf of that employed practitioner or that partner.

PART 7 - REQUESTS FOR SERVICES

10 The authority undertakes that where a request for a service, being a request of a kind referred to in sub-section 23DK(1) of the Health Insurance Act, is made to an employed practitioner and, pursuant to that request, that service is rendered by or on behalf of that practitioner in the course of that employment, the authority will take all reasonable measures to ensure that the practitioner retains, in accordance with that sub-section, the written request, or confirmation of the request, for that service.

(11) The authority undertakes that where a request by a treating practitioner for a service, being a request of a kind referred to in paragraph 23DK(2)(a) of the Health Insurance Act, is made to an employed practitioner and, in the course of that employment, that employed practitioner makes a request to another approved pathology practitioner for that service, the authority will take all reasonable measures to ensure that the employed practitioner retains, in accordance with sub-section 23DK(2) of the Health Insurance Act, the written request, or confirmation of the request, for that service made by that treating practitioner.

(12) The authority undertakes that where an employed practitioner is requested, under sub-section 23DK(3) of the Health Insurance Act, to produce a written request, or written confirmation of the request, for a service, being a request made to that practitioner in the course of that employment, the authority will take all reasonable measures to ensure that the practitioner produces, in accordance with sub-section 23DK(3), the written request, or confirmation of the request, for that service.

(13) The authority undertakes that it will take all reasonable measures to ensure that each of its employed practitioners confirms in writing, in accordance with sub-section 23DK(6) of the Health Insurance Act, any request of a kind referred to in that sub-section that is made by that practitioner in the course of that employment.

PART 8 - NOTICE OF MATTERS AFFECTING APPROVAL OF PREMISES

14 The authority undertakes that it will notify the Chief Commonwealth Medical Officer if -

(a) where a laboratory was a State accredited laboratory when the Minister approved it as an accredited pathology laboratory under sub-section 23DN(1) of the Health Insurance Act - the laboratory ceases to be a State accredited laboratory; and

(b) in any other case - a laboratory ceases to comply with the standards adopted by the National Pathology Accreditation Advisory Council and which are applicable to that laboratory,

and the authority also undertakes that it will make such notification in writing not later than 28 days after the day on which the appropriate event occurs.

PART 9 - INSPECTION OF PREMISES

15 The authority undertakes that it will, at any reasonable time, permit a person who -

(a) is authorised by the Chief Commonwealth Medical Officer to enter and inspect a laboratory of the authority; and

(b) produces evidence of being so authorised to the authority,

to-

(c) enter and inspect the laboratory;

(d) inspect any equipment used in relation to the rendering of services in the laboratory;

(e) inspect any process in the rendering of services in the laboratory;

(f) inspect documents and other records related to staffing, supervision and the rendering of services in the laboratory; or

(g) make and retain copies of, or take and retain extracts from, any such documents or records with proper regard for individual patient confidentiality.

16 The authority undertakes that it will provide an authorised person referred to in clause 15 with all reasonable facilities and assistance for the effective exercise of the powers referred to in clause 15.

PART 10 - OFFENCES

17 A relevant offence, in relation to this undertaking, is -

(a) an offence against sub-section 128A(1), 128A(2), 128B(1), 128B(2), 129(2), or paragraph 129AA(1)(a) or 129AA(1)(aa) of the Health Insurance Act; or

(b) an offence against section 6,7 or 7A or paragraph 86(1)(a) of the Crimes Act 1914, provided that that offence relates to an offence specified in sub-clause 17(a) of this undertaking.

Copies of those provisions are provided.

18 The authority undertakes not to take any action that would constitute a relevant offence.

PART 11 - SUPPLY OF INFORMATION

18 The authority undertakes that if any of the following circumstances takes place, or if the authority is aware that any of the following circumstances will take place, the authority will notify the Minister of the circumstance within 28 days of it taking place or the authority becoming aware that it will take place (whichever comes first) -

(a) there is a change in the name of the authority;

(b) there is a change in the address which the authority has given at the front of this undertaking;

(c) there is a change in the address of any laboratory of which the authority is the proprietor or a proprietor;

(d) where the authority is a body corporate, there is change in its directors, principal office bearers or principal shareholders;

(e) whether the authority has become a relevant person;

(f) whether one or more of the persons who derive, who can reasonably be expected to derive (whether directly or indirectly) financial benefit from the conduct, by the authority, of a business of rendering service is or has become a relevant person;

(g) whether the authority -

(i) is or has had a financial association with a relevant person; or

(ii) is or has been in a position to control the operations of a body corporate which is, or has been, an approved pathology authority and which is a relevant person; or

(h) where the authority is a body corporate, whether any officer or office holder of the body corporate, or any person who is in a position to control the body corporate -

(i) is or has had a financial association with a relevant person; or

(ii) is or has been in a position to control the operations of a body corporate which is, or has been, an approved pathology authority and which is a relevant person.

19 The authority undertakes that if an officer makes a written request to the authority to provide any information, specified in the request, on any matter relevant to the acceptance or the continuation of the acceptance of this undertaking, or of any previous pathology undertaking which the authority has given, then the authority will provide that information in writing not later than 28 days after the day on which the request was received.

PART 12 - PERSONS ACTING ON BEHALF OF THE AUTHORITY

20 The authority undertakes that where -

(a) whether by way of contract of employment or otherwise; and

(b) in relation to a matter in relation to which this undertaking is given,

any person -

(c) acts on behalf of the authority;

(d) is in a position to influence or control the activities of the authority;

(e) where the authority is a natural person, acts on behalf of a partnership or body corporate of which the authority is a partner, officer or an office holder; or

(f) where the authority is a natural person, is in a position to influence or control the activities of a body corporate or partnership of which the authority is a partner, officer or an office holder,

then the authority will take all reasonable measures to ensure that that person acts, in relation to that matter, as if that person had given the undertaking in respect of that matter.

PART 13 - ADVERTISING

21 The authority undertakes -

(a) that it will not make any statement, as advertising or in any other form; and

(b) that it will take all reasonable measures to prevent any other person from making any statement, as advertising or in any other form,

explaining or referring to the services which may be rendered by or on behalf of the authority where the sole or main purpose of such a statement is to promote the requesting of excessive pathology services from -

(c) any accredited pathology laboratory in which services are rendered by or on behalf of the authority; or

(d) any accredited pathology laboratory of which the authority is the proprietor or a proprietor.

22 The authority undertakes -

(a) that it will not publish, provide, distribute or make available any document; and

(b) that it will take all reasonable measures to prevent any other person from publishing, providing, distributing or making available any document,

which contains, provides or invites the supply of a pathology request form unless that document has been submitted to, and approved by, the Health Insurance Commission.

PART 14 - NOTICES

23 The authority undertakes to accept the following conditions in relation to the giving of notices -

(a) the Minister, or an officer, will give the authority any notice, request or other communication required by or for the purpose of this undertaking -

(i) in writing (including the use of telex, facsimile or similar methods);

(ii) signed by the Minister or the officer (personally or by reproduction); and

(iii) delivered or posted to the address which the authority has given for the purpose of correspondence (or any subsequent address notified under sub-clause 18(6));

(b) the authority will give the Minister, or an officer, any notice, request or other communication required by or for the purposes of this undertaking -

(i) in writing (including the use of telex, facsimile or similar methods);

(ii) signed by the authority, or signed on behalf of the authority (for which the authority accepts personal responsibility) personally or by reproduction; and

(iii) delivered or posted to the office of the Medical Director, Health Insurance Commission, at its postal address in the Australian Capital Territory; and

(c) unless the contrary is proved, any notice, request or other communication required by or for the purposes of this undertaking -

(i) from the Minister, from an officer or from the authority; and

(ii) which is prepared, addressed and posted in accordance into sub-clause 23(a) or 23(b),

will be presumed to have been received by the addressee at the time at which it would have been delivered in the normal course of the postal service.

PART 15 - DEFINITIONS

24 In this undertaking -

(a) "Chief Commonwealth Medical Officer" means the person for the time being occupying, or performing the duties of, the office of Chief Commonwealth Medical Officer in the Department of Health;

(b) "disqualified practitioner", in relation to a service, means a practitioner in relation to whom -

(i) a determination under sub-section 124F(2) of the Health Insurance Act is in effect, being a determination that the practitioner is disqualified in respect of the provision of professional services of a kind that includes that service;

(ii) a determination under paragraph 124F(2)(e) of the Health Insurance Act is in effect;

(iii) a determination of a type referred to in sub-paragraph 124FC(1)(e)(v) of the Health Insurance Act is in effect; or

(iv) a determination of the type referred to in sub-paragraph 124F(1)(e)(vi) of the Health Insurance Act is in effect in respect of services of a type that includes that services,

being a determination particulars of which have been published in the Commonwealth of Australia Gazette;

(c) "employed practitioner" means an approved pathology practitioner employed by the authority;

(d) "laboratory" means an accredited pathology laboratory of which the authority is the proprietor, or a proprietor;

(e) "National Pathology Accreditation Advisory Council" means the body of that name established by order made pursuant to sub-section 9(1) of the National Health Act 1953;

(f) "officer" means -

(i) an officer of the Department of Health;

(ii) a member of the Health Insurance Commission; or

(iii) a member of the staff of the Health Insurance Commission who is engaged pursuant to sub-section 28(1) of the Health Insurance Commission Act 1973;

(g) "relevant person" means -

(i) a practitioner who has been disqualified or otherwise barred from practice; or

(ii) any person who has been convicted of a relevant offence specified in clause 17;

(h) "service" means a pathology service to which an item in the pathology services table relates, and in respect of which medicare benefit has become, or may become, payable;

(i) "State accredited laboratory" means -

(i) in relation to a laboratory which is situated in New South Wales - a Pathology Laboratory accredited pursuant to the Pathology Laboratories Accreditation Act, 1981 of New South Wales; and

(ii) in relation to a laboratory which is situated in Victoria - an accredited pathology service under the Pathology Services Accreditation Act 1984 of Victoria; and

(j) "the Minister" means the Minister of State of the Commonwealth for the time being administering the Health Insurance Act 1973, and includes any Minister of State for the Commonwealth authorised to act for or an behalf of the Minister.

COMMONWEALTH OF AUSTRALIA

Health Insurance Act 1973

DETERMINATION OF PRINCIPLES FOR THE APPROVAL OF PREMISES AS AN ACCREDITED PATHOLOGY LABORATORY

I, NEAL BLEWETT, Minister of State for Community Services and Health, pursuant to sub-section 23DN (2) of the *Health Insurance Act 1973*, hereby determine that the principles specified in the Schedule shall be the principles to be applied in the approval of premises as an accredited pathology laboratory pursuant to sub-section 23DN (1) of the Act.

Dated this 26th day of November 1987.

NEAL BLEWETT
Minister of State
for Community Services and Health

SCHEDULE

Part 1 - Interpretation

1.1 In this determination, unless the contrary intention appears -

"Act" means the Health Insurance Act 1973;

"agency" means an inspection agency approved pursuant to sub-clause 4.1;

"approval", in relation to a relevant State law, means approval, accreditation or any other similar decision;

"division of pathology" means a division (other than division 9) of the pathology services table prescribed in Schedule 1A to the Act;

"isolated area" means an area in which the efficient provision of pathology services, in one or more divisions of pathology, is substantially restricted by reason of its distance or remoteness from a pathology laboratory in category 1,2, or 3 ;

"National Pathology Accreditation Advisory Council" means the body of that name established by Order made pursuant to sub-section 9(1) of the National Health Act 1953;

"pathologist" means a medical practitioner who, pursuant to a determination made under sub-section 61(3) of the Act, is to be recognised for the purposes of the Act as a specialist in the specialty of pathology;

"premises" includes a part of premises;

"relevant State" means New South Wales or Victoria;

"relevant State law" means -

(i) in relation to premises situated in New South Wales, the Pathology Laboratories Accreditation Act, 1981 of that State; and

(ii) in relation to premises situated in Victoria, the Pathology Services Accreditation Act 1984 of that State;

"Scientist" means a person who possesses one of the following qualifications -

(i) a degree or diploma in science, applied science or medical technology awarded after not less than 3 years full-time study, or an equivalent period of part-time study, in subjects relevant to the field of pathology at a university or other tertiary institution in Australia;

(ii) an associate qualification conferred by the Australian Institute of Medical Technologists prior to 1 December 1973; or

(iii) a qualification which the Minister is satisfied is equivalent to a qualification in paragraph (i) or (ii), and which will enable the person to assist in the rendering of pathology services in the laboratory with which the person is associated;

"Senior Scientist" means a Scientist who possesses one of the following qualification -

(i) a Doctorate of Philosophy in a subject relevant to the field of pathology;

(ii) a Fellowship of the Australian Association of Clinical Biochemists; or

(iii) a qualification which the Minister is satisfied is equivalent to a qualification in paragraph (i) or (ii),

and who has had not less than 10 years full-time experience relevant to the duties of the laboratory with which the person is associated; and

"Standards" means the standards adopted by the National Pathology Accreditation Advisory Council and as in force on the date on which this determination is made.

1.2 In this determination, a reference to supervision in an accredited pathology laboratory shall mean supervision of the rendering of pathology services under the following conditions -

(a) Category 1 Laboratory — A pathologist will usually be present during normal working hours and available for telephone consultation at other times.

In addition appropriately qualified and experienced senior scientific staff shall be present at the laboratory during normal working hours. These staff will have

supervisory responsibilities specifically delegated to them by the pathologist-in-charge.

Work performed at the laboratory outside normal working hours shall be carried out by scientific or technical staff approved to do so by the pathologist-in-charge, having regard to their training and experience.

(b) Category 2 Laboratory

A pathologist or a senior scientist qualified to be in charge will usually be present during normal working hours and will be available for telephone consultation at other times.

In addition, appropriately qualified and experienced senior scientific staff shall be present at the laboratory during normal working hours. These staff will have supervisory responsibilities specifically delegated to them by the pathologist or senior scientist in charge.

Work performed at the laboratory outside normal working hours shall be carried out by scientific, technical or other staff approved to do so by the pathologist or senior scientist in charge, having regard to their training and experience.

(c) Category 3 Laboratory

Where a Category 3 laboratory is an integral part of a Category 1 or 2 laboratory, apart from its geographic location, then it should be regarded for supervision purposes as being part of the Category 1 or 2 laboratory. Otherwise, it should be under the direction and control of a pathologist from a Category 1 or a pathologist or senior scientist from a Category 2 laboratory. In either case the supervisor shall -

(a) exercise a reasonable level of personal control over the rendering of the service; and

(b) have personal responsibility for the proper rendering of the service.

The pathologist or senior scientist under whose direction the Category 3 laboratory operates shall:

(a) approve and be responsible for operational practices and staffing of the laboratory.

(b) be available for immediate consultation on technical and medical issues while in attendance at the laboratory.

(c) regularly review the laboratory's internal and external quality control data and the methodology used, and discuss all aspects of the laboratory's performance with the scientific staff.

(d) exercise a reasonable level of personal control.

(e) be available for telephone consultation or equivalent at other times.

Onsite staff at a Category 3 laboratory shall include a scientist with qualifications and experience relevant to the laboratory's operation. Normally such qualifications and experience would be a Science or Applied Science degree in Biochemistry or Microbiology or Medical Laboratory Science and two years professional experience in a Category 1 or 2 laboratory. Such a person shall be present at the laboratory during normal working hours.

Work performed at the laboratory outside normal working hours shall be carried out by scientific or technical staff approved to do so by the pathologist or senior scientist in charge, having regard to their training and experience.

(d) Category 4 Laboratory — Such laboratories shall not gain full accreditation until they meet the requirements for a Category 1 or 3 laboratory.

For accreditation purposes, a Category 4 laboratory shall have on site during hours of operations a scientist or other person with sufficient qualifications and experience to warrant supervisory responsibilities in respect of the work done by the laboratory.

(e) Category 5 Laboratory — The medical practitioner shall be responsible for the proper performance of tests. The range of tests performed must be approved by the accrediting agency. The medical practitioner will usually be present during normal working hours and available for telephone consultation at other times.

(f) Category 6 Laboratory — The supervisor of a Category 6 laboratory shall be present at all times that tests are performed unless there are medical, scientific or technical support staff, approved by the supervisor whose qualifications and experience are adequate for the work performed at the laboratory. Such support staff will be present at all times while tests are being performed.

Where such support staff are available, the supervisor shall maintain regular contact with the laboratory and be available for consultation at all times.

(g) Category 7 Laboratory — The supervisor of a Category 7 laboratory should be a medical practitioner, pathologist or scientist with experience accepted by the accrediting agency. The supervisor will usually be present during normal working hours and available for telephone consultation at other times.

Staff at the laboratory when the supervisor is not present will include a person with appropriate experience with supervisory responsibilities specifically delegated by the laboratory supervisor.

(h) Category 8 Laboratory — Laboratories which do not fall into any of the categories as defined will require individual assessment and inspection for accreditation to determine if standards, including supervision, are adequate.

Part 2 - Principles of Approval

2.1 Premises shall not be approved as an accredited pathology laboratory unless -

(a) the premises are situated in a relevant State and are the subject of an application for approval in accordance with Part 3;

(b) the premises have been inspected by an agency in accordance with Part 4; or

(c) the premises are eligible to be approved in accordance with Part 5.

2.2 In addition to the provisions of Part 3 or Part 4, premises shall not be approved as an accredited pathology laboratory in accordance with those Parts unless the Minister is satisfied that the premises to which the application relates are operated to comply with the Standards, and in particular that there is, or are, in respect of the premises -

(a) sufficient professional and support staff with adequate training and experience to supervise and conduct the work of the laboratory;

(b) staff who can advise clinicians on the evaluation and interpretation of results of laboratory examinations and the precision and accuracy of methods employed in the laboratory;

(c) sufficient effective space and facilities for the satisfactory provision of the laboratory service;

(d) effective levels of control with respect to health and safety;

(e) procedures in place which ensure that -

(i) all specimens are fully identified and labelled and accompanied by written requests, signed by medical or dental practitioners or other authorised persons;

(ii) all specimens not conforming to (i) or of inadequate quality for the test involved, are rejected and the sender informed;

(iii) adequate techniques are used for the continued correct identification of specimens; and

(iv) specimens are retained by the laboratory for a time appropriate to the nature and origin of those specimens;

(f) equipment which is appropriate to the tests being performed and in good working order;

(g) proper laboratory methods, including methods recommended by the relevant professional organisation in Australia and, in the appropriate work areas, manuals containing all methods and procedures authorised for use in the laboratory;

(h) efficient quality control programs which will ensure that the results provided by the laboratory meet acceptable standards;

(i) a reporting system which ensures that -

(i) reports of results are furnished to requesting persons with a minimum of delay commensurate with good patient care, identifying the laboratory, the patient, the type of specimen, the date and, where appropriate, time of collection, the qualitative and/or quantitative results, units of concentration or activity and reference ranges where appropriate;

(ii) urgent reports are communicated by telephone or the like to the responsible medical or other authorised staff with due care to prevent mistakes;

(iii) reports made under (ii) above are followed by full written reports; and

(j) arrangements to record, in a readily accessible form, results on patient specimens and quality control material.

2.3 In the exercise of powers pursuant to section 23DN, the Minister shall not be under any duty to approve any premises as an accredited pathology laboratory until the Minister is satisfied that the principles in this determination have been complied with.

Part 3 - Relevant State laws

3.1 Where an application is made to the Commonwealth Department of Health for approval of premises situated in a relevant State, the applicant shall provide, at the time that the application is made, evidence (if any) that the premises have been approved pursuant to the relevant State law, including evidence (if any) that such approval has, at the time that the application is made, been suspended or revoked and not restored.

3.2 In deciding whether to approve or refuse to approve premises situated in a relevant State as an accredited pathology laboratory, the Minister shall have regard to the following matters -

(a) whether the applicant has, at any time, applied for approval pursuant to the relevant State law and, if not, the reasons for not so doing;

(b) whether the premises have not been approved pursuant to the relevant State law and, if not, the reasons for that decision;

(c) if the premises have been approved pursuant to the relevant State law, but have subsequently had the approval revoked or suspended and not later restored, the reasons for the revocation or suspensions; and

(d) the provisions of clause 2.2 of this determination.

Part 4 - Inspection by an Agency

4.1 An inspection agency shall not be approved for the purposes of this determination until the inspection agency has entered into a written agreement with the Commonwealth for the inspection of premises for the purpose of approval as an accredited pathology laboratory.

4.2 Premises may be approved as an accredited pathology laboratory where the applicant has, at the time that the application was made, provided evidence that -

(a) the premises have been inspected by an agency, which has reported that the premises comply with the Standards; or

(b) the premises are at the time that the application is made, registered with the National Association of Testing Authorities and the Royal College of Pathologists of Australasia, provided that -

(i) the premises were registered by reason of complying with the Standards; and

(ii) the Minister is satisfied that the premises have, since being registered, complied with the Standards.

4.3 Premises which have been approved pursuant to this Part shall not be approved for a period exceeding 12 months.

Part 5 - Transitional Arrangements

5.1 Notwithstanding any other provision of this determination, premises may be approved as an accredited pathology laboratory where -

(a) the applicant makes an application in accordance with this Part and, at that time, has made arrangements with an agency for the inspection of the premises to determine whether the premises comply with the Standards;

(b) the Minister is satisfied that, in respect of the premises;

(i) there are sufficient professional and support staff, with adequate training and experience, to supervise and conduct the work of the laboratory; and

(ii) the laboratory is enrolled in a relevant external quality assurance program or programs commensurate with the division or divisions of pathology for which the laboratory has sought approval; and

(c) the Minister is satisfied that an applicant would be unreasonably disadvantaged by being required to make a separate application for approval in accordance with Part 3 or Part 4.

5.2 Premises which have been approved pursuant to clause 5.1 shall not be approved for a period exceeding 12 months.

5.3 Where premises have been approved pursuant to clause 5.1, but an inspection by an agency has not been completed at the expiry of the period of approval, the premises may, upon a further application, be approved for a period not exceeding 12 months.

Part 6 - Categories of Accreditation

6.1 Where premises are to be approved as an accredited pathology laboratory, the premises shall not be approved until they have been allocated to a category of accreditation.

6.2 The categories of accreditation are -

(a) CATEGORY 1, being a laboratory in which pathology tests are performed under the full-time supervision of a pathologist.

(b) CATEGORY 2, being a laboratory in which a range of tests within only one division of pathology is performed which is under the full-time supervision of a pathologist who is qualified in that division of pathology or a senior scientist who is qualified in that division of pathology.

(c) CATEGORY 3, being a laboratory in which the range of pathology services provided and the standard of work in the laboratory is under the direction and control of a pathologist or senior scientist employed in an accredited pathology laboratory conforming to the description in category 1 or 2, and in which, where relevant, tests are performed only in the same division of pathology as in the category 2 laboratory.

(d) CATEGORY 4, which is a temporary category dealing with a laboratory of a recognised hospital not being a laboratory falling within category 1, 2 or 3; this category will cease to exist on 1 August 1989.

(e) CATEGORY 5, being a laboratory in which pathology services are provided by or under the supervision of a registered medical practitioner for patients of the medical practitioner or practitioners of whose practice the laboratory is a part.

(f) CATEGORY 6, being a laboratory in which is performed a limited range of pathology services where those services are of a specialised nature and are performed under the supervision of a person having special qualifications or skills in the field of those services.

(g) CATEGORY 7, being a laboratory located in an isolated area in which pathology services are provided under the supervision of a medical practitioner or a scientist.

(h) CATEGORY 8, being a laboratory of a type which does not fall within any other category.

6.3 The Minister shall not be under any duty to allocate premises to a category sought by an applicant.

Part 7 - Miscellaneous

7.1 Where the Minister is not satisfied that premises should be approved as an accredited pathology laboratory, in full or in part, the Minister shall notify the applicant of the intention to refuse the application.

7.2 An applicant to whom sub-clause 7.1 applies may, within 28 days of being notified of the intention of the Minister, provide further information in relation to the application and the Minister shall have regard to such information before a decision is made.

7.3 Where the applicant does not provide information within 28 days, the application shall be refused.

7.4 In the exercise of powers pursuant to section 23DN of the Act, the Minister may obtain such information and advice as the Minister thinks fit, and the Minister may convene a panel of such persons as are appropriate to provide advice on matters referred by the Minister from time to time.

CA03C118 CR202149-7-00S N.N.—8741747

COMMONWEALTH OF AUSTRALIA

National Health Act 1953

PHARMACEUTICAL BENEFITS

DECLARATION UNDER SECTION 85

No. PB 4 of 1987

I, JOHN STEWART DEEBLE, Acting First Assistant Secretary, Health Benefits Division, Department of Community Services and Health and Delegate of the Minister of State for Community Services and Health, pursuant to sub-section 85 (2) of the *National Health Act 1953*, hereby make the following Declaration:

1. This Declaration shall come into effect on 1 December 1987.
2. Declaration No. PB 2 under section 85 of the Act made on 22 July 1987 with effect from 1 August 1987, as amended by Declaration No. PB 3 made on 11 September 1987 with effect from 1 October 1987, is hereby revoked.
3. In this Declaration:

   "the Act" means the *National Health Act 1953*;

   "ready-prepared pharmaceutical benefit" means a drug or medicinal preparation in respect of which there is in force a determination under sub-section 85 (6) of the Act;

   "extemporaneously-prepared pharmaceutical benefit" means a pharmaceutical benefit other than a ready-prepared pharmaceutical benefit.
4. Part VII of the Act applies in relation to each of the drugs and medicinal preparations as are specified in Schedule 1.
5. A medicinal preparation composed of a compound that includes a pharmaceutical benefit specified in column 1 of Schedule 2, other than a compound specified in column 2 of that Schedule opposite to that pharmaceutical benefit, is not a medicinal preparation to which Part VII of the Act applies, unless that pharmaceutical benefit is also specified in Schedule 3, in which case the provisions of paragraphs 7 and 8 apply.
6. Part VII of the Act does not apply in relation to a medicinal preparation composed of a compound that includes a ready-prepared pharmaceutical benefit, other than Water for Injections or a pharmaceutical benefit specified in column 1 of Schedule 2.
7. Part VII of the Act applies in relation to medicinal preparations composed of one or more of the drugs or medicinal preparations specified in Schedule 3.
8. Part VII of the Act applies in relation to medicinal preparations composed of one or more of the drugs or medicinal preparations specified in Schedule 3 with the addition of one or more of the substances specified in Schedule 4.
9. The substances specified in Schedule 4 are additives for the purposes of paragraph 85 (2) (b) of the Act.
10. Part VII of the Act applies in relation to each of the drugs and medicinal preparations as are specified in Schedule 5.
11. The drugs and medicinal preparations specified in Schedule 5 are additional pharmaceutical benefits made available under arrangements provided for by section 100 of the Act.
12. Where circumstances are specified in column 2 of Schedule 1 or Schedule 3 opposite the name of a pharmaceutical benefit specified in column 1 of either of those Schedules, that pharmaceutical benefit is a relevant pharmaceutical benefit for the purposes of section 88A of the Act.
13. Where circumstances are specified in column 2 of Schedule 3 opposite the name of a pharmaceutical benefit specified in column 1 of that Schedule, those circumstances are also specified in relation to any medicinal preparation containing that pharmaceutical benefit.
14. The following circumstances are specified in relation to each relevant pharmaceutical benefit for the purposes of section 88A of the Act:
    (a) Where a class of persons is specified in column 2 of Schedule 1 or Schedule 3—that the pharmaceutical benefit is to be supplied for the treatment of a person included in that class of persons;
    (b) Where a disease or condition is specified in column 2 of Schedule 1 or Schedule 3—
        (i) if sub-paragraph (ii) does not apply—that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in relation to any person; or
        (ii) if the disease or condition is specified in relation to a specified class of persons—that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in a person included in that class of persons;
    (c) Where a purpose is specified in column 2 of Schedule 1 or Schedule 3—that the pharmaceutical benefit is to be supplied for that purpose;
    (d) Where it is specified in column 2 of Schedule 1 or Schedule 3 that the written authority of the Secretary is required—that an application for the written authority of the Secretary in relation to the supply of the pharmaceutical benefit has been made by a medical practitioner and the Secretary has approved the application.
15. Where a medical practitioner makes an application under sub-paragraph 14 (d) and the Secretary approves the application, the Secretary shall record the approval on a numbered authority and—
    (a) where, in the approval, the Secretary requires the medical practitioner to vary the prescription for the supply of the pharmaceutical benefit—return the approval to the medical practitioner; or
    (b) in any other case—return the approval to the medical practitioner or, if the medical practitioner so requests, forward the approval to the person to whom the pharmaceutical benefit is to be supplied.

SCHEDULE 1

Ready-prepared pharmaceutical benefits

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Acetazolamide B.P.	—
Acetazolamide Sodium	—
Acetazolamide Tablets B.P.	—
Acetylcysteine	Bronchiectasis Cystic fibrosis (mucoviscidosis)
Acrylic Resin	Ileostomy or colostomy conditions
Acyclovir	In respect of the eye ointment: Eye infections caused by herpes simplex virus where idoxuridine has proved ineffective In respect of the tablets: With the written authority of the Secretary: Moderate to severe initial genital herpes, confirmed by appropriate microbiological technique, and complicated by severe pain, systemic symptoms, or urinary retention Moderate to severe recurrent genital herpes (more than ten attacks per year), leading to severe psychosexual dysfunction, unresponsive to counselling and lifestyle correction
Adrenaline B.P.	—
Adrenaline Hydrochloride	—
Adrenaline Injection B.P.	—
"Albumaid XP"	Phenylketonuria
"Albumaid XPXT"	Tyrosinaemia
"Alfaré"	With the written authority of the Secretary: Biliary atresia Cystic fibrosis Enterokinase deficiency Intolerance to both milk protein and soya protein Severe diarrhoea of greater than two weeks duration in infants under the age of 4 months
Allopurinol B.P.	—
Allopurinol Tablets B.P.	—
Alprenolol Tablets B.P.	—
Aluminium Hydroxide and Magnesium Carbonate Co-dried Gel	—
Aluminium Hydroxide, Dried B.P.	—
Aluminium Hydroxide, Dried B.P. with Magnesium Hydroxide B.P.	—
Aluminium Hydroxide, Dried B.P. with Magnesium Trisilicate B.P. and Magnesium Hydroxide B.P.	—
Aluminium Hydroxide Mixture B.P.	—
Aluminium Hydroxide Mixture B.P. with Light Kaolin B.P. or Light Kaolin (Natural) B.P.	—
Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P.	—
Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. and Oxethazaine	—
Aluminium Sodium Polyhydroxy Monocarbonate Hexitol Complex	—
Aluminium Sodium Silicate	—
Amantadine Hydrochloride	The treatment of Parkinson's disease caused otherwise than by treatment with a drug
Ambenonium Chloride	—
Amiloride Hydrochloride Tablets B.P.	—
Aminacrine Hydrochloride B.P. 1968	—
Aminoglutethimide	With the written authority of the Secretary: Post-menopausal metastatic breast cancer in patients who have failed to respond adequately to endocrine manipulation Cushing's syndrome

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
"Aminogran Food Supplement"	Phenylketonuria
"Aminogran Mineral Mixture"	Phenylketonuria
Aminophylline B.P.	—
Aminophylline Injection B.P.	—
Aminophylline Tablets B.P.	—
Amiodarone Hydrochloride	With the written authority of the Secretary: For the continuing treatment of severe refractory cardiac arrhythmias where treatment with amiodarone hydrochloride was initiated in a hospital (in-patient or out-patient) For the continuing treatment of a patient who has already received, for more than 6 months, therapy with amiodarone hydrochloride for severe refractory cardiac arrhythmias
Amitriptyline Tablets B.P.	—
Ammonium Chloride B.P.	—
Amoxycillin Capsules B.P.	—
Amoxycillin Sodium	—
Amoxycillin Trihydrate B.P.	—
Amoxycillin Trihydrate B.P. with Potassium Clavulanate	—
Amoxycillin Trihydrate B.P. with Potassium Clavulanate and Purified Water B.P.	—
Amoxycillin Trihydrate B.P. with Purified Water B.P.	—
Amphotericin B.P.	—
Amphotericin Lozenges B.P.	—
Ampicillin Capsules B.P.	—
Ampicillin Sodium B.P.	—
Ampicillin Trihydrate B.P. with Purified Water B.P.	—
Amylobarbitone Sodium B.P.	Epilepsy
Antazoline Phosphate with Naphazoline Hydrochloride	—
Antazoline Sulphate with Naphazoline Nitrate B.P.	—
Aspirin B.P.	—
Aspirin Tablets B.P.	—
Aspirin Tablets, Dispersible B.P.	—
Atenolol	—
Atropine Eye Ointment B.P.	—
Atropine Methonitrate B.P.	—
Atropine Sulphate B.P.	—
Atropine Sulphate Injection B.P.	—
Atropine Sulphate Tablets B.P.	—
Auranofin	—
Aurothioglucose	—
Azathioprine Tablets B.P.	—
Baclofen Tablets B.P.	—
"Banish"	Ileostomy or colostomy conditions
Beclomethasone Dipropionate B.P.	Asthma
Bendrofluazide Tablets B.P.	—
Benzathine Penicillin B.P.	—
Benzathine Penicillin B.P. with Procaine Penicillin B.P., Benzylpenicillin Potassium B.P. and Water for Injections	—
Benzhexol Tablets B.P.	—
Benzocaine B.P. with Adrenaline B.P.	—
Benzoin Tincture, Compound B.P.	Ileostomy or colostomy conditions
Benztropine Injection B.P.	—
Benztropine Tablets B.P.	—
Benzyl Benzoate Application B.P.	—
Benzyl Benzoate B.P.	—
Benzylpenicillin Potassium B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Betamethasone Acetate with Betamethasone Sodium Phosphate B.P.	Alopecia areata For local intra-articular or peri-articular infiltration Granulomata, dermal Keloid Lichen planus hypertrophic Lichen simplex chronicus Lupus erythematosus, chronic discoid Necrobiosis lipoidica Uveitis
Betamethasone Dipropionate	—
Betamethasone Tablets B.P.	—
Betamethasone Valerate B.P.	—
Betamethasone Valerate Cream B.P.	—
Betamethasone Valerate Ointment B.P.	—
Bethanechol Chloride	—
Biperiden Hydrochloride	—
Biperiden Lactate Injection B.P.	—
Bisacodyl B.P.	Any disease or condition in a paraplegic or quadriplegic patient
Bisacodyl Suppositories B.P.	Any disease or condition in a paraplegic or quadriplegic patient For use by patients who are receiving long-term extensive nursing care in hospitals or nursing homes For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved
Bisacodyl Tablets B.P.	Any disease or condition in a paraplegic or quadriplegic patient For use by patients who are receiving long-term extensive nursing care in hospitals or nursing homes For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved
Bismuth Subcitrate	—
Bleomycin Sulphate	Germ cell neoplasms Lymphoma Squamous cell carcinoma
Bromocriptine Mesylate Capsules B.P.	With the written authority of the Secretary: Acromegaly, prior to surgery or radiotherapy or where surgery or radiotherapy is inappropriate Parkinson's disease Pathological hyperprolactinaemia where appropriate surgery or radiotherapy is not indicated or has already been used with incomplete resolution
Bromocriptine Mesylate Tablets B.P.	Urgent suppression of physiological lactation With the written authority of the Secretary: Acromegaly, prior to surgery or radiotherapy or where surgery or radiotherapy is inappropriate Parkinson's disease Pathological hyperprolactinaemia where appropriate surgery or radiotherapy is not indicated or has already been used with incomplete resolution
Bumetanide	—
Busulphan Tablets B.P.	—
Butyl Monoester Polymer with Ethanol B.P.	Ileostomy or colostomy conditions
Butyl Monoester Polymer with Isopropyl Alcohol B.P.	Ileostomy or colostomy conditions
Calciferol Tablets, High-Strength B.P.	Hypocalcaemia Hypoparathyroidism Osteomalacia following gastrectomy, severe steatorrhoea or renal failure Vitamin D-resistant rickets
Calcitonin (Human)—Synthetic	With the written authority of the Secretary: Proven active Paget's disease of bone, or hypercalcaemia, in patients unable to tolerate both pork and salmon calcitonin or who are resistant to treatment with either pork or salmon calcitonin

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Calcitonin (Pork) B.P.	With the written authority of the Secretary: Proven active Paget's disease of bone causing pain or disability Treatment initiated in a hospital (in-patient or out-patient) of hypercalcaemia For the continuation of treatment of patients already established on calcitonin under arrangements provided for by section 100 of the Act
Calcitriol	With the written authority of the Secretary: Hypocalcaemia due to renal disease Hypoparathyroidism Hypophosphataemic rickets Vitamin D-resistant rickets
Calcium Carbonate B.P.	Hypocalcaemia Osteoporosis Proven malabsorption
Calcium Carbonate B.P. with Calcium Lactate-Gluconate	Hypocalcaemia Osteoporosis Proven malabsorption
Calcium Folinate	Antidote to folic acid antagonists
Calcium Glubionate	—
Captopril	Moderate or severe hypertension For the continuing treatment of severe refractory cardiac failure where treatment with captopril was initiated in a hospital (in-patient or out-patient)
Carbachol B.P. 1973	—
Carbamazepine B.P.	—
Carbamazepine Tablets B.P.	—
Carbimazole Tablets B.P.	—
Carmellose Sodium B.P.	Ileostomy or colostomy conditions
Carmellose Sodium B.P. with Pectin and Gelatin B.P.	Ileostomy or colostomy conditions
Cefotaxime Sodium	Infections where positive bacteriological evidence confirms that cefotaxime sodium is an appropriate therapeutic agent Septicaemia, suspected or proven
Ceftriaxone Sodium	Infections where positive bacteriological evidence confirms that ceftriaxone sodium is an appropriate therapeutic agent Septicaemia, suspected or proven
Cephalexin B.P. with Purified Water B.P.	—
Cephalexin Capsules B.P.	—
Cephalothin Sodium B.P.	—
Cephazolin Sodium	Infections where positive bacteriological evidence confirms that cephazolin sodium is an appropriate therapeutic agent Septicaemia, suspected or proven
Charcoal, Activated B.P.	Ileostomy or colostomy conditions
Chloral Hydrate B.P.	—
Chlorambucil Tablets B.P.	—
Chloramine B.P.	Ileostomy or colostomy conditions
Chloramphenicol B.P.	—
Chloramphenicol B.P. with Polymyxin B Sulphate B.P.	—
Chloramphenicol Capsules B.P.	Bacterial meningitis Intracranial bacterial infections Intraocular infections Rickettsioses Typhoid Other serious infections where positive baceriological evidence confirms that chloramphenicol is the only appropriate antibiotic
Chloramphenicol Eye Drops B.P.	—
Chloramphenicol Eye Ointment B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Chloramphenicol Palmitate Mixture B.P.	Bacterial meningitis Intracranial bacterial infections Intraocular infections Rickettsioses Typhoid Other serious infections where positive bacteriological evidence confirms that chloramphenicol is the only appropriate antibiotic
Chloramphenicol Sodium Succinate B.P.	Bacterial meningitis Intracranial bacterial infections Intraocular infections Rickettsioses Typhoid Other serious infections where positive bacteriological evidence confirms that chloramphenicol is the only appropriate antibiotic
Chlorhexidine Gluconate	—
Chlormethiazole Capsules B.P.	With the written authority of the Secretary: Short-term alcohol or drug withdrawal therapy in a hospital or approved centre Status epilepticus
Chlormethiazole Edisylate B.P.	Short-term alcohol or drug withdrawal therapy in a hospital or approved centre Status epilepticus
Chloroquine Phosphate Tablets B.P.	—
Chloroquine Sulphate B.P.	—
Chloroquine Sulphate Injection B.P.	—
Chlorothiazide Tablets B.P.	—
Chlorpromazine Elixir B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Chlorpromazine Injection B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Chlorpromazine Suppositories B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Chlorpromazine Tablets B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Chlorpropamide Tablets B.P.	—
Chlortetracycline	—
Chlortetracycline Hydrochloride B.P.	—
Chlorthalidone Tablets B.P.	—
Cholera Vaccine B.P.	—
Cholestyramine	Bile salt malabsorption Hypercholesterolaemia Pruritus associated with partial biliary obstruction not responding to other therapy Severe diarrhoea associated with pelvic irradiation
Choline Theophyllinate B.P.	—
Chorionic Gonadotrophin B.P.	For use with bromocriptine mesylate in infertility associated with hyperprolactinaemia
Cimetidine	With the written authority of the Secretary: Duodenal ulcer (including pyloric ulcer), confirmed by x-ray, endoscopy or surgery Gastric ulcer, confirmed by x-ray, endoscopy or surgery Oesophageal stricture, recurrent, due to proven chronic ulcer occurring within gastric epithelium where dilatation has been required Severe ulcerating (erosive) oesophagitis, confirmed by endoscopy Ulcerating (erosive) oesophagitis in scleroderma Zollinger-Ellison syndrome, proven by investigation
Clindamycin Capsules B.P.	Gram-positive coccal infections where the infection cannot be safely and effectively treated with penicillin or a derivative of penicillin
Clindamycin Palmitate Hydrochloride with Purified Water B.P.	Gram-positive coccal infections where the infection cannot be safely and effectively treated with penicillin or a derivative of penicillin
Clioquinol B.P.	—
Clofibrate Capsules B.P.	Hypertriglyceridaemia Hypercholesterolaemia
Clomiphene Tablets B.P.	Anovulatory infertility Patients undergoing in-vitro fertilisation
Clomipramine Hydrochloride B.P.	Cataplexy associated with narcolepsy Obsessive compulsive disorders
Clonazepam	—
Clonidine Hydrochloride Tablets B.P.	—
Clopamide	—
Clorexolone	—
Clotrimazole B.P.	—
Cloxacillin Capsules B.P.	—
Cloxacillin Sodium B.P.	—
Cloxacillin Sodium B.P. with Purified Water B.P.	—
Codeine Phosphate B.P. with Aspirin B.P.	—
Codeine Phosphate B.P. with Paracetamol B.P.	—
Codeine Phosphate Tablets B.P.	—
Colchicine Tablets B.P.	—
Colestipol Hydrochloride	Hypercholesterolaemia
Colistin Sulphate B.P. with Neomycin Sulphate B.P.	—
Colistin Sulphomethate Sodium B.P.	—

Column 1 Pharmaceutical benefit	Column 2 Circumstances (if any) specified for the purposes of section 88A of the Act
Copper Sulphate B.P.C. 1973	—
Cortisone Tablets B.P.	—
Co-trimoxazole Mixture, Paediatric B.P.	—
Co-trimoxazole Tablets B.P.	—
Cyclopenthiazide Tablets B.P.	—
Cyclophosphamide B.P.	—
Cyclophosphamide Tablets B.P.	—
Cyproheptadine Tablets B.P.	Prevention of migraine
Cytarabine B.P.	—
Danazol	With the written authority of the Secretary: Endometriosis, proven by visual means Hereditary angio-oedema Menorrhagia, intractable primary
Dantrolene Sodium	Treatment of chronic spasticity
Dapsone Tablets B.P.	—
Debrisoquine Tablets B.P.	—
"De-Lact Infant"	Acute gastro-enteritis complicated by lactose intolerance in infants under the age of 12 months Proven lactose intolerance in infants under the age of 12 months
Demeclocycline Capsules B.P.	Syndrome of inappropriate antidiuretic hormone secretion, caused otherwise than by treatment with a drug
Desipramine Tablets B.P.	—
Desmopressin	—
Dexamethasone B.P.	—
Dexamethasone B.P. with Framycetin Sulphate B.P. and Gramicidin	—
Dexamethasone Sodium Metasulphobenzoate with Framycetin Sulphate B.P. and Gramicidin	—
Dexamethasone Sodium Phosphate B.P.	In respect of the injection, 5 mL vial containing equivalent of 120 mg dexamethasone phosphate: For use in a hospital In respect of the other injections: —
Dexamethasone Tablets B.P.	—
Dexamphetamine Tablets B.P.	With the written authority of the Secretary: For the treatment of a patient under the age of 21 years and who is hyperkinetic as a result of brain damage Narcolepsy
Dextran 40 Intravenous Infusion B.P. with Glucose B.P.	—
Dextran 40 Intravenous Infusion B.P. with Sodium Chloride B.P.	—
Dextran 70 Intravenous Infusion B.P. with Glucose B.P.	—
Dextran 70 Intravenous Infusion B.P. with Sodium Chloride B.P.	—
Diazepam B.P.	—
Diazepam Injection B.P.	—
Diazepam Tablets B.P.	—
Diazoxide Injection B.P.	—
Dichlorphenamide Tablets B.P.	—
Diclofenac Sodium	—
Dienoestrol B.P.	—
Difenoxin Hydrochloride with Atropine Sulphate B.P.	—
Diflunisal Tablets B.P.	—
"Digestelact"	With the written authority of the Secretary: Lactose intolerance
Digoxin Elixir, Paediatric B.P.	—
Digoxin Injection B.P.	—
Digoxin Tablets B.P.	—
Dihydroergotamine Mesylate B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Dihydrotachysterol B.P.	With the written authority of the Secretary: Hypoparathyroidism Osteomalacia following gastrectomy, severe steatorrhoea or renal failure Vitamin D-resistant rickets
Diloxanide Furoate Tablets B.P.	—
Diltiazem Hydrochloride	Angina where treatment with verapamil hydrochloride or nifedipine has failed or is inappropriate
Dimercaprol Injection B.P.	—
Dimethicones B.P.	In respect of the creams: Any disease or condition in a paraplegic or quadriplegic patient Ileostomy or colostomy conditions Use with surgical appliances In respect of the solution: Ileostomy or colostomy conditions
Diphenoxylate Hydrochloride B.P. with Atropine Sulphate B.P.	—
Diphtheria and Tetanus Vaccine, Adsorbed B.P.	—
Diphtheria and Tetanus Vaccine, Adsorbed B.P., Diluted	—
Diphtheria Antitoxin B.P.	—
Diphtheria, Tetanus and Pertussis Vaccine, Adsorbed B.P.	—
Diphtheria Vaccine, Adsorbed B.P.	—
Diphtheria Vaccine, Adsorbed B.P., Diluted	—
Dipivefrine Hydrochloride	—
Dipyridamole Tablets B.P.	With the written authority of the Secretary: Biopsy proven glomerulonephritis Mesangiocapillary renal disease Renal allograft Patients with cardiac prosthesis
Disodium Etidronate	With the written authority of the Secretary: Active Paget's disease of bone when calcitonin has been found to be unsatisfactory due to lack of efficacy or unacceptable side effects
Disopyramide Capsules B.P.	—
Disopyramide Phosphate Capsules B.P.	—
Docusate Sodium B.P. with Bisacodyl B.P.	Any disease or condition in a paraplegic or quadriplegic patient For use by patients who are receiving long-term extensive nursing care in hospitals or nursing homes For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved
Domperidone	—
Dothiepin Capsules B.P.	—
Dothiepin Hydrochloride B.P.	—
Doxepin Capsules B.P.	—
Doxepin Hydrochloride B.P.	—
Doxorubicin Hydrochloride	—
Doxycycline Capsules B.P.	—
Doxycycline Hydrochloride B.P.	In respect of the capsules, 50 mg (base) (containing enteric coated pellets) and the tablets, 50 mg (base): Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne In respect of the other capsules and tablets: —
Dydrogesterone Tablets B.P.	With the written authority of the Secretary: Endometriosis, proven by visual means
Econazole Nitrate B.P.	—
Econazole Nitrate Cream B.P.	—
Econazole Nitrate Pessaries B.P.	—
Ecothiopate Iodide B.P.	—

Column 1 Pharmaceutical benefit	Column 2 Circumstances (if any) specified for the purposes of section 88A of the Act
Enalapril Maleate	Moderate or severe hypertension For the continuing treatment of severe refractory cardiac failure where treatment with enalapril maleate was initiated in a hospital (in-patient or out-patient)
Epicillin	—
Ergocalciferol B.P.	Hypocalcaemia Hypoparathyroidism Osteomalacia following gastrectomy, severe steatorrhoea or renal failure Vitamin D-resistant rickets
Ergometrine and Oxytocin Injection B.P.	—
Ergometrine Injection B.P.	—
Ergometrine Tablets B.P.	—
Ergotamine Tablets B.P.	—
Ergotamine Tartrate B.P. with Caffeine B.P.	—
Ergotamine Tartrate B.P. with Caffeine B.P. and Cyclizine Hydrochloride B.P.	—
Ergotamine Tartrate B.P. with Caffeine Citrate B.P.C. 1959 and Diphenhydramine Hydrochloride B.P.	—
Erythromycin B.P.	—
Erythromycin Estolate B.P.	—
Erythromycin Ethyl Succinate B.P.	—
Erythromycin Ethyl Succinate B.P. with Purified Water B.P.	—
Erythromycin Lactobionate	—
Erythromycin Stearate	—
Erythromycin Stearate Tablets B.P.	—
Erythromycin Tablets B.P.	—
Ethacrynic Acid Tablets B.P.	Patients who are hypersensitive to other oral diuretics
Ethanolamine Oleate Injection B.P.	—
Ethinyloestradiol Tablets B.P.	—
Ethosuximide Capsules B.P.	—
Ethosuximide Elixir B.P.	—
Ethyloestrenol Tablets B.P.	With the written authority of the Secretary: Osteoporosis Patients on long-term treatment with corticosteroids
Ethynodiol Diacetate B.P. with Ethinyloestradiol B.P.	—
Etretinate	With the written authority of the Secretary: Darier's disease Erythrokeratoderma Pityriasis rubra pilaris Severe congenital ichthyosis (lamellar, bullous and sex linked) Severe intractable psoriasis Severe palmo-plantar keratoderma
Fenoterol Hydrobromide B.P.	—
Ferrous Aminoacetosulphate	—
Ferrous Gluconate B.P.	—
Ferrous Gluconate Tablets B.P.	—
Ferrous Sulphate, Dried B.P.	—
Ferrous Sulphate, Dried B.P. with Folic Acid B.P.	—
Flecainide Acetate	For the continuing treatment of cardiac arrhythmias where treatment with flecainide acetate was initiated in a hospital (in-patient or out-patient)
Fluclorolone Acetonide B.P.	—
Flucloxacillin Capsules B.P.	—
Flucloxacillin Sodium B.P.	—
Flucloxacillin Sodium B.P. with Purified Water B.P.	—
Flucytosine Tablets B.P.	Invasive or systemic fungal infections such as candidiasis, cryptococcosis and chromoblastomycosis
Fludrocortisone Tablets B.P.	—
Flumethasone Pivalate with Clioquinol B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Fluocortolone Pivalate and Fluocortolone Hexanoate Cream B.P.	—
Fluocortolone Pivalate and Fluocortolone Hexanoate Ointment B.P.	—
Fluorometholone	—
Fluorouracil Injection B.P.	—
Fluoxymesterone Tablets B.P.	With the written authority of the Secretary: Aplastic anaemias, proven Carcinoma of the breast Hypogonadism Osteoporosis
Fluphenazine Decanoate Injection B.P.	Chorea Hyperactive states of organic or toxic delirium Major pyschoses including: Major organic pyschoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness
Fluphenazine Hydrochloride B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic pyschoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness
Fluphenazine Tablets B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic pyschoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness
Folic Acid B.P.	—
Folic Acid Tablets B.P.	—
Fosfestrol Sodium B.P.	Carcinoma of the prostate
Framycetin Sulphate B.P.	—
Frusemide B.P.	—
Frusemide Injection B.P.	—
Frusemide Tablets B.P.	In respect of the 500 mg strength: Renal failure In respect of the other strengths: —
Fusidic Acid Mixture B.P.	For use in combination with another antibiotic in the treatment of serious staphylococcal infections confirmed by bacteriological evidence
"Galactomin, Formula No. 17"	With the written authority of the Secretary: Galactosaemia Conditions needing an extreme restriction of lactose in the diet of a patient under the age of 4 years
Gas-gangrene Antitoxin, Mixed B.P.	—
Gentamicin Eye Drops B.P.	Invasive ocular infection Perioperative use Suspected pseudomonal eye infection
Gentamicin Injection B.P.	—
Glibenclamide Tablets B.P.	—
Gliclazide	—
Glucagon Hydrochloride	—
Glucose and Ketone Indicator—Urine	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P.	—
Glucose Indicator—Blood	—
Glucose Indicator—Urine	—
Glucose Intravenous Infusion B.P.	—
Glyceryl Trinitrate	—
Glyceryl Trinitrate Tablets B.P.	—
Griseofulvin Tablets B.P.	Recalcitrant tinea infections Kerion
Haloperidol B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic pyschoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness
Haloperidol Tablets B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness
Heparin Injection B.P. (Calcium Salt)	—
Heparin Injection B.P. (Sodium Salt)	—
Hexamine Hippurate	—
Hexamine Mandelate	—
Homatropine Hydrobromide B.P.	—
Hydralazine Hydrochloride Tablets B.P.	—
Hydrochlorothiazide B.P. with Amiloride Hydrochloride B.P.	—
Hydrochlorothiazide B.P. with Triamterene B.P.	—
Hydrochlorothiazide Tablets B.P.	—
Hydrocortisone B.P.	—
Hydrocortisone Acetate B.P.	In respect of the rectal foam: Proctitis Ulcerative colitis In respect of the other forms: —
Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P.	—
Hydrocortisone Acetate Cream B.P.	—
Hydrocortisone Acetate Injection B.P.	Alopecia areata For local intra-articular or peri-articular infiltration Granulomata, dermal Keloid Lichen planus hypertrophic Lichen simplex chronicus Lupus erythematosus, chronic discoid
Hydrocortisone Acetate Ointment B.P.	—
Hydrocortisone Sodium Succinate B.P.	In respect of the injection set containing equivalent of 500 mg hydrocortisone and 4 mL solvent: Any disease or condition in a patient receiving treatment in a hospital In respect of the other injection sets: —
Hydroxocobalamin Injection B.P.	Pernicious anaemia and other proven vitamin B12 deficiencies Post-gastrectomy treatment Sub-acute combined degeneration of the cord
Hydroxychloroquine Tablets B.P.	—
Hydroxyurea Capsules B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Hyoscyamine Hydrobromide with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.	—
Hyoscyamine Sulphate B.P. with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.	—
Hypromellose 4500 B.P.	—
Hypromellose 4500 B.P. with Dextran 70	—
Ibuprofen Tablets B.P.	—
Idoxuridine B.P.	—
Idoxuridine Eye Drops B.P.	—
Imipramine Hydrochloride B.P.	—
Imipramine Tablets B.P.	—
Indapamide	—
Indomethacin Capsules B.P.	—
Indomethacin Suppositories B.P.	—
Influenza Vaccine (Split Virion), Inactivated B.P.	For prophylaxis of persons at special risk of adverse consequences from infections of the lower respiratory tract
Insect Allergen Extract—Bull Ant	—
Insect Allergen Extract—Honey Bee Venom	—
Insect Allergen Extract—Jumper Ant	—
Insect Allergen Extract—Mosquito	—
Insect Allergen Extract—Paper Wasp Venom	—
Insulin Injection B.P.	—
Insulin Injection, Biphasic B.P.	—
Insulin Injection, Isophane B.P.	—
Insulin Injection, Isophane B.P. and Insulin Injection, Neutral B.P.	—
Insulin Injection, Neutral B.P.	—
Insulin Injection, Protamine Zinc B.P.	—
Insulin Isophane, Human (Synthetic)	Diabetics exhibiting lipoatrophy, lipohypertrophy, local allergy or immunologic resistance Newly diagnosed insulin dependent diabetics
Insulin Isophane, Human (Synthetic) and Insulin Neutral, Human (Synthetic)	Diabetics exhibiting lipoatrophy, lipohypertrophy, local allergy or immunologic resistance Newly diagnosed insulin dependent diabetics
Insulin Neutral, Human (Synthetic)	Diabetics exhibiting lipoatrophy, lipohypertrophy, local allergy or immunologic resistance Newly diagnosed insulin dependent diabetics
Insulin Zinc Suspension B.P.	—
Insulin Zinc Suspension (Amorphous) B.P.	—
Insulin Zinc Suspension (Crystalline) B.P.	—
Insulin Zinc Suspension (Crystalline), Human (Synthetic)	Diabetics exhibiting lipoatrophy, lipohypertrophy, local allergy or immunologic resistance Newly diagnosed insulin dependent diabetics
Insulin Zinc Suspension, Human (Synthetic)	Diabetics exhibiting lipoatrophy, lipohypertrophy, local allergy or immunologic resistance Newly diagnosed insulin dependent diabetics
Intraperitoneal Dialysis Solutions B.P.C. 1973	—
Ipratropium Bromide	—
Iron Dextran Injection B.P.	—
Iron Polymaltose Complex	—
Iron Sorbitol Injection B.P.	—
Isoconazole Nitrate	—
Isoniazid Tablets B.P.	—
Isopropyl Monoester Polymer with Isopropyl Alcohol B.P.	Ileostomy or colostomy conditions
Isosorbide Dinitrate Tablets B.P.	—
Isotretinoin	With the written authority of the Secretary: Severe cystic acne not responsive to other therapy
Kaolin, Light B.P. or Light Kaolin (Natural) B.P. with Pectin	—
Ketoprofen B.P.	—
Ketoprofen Capsules B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Labetalol Hydrochloride Tablets B.P.	—
Lactulose Solution B.P.	With the written authority of the Secretary: Hepatic coma or pre-coma (chronic portosystemic encephalopathy) Terminal malignant neoplasia
Lauramine Oxide with Octoxinol	Ileostomy or colostomy conditions
Leuprorelin Acetate	With the written authority of the Secretary: Advanced cancer of the prostate
Levodopa and Carbidopa Tablets B.P.	—
Levodopa B.P. with Benserazide	—
Levodopa Tablets B.P.	—
Levonorgestrel B.P.	—
Levonorgestrel B.P. with Ethinyloestradiol B.P.	—
Lignocaine Hydrochloride B.P.	—
Lignocaine Hydrochloride Injection B.P.	—
Lincomycin Injection B.P.	—
Lindane B.P.	—
Lindane Cream B.P.	—
Liothyronine Tablets B.P.	—
Lithium Carbonate B.P.	—
Lithium Carbonate Tablets B.P.	—
"Locasol New Formula"	With the written authority of the Secretary: Hypercalcaemia in children under the age of 2 years Osteopetrosis
"Lofenalac"	Phenylketonuria
Loperamide Hydrochloride	—
Lypressin	—
Maldison	—
"Maxamaid XP"	Phenylketonuria
Medroxyprogesterone Acetate B.P.	In respect of the injections, the oral suspension and the tablets, 100 mg, 200 mg and 250 mg: Breast cancer Endometrial cancer Renal cell cancer In respect of the tablet, 10 mg: — In respect of the tablet, 500 mg: Advanced breast cancer
Medrysone	—
Mefenamic Acid Capsules B.P.	Dysmenorrhoea Menorrhagia
Mefruside	—
Megestrol Acetate B.P.	Breast cancer
Melphalan Tablets B.P.	—
Mercaptopurine Tablets B.P.	—
Metformin Tablets B.P.	—
Methacycline Hydrochloride B.P.C. 1973	—
Methadone Injection B.P.	Severe disabling pain not responding to non-narcotic analgesics
Methadone Tablets B.P.	Severe disabling pain not responding to non-narcotic analgesics
Methdilazine Hydrochloride	Prevention of migraine
Methenolone Acetate	With the written authority of the Secretary: Osteoporosis Patients on long-term treatment with corticosteroids
Methotrexate B.P.	—
Methotrexate Injection B.P.	—
Methotrexate Tablets B.P.	—
Methsuximide	—
Methyclothiazide	—
Methyldopa Tablets B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Methylphenobarbitone B.P.	Epilepsy
Methylprednisolone Acetate Injection B.P.	For local intra-articular or peri-articular infiltration
Methylprednisolone Sodium Succinate	—
Methyl Salicylate Liniment A.P.F.	—
Methyltestosterone Tablets B.P.	In respect of the 5 mg strength: Hypogonadism in patients under the age of 16 years In respect of the other strengths: Carcinoma of the breast Hypogonadism Klinefelter's syndrome (seminiferous tubule dysgenesis)
Methysergide Tablets B.P.	—
Metoclopramide Hydrochloride B.P.	—
Metoclopramide Injection B.P.	—
Metoclopramide Tablets B.P.	—
Metolazone	—
Metoprolol Tartrate	—
Metronidazole Benzoate	—
Metronidazole B.P.	Prophylaxis in large bowel surgery Treatment, in a hospital, of acute anaerobic sepsis
Metronidazole Suppositories B.P.	—
Metronidazole Tablets B.P.	—
Mexiletine Hydrochloride Capsules B.P.	—
Mianserin Hydrochloride Tablets B.P.	With the written authority of the Secretary: Depressive illness in persons with cardiovascular disease or bladder neck dysfunction
Miconazole	—
Miconazole Nitrate B.P.	—
Miconazole Nitrate Cream B.P.	—
Minocycline Hydrochloride	—
Minoxidil	With the written authority of the Secretary: For the continuing treatment of severe refractory hypertensive disease where treatment with minoxidil was initiated in a hospital (in-patient or out-patient) For the continuing treatment of a patient who has already received, for more than 6 months, therapy with minoxidil for severe refractory hypertension
Misoprostol	With the written authority of the Secretary: Duodenal ulcer (including pyloric ulcer), confirmed by radiology, endoscopy or surgery Gastric ulcer, confirmed by radiology, endoscopy or surgery
Mithramycin	For use in a hospital for: Inoperable testicular neoplasm Symptomatic hypercalcaemia and hypercalcinuria associated with advanced neoplasia
Mitozantrone Hydrochloride	Metastatic or locally advanced breast cancer
Morphine Sulphate B.P. with Tacrine Hydrochloride	Severe intractable pain
Morphine Sulphate Injection B.P.	—
Morphine Sulphate Tablets B.P.	Severe disabling pain not responding to non-narcotic analgesics
"M.S.U.D. AID"	Maple syrup urine disease
Mustine Hydrochloride B.P.	—
Nalidixic Acid Mixture B.P.	For use as a urinary antiseptic in patients with neurogenic bladder Urinary tract infections where current clinical and bacteriological evidence confirm that nalidixic acid is an appropriate therapeutic agent
Nalidixic Acid Tablets B.P.	For use as a urinary antiseptic in patients with neurogenic bladder Urinary tract infections where current clinical and bacteriological evidence confirm that nalidixic acid is an appropriate therapeutic agent
Naloxone Hydrochloride	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Nandrolone Decanoate Injection B.P.	With the written authority of the Secretary: Carcinoma of the breast Osteoporosis Patients on long-term treatment with corticosteroids
Nandrolone Phenylpropionate Injection B.P.	With the written authority of the Secretary: Carcinoma of the breast Osteoporosis Patients on long-term treatment with corticosteroids
Naphazoline Hydrochloride	—
Naproxen B.P.	—
Naproxen Tablets B.P.	—
Natamycin	—
Neomycin Sulphate Eye Drops B.P.	—
Neomycin Tablets B.P.	Acute leukaemia during induction of remission with chemotherapy Bowel sterilisation preparatory to major surgery Encephalopathy, hepatic
Neomycin Undecenoate with Bacitracin Zinc B.P.	—
Neostigmine Injection B.P.	—
Neostigmine Tablets B.P.	—
Niclosamide Tablets B.P.	—
Nicotinic Acid Tablets B.P.	—
Nifedipine	—
Nitrazepam Tablets B.P.	—
Nitrofurantoin B.P.	—
Nitrofurantoin Mixture B.P.	—
Nitrofurantoin Tablets B.P.	—
Norethisterone Acetate B.P.	Carcinoma of the breast Carcinoma of the prostate
Norethisterone Acetate B.P. with Ethinyloestradiol B.P.	—
Norethisterone B.P. with Ethinyloestradiol B.P.	—
Norethisterone B.P. with Mestranol B.P.	—
Norethisterone Tablets B.P.	—
Norfloxacin	Acute bacterial enterocolitis Urinary tract infection
Norgestrel with Ethinyloestradiol B.P.	—
Nortriptyline Hydrochloride B.P.	—
Nortriptyline Tablets B.P.	—
"Nutramigen"	With the written authority of the Secretary: Allergy to both cows' milk and soy protein in children under the age of 2 years Cystic fibrosis (mucoviscidosis) Galactosaemia Glycogen storage disease due to glucose-6-phosphatase deficiency in children under the age of 2 years Homocystinuria Lactose intolerance
Nystatin B.P.	—
Nystatin Mixture B.P.	—
Nystatin Ointment B.P.	—
Nystatin Pessaries B.P.	—
Nystatin Tablets B.P.	—
"Odortrol"	Ileostomy or colostomy conditions
Oestradiol Valerate	—
Oestrogens—Conjugated	—
Oestrone B.P.C. 1954	—
Ornidazole	—
Orphenadrine Hydrochloride Tablets B.P.	Parkinsonism
Oxazepam Tablets B.P.	—
Oxprenolol Hydrochloride B.P.	—
Oxprenolol Tablets B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Oxycodone Hydrochloride	Severe disabling pain not responding to non-narcotic analgesics
Oxycodone Pectinate	Severe disabling pain not responding to non-narcotic analgesics
Oxymetholone Tablets B.P.	With the written authority of the Secretary: Aplastic anaemias, proven Myelosclerosis
Oxytetracycline Hydrochloride B.P.	—
Oxytocin Injection B.P.	—
Pancreatin B.P.	Cystic fibrosis (mucoviscidosis) Following pancreatico-duodenectomy Pancreatic steatorrhoea
Pancrelipase	Cystic fibrosis (mucoviscidosis) Following pancreatico-duodenectomy Pancreatic steatorrhoea
Papaveretum B.P.C. 1973	—
Papaveretum B.P.C. 1973 with Hyoscine Hydrobromide B.P.	—
Paracetamol B.P.	—
Paracetamol Tablets B.P.	—
Paraffin, Soft White B.P.	Ileostomy or colostomy conditions
Paraffin, Soft White B.P. with Liquid Paraffin B.P.	—
Penicillamine B.P.	Acute heavy metal intoxication Cystinosis Cystinuria with calculus formation Haemoglobinuria, paroxysmal cold Severe rheumatoid arthritis Wilson's disease (hepatolenticular degeneration)
Penicillamine Tablets B.P.	Acute heavy metal intoxication Cystinosis Cystinuria with calculus formation Haemoglobinuria, paroxysmal cold Severe rheumatoid arthritis Wilson's disease (hepatolenticular degeneration)
Perhexiline Maleate	With the written authority of the Secretary: Angina not responding to other therapy
Pericyazine	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Pethidine Injection B.P.	—
Pethidine Tablets B.P.	With the written authority of the Secretary: Disabling pain associated with proven malignant neoplasia
Phenelzine Tablets B.P.	Depressive illness resistant to treatment with either tricyclic antidepressants or electroconvulsive therapy Phobic states
Phenethicillin Capsules B.P.	—
Phenethicillin Potassium B.P. with Purified Water B.P.	—
Phenethicillin Tablets B.P.	—
Phenindione Tablets B.P.	—
Phenobarbitone Injection B.P.	Epilepsy
Phenobarbitone Tablets B.P.	Epilepsy
Phenoxybenzamine Capsules B.P.	With the written authority of the Secretary: Neurogenic urinary retention Phaeochromocytoma
Phenoxymethylpenicillin (Benzathine Salt)	—
Phenoxymethylpenicillin (Hydrabamine Salt)	—
Phenoxymethylpenicillin Potassium Capsules B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Phenoxymethylpenicillin Potassium Tablets B.P.	—
Phensuximide B.P.C. 1973	—
Phenylephrine Hydrochloride B.P.	—
Phenytoin B.P.	—
Phenytoin Capsules B.P.	—
Phenytoin Injection B.P.	—
Phenytoin Mixture B.P.	—
Phytomenadione Injection B.P.	—
Pilocarpine	With the written authority of the Secretary: Chronic glaucoma when other miotics are not tolerated
Pilocarpine Hydrochloride B.P.	—
Pindolol B.P.	—
Pindolol Tablets B.P.	—
Piroxicam	—
Pizotifen Malate	—
"PK AID I"	Phenylketonuria
"PK AID II"	Phenylketonuria
Plague Vaccine B.P. 1973	—
Pneumococcal Vaccine, Polyvalent	Splenectomised persons over the age of 2 years Persons with Hodgkin's disease Persons at high risk of pneumococcal infections
Polygeline	—
Polyisobutylene	Ileostomy or colostomy conditions
Polymyxin B Sulphate B.P. with Bacitracin B.P. 1968 and Neomycin Sulphate B.P.	—
Polymyxin B Sulphate B.P. with Bacitracin Zinc B.P. and Neomycin Sulphate B.P.	—
Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin	—
Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P.	—
Polyvinyl Alcohol	—
Polyvinyl Alcohol with Povidone B.P.	—
Polyvinylpyrrolidone and Vinyl Acetate Copolymer	Ileostomy or colostomy conditions
"Portagen"	With the written authority of the Secretary: Patients requiring a ketogenic diet for intractable childhood epilepsy Proven malabsorption
Potassium Chloride B.P.	—
Potassium Chloride B.P. with Potassium Bicarbonate Efferverscent Tablets	—
Pralidoxime Iodide	—
Prazosin Hydrochloride	—
Prednisolone Acetate	In respect of the injection: For local intra-articular or peri-articular infiltration In respect of the eye drops: —
Prednisolone Acetate with Phenylephrine Hydrochloride B.P.	Corneal grafts Uveitis
Prednisolone B.P.	—
Prednisolone Sodium Phosphate B.P.	In respect of the retention enema and the suppositories: Proctitis Ulcerative colitis In respect of the eye/ear drops: —
Prednisolone Stearoylglycolate	—
Prednisolone Tablets B.P.	—
Prednisone Tablets B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
"Pregestimil"	With the written authority of the Secretary: Biliary atresia Cystic fibrosis Enterokinase deficiency Intolerance to both milk protein and soya protein Severe diarrhoea of greater than two weeks duration in infants under the age of 4 months
Primaquine Tablets B.P.	—
Primidone Tablets B.P.	—
Probenecid Tablets B.P.	—
Probucol	With the written authority of the Secretary: Familial hypercholesterolaemia inadequately responsive to diet and a course of cholesterol lowering resin
Procainamide Hydrochloride B.P.	—
Procainamide Injection B.P.	—
Procaine Penicillin Injection B.P.	—
Procarbazine Hydrochloride	—
Prochlorperazine	—
Prochlorperazine Edisylate	—
Prochlorperazine Injection B.P.	—
Prochlorperazine Tablets B.P.	—
Procyclidine Tablets B.P.	—
Promethazine Hydrochloride Injection B.P.	—
Promethazine Theoclate Tablets B.P.	—
Propantheline Tablets B.P.	Chronic neurogenic incontinence of urine
Propranolol Injection B.P.	—
Propranolol Tablets B.P.	—
Propylthiouracil Tablets B.P.	—
Protamine Sulphate Injection B.P.	—
Pyrantel Embonate	—
Pyridostigmine Injection B.P.	—
Pyridostigmine Tablets B.P.	—
Pyridoxine Hydrochloride B.P.	—
Pyridoxine Hydrochloride Tablets B.P.	Anaemia proved to be responsive to pyridoxine Convulsions responsive to pyridoxine Homocystinuria Primary hyperoxaluria Radiation sickness Sideroblastic (refractory) anaemia Treatment and prophylaxis of peripheral neuritis caused or likely to be caused by isoniazid therapy
Pyrimethamine B.P. with Dapsone B.P.	—
Pyrimethamine B.P. with Sulfadoxine B.P.	—
Pyrimethamine Tablets B.P.	—
Quinethazone	—
Quinidine Bisulphate B.P.	—
Quinidine Sulphate B.P.	—
Quinidine Sulphate Tablets B.P.	—
Quinine Bisulphate Tablets B.P.	—
Quinine Sulphate Tablets B.P.	—
Ranitidine Hydrochloride	With the written authority of the Secretary: Duodenal ulcer (including pyloric ulcer), confirmed by x-ray, endoscopy or surgery Gastric ulcer, confirmed by x-ray, endoscopy or surgery Oesophageal stricture, recurrent, due to proven chronic ulcer occurring within gastric epithelium where dilatation has been required Severe ulcerating (erosive) oesophagitis, confirmed by endoscopy Ulcerating (erosive) oesophagitis in scleroderma Zollinger-Ellison syndrome, proven by investigation
Red-back Spider Antivenom	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Rifampicin B.P.	Prophylaxis of meningococcal disease in close contacts and carriers With the written authority of the Secretary: Leprosy in adults
Rolitetracycline	—
Salbutamol B.P.	—
Salbutamol Sulphate B.P.	—
Salbutamol Tablets B.P.	—
Salcatonin Injection B.P.	With the written authority of the Secretary: Proven active Paget's disease of bone causing pain or disability Treatment initiated in a hospital (in-patient or out-patient) of hypercalcaemia For the continuation of treatment of patients already established on calcitonin under arrangements provided for by section 100 of the Act
Silver Sulphadiazine with Chlorhexidine Gluconate	In respect of the cream, 10 mg-2 mg per g, 50 g and the cream, 10 mg-2 mg per g, 100 g: For the prevention and treatment of infection in partial or full skin thickness loss due to burns or epidermolysis bullosa Stasis ulcers In respect of the cream, 10 mg-2 mg per g, 500 g: With the written authority of the Secretary: Treatment, in a hospital, of burns
Sodium Acid Citrate B.P.	—
Sodium Acid Phosphate B.P.	With the written authority of the Secretary: Familial hypophosphataemia Hypercalcaemia Hypophosphataemic rickets Vitamin D-resistant rickets
Sodium Aurothiomalate Injection B.P.	—
Sodium Bicarbonate Intravenous Infusion B.P.	—
Sodium Calciumedetate B.P.	—
Sodium Chloride and Glucose Intravenous Infusion B.P.	—
Sodium Chloride B.P. with Potassium Chloride B.P. and Calcium Chloride B.P. in Water for Injections	—
Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.	—
Sodium Chloride Intravenous Infusion B.P.	—
Sodium Citro-Tartrate	—
Sodium Cromoglycate B.P.	In respect of the eye drops: With the written authority of the Secretary: Vernal kerato-conjunctivitis In respect of the nebuliser solution: Use in a power-operated nebuliser for prophylaxis of asthma in persons who are unable to use the capsule or metered aerosol spray for oral inhalation In respect of the metered aerosol spray: —
Sodium Cromoglycate Insufflation B.P.	—
Sodium Fusidate B.P.	For use in combination with another antibiotic in the treatment of serious staphylococcal infections confirmed by bacteriological evidence
Sodium Lactate Compound Intravenous Infusion B.P.	—
Sodium Lactate Compound Intravenous Infusion B.P. with Anhydrous Glucose B.P.	—
Sodium Lactate Intravenous Infusion B.P.	—
Sodium Nitroprusside B.P.	—
Sodium Salicylate B.P.	—
Sodium Valproate B.P.	—
Sodium Valproate Elixir B.P.	—
Spectinomycin Hydrochloride B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Spironolactone Tablets B.P.	Female hirsutism Hyperaldosteronism
Staphylococcus Toxoid B.P. 1968	—
Sterculia B.P.	Ileostomy or colostomy conditions
Sterculia B.P. with Frangula Bark B.P.	Any disease or condition in a paraplegic or quadriplegic patient For use by patients who are receiving long-term extensive nursing care in hospitals or nursing homes For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved
Stilboestrol Tablets B.P.	—
Streptokinase B.P.	—
Sucralfate	—
Sulindac Tablets B.P.	—
Sulphacetamide Sodium B.P.	—
Sulphadimidine Tablets B.P.	—
Sulphafurazole B.P.	—
Sulphafurazole Tablets B.P.	—
Sulphamethizole B.P.	—
Sulphamethizole Tablets B.P.	—
Sulphapyridine Tablets B.P.	—
Sulphasalazine	Crohn's disease Rheumatoid arthritis Ulcerative colitis
Sulphinpyrazone Tablets B.P.	Glomerulonephritis Gout Renal transplantation
Sulthiame Tablets B.P.	—
Surgical Cement	Any disease or condition in a paraplegic or quadriplegic patient For use with surgical appliances Ileostomy or colostomy conditions
Surgical Cement Solvent	Any disease or condition in a paraplegic or quadriplegic patient For use with surgical appliances Ileostomy or colostomy conditions
Tamoxifen Citrate Tablets B.P.	Recurrent or metastatic breast cancer
Temazepam	—
Terbutaline Sulphate B.P.	—
Terbutaline Sulphate Tablets B.P.	—
"Teric" N8 with Lauryldimethylbenzyl Ammonium Chloride	Any disease or condition in a paraplegic or quadriplegic patient Ileostomy or colostomy conditions
Testosterone Enanthate B.P.	Hypogonadism Klinefelter's syndrome (seminiferous tubule dysgenesis)
Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P. and Testosterone Isocaproate B.P.	Gigantism Hypogonadism Klinefelter's syndrome (seminiferous tubule dysgenesis)
Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.	Gigantism Hypogonadism Klinefelter's syndrome (seminiferous tubule dysgenesis)
Testosterone Propionate Injection B.P.	Hypogonadism Klinefelter's syndrome (seminiferous tubule dysgenesis)
Tetanus Vaccine, Adsorbed B.P.	—
Tetrabenazine	Chorea not adequately controlled by other drug therapy
Tetracosactrin Zinc Injection B.P.	With the written authority of the Secretary: Hypsarrhythmia Multiple sclerosis, acute exacerbation Treatment of children who need long-term corticosteroid therapy but who are in danger of growth suppression as a result Treatment of patients who are being withdrawn from long-term corticosteroid therapy Ulcerative colitis, proven, not responding to parenteral corticosteroids

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Tetracycline B.P. with a buffering agent	—
Tetracycline B.P. with a buffering agent and Nystatin B.P.	—
Tetracycline Capsules B.P.	—
Tetracycline Hydrochloride B.P. with Nystatin B.P.	—
Theophylline B.P.	—
Thiabendazole Tablets B.P.	—
Thiamine Hydrochloride Injection B.P.	—
Thiamine Hydrochloride Tablets B.P.	—
Thiethylperazine Malate	—
Thiethylperazine Maleate	—
Thioguanine Tablets B.P.	—
Thiopropazate Hydrochloride Tablets B.P.	Chorea
Thioridazine Hydrochloride B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Thioridazine Tablets B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Thiotepa B.P.	—
Thyroxine Tablets B.P.	—
Ticarcillin Sodium	Infections where positive bacteriological evidence confirms that ticarcillin sodium is an appropriate therapeutic agent Septicaemia, suspected or proven
Timolol Maleate Eye Drops B.P.	—
Timolol Maleate Tablets B.P.	—
Tinidazole	—
Tobramycin B.P.	Invasive ocular infection Perioperative use Suspected pseudomonal eye infection
Tobramycin Injection B.P.	Infections where positive bacteriological evidence confirms that tobramycin is an appropriate antibiotic Septicaemia, suspected or proven
Tolazamide Tablets B.P.	—
Tolbutamide Tablets B.P.	—
Tranexamic Acid Tablets B.P.	Hereditary angio-oedema
Tranylcypromine Tablets B.P.	Depressive illness resistant to treatment with either tricyclic antidepressants or electroconvulsive therapy Phobic states
Triamcinolone Acetonide B.P.	Alopecia areata For local intra-articular or peri-articular infiltration Granulomata, dermal Keloid Lichen planus hypertrophic Lichen simplex chronicus Lupus erythematosus, chronic discoid Necrobiosis lipoidica Psoriasis

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.	—
Triamcinolone Acetonide Cream B.P.	—
Triamcinolone Acetonide Ointment B.P.	—
Triamterene B.P.	—
Trifluoperazine Hydrochloride B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Trifluoperazine Hydrochloride Tablets B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Triglycerides Oil, Medium Chain	With the written authority of the Secretary: Abetalipoproteinaemia Intestinal lymphangiectasia Intractable childhood epilepsy requiring a ketogenic diet Short-term nutritional support in severe steatorrhoea Steatorrhoea due to distal small bowel resection
Trimetaphan Camsylate B.P. 1968	—
Trimethoprim Tablets B.P.	—
Trimipramine	—
Trimipramine Tablets B.P.	—
Trioxysalen	Vitiligo
Typhoid Vaccine B.P.	—
Typhus Vaccine B.P.	—
Urea Cream B.P.	—
Vancomycin Hydrochloride B.P.	Any disease or condition in a patient receiving treatment in a hospital Endophthalmitis
Vasopressin Tannate	—
Verapamil Hydrochloride B.P.	—
Verapamil Hydrochloride Injection B.P.	—
Verapamil Hydrochloride Tablets B.P.	—
Vidarabine	Eye infections caused by herpes simplex virus where idoxuridine has proved ineffective
Vinblastine Sulphate B.P.	—
Vincristine Sulphate B.P.	—
Warfarin Tablets B.P.	—
Water for Injections B.P.	—
Wool Alcohols Ointment B.P.	—
"Zerodor"	Ileostomy or colostomy conditions
Zinc Oxide B.P.	—
Zinc Sulphate B.P. with Phenylephrine Hydrochloride B.P.	—

SCHEDULE 2

Allowable compounds of ready-prepared pharmaceutical benefits

Column 1 *Pharmaceutical benefit*	*Column 2* *Allowable compounds*
Adrenaline B.P.	Benzocaine B.P. with Adrenaline B.P.
Aluminium Hydroxide, Dried B.P.	Aluminium Hydroxide, Dried B.P. with Magnesium Hydroxide B.P. Aluminium Hydroxide, Dried B.P. with Magnesium Hydroxide B.P. and Magnesium Trisilicate B.P.
Aluminium Hydroxide Mixture B.P.	Aluminium Hydroxide Mixture B.P. with Light Kaolin B.P. or Light Kaolin (Natural) B.P. Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. and Oxethazaine
Amiloride Hydrochloride B.P.	Hydrochlorothiazide B.P. with Amiloride Hydrochloride B.P.
Amoxycillin Trihydrate B.P.	Amoxycillin Trihydrate B.P. with Potassium Clavulanate Amoxycillin Trihydrate B.P. with Potassium Clavulanate and Purified Water B.P. Amoxycillin Trihydrate B.P. with Purified Water B.P.
Ampicillin Trihydrate B.P.	Ampicillin Trihydrate B.P. with Purified Water B.P.
Antazoline Phosphate	Antazoline Phosphate with Naphazoline Hydrochloride
Antazoline Sulphate	Antazoline Sulphate with Naphazoline Nitrate B.P.
Aspirin B.P.	Codeine Phosphate B.P. with Aspirin B.P.
Atropine Sulphate B.P.	Difenoxin Hydrochloride with Atropine Sulphate B.P. Diphenoxylate Hydrochloride B.P. with Atropine Sulphate B.P. Hyoscyamine Hydrobromide with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P. Hyoscyamine Sulphate B.P. with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.
Bacitracin B.P. 1968	Polymyxin B Sulphate B.P. with Bacitracin B.P. 1968 and Neomycin Sulphate B.P.
Bacitracin Zinc B.P.	Neomycin Undecenoate with Bacitracin Zinc B.P. Polymyxin B Sulphate B.P. with Bacitracin Zinc B.P. and Neomycin Sulphate B.P.
Benserazide	Levodopa B.P. with Benserazide
Benzathine Penicillin B.P.	Benzathine Penicillin B.P. with Procaine Penicillin B.P., Benzylpenicillin Potassium B.P. and Water for Injections
Benzocaine B.P.	Benzocaine B.P. with Adrenaline B.P.
Benzylpenicillin Potassium B.P.	Benzathine Penicillin B.P. with Procaine Penicillin B.P., Benzylpenicillin Potassium B.P. and Water for Injections
Betamethasone Acetate	Betamethasone Acetate with Betamethasone Sodium Phosphate B.P.
Betamethasone Sodium Phosphate B.P.	Betamethasone Acetate with Betamethasone Sodium Phosphate B.P.
Bisacodyl B.P.	Docusate Sodium B.P. with Bisacodyl B.P.
Butyl Monoester Polymer	Butyl Monoester Polymer with Ethanol B.P. Butyl Monoester Polymer with Isopropyl Alcohol B.P.
Caffeine B.P.	Ergotamine Tartrate B.P. with Caffeine B.P. Ergotamine Tartrate B.P. with Caffeine B.P. and Cyclizine Hydrochloride B.P.
Caffeine Citrate B.P.C. 1959	Ergotamine Tartrate B.P. with Caffeine Citrate B.P.C. 1959 and Diphenhydramine Hydrochloride B.P.
Calcium Carbonate B.P.	Calcium Carbonate B.P. with Calcium Lactate-Gluconate
Calcium Chloride B.P.	Sodium Chloride B.P. with Potassium Chloride B.P. and Calcium Chloride B.P. in Water for Injections
Calcium Lactate-Gluconate	Calcium Carbonate B.P. with Calcium Lactate-Gluconate
Carmellose Sodium B.P.	Carmellose Sodium B.P. with Pectin and Gelatin B.P.
Cephalexin B.P.	Cephalexin B.P. with Purified Water B.P.
Chloramphenicol B.P.	Chloramphenicol B.P. with Polymyxin B Sulphate B.P.
Chlorhexidine Gluconate	Silver Sulphadiazine with Chlorhexidine Gluconate
Citric Acid B.P.	Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P.
Clindamycin Palmitate Hydrochloride	Clindamycin Palmitate Hydrochloride with Purified Water B.P.

Column 1 *Pharmaceutical benefit*	*Column 2* *Allowable compounds*
Cloxacillin Sodium B.P.	Cloxacillin Sodium B.P. with Purified Water B.P.
Codeine Phosphate B.P.	Codeine Phosphate B.P. with Aspirin B.P. Codeine Phosphate B.P. with Paracetamol B.P.
Colistin Sulphate B.P.	Colistin Sulphate B.P. with Neomycin Sulphate B.P.
Cyclizine Hydrochloride B.P.	Ergotamine Tartrate B.P. with Caffeine B.P. and Cyclizine Hydrochloride B.P.
Dapsone B.P.	Pyrimethamine B.P. with Dapsone B.P.
Dexamethasone B.P.	Dexamethasone B.P. with Framycetin Sulphate B.P. and Gramicidin
Dexamethasone Sodium Metasulphobenzoate	Dexamethasone Sodium Metasulphobenzoate with Framycetin Sulphate B.P. and Gramicidin
Dextran 40 Intravenous Infusion B.P.	Dextran 40 Intravenous Infusion B.P. with Glucose B.P. Dextran 40 Intravenous Infusion B.P. with Sodium Chloride B.P.
Dextran 70	Hypromellose 4500 B.P. with Dextran 70
Dextran 70 Intravenous Infusion B.P.	Dextran 70 Intravenous Infusion B.P. with Glucose B.P. Dextran 70 Intravenous Infusion B.P. with Sodium Chloride B.P.
Difenoxin Hydrochloride	Difenoxin Hydrochloride with Atropine Sulphate B.P.
Diphenhydramine Hydrochloride B.P.	Ergotamine Tartrate B.P. with Caffeine Citrate B.P.C. 1959 and Diphenhydramine Hydrochloride B.P.
Diphenoxylate Hydrochloride B.P.	Diphenoxylate Hydrochloride B.P. with Atropine Sulphate B.P.
Docusate Sodium B.P.	Docusate Sodium B.P. with Bisacodyl B.P.
Ergotamine Tartrate B.P.	Ergotamine Tartrate B.P. with Caffeine B.P. Ergotamine Tartrate B.P. with Caffeine B.P. and Cyclizine Hydrochloride B.P. Ergotamine Tartrate B.P. with Caffeine Citrate B.P.C. 1959 and Diphenhydramine Hydrochloride B.P.
Erythromycin Ethyl Succinate B.P.	Erythromycin Ethyl Succinate B.P. with Purified Water B.P.
Ethanol B.P.	Butyl Monoester Polymer with Ethanol B.P.
Ethinyloestradiol B.P.	Ethynodiol Diacetate B.P. with Ethinyloestradiol B.P. Levonorgestrel B.P. with Ethinyloestradiol B.P. Norethisterone Acetate B.P. with Ethinyloestradiol B.P. Norethisterone B.P. with Ethinyloestradiol B.P. Norgestrel with Ethinyloestradiol B.P.
Ethynodiol Diacetate B.P.	Ethynodiol Diacetate B.P. with Ethinyloestradiol B.P.
Ferrous Sulphate, Dried B.P.	Ferrous Sulphate, Dried B.P. with Folic Acid B.P.
Flucloxacillin Sodium B.P.	Flucloxacillin Sodium B.P. with Purified Water B.P.
Flumethasone Pivalate	Flumethasone Pivalate with Clioquinol B.P.
Folic Acid B.P.	Ferrous Sulphate, Dried B.P. with Folic Acid B.P.
Framycetin Sulphate B.P.	Dexamethasone B.P. with Framycetin Sulphate B.P. and Gramicidin Dexamethasone Sodium Metasulphobenzoate with Framycetin Sulphate B.P. and Gramicidin
Frangula Bark B.P.	Sterculia B.P. with Frangula Bark B.P.
Gelatin B.P.	Carmellose Sodium B.P. with Pectin and Gelatin B.P.
Glucose B.P.	Dextran 40 Intravenous Infusion B.P. with Glucose B.P. Dextran 70 Intravenous Infusion B.P. with Glucose B.P.
Glucose, Anhydrous B.P.	Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P. Sodium Lactate Compound Intravenous Infusion B.P. with Anhydrous Glucose B.P.
Gramicidin	Dexamethasone B.P. with Framycetin Sulphate B.P. and Gramicidin Dexamethasone Sodium Metasulphobenzoate with Framycetin Sulphate B.P. and Gramicidin Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.
Hydrochlorothiazide B.P.	Hydrochlorothiazide B.P. with Amiloride Hydrochloride B.P. Hydrochlorothiazide B.P. with Triamterene B.P.
Hydrocortisone B.P.	Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P.

Column 1 *Pharmaceutical benefit*	*Column 2* *Allowable compounds*
Hydrocortisone Acetate B.P.	Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P.
Hyoscine Hydrobromide B.P.	Hyoscyamine Hydrobromide with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P. Hyoscyamine Sulphate B.P. with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P. Papaveretum B.P.C. 1973 with Hyoscine Hydrobromide B.P.
Hyoscyamine Hydrobromide	Hyoscyamine Hydrobromide with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.
Hyoscyamine Sulphate B.P.	Hyoscyamine Sulphate B.P. with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.
Hypromellose 4500 B.P.	Hypromellose 4500 B.P. with Dextran 70
Insulin Injection, Isophane B.P.	Insulin Injection, Isophane B.P. and Insulin Injection, Neutral B.P.
Insulin Injection, Neutral B.P.	Insulin Injection, Isophane B.P. and Insulin Injection, Neutral B.P.
Insulin Isophane, Human (Synthetic)	Insulin Isophane, Human (Synthetic) and Insulin Neutral, Human (Synthetic)
Insulin Neutral, Human (Synthetic)	Insulin Isophane, Human (Synthetic) and Insulin Neutral, Human (Synthetic)
Isopropyl Alcohol B.P.	Butyl Monoester Polymer with Isopropyl Alcohol B.P. Isopropyl Monoester Polymer with Isopropyl Alcohol B.P.
Isopropyl Monoester Polymer	Isopropyl Monoester Polymer with Isopropyl Alcohol B.P.
Kaolin, Light B.P. or Light Kaolin (Natural) B.P.	Aluminium Hydroxide Mixture B.P. with Light Kaolin B.P. or Light Kaolin (Natural) B.P. Kaolin, Light B.P. or Light Kaolin (Natural) B.P. with Pectin
Lauramine Oxide	Lauramine Oxide with Octoxinol
Lauryldimethylbenzyl Ammonium Chloride	"Teric" N8 with Lauryldimethylbenzyl Ammonium Chloride
Levodopa B.P.	Levodopa B.P. with Benserazide
Levonorgestrel B.P.	Levonorgestrel B.P. with Ethinyloestradiol B.P.
Magnesium Chloride B.P.	Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.
Magnesium Hydroxide B.P.	Aluminium Hydroxide, Dried B.P. with Magnesium Hydroxide B.P. Aluminium Hydroxide, Dried B.P. with Magnesium Trisilicate B.P. and Magnesium Hydroxide B.P. Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. and Oxethazaine
Magnesium Trisilicate B.P.	Aluminium Hydroxide, Dried B.P. with Magnesium Trisilicate B.P. and Magnesium Hydroxide B.P.
Mestranol B.P.	Norethisterone B.P. with Mestranol B.P.
Morphine Sulphate B.P.	Morphine Sulphate B.P. with Tacrine Hydrochloride B.P.
Naphazoline Hydrochloride	Antazoline Phosphate with Naphazoline Hydrochloride
Naphazoline Nitrate B.P.	Antazoline Sulphate with Naphazoline Nitrate B.P.
Neomycin Sulphate B.P.	Colistin Sulphate B.P. with Neomycin Sulphate B.P. Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P. Polymyxin B Sulphate B.P. with Bacitracin B.P. 1968 and Neomycin Sulphate B.P. Polymyxin B Sulphate B.P. with Bacitracin Zinc B.P. and Neomycin Sulphate B.P. Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P. Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.
Neomycin Undecenoate	Neomycin Undecenoate with Bacitracin Zinc B.P.
Norethisterone Acetate B.P.	Norethisterone Acetate B.P. with Ethinyloestradiol B.P.
Norethisterone B.P.	Norethisterone B.P. with Ethinyloestradiol B.P. Norethisterone B.P. with Mestranol B.P.
Norgestrel	Norgestrel with Ethinyloestradiol B.P.

Column 1 *Pharmaceutical benefit*	*Column 2* *Allowable compounds*
Nystatin B.P.	Tetracycline B.P. with a buffering agent and Nystatin B.P. Tetracycline Hydrochloride B.P. with Nystatin B.P. Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.
Octoxinol	Lauramine Oxide with Octoxinol
Oxethazaine	Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. and Oxethazaine
Papaveretum B.P.C. 1973	Papaveretum B.P.C. 1973 with Hyoscine Hydrobromide B.P.
Paracetamol B.P.	Codeine Phosphate B.P. with Paracetamol B.P.
Paraffin, Liquid B.P.	Paraffin, Soft White B.P. with Liquid Paraffin B.P.
Paraffin, Soft White B.P.	Paraffin, Soft White B.P. with Liquid Paraffin B.P.
Pectin	Carmellose Sodium B.P. with Pectin and Gelatin B.P. Kaolin, Light B.P. or Light Kaolin (Natural) B.P. with Pectin
Phenethicillin Potassium B.P.	Phenethicillin Potassium B.P. with Purified Water B.P.
Phenylephrine Hydrochloride B.P.	Prednisolone Acetate with Phenylephrine Hydrochloride B.P. Zinc Sulphate B.P. with Phenylephrine Hydrochloride B.P.
Polymyxin B Sulphate B.P.	Chloramphenicol B.P. with Polymyxin B Sulphate B.P. Polymyxin B Sulphate B.P. with Bacitracin B.P. 1968 and Neomycin Sulphate B.P. Polymyxin B Sulphate B.P. with Bacitracin Zinc B.P. and Neomycin Sulphate B.P. Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P.
Polyvinyl Alcohol	Polyvinyl Alcohol with Povidone B.P.
Potassium Chloride B.P.	Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P. Sodium Chloride B.P. with Potassium Chloride B.P. and Calcium Chloride B.P. in Water for Injections Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.
Potassium Clavulanate	Amoxycillin Trihydrate B.P. with Potassium Clavulanate Amoxycillin Trihydrate B.P. with Potassium Clavulanate and Purified Water B.P.
Povidone B.P.	Polyvinyl Alcohol with Povidone B.P.
Prednisolone Acetate	Prednisolone Acetate with Phenylephrine Hydrochloride B.P.
Procaine Penicillin B.P.	Benzathine Penicillin B.P. with Procaine Penicillin B.P., Benzylpenicillin Potassium B.P. and Water for Injections
Pyrimethamine B.P.	Pyrimethamine B.P. with Dapsone B.P. Pyrimethamine B.P. with Sulfadoxine B.P.
Silver Sulphadiazine	Silver Sulphadiazine with Chlorhexidine Gluconate
Sodium Acetate B.P.	Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.
Sodium Chloride B.P.	Dextran 40 Intravenous Infusion B.P. with Sodium Chloride B.P. Dextran 70 Intravenous Infusion B.P. with Sodium Chloride B.P. Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P. Sodium Chloride B.P. with Potassium Chloride B.P. and Calcium Chloride B.P. in Water for Injections Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.
Sodium Citrate B.P.	Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P.
Sodium Gluconate	Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.
Sodium Lactate Compound Intravenous Infusion B.P.	Sodium Lactate Compound Intravenous Infusion B.P. with Anhydrous Glucose B.P.

Column 1 *Pharmaceutical benefit*	*Column 2* *Allowable compounds*
Sulfadoxine B.P.	Pyrimethamine B.P. with Sulfadoxine B.P.
Sterculia B.P.	Sterculia B.P. with Frangula Bark B.P.
Tacrine Hydrochloride	Morphine Sulphate B.P. with Tacrine Hydrochloride
"Teric" N8	"Teric" N8 with Lauryldimethylbenzyl Ammonium Chloride
Testosterone Decanoate B.P.	Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.
Testosterone Isocaproate B.P.	Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P. and Testosterone Isocaproate B.P. Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.
Testosterone Phenylpropionate B.P.	Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P. and Testosterone Isocaproate B.P. Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.
Testosterone Propionate B.P.	Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P. and Testosterone Isocaproate B.P. Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.
Tetracycline B.P.	Tetracycline B.P. with a buffering agent Tetracycline B.P. with a buffering agent and Nystatin B.P.
Tetracycline Hydrochloride B.P.	Tetracycline Hydrochloride B.P. with Nystatin B.P.
Triamcinolone Acetonide B.P.	Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.
Triamterene B.P.	Hydrochlorothiazide B.P. with Triamterene B.P.
Water, Purified B.P.	Amoxycillin Trihydrate B.P. with Potassium Clavulanate and Purified Water B.P. Amoxycillin Trihydrate B.P. with Purified Water B.P. Ampicillin Trihydrate B.P. with Purified Water B.P. Cephalexin B.P. with Purified Water B.P. Clindamycin Palmitate Hydrochloride with Purified Water B.P. Cloxacillin Sodium B.P. with Purified Water B.P. Erythromycin Ethyl Succinate B.P. with Purified Water B.P. Flucloxacillin Sodium B.P. with Purified Water B.P. Phenethicillin Potassium B.P. with Purified Water B.P.
Zinc Sulphate B.P.	Zinc Sulphate B.P. with Phenylephrine Hydrochloride B.P.

SCHEDULE 3

Drugs or medicinal preparations which may be used as ingredients of extemporaneously-prepared pharmaceutical benefits

Column 1	*Column 2*
Pharmaceutical benefit	*Circumstances (if any) specified for the purposes of section 88A of the Act*
Acacia B.P.	—
Acetic Acid (33 per cent) B.P.	—
Acriflavine B.P.C. 1963	—
Adrenaline B.P.	May only be prescribed in eye drops
Alum B.P.	—
Aluminium Acetate Solution B.P.	—
Aminophylline B.P.	—
Ammonia Spirit, Aromatic B.P.	—
Ammoniated Mercury B.P. 1973	—
Ascorbic Acid B.P.	Use as ingredient of Ferrous Sulphate Mixture A.P.F. and Ferrous Sulphate Mixture C.F. A.P.F.
Aspirin B.P.	—
Atropine Sulphate B.P.	—
Beeswax, White B.P.	—
Belladonna Tincture B.P.	—
Bentonite B.P.	—
Benzocaine B.P.	—
Benzoic Acid B.P.	—
Benzoin Tincture, Compound B.P.	—
Cade Oil B.P.C. 1973	—
Calamine B.P.	—
Calcium Hydroxide B.P.	—
Camphor Spirit, Compound A.P.F.	—
Cetomacrogol Emulsifying Wax B.P.	—
Cetostearyl Alcohol B.P.	—
Cetrimide B.P.	—
Chlorbutol B.P.	—
Chlorinated Lime B.P.	—
Chlorocresol B.P.	—
Citric Acid Monohydrate B.P.	—
Clioquinol B.P.	—
Coal Tar B.P.	—
Coal Tar, Prepared B.P. 1973	—
Coal Tar Solution B.P.	—
Cocaine Hydrochloride B.P.	—
Coconut Oil B.P.	—
Codeine Phosphate B.P.	—
Collodion, Flexible B.P.	—
Crystal Violet B.P.	—
Dithranol B.P.	—
Emulsifying Wax B.P.	—
Ephedrine Hydrochloride B.P.	May only be prescribed in nasal instillations
Ferrous Sulphate B.P.	—
Ferrous Sulphate, Dried B.P.	—
Formaldehyde Solution B.P.	—
Gentian Infusion, Compound, Concentrated B.P.	—
Glycerol B.P.	—
Hydrochloric Acid B.P.	—
Hyoscyamus Liquid Extract B.P.C. 1973	—
Ichthammol B.P.	—
Iodine B.P.	—
Ipecacuanha Tincture B.P.	—
Kaolin, Light B.P.	—
Kaolin, Light (Natural) B.P.	—
Lactic Acid B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Lactose B.P.	—
Lavender Oil, Spike B.P.C. 1968	—
Lemon Spirit B.P.	—
Lignocaine Hydrochloride B.P.	—
Liquorice Liquid Extract B.P.	—
Lobelia Tincture, Ethereal B.P.C. 1973	—
Magenta B.P.C. 1973	—
Magnesium Carbonate, Light B.P.	—
Magnesium Sulphate B.P.	May only be prescribed for other than oral use
Magnesium Trisilicate B.P.	—
Menthol B.P.	—
Methyl Salicylate B.P.	—
Methyl Salicylate Ointment, Compound A.P.F. 1934	—
Morphine Hydrochloride B.P.	—
Oily Cream A.P.F.	—
Oleic Acid B.P.	—
Opium Tincture B.P.	—
Orange Tincture B.P.	—
Paraffin, Hard B.P.	—
Paraffin, Light Liquid B.P.	—
Paraffin, Liquid B.P.	May only be prescribed for other than oral use
Paraffin, Soft White B.P.	—
Paraffin, Soft Yellow B.P.	—
Phenobarbitone B.P.	May only be prescribed for the treatment of epilepsy
Phenobarbitone Sodium B.P.	May only be prescribed for the treatment of epilepsy
Phenol B.P.	May not be prescribed in ear drops
Phenoxyethanol B.P.	—
Pilocarpine Hydrochloride B.P.	—
Pilocarpine Nitrate B.P.	—
Podophyllum Resin B.P.	—
Potassium Citrate B.P.	—
Potassium Iodide B.P.	—
Potassium Permanganate B.P.	—
Propylene Glycol B.P.	—
Pumilio Pine Oil B.P.	—
Raspberry Syrup B.P.	—
Red Syrup A.P.F.	—
Resorcinol B.P.	—
Salicylic Acid B.P.	—
Siberian Fir Oil B.P.C. 1949	—
Silver Nitrate B.P.	—
Soap, Soft B.P.	—
Sodium Acid Phosphate B.P.	—
Sodium Bicarbonate B.P.	—
Sodium Chloride B.P.	—
Sodium Citrate B.P.	—
Sodium Phosphate B.P.	—
Squill Oxymel B.P.	—
Starch B.P.	—
Stramonium Tincture B.P.	—
Sulphur, Precipitated B.P.	—
Sulphurated Potash B.P.C. 1973	—
Syrup B.P.	—
Talc, Purified B.P., sterilised	—
Testosterone B.P.	May only be prescribed in creams
Theophylline B.P.	—
Thymol B.P.	—

Column 1 *Pharmaceutical benefit*	*Column 2* *Circumstances (if any) specified for the purposes of section 88A of the Act*
Thymol Mouth Wash, Compound A.P.F.	—
Titanium Dioxide B.P.	—
Tolu Syrup B.P.	—
Tragacanth B.P.	—
Tragacanth Powder, Compound B.P.	—
Trichloroacetic Acid B.P.	—
Triethanolamine B.P.	—
Turpentine Liniment B.P.	—
Water for Injections B.P.	May only be prescribed in eye drops and eye lotions
Water, Purified B.P.	—
Wool Alcohols B.P.	—
Wool Fat B.P.	—
Wool Fat, Hydrous B.P.	—
Zinc Oxide B.P.	—
Zinc Sulphate B.P.	—

SCHEDULE 4

Additives

Acetone B.P.
Anise Water, Concentrated B.P.
Arachis Oil B.P.
Borax B.P.
Boric Acid B.P.
Castor Oil B.P.
Chlorhexidine Acetate B.P.
Chlorhexidine Gluconate Solution B.P.
Chloroform B.P.
Ethanol (96 per cent) B.P.
Ethanols, Dilute B.P.
Ether, Solvent B.P.
Eucalyptus Oil B.P.
Glucose for Oral Use B.P.
Honey, Purified B.P.
Industrial Methylated Spirit B.P.
Olive Oil B.P. 1973
Peppermint Oil B.P.
Peppermint Water, Concentrated A.P.F.
Pholcodine Citrate Syrup B.P.C. 1959
Sodium Thiosulphate B.P.
Turpentine Oil B.P.

SCHEDULE 5

Additional pharmaceutical benefits made available under arrangements provided for by section 100 of the Act

Anthrax Antiserum
Anthrax Vaccine
Anti-Haemophilic Factor of Animal Origin
Antirabies Immunoglobulin Injection B.P.
Bacillus Calmette-Guérin Vaccine B.P.
Bacillus Calmette-Guérin Vaccine, Percutaneous B.P.
Black Snake Antivenom
Botulinum Antitoxin B.P.
Box Jellyfish Antivenom
Brown Snake Antivenom
Death Adder Antivenom
Formaldehyde Solution B.P.
Funnel-Web Spider Antivenom
Haemodialysis Solutions B.P.
Haemodialysis Solutions B.P.C. 1973
Haemodialysis Solutions, Concentrated B.P.
Haemodialysis Solutions, Concentrated B.P.C. 1973
Intraperitoneal Dialysis Solutions, Concentrated
Menopausal Gonadotrophin, Human
Methadone Hydrochloride B.P.
Pituitary Gonadotrophin, Human
Pituitary Growth Hormone, Human
Rabies Vaccine B.P.
Snake Bite Antivenom, Polyvalent
Sodium Hypochlorite Solution, Strong B.P.
Sodium Hypochlorite Solution 52.5 mg per mL
Somatrem
Stone Fish Antivenom
Taipan Antivenom
Tiger Snake Antivenom
Tuberculin Purified Protein Derivative B.P.
Tuberculin Purified Protein Derivatives, Atypical

Dated this 1st day of December 1987.

J. S. DEEBLE
Acting First Assistant Secretary
Health Benefits Division
Delegate of the Minister of State for Community Services and Health

N.N.—8714828 B

National Health Act 1953

PHARMACEUTICAL BENEFITS

DETERMINATION UNDER SECTIONS 85, 85A AND 88

I, JOHN STEWART DEEBLE, Acting First Assistant Secretary, Health Benefits Division, Department of Community Services and Health and Delegate of the Minister of State for Community Services and Health, pursuant to sections 85, 85A and 88 of the *National Health Act 1953*, hereby make the following Determination:

1. This Determination shall come into operation on the first day of December 1987.

2. The Determinations of 1 August 1987, 1 September 1987 and 1 October 1987 made under sections 85, 85A and 88 of the *National Health Act 1953* are revoked.

3. In the Schedules to this Determination:
'amp.' means ampoule;
'cm' means centimetre;
'fl oz' means fluid ounce of 480 minims;
'g' means gram;
'I.M.' means intramuscular;
'I.U.' means international unit;
'I.V.' means intravenous;
'kg' means kilogram;
'L' means litre;
'lb' means pound of 16 ounces;
'm' means metre;
'M.' means million of organisms;
'mg' means milligram;
'mL' means millilitre;
'mm' means millimetre;
'mmol' means millimole;
'S.C.' means subcutaneous;
'Sch. 2' means the Second Schedule to this Determination;
'Sch. 3' means the Third Schedule to this Determination.

4. Where the strength, type of unit, size of unit or other particulars of form are specified in the column headed 'Form' in the First Schedule to this Determination in relation to a drug or medicinal preparation referred to in sub-section 85 (2) of the *National Health Act 1953* the name of which is specified in that Schedule, those particulars refer to the form or forms of the drug or medicinal preparation that is or are allowable for the purposes of Part VII of that Act to the effect that the drug or medicinal preparation in that form or in each of those forms is a pharmaceutical benefit when prescribed by a medical practitioner.

5. Where the strength, type of unit, size of unit or other particulars of form are specified in the column headed 'Form' in the Third Schedule to this Determination in relation to a drug or medicinal preparation referred to in sub-section 85 (2) of the *National Health Act 1953* the name of which is specified in that Schedule, those particulars refer to the form or forms of the drug or medicinal preparation that is or are allowable for the purposes of Part VII of that Act to the effect that the drug or medicinal preparation in that form or in each of those forms is a pharmaceutical benefit referred to in sub-section 88 (1A) of that Act for the supply of which a participating dental practitioner is authorized to write a prescription.

6. The purposes set out in the column headed 'Purposes' in Part 2 of the First Schedule to this Determination are the only purposes for which a medical practitioner may prescribe the maximum quantities and number of repeats specified in that Part in relation to those pharmaceutical benefits specified in that same Part.

7. The manner, if any, in which a pharmaceutical benefit specified in the First and Third Schedules to this Determination is to be administered in relation to the pharmaceutical benefit is set out in those Schedules in the column headed 'Manner of administration'.

8. The maximum quantity or number of units of a pharmaceutical benefit that may, in one prescription, be directed to be supplied on any one occasion is:

(a) where the name of the pharmaceutical benefit is specified—
  (i) in Part 1 of the First Schedule to this Determination—the quantity or number, if any, specified in that Part of the Schedule in the column headed 'Maximum quantity' in relation to the pharmaceutical benefit; or
  (ii) in Part 2 of the First Schedule to this Determination and the pharmaceutical benefit is prescribed in accordance with the provisions of the column headed 'Purposes'—the quantity or number, if any, in that Part of the Schedule in the column headed 'Maximum quantity' in relation to the pharmaceutical benefit; or
  (iii) if reference is made to the Second Schedule in the column headed 'Maximum quantity' in the First Schedule the quantity or number, if any, specified in the column headed 'Maximum quantity' in the Second Schedule to this Determination in relation to the form of the pharmaceutical benefit; or
  (iv) in the Third Schedule to this Determination—the quantity or number, if any, specified in that Part of the Schedule in the column headed 'Maximum quantity' in relation to the pharmaceutical benefit; or
(b) in any other case—the quantity or number, if any, specified in the column headed 'Maximum quantity' in that Second Schedule in relation to the form of the pharmaceutical benefit.

9. The maximum number of occasions, if any, on which the supply of a pharmaceutical benefit may, in one prescription, be directed by a medical practitioner to be repeated is:

(a) where the name of the pharmaceutical benefit is specified—
  (i) in Part 1 of the First Schedule to this Determination—the quantity or number, if any, specified in that Part of the Schedule in the column headed 'Number of repeats' in relation to the pharmaceutical benefit; or
  (ii) in Part 2 of the First Schedule to this Determination and the pharmaceutical benefit is prescribed in accordance with the provisions of the column headed 'Purposes'—the quantity or number, if any, in that Part of the Schedule in the column headed 'Number of repeats' in relation to the pharmaceutical benefit; or
  (iii) if reference is made to the Second Schedule in the column headed 'Number of repeats' in the First Schedule, the quantity or number, if any, specified in the column headed 'Number of repeats' in the Second Schedule to this Determination in relation to the form of the pharmaceutical benefit; or
(b) in any other case—the number, if any, specified in the column headed 'Number of repeats' in that Second Schedule in relation to the form of the pharmaceutical benefit.

10. The name of the manufacturer or the names of manufacturers denoted in accordance with the following table by letters appearing in the column headed 'Brand' in the First and Third Schedules to this Determination in relation to a drug or medicinal preparation the name of which is specified in those Schedules is the brand or brands under which the drug or medicinal preparation may be supplied under Part VII of the *National Health Act 1953* as a pharmaceutical benefit:

Letters	*Manufacturer's Name*
AB	Abbott Australasia Pty Ltd
AF	Alphapharm Pty Ltd
AG	Allergan Pharmaceuticals Pty Ltd
AM	Ames Company, Division of Miles Laboratories Australia Pty Ltd
AP	Astra Pharmaceuticals Pty Ltd
AQ	Alcon Laboratories (Australia) Pty Ltd
AY	Ayerst Laboratories Pty Ltd
BC	Bristol Laboratories Pty Ltd
BF	Barnes-Hind Pty Limited
BH	Biopharm Pty Ltd
BL	David Bull Laboratories Proprietary Limited
BN	Bayer Pharmaceutical Company
BO	Boehringer Mannheim, GmbH, Germany
BR	Beecham Research Laboratories
BT	The Boots Company (Australia) Pty Ltd
BW	Wellcome Australia Limited
BY	Boehringer Ingelheim Pty Ltd
BZ	Boucher & Muir Pty Ltd
CG	Ciba-Geigy Australia Limited
CL	Cilag Pty Limited
CN	CSL-Novo Pty Limited
CS	Commonwealth Serum Laboratories
DF	Difrex (Aust.) Laboratories
DH	Drug Houses of Australia Pty Ltd
DL	Dista Products (Australia) & Company
DY	Denyer Brothers
EG	Eagle Pharmaceuticals Pty Ltd
FA	F. H. Faulding and Co. Ltd
FC	Fisons Pty Ltd
FE	Farmitalia Carlo Erba
FL	Florafaun Pty Ltd
FM	Fawns and McAllan Pty Ltd
FR	Charles E. Frosst, Division of Merck Sharp & Dohme (Australia) Pty Ltd
GB	Gist-Brocades nv, The Netherlands
GF	Gelflex Laboratories
GL	Glaxo
GP	G.P. Laboratories
HA	Hamilton Laboratories Pty Ltd
HO	Hollister Incorporated, U.S.A.
HP	Hoechst Australia Ltd
IC	ICI Australia Operations Pty Ltd
IQ	The Ioquin Company
JP	Janssen Pharmaceutica Pty Ltd
KN	Knoll A. G., Germany
KY	Key Pharmaceuticals Pty Ltd
LA	L.A. Chemicals Pty Ltd
LE	Lederle Laboratories Division, Cyanamid Australia Pty Ltd
LH	Lipha Pharmaceuticals, London, U.K.
LY	Eli Lilly (Australia) and Company
MB	May & Baker Australia Pty Ltd
MG	J. McGloin Pty Ltd
MJ	Mead Johnson
MK	Merck Sharp & Dohme (Australia) Pty Ltd
ML	Merrell Dow Pharmaceuticals Australia Pty Ltd
NN	Nelson Laboratories (Sales) Pty Ltd
NR	Nordia, Denmark
NS	Nicholas Kiwi (Pacific) Pty Ltd
NT	Nestlé Australia Ltd
NW	Norwich Eaton Pharmaceuticals Pty Limited
OL	Owen Laboratories
OR	Organon (Australia) Pty Ltd
PD	Parke Davis Pty Ltd
PF	Pfizer Pty Ltd
PR	Prosana Laboratories Pty Ltd
PS	Pharmacia (Australia) Pty Ltd
PT	CP Protea
QE	Queensland Ethicals
RC	Reckitts Pty Ltd
RG	Rorer Australia Pty Ltd
RK	Riker Laboratories Australia Pty Ltd
RL	Roussel Pharmaceuticals Pty Ltd
RO	Roche Products Pty Ltd
RS	A. H. Robins Pty Limited
RT	Rocke Tompsitt & Co. Ltd
SC	Schering Pty Ltd, Australian subsidiary of Schering A. G., Berlin
SD	Syntex Pharmaceuticals Ltd
SE	Servier Laboratories (Aust.) Pty Ltd
SH	Essex Laboratories Pty Ltd, Australian subsidiary of Schering Corporation, U.S.A.
SI	Sigma Co. Ltd
SJ	Sharpe Laboratories Pty Ltd
SK	Smith Kline & French Laboratories (Aust.) Ltd
SL	Soul Pattinson Laboratories Pty Ltd
SN	Smith & Nephew (Aust.) Pty Ltd
SQ	E. R. Squibb & Sons Pty Ltd
SR	Searle Laboratories
ST	A. E. Stansen & Co. Pty Ltd
SU	Sauter Laboratories (Aust.) Pty Ltd
SV	Stafford-Miller Limited
SZ	Sandoz Australia Pty Ltd
TO	R. D. Toppin and Sons Pty Ltd
TV	Travenol Laboratories Pty Ltd
UP	Upjohn Pty Ltd
US	USV Pharmaceuticals, a Division of Rorer Australia Pty Ltd
UW	United Works of Pharmaceutical & Dietetic Products, Hungary
VF	Vifor S.A., Geneva
WH	H. W. Woods Pty Ltd
WL	Winthrop Laboratories
WW	Wm R. Warner & Co. Pty Ltd
WY	Wyeth Pharmaceuticals Pty Ltd
ZR	Zero Chemicals (Aust.) Pty Ltd
ZY	Zyma Pharmaceuticals

FIRST SCHEDULE—PART 1

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Acetazolamide B.P.	Capsule, 500 mg (sustained release)	Oral	50	3	LE
Acetazolamide Sodium with any determined brand of Water for Injections or other solvent	Injection, 500 mg vial (with required solvent)	Injection	1	..	LE
Acetazolamide Tablets B.P.	250 mg	Oral	50	6	LE
Acetylcysteine B.P.	Solution, 200 mg per mL, 10 mL	Inhalation	5	3	AP
Acrylic Resin	Solution, 125 g aerosol spray pack	Application	1	..	AP
Acyclovir	Eye ointment, 30 mg per g, 4.5 g	Application to the eye	1	..	BW
	Tablet, 200 mg	Oral	25	..	BW
Adrenaline B.P.	Eye drops, 5 mg per mL, 7.5 mL	Application to the eye	1	6	BF
	Eye drops, 10 mg per mL, 7.5 mL	Application to the eye	1	6	BF
	Extemporaneously prepared eye drops	Application to the eye	Sch. 2	Sch. 2	
Adrenaline Hydrochloride	Eye drops, 5 mg (base) per mL, 10 mL	Application to the eye	1	6	AG
	Eye drops, 10 mg (base) per mL, 10 mL	Application to the eye	1	6	AG, AQ
	Eye drops, 20 mg (base) per mL, 10 mL	Application to the eye	1	6	AG, AQ
Adrenaline Injection B.P.	Adrenaline, 1 in 1,000, 1 mL	Injection	5	1	AP, SI
"Albumaid XP"	Powder, 200 g	Oral	10	5	SJ
"Albumaid XPXT"	Powder, 200 g	Oral	10	5	SJ
"Alfaré"	Powder, 400 g	Oral	2	20	NT
Allopurinol B.P.	Capsule, 100 mg	Oral	100	5	FM
	Capsule, 300 mg	Oral	30	5	FM
Allopurinol Tablets B.P.	100 mg	Oral	100	5	BW, DH, PT, US
	300 mg	Oral	30	5	BW, DH, PT, US
Alprenolol Tablets B.P.	100 mg	Oral	100	5	AP, BR
Aluminium Hydroxide and Magnesium Carbonate Co-dried Gel	Tablet, 375 mg	Oral	100	5	GL, WY
Aluminium Hydroxide Dried B.P.	Tablet, 300 mg	Oral	100	5	WY
Aluminium Hydroxide Dried B.P. with Magnesium Hydroxide B.P.	Dispersible tablet, 230 mg-230 mg	Oral	100	5	BW
	Tablet, 200 mg-200 mg	Oral	100	5	PD, WW
Aluminium Hydroxide Dried B.P. with Magnesium Trisilicate B.P. and Magnesium Hydroxide B.P.	Suspension, 250 mg-120 mg-120 mg per 5 mL, 500 mL	Oral	1	5	FM
	Tablet, 250 mg-120 mg-120 mg	Oral	100	5	FM
Aluminium Hydroxide Mixture B.P.	Suspension, 320 mg per 5 mL, 500 mL	Oral	1	5	DH, PR, WY
Aluminium Hydroxide Mixture B.P. with Light Kaolin B.P. or Light Kaolin (Natural) B.P.	Suspension, 137 mg-1 g per 5 mL, 500 mL	Oral	1	2	WY
Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P.	Suspension, 200 mg-200 mg per 5 mL, 500 mL	Oral	1	5	DH, PD, SC, WW
	Suspension, 215 mg-80 mg per 5 mL, 500 mL	Oral	1	5	WY
	Suspension, 300 mg-100 mg per 5 mL, 500 mL	Oral	1	5	WY
Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. and Oxethazaine	Suspension, 306 mg-97.5 mg-10 mg per 5 mL, 500 mL	Oral	1	5	WY
Aluminium Sodium Polyhydroxy Monocarbonate Hexitol Complex	Tablet, 300 mg	Oral	100	5	WL
Aluminium Sodium Silicate	Powder, 100 g	Oral	1	5	SC
Amantadine Hydrochloride	Capsule, 100 mg	Oral	100	5	BT, CG

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Ambenonium Chloride	Tablet, 10 mg	Oral	100	2	WL
Amiloride Hydrochloride Tablets B.P.	5 mg	Oral	50	3	AF, MK
Aminacrine Hydrochloride B.P. 1968	Eye drops, 3 mg in 15 mL	Application to the eye	1	2	SI
Aminoglutethimide	Tablet, 250 mg	Oral	100	..	CG
"Aminogran Food Supplement"	Powder, 500 g	Oral	1	5	GL
"Aminogran Mineral Mixture"	Powder, 250 g	Oral	1	5	GL
Aminophylline B.P.	Mixture, 105 mg per 5 mL, 500 mL	Oral	1	5	FC
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Aminophylline Injection B.P.	Ampoule, 250 mg in 10 mL	I.V. injection	5	..	BT, SI
Aminophylline Tablets B.P.	100 mg	Oral	100	5	HA
Amiodarone Hydrochloride	Tablet, 100 mg	Oral	30	..	RC
	Tablet, 200 mg	Oral	30	..	RC
Amitriptyline Tablets B.P.	10 mg	Oral	50	2	AF, MK, PT, RO
	25 mg	Oral	50	2	AF, MK, NS, PT, RO
	50 mg	Oral	50	2	AF
Ammonium Chloride B.P.	Tablet, 500 mg	Oral	100	3	FM
Amoxycillin Capsules B.P.	250 mg (base)	Oral	20	1	AF, BR, CS, PT, SI
	500 mg (base)	Oral	20	1	AF, BR, CS, PT, SI
Amoxycillin Sodium	Injection, 250 mg (base) vial with 3 mL solvent	Injection	5	1	PT
	Injection, 500 mg (base) vial with 3 mL solvent	Injection	5	1	PT
	Injection, 1 g (base) vial with 4 mL solvent	Injection	5	1	PT
Amoxycillin Trihydrate B.P.	Tablet, chewable, 250 mg (base)	Oral	20	1	BR, CS
	Tablet, dispersible, 3 g (base)	Oral	1	..	BR, CS
Amoxycillin Trihydrate B.P. with Potassium Clavulanate	Tablet, 250 mg (base)-125 mg (acid)	Oral	15	1	BR
	Tablet, 500 mg (base)-125 mg (acid)	Oral	15	1	BR
Amoxycillin Trihydrate B.P. with Potassium Clavulanate and Purified Water B.P.	Powder for syrup, 125 mg (base)-31.25 mg (acid) per 5 mL, 75 mL	Oral	1	1	BR
	Powder for syrup, 250 mg (base)-62.5 mg (acid) per 5 mL, 75 mL	Oral	1	..	BR
Amoxycillin Trihydrate B.P. with Purified Water B.P.	Powder for paediatric drops, 100 mg (base) per mL, 20 mL	Oral	1	1	BR
	Powder for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	1	BR, CS, PT, SI
	Powder for syrup, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	BR, CS, PT, SI
Amphotericin B.P.	Cream, 30 mg per g, 15 g	Application	1	1	SQ
	Ointment, 30 mg per g, 15 g	Application	1	1	SQ
	Suspension, 100 mg per mL, 24 mL	Oral	1	1	SQ
	Tablet, 100 mg	Oral	50	..	SQ
Amphotericin B.P. with any determined brand of Water for Injections or other solvent	Injection, 50 mg vial (with required solvent)	Injection	1	..	SQ
Amphotericin Lozenges B.P.	10 mg	Oral	20	1	SQ
Ampicillin Capsules B.P.	250 mg	Oral	24	1	BR, CS, PT
	500 mg	Oral	24	..	BR, CS, PT

Name of Pharmaceutical Benefit	Form (strength, type, size, etc.)	Manner of administration	Maximum quantity	Number of repeats	Brand
Ampicillin Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 250 mg (base) vial (with required solvent)	Injection	5	1	CS, PT
	Injection, 500 mg (base) vial (with required solvent)	Injection	5	1	BR, CS, PT
	Injection, 1 g (base) vial (with required solvent)	Injection	5	1	CS, PT
Ampicillin Trihydrate B.P. with Purified Water B.P.	Powder for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	1	BR, CS
	Powder for syrup, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	BR, CS
Amylobarbitone Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 500 mg amp. (with required solvent)	Injection	2	..	LY
Antazoline Phosphate with Naphazoline Hydrochloride	Eye drops, 5 mg-500 micrograms per mL, 15 mL	Application to the eye	1	2	AG
Antazoline Sulphate with Naphazoline Nitrate B.P.	Eye drops, 5 mg-250 micrograms per mL, 10 mL	Application to the eye	1	2	ZY
Aspirin B.P.	Tablet, 325 mg (buffered)	Oral	100	1	AP
	Tablet, 650 mg (enteric coated)	Oral	100	2	SK
	Tablet, 650 mg (sustained release)	Oral	100	2	BT
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Aspirin Tablets B.P.	300 mg	Oral	100	1	SI
Aspirin Tablets, Dispersible B.P.	300 mg	Oral	100	1	RC
Atenolol	Tablet, 50 mg	Oral	30	5	IC
Atropine Eye Ointment B.P.	10 mg per g, 4 g	Application to the eye	1	..	PD
Atropine Methonitrate B.P.	Alcoholic solution, 6 mg per mL, 15 mL	Oral	1	..	WL
	Tablet, 1 mg	Oral	50	2	WL
Atropine Sulphate B.P.	Eye drops, 5 mg per mL, 15 mL	Application to the eye	1	2	SI
	Eye drops, 10 mg per mL, 15 mL	Application to the eye	1	2	SI
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Atropine Sulphate Injection B.P.	Ampoule, 600 micrograms in 1 mL	Injection	5	1	AP, BT
	Ampoule, 1.2 mg in 1 mL	Injection	5	1	AP, BT
Atropine Sulphate Tablets B.P.	600 micrograms	Oral	100	2	FM
Auranofin	Tablet, 3 mg	Oral	60	5	SK
Aurothioglucose	Injection, 50 mg per mL, 10 mL	Injection	1	..	SH
Azathioprine Tablets B.P.	50 mg	Oral	100	2	AF, BW
Baclofen Tablets B.P.	10 mg	Oral	100	5	CG
	25 mg	Oral	100	5	CG
"Banish"	Liquid, 15 mL		1	..	DY
Beclomethasone Dipropionate B.P.	Capsule, 100 micrograms	Inhalation by mouth	100	5	GL
	Spray, metered aerosol, 12 mg in 20.4 g (200 dose)	Inhalation by mouth	1	5	GL, SH
	Spray, metered aerosol, 24 mg in 20.4 g (200 dose)	Inhalation by mouth	1	5	GL
Bendrofluazide Tablets B.P.	2.5 mg	Oral	50	3	BT, PT
	5 mg	Oral	50	3	BT, PT
Benzathine Penicillin B.P.	Injection, 1.8 g in 4 mL disposable syringe	Injection	1	..	WY
Benzathine Penicillin B.P. with Procaine Penicillin B.P., Benzylpenicillin Potassium B.P. and Water for Injections	Injection, 450 mg-300 mg-187 mg vial with 2 mL water for injections	Injection	1	..	WY
Benzhexol Tablets B.P.	2 mg	Oral	100	5	LE, PT
	5 mg	Oral	100	2	LE, PT

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Benzocaine B.P. with Adrenaline B.P.	Ointment, compound, 50 g		1	1	GP
	Suppositories, compound, 12		1	1	GP
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Benzoin Tincture, Compound B.P.	Spray, aerosol, 3.5 mL per 10 mL, 167 mL	Application	1	..	EG
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Benztropine Injection B.P.	Ampoule, 2 mg in 2 mL	Injection	5	..	MK
Benztropine Tablets B.P.	2 mg	Oral	30	5	MK
Benzyl Benzoate Application B.P.	50 g in 200 mL	Application	1	2	MG
Benzyl Benzoate B.P.	Application, 50 g in 200 mL	Application	1	2	MB
Benzylpenicillin Potassium B.P. with any determined brand of Water for Injections or other solvent	Injection, 300 mg vial (with required solvent)	Injection	5	1	CS
	Injection, 600 mg vial (with required solvent)	Injection	5	1	CS, GL
	Injection, 3 g vial (with required solvent)	Injection	10	..	CS
	Injection, 6 g vial (with required solvent)	Injection	10	..	CS
Betamethasone Acetate with Betamethasone Sodium Phosphate B.P.	Injection, 3 mg-3.9 mg in 1 mL amp.	Injection	5	..	SH
Betamethasone Dipropionate	Cream, 500 micrograms (base) per g, 15 g	Application	1	1	SH
	Ointment, 500 micrograms (base) per g, 15 g	Application	1	1	SH
	Scalp lotion, 500 micrograms (base) per mL, 30 mL	Application to the scalp	1	1	SH
Betamethasone Tablets B.P.	500 micrograms	Oral	30	4	SH
Betamethasone Valerate B.P.	Gel, 500 micrograms (base) per g, 15 g	Application	1	1	GL
Betamethasone Valerate Cream B.P.	200 micrograms (base) per g, 100 g	Application	2	..	GL, SH
	500 micrograms (base) per g, 15 g	Application	1	1	GL, SH
Betamethasone Valerate Ointment B.P.	200 micrograms (base) per g, 100 g	Application	2	..	SH
	500 micrograms (base) per g, 15 g	Application	1	1	GL, SH
Bethanechol Chloride	Injection, 5 mg in 1 mL amp.	Injection	2	..	MK
	Tablet, 10 mg	Oral	100	2	HA, MK
Biperiden Hydrochloride	Tablet, 2 mg	Oral	100	5	KN
Biperiden Lactate Injection B.P.	5 mg in 1 mL	Injection	5	..	KN
Bisacodyl B.P.	Enema, 10 mg in 5 mL, 25	Enema	1	2	PT
Bisacodyl Suppositories B.P.	10 mg, 10		1	..	BY
Bisacodyl Tablets B.P.	5 mg	Oral	100	2	PT
Bismuth Subcitrate	Tablet, 107.7 mg (as Bi)	Oral	112	2	PD
Bleomycin Sulphate with any determined brand of Water for Injections or other solvent	Injections, 15 mg (base) (with required solvent), 10	Injection	1	..	BC
Bromocriptine Mesylate Capsules B.P.	5 mg (base)	Oral	60	..	SZ
	10 mg (base)	Oral	100	..	SZ
Bromocriptine Mesylate Tablets B.P.	2.5 mg (base)	Oral	30	..	SZ
Bumetanide	Tablet, 1 mg	Oral	50	3	AP
Busulphan Tablets B.P.	2 mg	Oral	100	..	BW
Butyl Monoester Polymer with Ethanol B.P.	Paste, 60 g	Application	1	..	SQ
Butyl Monoester Polymer with Isopropyl Alcohol B.P.	Protective dressing aerosol, 120 g	Application	1	..	DY
	Protective dressing solution, 59 mL	Application	1	..	DY
	Protective dressing wipes, 50		1	..	DY

Name of Pharmaceutical Benefit	Form (strength, type, size, etc.)	Manner of administration	Maximum quantity	Number of repeats	Brand
Calciferol Tablets, High-Strength B.P.	250 micrograms	Oral	100	5	GL
Calcitonin (Human)—Synthetic	Injections, 0.5 mg with 2 mL amp. solvent, 5	Injection	3	..	CG
Calcitonin (Pork) B.P.	Injections, 160 I.U. vial with 2 mL vial gelatin solvent, 10	Injection	2	..	RG
Calcitriol	Capsule, 0.25 micrograms	Oral	100	..	RO
Calcium Carbonate B.P.	Tablet, 1.5 g (equivalent to 600 mg calcium)	Oral	60	2	LE
	Tablet (chewable), 1.25 g (equivalent to 500 mg calcium)	Oral	60	2	RK
Calcium Carbonate B.P. with Calcium Lactate-Gluconate	Tablet, compound effervescent, equivalent to 1 g calcium	Oral	30	2	SZ
Calcium Folinate	Injection, 3 mg in 1 mL amp.	Injection	5	..	BL
	Tablet, 15 mg	Oral	10	..	LE
Calcium Glubionate	Injection, 1.375 g in 10 mL amp.	Injection	5	1	SZ
Captopril	Tablet, 12.5 mg	Oral	90	5	SQ
	Tablet, 25 mg	Oral	90	5	SQ
	Tablet, 50 mg	Oral	90	5	SQ
Carbachol B.P. 1973	Eye drops, 15 mg per mL, 15 mL	Application to the eye	1	6	AQ
	Eye drops, 30 mg per mL, 15 mL	Application to the eye	1	6	AQ
Carbamazepine B.P.	Syrup, 100 mg per 5 mL, 300 mL	Oral	1	5	CG
Carbamazepine Tablets B.P.	100 mg	Oral	200	2	CG
	200 mg	Oral	200	2	AF, CG, PT
Carbimazole Tablets B.P.	5 mg	Oral	100	4	NS
Carmellose Sodium B.P.	Rings, 10 mm to 50 mm, compound adhesive, 30	Topical	1	..	ST
	Strip pack, compound adhesive (10 cm x 2 m)	Topical	1	..	ST
	Wafers, compound adhesive, pack of 5	Topical	1	5	ST
Carmellose Sodium B.P. with Pectin and Gelatin B.P.	Paste, 167 mg-167 mg-167 mg per g, 15 g	Application	1	..	SQ
	Powder, 333 mg-333 mg-333 mg per g, 15 g	Application	1	..	SQ
Cefotaxime Sodium with any determined brand of Water for Injections or other solvent	Injection, 1 g (base) (with required solvent)	Injection	5	..	RL
	Injection, 2 g (base) (with required solvent)	Injection	5	..	RL
Ceftriaxone Sodium with any determined brand of Water for Injections or other solvent	Injection, 250 mg (base) (with required solvent)	Injection	2	..	RO
	Injection, 500 mg (base) (with required solvent)	Injection	2	..	RO
	Injection, 1 g (base) (with required solvent)	Injection	2	..	RO
	Injection, 2 g (base) (with required solvent)	Injection	2	..	RO
Cephalexin B.P. with Purified Water B.P.	Granules for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	1	GL, LY
	Granules for syrup, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	GL, LY
Cephalexin Capsules B.P.	250 mg	Oral	20	1	GL, LY
	500 mg	Oral	20	1	GL, LY

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Cephalothin Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 1 g (base) (with required solvent)	Injection	5	..	GL, LY
	Injection, 2 g (base) (with required solvent)	Injection	1	..	LY
	Injection, 4 g (base) (with required solvent)	Injection	1	..	LY
Cephazolin Sodium with any determined brand of Water for Injections or other solvent	Injection, 500 mg (base) (with required solvent)	Injection	5	..	LY
	Injection, 1 g (base) (with required solvent)	Injection	5	..	LY
Charcoal, Activated B.P.	Tablet, 300 mg	Oral	500	1	EG, QE, TO
Chloral Hydrate B.P.	Capsule, 500 mg	Oral	25	..	SQ
	Mixture, 250 mg per 5 mL, 200 mL	Oral	1	..	DH
Chlorambucil Tablets B.P.	2 mg	Oral	100	2	BW
	5 mg	Oral	100	2	BW
Chloramine B.P.	Tablet, deodorant, 120 mg		500	..	PT
Chloramphenicol B.P.	Ear drops (aqueous), 5 mg per mL, 5 mL	Application to the ear	1	2	PD
Chloramphenicol B.P. with Polymyxin B Sulphate B.P.	Eye drops, 5 mg-5,000 units per mL, 10 mL	Application to the eye	1	2	PD
	Eye ointment, 10 mg-5,000 units per g, 4 g	Application to the eye	1	..	PD
Chloramphenicol Capsules B.P.	250 mg	Oral	16	..	PD
Chloramphenicol Eye Drops B.P.	5 mg per mL, 10 mL	Application to the eye	1	2	AG, PD, SI, US
Chloramphenicol Eye Ointment B.P.	10 mg per g, 4 g	Application to the eye	1	..	PD, SI
Chloramphenicol Palmitate Mixture B.P.	125 mg per 5 mL, 100 mL	Oral	1	..	PD
Chloramphenicol Sodium Succinate B.P. with any determined brand of Water for Injections or other solvent	Injection, 1 g vial (with required solvent)	Injection	3	..	PD
Chlorhexidine Gluconate	Solution, 50 mg per mL, 200 mL		1	1	IC
Chlormethiazole Capsules B.P.	192 mg	Oral	50	..	AP
Chlormethiazole Edisylate B.P.	Injection, 8 mg per mL, 500 mL	Injection	1	..	AP
Chloroquine Phosphate Tablets B.P.	250 mg	Oral	100	..	PT
Chloroquine Sulphate B.P.	Tablet, 200 mg	Oral	100	..	MB
Chloroquine Sulphate Injection B.P.	Ampoule, 40 mg per mL, 5 mL	Injection	5	1	MB
Chlorothiazide Tablets B.P.	500 mg	Oral	50	3	FM, FR, PT
Chlorpromazine Elixir B.P.	25 mg per 5 mL, 100 mL	Oral	1	4	MB
Chlorpromazine Injection B.P.	Ampoule, 25 mg in 1 mL	Injection	10	..	MB
	Ampoule, 50 mg in 2 mL	Injection	10	..	MB
Chlorpromazine Suppositories B.P.	100 mg, 5		1	2	MB
Chlorpromazine Tablets B.P.	10 mg	Oral	100	1	MB, PT
	25 mg	Oral	100	1	MB, PT
	50 mg	Oral	100	1	MB, PT
	100 mg	Oral	100	1	MB, PT
Chlorpropamide Tablets B.P.	250 mg	Oral	100	5	PF, PT
Chlortetracycline	Cream, equivalent to 30 mg per g Chlortetracycline Hydrochloride, 15 g	Application	1	..	LE
Chlortetracycline Hydrochloride B.P.	Ointment, 30 mg per g, 15 g	Application	1	..	LE
Chlorthalidone Tablets B.P.	25 mg	Oral	50	3	CG
Cholera Vaccine B.P.	Injection, 8,000 M. per 1 mL amp.	Injection	2	..	CS

Name of Pharmaceutical Benefit	Form (strength, type, size, etc.)	Manner of administration	Maximum quantity	Number of repeats	Brand
Cholestyramine	Sachets, containing 9 g powder (equivalent to 4 g cholestyramine), 50	Oral	2	5	AP
Choline Theophyllinate B.P.	Elixir, 50 mg per 5 mL, 500 mL	Oral	1	5	PD
	Syrup, 50 mg per 5 mL, 500 mL	Oral	1	5	WW
	Tablet, 100 mg	Oral	100	5	WW
	Tablet, 200 mg	Oral	100	5	PD, WW
Chorionic Gonadotrophin B.P.	Injection, 5,000 units (set containing one ampoule powder for injection and one ampoule solvent 1 mL)	Injection	2	..	CS
Cimetidine	Tablet, 200 mg	Oral	120	..	CS, SK
	Tablet, 400 mg	Oral	60	..	CS, SK
Clindamycin Capsules B.P.	75 mg	Oral	25	..	UP
	150 mg	Oral	25	..	UP
Clindamycin Palmitate Hydrochloride with Purified Water B.P.	Granules for syrup, 75 mg (base) per 5 mL, 100 mL	Oral	1	..	UP
Clioquinol B.P.	Cream, 10 mg per g, 30 g	Application	1	..	CG
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Clofibrate Capsules B.P.	500 mg	Oral	100	5	IC, PT
Clomiphene Tablets B.P.	50 mg, 5	Oral	2	5	ML
Clomipramine Hydrochloride B.P.	Tablet, 25 mg	Oral	50	1	CG
Clonazepam	Injection, 1 mg in 2 mL (set containing solution 1 mg in 1 mL and 1 mL diluent)	Injection	5	..	RO
	Paediatric drops, 2.5 mg in 1 mL, 10 mL	Oral	1	1	RO
	Tablet, 500 micrograms	Oral	200	2	RO
	Tablet, 2 mg	Oral	200	2	RO
Clonidine Hydrochloride Tablets B.P.	100 micrograms	Oral	100	5	BY
	150 micrograms	Oral	100	5	BY
Clopamide	Tablet, 5 mg	Oral	50	3	SZ
Clorexolone	Tablet, 25 mg	Oral	50	3	MB
Clotrimazole B.P.	Cream, 10 mg per g, 20 g	Application	1	1	BN, SH
	Lotion, 10 mg per mL, 20 mL	Application	1	1	BN, SH
	Pessaries, 100 mg, 6		1	..	BN, SH
	Pessary, 500 mg		1	..	BN
	Vaginal cream, 50 mg per 5 g, 35 g		1	..	BN, SH
	Vaginal cream, 100 mg per 5 g, 20 g		1	..	BN
Cloxacillin Capsules B.P.	250 mg (base)	Oral	24	..	AF, BR, CS
	500 mg (base)	Oral	24	..	AF, BR, CS
Cloxacillin Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 250 mg (base) (with required solvent)	Injection	5	..	BR, CS
	Injection, 500 mg (base) (with required solvent)	Injection	5	..	BR, CS
	Injection, 1 g (base) (with required solvent)	Injection	5	..	BR, CS
Cloxacillin Sodium B.P. with Purified Water B.P.	Powder for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	..	CS
Codeine Phosphate B.P. with Aspirin B.P.	Tablet, 30 mg-325 mg	Oral	20	..	BW
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Codeine Phosphate B.P. with Paracetamol B.P.	Tablet, 30 mg-500 mg	Oral	20	..	WL
Codeine Phosphate Tablets B.P.	30 mg	Oral	20	..	DH, FA, FM, US
Colchicine Tablets B.P.	500 micrograms	Oral	100	2	DH, PR, PT, RT
Colestipol Hydrochloride	Sachets, 5 g, 120	Oral	1	5	UP

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Colistin Sulphate B.P. with Neomycin Sulphate B.P.	Ear drops, 3 mg (base)-3.3 mg (base) per mL, 10 mL	Application to the ear	1	2	WW
Colistin Sulphomethate Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 150 mg (with required solvent)	Injection	5	..	WW
Copper Sulphate B.P.C. 1973	Tablets, diagnostic compound, 36		2	3	AM
Cortisone Tablets B.P.	5 mg	Oral	50	4	PT
	25 mg	Oral	60	4	PT
Co-trimoxazole Mixture, Paediatric B.P.	40 mg-200 mg per 5 mL, 100 mL	Oral	1	1	AF, BW, PT, RO
Co-trimoxazole Tablets B.P.	80 mg-400 mg	Oral	10	..	AF, BW, PT, RO
	160 mg-800 mg	Oral	10	..	AF, BW, PT, RO
Cyclopenthiazide Tablets B.P.	500 micrograms	Oral	50	3	CG
Cyclophosphamide B.P. with any determined brand of Water for Injections or other solvent	Injection, 100 mg vial (with required solvent)	Injection	6	..	FE
	Injection, 200 mg vial (with required solvent)	Injection	6	..	FE
	Injection, 500 mg vial (with required solvent)	Injection	2	..	FE
	Injection, 1 g vial (with required solvent)	Injection	1	..	FE
Cyclophosphamide Tablets B.P.	50 mg	Oral	50	2	FE
Cyproheptadine Tablets B.P.	4 mg	Oral	100	2	FR
Cytarabine B.P.	Injection, 40 mg in 2 mL amp.	Injection	10	1	BT
	Injection, 100 mg in 5 mL amp.	Injection	10	1	BT
	Injection, 500 mg in 25 mL amp.	Injection	2	1	BT
	Injection set containing 100 mg and 5 mL solvent	Injection	10	1	UP
Danazol	Capsule, 100 mg	Oral	100	..	WL
	Capsule, 200 mg	Oral	100	..	WL
Dantrolene Sodium	Capsule, 25 mg	Oral	100	2	NW
	Capsule, 50 mg	Oral	100	2	NW
Dapsone Tablets B.P.	100 mg	Oral	100	2	IC
Debrisoquine Tablets B.P.	10 mg (base)	Oral	100	5	RO
	20 mg (base)	Oral	100	5	RO
"De-Lact Infant"	Powder, 500 g	Oral	2	..	SJ
Demeclocycline Capsules B.P.	150 mg	Oral	100	3	LE
Desipramine Tablets B.P.	25 mg	Oral	50	2	CG
Desmopressin	Nasal solution, 100 micrograms per mL, 2.5 mL dropper bottle	Nasal	5	2	PT
Dexamethasone B.P.	Eye drops, 1 mg per mL, 5 mL	Application to the eye	1	2	AQ
Dexamethasone B.P. with Framycetin Sulphate B.P. and Gramicidin	Ear ointment, 500 micrograms-5 mg-50 micrograms per g, 5 g	Application to the ear	1	2	RL
Dexamethasone Sodium Metasulphobenzoate with Framycetin Sulphate B.P. and Gramicidin	Ear drops, 500 micrograms (base)-5 mg-50 micrograms per mL, 8 mL	Application to the ear	1	2	RL
Dexamethasone Sodium Phosphate B.P.	Injection, 1 mL amp. containing equivalent of 4 mg Dexamethasone Phosphate	Injection	5	..	MK
	Injection, 1 mL vial containing equivalent of 5 mg Dexamethasone Phosphate	Injection	5	..	OR
	Injection, 2 mL vial containing equivalent of 8 mg Dexamethasone Phosphate	Injection	5	..	MK

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
	Injection, 5 mL vial containing equivalent of 120 mg Dexamethasone Phosphate	Injection	1	..	MK
Dexamethasone Tablets B.P.	500 micrograms	Oral	30	4	OR, PT
	4 mg	Oral	30	4	PT
Dexamphetamine Tablets B.P.	5 mg	Oral	100	..	SI
Dextran 40 Intravenous Infusion B.P. with Glucose B.P.	100 mg per mL-139 mmol per 500 mL, 500 mL	Injection	3	..	PS
Dextran 40 Intravenous Infusion B.P. with Sodium Chloride B.P.	100 mg per mL-77 mmol per 500 mL, 500 mL	Injection	3	..	PS
Dextran 70 Intravenous Infusion B.P. with Glucose B.P.	60 mg per mL-139 mmol per 500 mL, 500 mL	Injection	3	..	PS
Dextran 70 Intravenous Infusion B.P. with Sodium Chloride B.P.	60 mg per mL-77 mmol per 500 mL, 500 mL	Injection	3	..	PS
Diazepam B.P.	Syrup, 2 mg per 5 mL, 100 mL	Oral	1	..	RO
Diazepam Injection B.P.	10 mg in 2 mL	Injection	5	..	BL, RO
Diazepam Tablets B.P.	2 mg	Oral	50	..	AF, PT, RO, SU
	5 mg	Oral	50	..	AF, PT, RO, SU
Diazoxide Injection B.P.	300 mg in 20 mL	Injection	1	..	BL, SH
Dichlorphenamide Tablets B.P.	50 mg	Oral	50	6	MK
Diclofenac Sodium	Tablet, 50 mg (enteric coated)	Oral	50	3	CG
Dienoestrol B.P.	Cream, 500 micrograms per 5 g, 85 g		1	1	CL
Difenoxin Hydrochloride with Atropine Sulphate B.P.	Tablet, 500 micrograms-25 micrograms	Oral	20	..	PT
Diflunisal Tablets B.P.	250 mg	Oral	50	3	MK
"Digestelact"	Powder, 500 g	Oral	2	20	SJ
Digoxin Elixir, Paediatric B.P.	50 micrograms per mL, 100 mL	Oral	1	3	BW
Digoxin Injection B.P.	Ampoule, 500 micrograms in 2 mL	Injection	5	1	BW
Digoxin Tablets B.P.	62.5 micrograms	Oral	100	3	BW
	250 micrograms	Oral	50	3	BW
Dihydroergotamine Mesylate B.P.	Injection, 1 mg in 1 mL amp.	Injection	5	..	SZ
Dihydrotachysterol B.P.	Capsule, 125 micrograms	Oral	100	..	WL
Diloxanide Furoate Tablets B.P.	500 mg	Oral	30	..	BT
Diltiazem Hydrochloride	Tablet, 60 mg	Oral	100	5	IC
Dimercaprol Injection B.P.	Ampoule, 100 mg in 2 mL	Injection	12	..	BT
Dimethicones B.P.	Cream, 100 mg per g, 50 g	Application	1	..	HA
	Cream, 100 mg per g, 75 g	Application	1	..	FA
	Solution, 100 mg per mL, 180 mL aerosol spray pack	Application	1	..	EG
Diphenoxylate Hydrochloride B.P. with Atropine Sulphate B.P.	Tablet, 2.5 mg-25 micrograms	Oral	20	..	SR
Diphtheria and Tetanus Vaccine, Adsorbed B.P.	Injection, 0.5 mL amp.	Injection	3	..	CS
Diphtheria and Tetanus Vaccine, Adsorbed B.P. Diluted	Injection, 0.5 mL amp. For immunization of adults and children over the age of 8 years	Injection	3	..	CS
Diphtheria Antitoxin B.P.	Injection, 10,000 units amp.	Injection	2	1	CS
Diphtheria, Tetanus and Pertussis Vaccine, Adsorbed B.P.	Injection, 0.5 mL amp.	Injection	3	..	CS, PD
Diphtheria Vaccine, Adsorbed B.P.	Injection, 0.5 mL amp.	Injection	2	1	CS
Diphtheria Vaccine, Adsorbed B.P. Diluted	Injection, 0.5 mL amp. For immunization of adults and children over the age of 8 years	Injection	2	..	CS

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Dipivefrine Hydrochloride	Eye drops, 1 mg per mL, 10 mL	Application to the eye	1	6	AG
Dipyridamole Tablets B.P.	100 mg	Oral	100	..	BY, PT
Disodium Etidronate	Tablet, 200 mg	Oral	60	..	NW
Disopyramide Capsules B.P.	100 mg	Oral	100	5	RL
	150 mg	Oral	100	5	RL
Disopyramide Phosphate Capsules B.P.	100 mg (base)	Oral	100	5	SR
	150 mg (base)	Oral	100	5	SR
Docusate Sodium B.P. with Bisacodyl B.P.	Suppositories, 100 mg-10 mg, 5		2	..	FM
Domperidone	Tablet, 10 mg	Oral	25	..	JP
Dothiepin Capsules B.P.	25 mg	Oral	50	2	BT
Dothiepin Hydrochloride B.P.	Tablet, 75 mg	Oral	30	2	BT
Doxepin Capsules B.P.	10 mg (base)	Oral	50	2	AF, PF
	25 mg (base)	Oral	50	2	AF, PF
Doxepin Hydrochloride B.P.	Tablet, 50 mg (base)	Oral	50	2	AF
Doxorubicin Hydrochloride	Powder for I.V. injection, 10 mg vial	Injection	4	..	FE
	Powder for I.V. injection, 20 mg vial	Injection	4	..	FE
	Powder for I.V. injection, 50 mg vial	Injection	3	..	FE
Doxycycline Capsules B.P.	100 mg	Oral	7	1	PT
Doxycycline Hydrochloride B.P.	Capsule, 50 mg (base) (containing enteric coated pellets)	Oral	25	5	FA
	Capsule, 100 mg (base) (containing enteric coated pellets)	Oral	7	1	FA
	Tablet, 50 mg (base)	Oral	25	5	AF, PF
	Tablet, 100 mg (base)	Oral	7	1	AF, PF
Dydrogesterone Tablets B.P.	10 mg	Oral	50	..	CL
Econazole Nitrate B.P.	Lotion, 10 mg per mL, 20 mL	Application	1	1	SK, SQ
Econazole Nitrate Cream B.P.	10 mg per g, 20 g	Application	1	1	SK, SQ
	75 mg per 5 g, 35 g	Application	1	..	SQ
Econazole Nitrate Pessaries B.P.	150 mg, 3		1	..	SK, SQ
Ecothiopate Iodide B.P.	Eye drops, 300 micrograms per mL (1.5 mg and 5 mL vial of solvent)	Application to the eye	1	6	AY
	Eye drops, 600 micrograms per mL (3 mg and 5 mL vial of solvent)	Application to the eye	1	6	AY
	Eye drops, 1.25 mg per mL (6.25 mg and 5 mL vial of solvent)	Application to the eye	1	6	AY
	Eye drops, 2.5 mg per mL (12.5 mg and 5 mL vial of solvent)	Application to the eye	1	6	AY
Enalapril Maleate	Tablet, 5 mg	Oral	30	5	MK
	Tablet, 10 mg	Oral	30	5	MK
	Tablet, 20 mg	Oral	30	5	MK
Epicillin	Capsule, 250 mg	Oral	25	1	SQ
	Capsule, 500 mg	Oral	12	1	SQ
Ergocalciferol B.P.	Solution, alcoholic, 15 mg in 1.5 mL ampoule	Oral	3	5	RL
Ergometrine and Oxytocin Injection B.P.	Ampoule, 500 micrograms-5 units in 1 mL	Injection	5	..	SZ
Ergometrine Injection B.P.	Ampoule, 250 micrograms in 1 mL	Injection	5	..	BL
Ergometrine Tablets B.P.	200 micrograms	Oral	24	..	LY
Ergotamine Tablets B.P.	1 mg	Oral	50	2	WL
Ergotamine Tartrate B.P. with Caffeine B.P.	Suppositories, compound, 6		1	2	SZ
	Tablet, 1 mg-100 mg	Oral	50	2	SZ

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Ergotamine Tartrate B.P. with Caffeine B.P. and Cyclizine Hydrochloride B.P.	Tablet, 2 mg-100 mg-50 mg	Oral	50	2	BW
Ergotamine Tartrate B.P. with Caffeine Citrate B.P.C. 1959 and Diphenhydramine Hydrochloride B.P.	Capsule, 1 mg-100 mg-25 mg	Oral	50	2	PD
Erythromycin B.P.	Capsule, 125 mg (containing enteric coated pellets)	Oral	25	1	FA
	Capsule, 250 mg (containing enteric coated pellets)	Oral	25	1	FA, LY
Erythromycin Estolate B.P.	Drops, paediatric, 100 mg (base) per mL, 10 mL	Oral	1	1	LY
	Suspension, 125 mg (base) per 5 mL, 100 mL	Oral	1	1	LY
Erythromycin Ethyl Succinate B.P.	Injection, 100 mg (base) in 2 mL	I.M. injection	5	..	AB
	Tablet, chewable, 200 mg (base)	Oral	25	1	AB
Erythromycin Ethyl Succinate B.P. with Purified Water B.P.	Granules for suspension, 200 mg (base) per 5 mL, 100 mL	Oral	1	1	AB
Erythromycin Lactobionate	Infusion, I.V., 300 mg (base)	Injection	5	..	AB
	Infusion, I.V., 1 g (base)	Injection	1	..	AB
Erythromycin Stearate B.P.	Capsule, 250 mg (base)	Oral	25	1	AB, PT
	Suspension, 125 mg (base) per 5 mL, 100 mL	Oral	1	1	AB
	Suspension, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	AB
Erythromycin Stearate Tablets B.P.	250 mg (base)	Oral	25	1	AB
Erythromycin Tablets B.P.	250 mg	Oral	25	1	UP
Ethacrynic Acid Tablets B.P.	50 mg	Oral	50	3	MK
Ethanolamine Oleate Injection B.P.	50 mg per mL, 2 mL	Injection	5	1	GL
Ethinyloestradiol Tablets B.P.	10 micrograms	Oral	100	2	GL
	20 micrograms	Oral	100	2	GL, SC
	50 micrograms	Oral	100	2	GL
Ethosuximide Capsules B.P.	250 mg	Oral	200	2	PD
Ethosuximide Elixir B.P.	250 mg per 5 mL, 250 mL	Oral	1	4	PD
Ethyloestrenol Tablets B.P.	2 mg	Oral	100	3	OR
Ethynodiol Diacetate B.P. with Ethinyloestradiol B.P.	Pack containing 21 tablets, 500 micrograms-50 micrograms and 7 inert tablets	Oral	4	2	SR
	Pack containing 21 tablets, 1 mg-50 micrograms and 7 inert tablets	Oral	4	2	SR
	Tablets, 500 micrograms-50 micrograms, 21	Oral	4	2	SR
	Tablets, 1 mg-50 micrograms, 21	Oral	4	2	SR
Etretinate	Capsule, 10 mg	Oral	100	..	RO
	Capsule, 25 mg	Oral	100	..	RO
Fenoterol Hydrobromide B.P.	Elixir, 2.5 mg per 5 mL, 300 mL	Oral	1	5	BY
	Solution, 1 mg per mL, 20 mL	Inhalation	1	5	BY
	Spray, metered aerosol, 60 mg in 21 g (300 dose)	Inhalation	1	5	BY
Ferrous Aminoacetosulphate	Syrup, 100 mL	Oral	1	4	NN
Ferrous Gluconate B.P.	Elixir, 300 mg per 5 mL, 100 mL	Oral	1	4	WL
Ferrous Gluconate Tablets B.P.	300 mg	Oral	100	2	WL
Ferrous Sulphate Dried B.P.	Capsule, 320 mg, equivalent to 96 mg Ferrous Iron (delayed release)	Oral	30	2	SK
	Tablet, 320 mg, equivalent to 96 mg Ferrous Iron (delayed release)	Oral	30	2	CG

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
	Tablet, 350 mg, equivalent to 105 mg Ferrous Iron (sustained release)	Oral	30	2	AB, PT
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Ferrous Sulphate Dried B.P. with Folic Acid B.P.	Capsule, 270 mg, equivalent to 80 mg Ferrous Iron-300 micrograms (delayed release)	Oral	30	2	SK
	Tablet, 270 mg, equivalent to 80 mg Ferrous Iron-300 micrograms (delayed release)	Oral	30	2	PT
	Tablet, 270 mg, equivalent to 80 mg Ferrous Iron-300 micrograms (sustained release)	Oral	30	2	AB
Flecainide Acetate	Tablet, 100 mg	Oral	60	5	RK
Fluclorolone Acetonide B.P.	Cream, 250 micrograms per g, 15 g	Application	1	1	SD
Flucloxacillin Capsules B.P.	250 mg (base)	Oral	24	..	AF, BR, CS
	500 mg (base)	Oral	24	..	AF, BR, CS
Flucloxacillin Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 250 mg (base) (with required solvent)	Injection	5	..	CS
	Injection, 500 mg (base) (with required solvent)	Injection	5	..	BR, CS
	Injection, 1 g (base) (with required solvent)	Injection	5	..	BR, CS
Flucloxacillin Sodium B.P. with Purified Water B.P.	Powder for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	..	BR, CS
Flucytosine Tablets B.P.	500 mg	Oral	100	..	RO
Fludrocortisone Tablets B.P.	100 micrograms	Oral	100	3	SQ
Flumethasone Pivalate with Clioquinol B.P.	Ear drops, 200 micrograms-10 mg per mL, 7.5 mL	Application to the ear	1	..	CG
Fluocortolone Pivalate and Fluocortolone Hexanoate Cream B.P.	400 micrograms-400 micrograms per g, 100 g	Application	2	..	SC
	1 mg-1 mg per g, 15 g	Application	1	1	SC
Fluocortolone Pivalate and Fluocortolone Hexanoate Ointment B.P.	1 mg-1 mg per g, 15 g	Application	1	1	SC
	Anhydrous base, 1 mg-1 mg per g, 15 g	Application	1	1	SC
Fluorometholone	Eye drops, 1 mg per mL, 5 mL	Application to the eye	1	6	AG, AQ
Fluorouracil Injection B.P.	Ampoule, 250 mg in 10 mL	Injection	10	..	RO
	Ampoule, 500 mg in 10 mL	Injection	5	1	FE
Fluoxymesterone Tablets B.P.	5 mg	Oral	100	3	UP
Fluphenazine Decanoate Injection B.P.	Ampoule, 12.5 mg in 0.5 mL	Injection	5	..	SQ
	Ampoule, 50 mg in 2 mL	Injection	5	..	SQ
	Syringe, disposable, 25 mg in 1 mL	Injection	5	..	SQ
Fluphenazine Hydrochloride B.P.	Elixir, 500 micrograms per mL, 60 mL	Oral	1	4	SQ
Fluphenazine Tablets B.P.	1 mg	Oral	100	1	SQ
	2.5 mg	Oral	100	1	SQ
	5 mg	Oral	100	1	SQ
Folic Acid B.P.	Injection, 15 mg in 1 mL amp.	Injection	10	..	AB
Folic Acid Tablets B.P.	500 micrograms	Oral	100	..	DH, PT, SI
	5 mg	Oral	100	2	DH, FM, NN, PR, PT, RT, SI, US
Fosfestrol Sodium B.P.	Injection, 250 mg in 5 mL	Injection	10	..	BC
	Tablet, 120 mg	Oral	100	2	BC
Framycetin Sulphate B.P.	Eye/ear drops, 5 mg per mL, 8 mL	Application to the eye/ear	1	2	RL
	Eye ointment, 5 mg per g, 5 g	Application to the eye	1	..	RL

Name of Pharmaceutical Benefit	Form (strength, type, size, etc.)	Manner of administration	Maximum quantity	Number of repeats	Brand
Frusemide B.P.	Solution, 10 mg per mL, 30 mL	Oral	1	3	HP
Frusemide Injection B.P.	Ampoule, 20 mg in 2 mL	Injection	5	..	AF, HP
Frusemide Tablets B.P.	20 mg	Oral	50	3	FM, HP
	40 mg	Oral	50	3	FM, HP, PT
	500 mg	Oral	50	3	FM, HP
Fusidic Acid Mixture B.P.	50 mg per mL, 90 mL	Oral	1	..	SK
"Galactomin, Formula No. 17"	Powder, 454 g	Oral	2	20	KY
Gas-gangrene Antitoxin, Mixed B.P.	Injection, 1 amp. containing 10,000 units Perfringens; 5,000 units Septicum; 10,000 units Novyi	Injection	2	1	CS
Gentamicin Eye Drops B.P.	3 mg (base) per mL, 5 mL	Application to the eye	1	2	AG
Gentamicin Injection B.P.	Ampoule, 40 mg (base) in 1 mL	Injection	5	..	BL, SH
	Ampoule, 60 mg (base) in 1.5 mL	Injection	5	..	BL, SH
	Ampoule, 80 mg (base) in 2 mL	Injection	5	..	BL, RL, SH
	Syringe, disposable, 80 mg (base)	Injection	5	..	SH
Glibenclamide Tablets B.P.	5 mg	Oral	100	5	HP, RC
Gliclazide	Tablet, 80 mg	Oral	100	5	SE
Glucagon Hydrochloride	Injection, 1 I.U. with diluent	Injection	1	1	CN, LY
Glucose and Ketone Indicator—Urine	100 reagent strips		1	2	AM
Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P.	Powder, 36.354 g-354 mg-903 mg-606 mg-1.781 g per sachet, 6	Oral	1	..	DH
Glucose Indicator—Blood	50 reagent strips (Ames-BG)		2	5	AM
	50 reagent strips (BM-Test-BG)		2	5	BO
	50 reagent strips (BM-Test-Glycemie 20-800)		2	5	BO
	50 reagent strips (Glucostix)		2	5	AM
Glucose Indicator—Urine	4 m dispenser		1	2	LY
	100 reagent strips (Clinistix)		1	2	AM
	100 reagent strips (Diastix)		1	2	AM
Glucose Intravenous Infusion B.P.	278 mmol per L, 1 L	Injection	5	1	AB, GF, TV
	555 mmol per L, 1 L	Injection	5	1	AB, TV
	1,110 mmol per L, 1 L	Injection	2	1	AB
	1,387 mmol per L, 1 L	Injection	2	1	AB, TV
	Ampoule, 5 g in 10 mL	Injection	5	..	AP
	1,387 mmol per 500 mL, 500 mL	Injection	2	1	AB
Glyceryl Trinitrate	Ointment, 20 mg per g, 60 g	Application	1	5	PT
	Transdermal disc, 16 mg	Application	30	2	SR
	Transdermal disc, 32 mg	Application	30	2	SR
	Transdermal pad, 25 mg	Application	30	2	CG
	Transdermal pad, 50 mg	Application	30	2	CG
Glyceryl Trinitrate Tablets B.P.	600 micrograms, 100	Oral	1	5	BW
Griseofulvin Tablets B.P.	125 mg	Oral	100	2	GL, IC
	330 mg	Oral	28	2	PT, SH
	500 mg	Oral	28	2	GL, IC
Haloperidol B.P.	Injection, 5 mg in 1 mL amp.	Injection	10	..	SR
Haloperidol Tablets B.P.	1.5 mg	Oral	100	1	SR
	5 mg	Oral	50	1	SR
Heparin Injection B.P. (Calcium Salt)	5,000 I.U. in 0.2 mL	Injection	5	5	BL, CS, FC
	5,000 I.U. in 0.5 mL	Injection	5	5	CS
	12,500 I.U. in 0.5 mL	Injection	2	5	BL, CS
	25,000 I.U. in 1 mL	Injection	2	5	BL, CS

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Heparin Injection B.P. (Sodium Salt)	Ampoule, 5,000 units per 0.2 mL	Injection	5	5	BL, CS, FC
	Ampoule, 5,000 units per 1 mL	Injection	5	5	BL, CS, FC
	Ampoule, 20,000 units per 20 mL	Injection	12	5	BL
	Ampoule, 25,000 units per 5 mL	Injection	2	5	CS, FC
	Vial, 35,000 units per 35 mL	Injection	12	5	CS, FC
Hexamine Hippurate	Tablet, 1 g	Oral	100	5	RK
Hexamine Mandelate	Tablet, 250 mg	Oral	100	5	WW
	Tablet, 500 mg	Oral	100	5	WW
	Tablet, 1 g	Oral	100	5	WW
Homatropine Hydrobromide B.P.	Eye drops, 20 mg per mL, 15 mL	Application to the eye	1	2	AG, AQ
	Eye drops, 50 mg per mL, 15 mL	Application to the eye	1	2	AG, AQ
Hydralazine Hydrochloride Tablets B.P.	25 mg	Oral	100	5	AF, CG, PT
	50 mg	Oral	100	5	AF, CG, PT
Hydrochlorothiazide B.P. with Amiloride Hydrochloride B.P.	Tablet, 50 mg-5 mg	Oral	50	3	AF, MK, PT
Hydrochlorothiazide B.P. with Triamterene B.P.	Tablet, 25 mg-50 mg	Oral	50	3	SK
Hydrochlorothiazide Tablets B.P.	25 mg	Oral	50	3	CG, MK
	50 mg	Oral	50	3	CG, MK
Hydrocortisone B.P.	Tablet, 4 mg	Oral	50	4	PT
	Tablet, 20 mg	Oral	60	4	PT
Hydrocortisone Acetate B.P.	Eye drops, 5 mg per mL, 10 mL	Application to the eye	1	2	SI
	Eye drops, 10 mg per mL, 10 mL	Application to the eye	1	2	SI
	Eye drops, 25 mg per mL, 5 mL	Application to the eye	1	2	SI
	Eye drops, 25 mg per mL, 10 mL	Application to the eye	1	2	SI
	Eye ointment, 5 mg per g, 4 g	Application to the eye	1	..	UP
	Eye ointment, 5 mg per g, 5 g	Application to the eye	1	..	SI
	Eye ointment, 10 mg per g, 5 g	Application to the eye	1	..	SI
	Rectal foam, 100 mg per g, aerosol, 25 g		2	1	SV
Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P.	Ear drops, 15 mg-3.5 mg (base) per mL, 5 mL	Application to the ear	1	..	UP
	Ear ointment, 15 mg-3.5 mg (base) per g, 4 g	Application to the ear	1	2	UP
Hydrocortisone Acetate Cream B.P.	10 mg per g, 30 g	Application	1	1	NN, PD, PR, SI, SQ, UP, US
	10 mg per g, 50 g	Application	1	1	NN, PD, PR, SI, SQ, UP, US
Hydrocortisone Acetate Injection B.P.	Ampoule, 25 mg in 1 mL	Intra-articular injection	5	..	PT
Hydrocortisone Acetate Ointment B.P.	10 mg per g, 30 g	Application	1	1	NN, PD, PR, SI, SQ, UP
	10 mg per g, 50 g	Application	1	1	NN, PD, PR, SI, SQ, UP

Name of Pharmaceutical Benefit	Form (strength, type, size, etc.)	Manner of administration	Maximum quantity	Number of repeats	Brand
Hydrocortisone Sodium Succinate B.P.	Injection set containing equivalent of 100 mg Hydrocortisone and 2 mL solvent	Injection	2	..	NR, UP
	Injection set containing equivalent of 250 mg Hydrocortisone and 2 mL solvent	Injection	1	..	UP
	Injection set containing equivalent of 500 mg Hydrocortisone and 4 mL solvent	Injection	2	..	UP
Hydroxocobalamin Injection B.P.	1 mg in 1 mL amp.	Injection	3	..	GL
Hydroxychloroquine Tablets B.P.	200 mg	Oral	100	1	WL
Hydroxyurea Capsules B.P.	500 mg	Oral	100	..	SQ
Hyoscyamine Hydrobromide with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.	Tablet, 101.1 micrograms-14.8 micrograms-10.7 micrograms	Oral	100	2	FM
	Tablet, 151.6 micrograms-22.2 micrograms-16.0 micrograms	Oral	100	2	FM
Hyoscyamine Sulphate B.P. with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.	Tablet, 103.7 micrograms-19.4 micrograms-6.5 micrograms	Oral	100	2	RS
Hypromellose 4500 B.P.	Eye drops, 5 mg per mL, 15 mL	Application to the eye	1	6	AG, AQ, SI
	Eye drops, 10 mg per mL, 15 mL	Application to the eye	1	6	SI
Hypromellose 4500 B.P. with Dextran 70	Eye drops, 3 mg-1 mg per mL, 15 mL	Application to the eye	1	6	AQ
Ibuprofen Tablets B.P.	200 mg	Oral	50	3	AF, BT, PT
	400 mg	Oral	50	3	BT, PT
Idoxuridine B.P.	Eye ointment, 5 mg per g, 5 g	Application to the eye	1	..	SK
	Ointment, 5 mg per g, 5 g	Topical application	1	..	SK
Idoxuridine Eye Drops B.P.	1 mg per mL, 15 mL	Application to the eye	1	2	AG, SK
Imipramine Hydrochloride B.P.	Injection, 25 mg in 2 mL amp.	Injection	10	..	CG
Imipramine Tablets B.P.	10 mg	Oral	50	2	CG, PT
	25 mg	Oral	50	2	CG, PT, UW
Indapamide	Tablet, 2.5 mg	Oral	30	3	SE
Indomethacin Capsules B.P.	25 mg	Oral	50	3	AF, MK, PT
Indomethacin Suppositories B.P.	100 mg		20	3	MK
Influenza Vaccine (Split Virion), Inactivated B.P.	Injection containing antigens representative of the following types: A/Singapore/6/86 (H1N1)-like strain 15 micrograms haemagglutinin; A/Mississippi/1/85 (H3N2)-like strain 15 micrograms haemagglutinin; B/Ann Arbor/1/86-like strain 15 micrograms haemagglutinin; 0.5 mL prefilled syringe	Injection	1	..	CS, MB
Insect Allergen Extract—Bull Ant	Injection set, strengths A, B, C each of 5 mL vial	Injection	1	..	CS
	Injection set, strengths A, B, C, D each of 5 mL vial	Injection	1	..	CS
	Injection, C strength, 5 mL vial	Injection	1	..	CS

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
	Injection, D strength, 5 mL vial	Injection	1	..	CS
Insect Allergen Extract—Honey Bee Venom	Injection set containing 550 micrograms vial with 9 mL vial solvent and 3 vials diluent 1.8 mL	Injection	1	..	BN
Insect Allergen Extract—Jumper Ant	Injection set, strengths A, B, C each of 5 mL vial	Injection	1	..	CS
	Injection set, strengths A, B, C, D each of 5 mL vial	Injection	1	..	CS
	Injection, C strength, 5 mL vial	Injection	1	..	CS
	Injection, D strength, 5 mL vial	Injection	1	..	CS
Insect Allergen Extract—Mosquito	Injection set, strengths A, B, C each of 5 mL vial	Injection	1	..	CS
	Injection set, strengths A, B, C, D each of 5 mL vial	Injection	1	..	CS
	Injection, C strength, 5 mL vial	Injection	1	..	CS
	Injection, D strength, 5 mL vial	Injection	1	..	CS
Insect Allergen Extract—Paper Wasp Venom	Injection set containing 550 micrograms vial with 9 mL vial solvent and 3 vials diluent 1.8 mL	Injection	1	..	BN
Insulin Injection B.P.	Vial, (bovine) 100 units per mL, 10 mL	Injection	5	2	CN
	Vial, (bovine) 300 units per mL, 5 mL	Injection	10	2	CN
Insulin Injection, Biphasic B.P.	Vial, (mixed porcine/bovine) 100 units per mL, 10 mL	Injection	5	2	CN
Insulin Injection, Isophane B.P.	Vial, (bovine) 100 units per mL, 10 mL	Injection	5	2	CN, FC
	Vial, (porcine) 100 units per mL, 10 mL	Injection	5	2	BW, CN
Insulin Injection, Isophane B.P. and Insulin Injection, Neutral B.P.	Vial, (porcine) 50 units-50 units per mL, 10 mL	Injection	5	2	BW
	Vial, (porcine) 70 units-30 units per mL, 10 mL	Injection	5	2	BW, CN
Insulin Injection, Neutral B.P.	Cartridges, (porcine) 100 units per mL, 1.5 mL, 5	Injection	7	2	CN
	Cartridges, (porcine) 100 units per mL, 2 mL, 5	Injection	5	2	BW
	Vial, (bovine) 100 units per mL, 10 mL	Injection	5	2	FC
	Vial, (porcine) 100 units per mL, 10 mL	Injection	5	2	BW, CN
Insulin Injection, Protamine Zinc B.P.	Vial, (bovine) 100 units per mL, 10 mL	Injection	5	2	CN
Insulin Isophane, Human (Synthetic)	Injection, 100 units per mL, 10 mL vial	Injection	5	2	BW, CN, LY
Insulin Isophane, Human (Synthetic) and Insulin Neutral, Human (Synthetic)	Injection, 50 units-50 units per mL, 10 mL vial	Injection	5	2	BW
	Injection, 70 units-30 units per mL, 10 mL vial	Injection	5	2	BW, CN
Insulin Neutral, Human (Synthetic)	Injection, 100 units per mL, 10 mL vial	Injection	5	2	BW, CN, LY
	Injection, cartridges, 100 units per mL, 1.5 mL, 5	Injection	7	2	CN
Insulin Zinc Suspension B.P.	Injection, (bovine) 100 units per mL, 10 mL vial	Injection	5	2	CN
	Injection, (porcine) 100 units per mL, 10 mL vial	Injection	5	2	CN
Insulin Zinc Suspension (Amorphous) B.P.	Injection, (porcine) 100 units per mL, 10 mL vial	Injection	5	2	CN

Name of Pharmaceutical Benefit	Form (strength, type, size, etc.)	Manner of administration	Maximum quantity	Number of repeats	Brand
Insulin Zinc Suspension (Crystalline) B.P.	Injection, (bovine) 100 units per mL, 10 mL vial	Injection	5	2	CN
Insulin Zinc Suspension (Crystalline), Human (Synthetic)	Injection, 100 units per mL, 10 mL vial	Injection	5	2	CN
Insulin Zinc Suspension, Human (Synthetic)	Injection, 100 units per mL, 10 mL vial	Injection	5	2	CN
Intraperitoneal Dialysis Solutions B.P.C. 1973	1 L (Glucose 83 mmol per L), 12	Injection	2	1	TV
	1 L (Glucose 236 mmol per L), 10	Injection	2	1	TV
Ipratropium Bromide	Nebuliser solution, 250 micrograms per mL, 20 mL	Inhalation	1	5	BY
	Spray, metered aerosol, 20 micrograms per dose, 200 dose, 10 mL	Inhalation	1	5	BY
Iron Dextran Injection B.P.	Ampoule, 2 mL	Injection	5	..	FC
Iron Polymaltose Complex	Injection, 100 mg (Iron) in 2 mL amp.	Injection	5	..	SI
	Tablet, 40 mg (Iron)	Oral	100	2	SI
Iron Sorbitol Injection B.P.	Ampoule, 50 mg (Iron) per mL, 2 mL	I.M. injection	5	..	AP
Isoconazole Nitrate	Cream, 10 mg per g, 20 g	Application	1	1	SC
	Lotion, 10 mg per mL, 20 mL	Application	1	1	SC
	Pessaries, 300 mg, 2		1	..	SC
Isoniazid Tablets B.P.	50 mg	Oral	200	2	FM
	100 mg	Oral	100	2	FM
Isopropyl Monoester Polymer with Isopropyl Alcohol B.P.	Gel, adhesive protective, 28.35 g	Application	1	..	HO
Isosorbide Dinitrate Tablets B.P.	5 mg (sublingual)	Oral	100	5	AY, PD
	10 mg	Oral	100	5	AY, PD
Isotretinoin	Capsule, 10 mg	Oral	60	3	RO
	Capsule, 20 mg	Oral	60	3	RO
Kaolin, Light B.P. or Light Kaolin (Natural) B.P. with Pectin	Suspension, 5.91 g-132 mg per 30 mL, 375 mL	Oral	1	2	UP
Ketoprofen B.P.	Capsule, 100 mg (sustained release)	Oral	50	3	MB
	Suppository, 100 mg		20	3	MB
Ketoprofen Capsules B.P.	50 mg	Oral	50	3	MB
	100 mg	Oral	50	3	MB
Labetalol Hydrochloride Tablets B.P.	100 mg	Oral	100	5	AF, GL
	200 mg	Oral	100	5	AF, GL
Lactulose Solution B.P.	3.34 g per 5 mL, 500 mL	Oral	1	..	CL
Lauramine Oxide with Octoxinol	Cleansing solution, compound, 80 mg-10 mg per g, 240 mL		1	..	DY
Leuprorelin Acetate	Injection, 5 mg per mL, 2.8 mL vial	Injection	2	2	AB
Levodopa and Carbidopa Tablets B.P.	100 mg-10 mg	Oral	100	5	MK
	100 mg-25 mg	Oral	100	5	MK
	250 mg-25 mg	Oral	100	5	MK
Levodopa B.P. with Benserazide	Capsule, 50 mg-12.5 mg	Oral	100	5	RO
	Capsule, 100 mg-25 mg	Oral	100	5	RO
	Capsule, 200 mg-50 mg	Oral	100	5	RO
	Tablet, 200 mg-50 mg	Oral	100	5	RO
Levodopa Tablets B.P.	100 mg	Oral	50	5	RO
	250 mg	Oral	100	5	RO
	500 mg	Oral	250	5	RO
Levonorgestrel B.P.	Tablets, 30 micrograms, 28	Oral	4	2	SC, WY
Levonorgestrel B.P. with Ethinyloestradiol B.P.	Pack containing 21 tablets, 125 micrograms-50 micrograms and 7 inert tablets	Oral	4	2	SC, WY
	Pack containing 21 tablets, 150 micrograms-30 micrograms and 7 inert tablets	Oral	4	2	SC, WY

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
	Pack containing 21 tablets, 250 micrograms-50 micrograms and 7 inert tablets	Oral	4	2	SC, WY
	Pack containing 11 tablets, 50 micrograms-50 micrograms and 10 tablets, 125 micrograms-50 micrograms	Oral	4	2	WY
	Pack containing 11 tablets, 50 micrograms-50 micrograms, 10 tablets, 125 micrograms-50 micrograms and 7 inert tablets	Oral	4	2	SC, WY
	Pack containing 6 tablets, 50 micrograms-30 micrograms, 5 tablets, 75 micrograms-40 micrograms and 10 tablets, 125 micrograms-30 micrograms	Oral	4	2	SC, WY
	Pack containing 6 tablets, 50 micrograms-30 micrograms, 5 tablets, 75 micrograms-40 micrograms, 10 tablets, 125 micrograms-30 micrograms and 7 inert tablets	Oral	4	2	SC, WY
	Tablets, 125 micrograms-50 micrograms, 21	Oral	4	2	SC
	Tablets, 150 micrograms-30 micrograms, 21	Oral	4	2	SC, WY
	Tablets, 250 micrograms-50 micrograms, 21	Oral	4	2	SC, WY
Lignocaine Hydrochloride B.P.	Injection, 100 mg in 5 mL	Injection	2	..	AP
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Lignocaine Hydrochloride Injection B.P.	Syringe, disposable, 300 mg in 3 mL	I.M. injection	1	..	AP
	500 mg in 5 mL	Infusion	5	..	AP
Lincomycin Injection B.P.	Ampoule, 300 mg (base) in 1 mL	Injection	5	..	UP
	Ampoule, 600 mg (base) in 2 mL	Injection	5	..	UP
Lindane B.P.	Head lotion, 2 mg per mL, 200 mL	Application	1	..	IC
	Lotion concentrate, 10 mg per mL, 200 mL	Application	1	..	IC
Lindane Cream B.P.	10 mg per g, 200 g	Application	1	2	IC
Liothyronine Tablets B.P.	20 micrograms	Oral	100	1	GL
Lithium Carbonate B.P.	Tablet, 400 mg (delayed release)	Oral	100	3	PT
Lithium Carbonate Tablets B.P.	250 mg	Oral	100	5	DH, PT
"Locasol New Formula"	Powder, 450 g	Oral	2	20	KY
"Lofenalac"	Powder, 1 lb	Oral	5	5	MJ
Loperamide Hydrochloride	Capsule, 2 mg	Oral	12	..	JP
Lypressin	Spray, nasal, 50 units per mL. 5 mL	Nasal spray	10	2	SZ
Maldison	Lotion, 5 mg per mL, 100 mL	Application	1	..	FL
"Maxamaid XP"	Powder, 200 g	Oral	5	5	SJ
Medroxyprogesterone Acetate B.P.	Injection, 50 mg in 1 mL vial	Injection	1	..	UP
	Injection, 150 mg in 1 mL vial	Injection	1	..	UP
	Injection, 500 mg in 2.5 mL vial	Injection	1	..	FE
	Oral suspension, 100 mg per mL, 100 mL	Oral	1	2	UP
	Tablet, 10 mg	Oral	30	5	UP
	Tablet, 100 mg	Oral	100	2	FE, UP
	Tablet, 200 mg	Oral	60	2	FE, UP
	Tablet, 250 mg	Oral	60	2	UP
	Tablet, 500 mg	Oral	30	2	FE, UP

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Medrysone	Eye drops, 10 mg per mL, 5 mL	Application to the eye	1	6	AG
Mefenamic Acid Capsules B.P.	250 mg	Oral	50	2	AF, PD
Mefruside	Tablet, 25 mg	Oral	50	3	BN
Megestrol Acetate B.P.	Tablet, 40 mg	Oral	100	2	BC
Melphalan Tablets B.P.	2 mg	Oral	100	..	BW
	5 mg	Oral	100	..	BW
Mercaptopurine Tablets B.P.	50 mg	Oral	100	2	BW
Metformin Tablets B.P.	500 mg	Oral	100	5	AF, DF, LH
Methacycline Hydrochloride B.P. 1973	Capsule, 150 mg	Oral	21	1	WW
	Capsule, 300 mg	Oral	11	1	WW
Methadone Injection B.P.	Ampoule, 10 mg in 1 mL	Injection	5	..	BW
Methadone Tablets B.P.	5 mg	Oral	20	..	BW
	10 mg	Oral	20	..	BW
Methdilazine Hydrochloride	Tablet, 4 mg	Oral	100	2	GL
	Tablet, 8 mg	Oral	100	2	GL
Methenolone Acetate	Tablet, 5 mg	Oral	100	3	SC
Methotrexate B.P. with any determined brand of Water for Injections or other solvent	Injection, 50 mg vial (with required solvent)	Injection	5	..	LE
Methotrexate Injection B.P.	Vial, 5 mg in 2 mL	Injection	5	..	LE
	Vial, 50 mg in 2 mL	Injection	5	..	BL, LE
Methotrexate Tablets B.P.	2.5 mg	Oral	100	2	FE, LE
	10 mg	Oral	100	2	FE
Methsuximide	Capsule, 300 mg	Oral	200	2	PD
Methyclothiazide	Tablet, 2.5 mg	Oral	50	3	AB
	Tablet, 5 mg	Oral	50	3	AB
Methyldopa Tablets B.P.	125 mg	Oral	100	5	MK
	250 mg	Oral	100	5	AF, MK, US
Methylphenobarbitone B.P.	Tablet, 30 mg	Oral	200	2	WL
	Tablet, 60 mg	Oral	200	2	WL
	Tablet, 200 mg	Oral	200	2	WL
Methylprednisolone Acetate Injection B.P.	Vial, 40 mg in 1 mL	Injection	5	..	UP
Methylprednisolone Sodium Succinate	Injection, 40 mg (base) in 1 mL amp.	Injection	5	..	UP
Methyl Salicylate Liniment A.P.F.	100 mL	Application	1	1	DH, MG, NN, PR, QE, SI, TO
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Methyltestosterone Tablets B.P.	5 mg	Oral	100	2	PT
	25 mg	Oral	100	2	CL, PT
	50 mg	Oral	100	2	PT
Methysergide Tablets B.P.	1 mg (base)	Oral	100	2	SZ
Metoclopramide Hydrochloride B.P.	Syrup, 5 mg per 5 mL, 100 mL	Oral	1	..	BR, US
Metoclopramide Injection B.P.	Ampoule, 10 mg in 2 mL	Injection	10	..	BR
Metoclopramide Tablets B.P.	10 mg	Oral	25	..	AF, BR, PT, US
Metolazone	Tablet, 2.5 mg	Oral	50	3	SR
Metoprolol Tartrate	Tablet, 50 mg	Oral	100	5	AP, CG
	Tablet, 100 mg	Oral	60	5	AP, CG
Metronidazole Benzoate	Suspension, 320 mg per 5 mL, 100 mL	Oral	1	..	MB
Metronidazole B.P.	Intravenous infusion, 500 mg in 100 mL	Injection	1	..	BL, MB
Metronidazole Suppositories B.P.	500 mg, 10		1	..	MB, PT
	1 g, 10		1	..	MB

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Metronidazole Tablets B.P.	200 mg	Oral	21	1	MB, PT, SR
	250 mg	Oral	21	1	CL
	400 mg	Oral	5	1	MB
	500 mg	Oral	4	1	CL
Mexiletine Hydrochloride Capsules B.P.	50 mg	Oral	100	5	BY
	200 mg	Oral	100	5	BY
Mianserin Hydrochloride Tablets B.P.	10 mg	Oral	50	..	OR
	20 mg	Oral	50	..	OR
Miconazole	Oral gel, 20 mg per mL, 20 g	Oral	1	1	JP
	Tincture, 20 mg per mL, 20 mL	Application	1	1	JP
Miconazole Nitrate B.P.	Lotion, 20 mg per g, 20 g	Application	1	1	JP
	Pessaries, 100 mg, 7		1	..	CL, JP
	Pessaries, 200 mg, 3		1	..	CL
Miconazole Nitrate Cream B.P.	20 mg per g, 20 g	Application	1	1	CL, JP
	20 mg per g, 40 g	Application	1	..	CL, JP
Minocycline Hydrochloride	Capsule, 100 mg	Oral	11	..	LE
Minoxidil	Tablet, 10 mg	Oral	100	..	UP
	Tablet, 25 mg	Oral	100	..	UP
Misoprostol	Tablet, 200 micrograms	Oral	120	..	SR
Mithramycin	Injection, 2.5 mg (with required solvent)	Injection	5	..	PF
Mitozantrone Hydrochloride	Injection, 20 mg (base) in 10 mL vial	Injection	1	..	LE
	Injection, 25 mg (base) in 12.5 mL vial	Injection	1	..	LE
	Injection, 30 mg (base) in 15 mL vial	Injection	1	..	LE
Morphine Sulphate B.P. with Tacrine Hydrochloride	Tablet, 30 mg-15 mg	Oral	20	..	WH
Morphine Sulphate Injection B.P.	Ampoule, 10 mg in 1 mL	Injection	5	..	BL, BT, SI
	Ampoule, 15 mg in 1 mL	Injection	5	..	BL, BT, SI
	Ampoule, 30 mg in 1 mL	Injection	5	..	BL
Morphine Sulphate Tablets B.P.	30 mg	Oral	20	..	FM
"M.S.U.D. AID"	Powder, 200 g	Oral	5	5	SJ
Mustine Hydrochloride B.P. with any determined brand of Water for Injections or other solvent	Injection, 10 mg amp. (with required solvent)	Injection	4	..	BT
Nalidixic Acid Mixture B.P.	50 mg per mL, 200 mL	Oral	1	2	WL
Nalidixic Acid Tablets B.P.	500 mg	Oral	56	2	WL
Naloxone Hydrochloride	Injection, 40 micrograms in 2 mL amp.	Injection	5	..	BT
	Injection, 400 micrograms in 1 mL disposable injection set	Injection	1	..	CS
	Injection, 800 micrograms in 2 mL disposable injection set	Injection	1	..	CS
	Injection, 2 mg in 5 mL disposable injection set	Injection	1	..	CS
Nandrolone Decanoate Injection B.P.	Disposable syringe, 50 mg in 1 mL	Injection	1	3	OR
Nandrolone Phenylpropionate Injection B.P.	Ampoule, 25 mg in 1 mL	Injection	3	3	OR
Naphazoline Hydrochloride	Eye drops, 1 mg per mL, 15 mL	Application to the eye	1	2	AG
Naproxen B.P.	Suppository, 500 mg		20	3	SD
Naproxen Tablets B.P.	250 mg	Oral	50	3	AF, SD
	500 mg	Oral	50	3	SD
Natamycin	Cream, 20 mg per g, 15 g	Application	1	1	GB
	Pessaries, 25 mg, 20		1	..	GB

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
	Suspension, 10 mg per mL, 5 mL	Oral	1	1	GB
	Tablet, 100 mg	Oral	50	..	GB
Neomycin Sulphate Eye Drops B.P.	5 mg per mL, 10 mL	Application to the eye	1	2	SI
Neomycin Tablets B.P.	500 mg	Oral	25	1	CL, PT
Neomycin Undecenoate with Bacitracin Zinc B.P.	Ear ointment, 12 mg (3.5 mg base)-400 units per g, 10 g	Application to the ear	1	..	HA
Neostigmine Injection B.P.	Ampoule, 500 micrograms in 1 mL	Injection	5	3	RO
	Ampoule, 2.5 mg in 1 mL	Injection	5	3	RO
Neostigmine Tablets B.P.	15 mg	Oral	100	2	RO
Niclosamide Tablets B.P.	500 mg	Oral	4	..	BN
Nicotinic Acid Tablets B.P.	25 mg	Oral	100	2	DH, US
	50 mg	Oral	100	2	DH, RT, SI, US
	100 mg	Oral	100	2	DH, US
	250 mg	Oral	100	2	DH
Nifedipine	Capsule, 10 mg	Oral	100	5	AF, BN
	Tablet, 20 mg	Oral	60	5	BN
Nitrazepam Tablets B.P.	5 mg	Oral	25	..	AF, PT, RO
Nitrofurantoin B.P.	Capsule, 50 mg	Oral	30	1	NW
	Capsule, 100 mg	Oral	30	1	NW
Nitrofurantoin Mixture B.P.	25 mg per 5 mL, 200 mL	Oral	1	..	NW
Nitrofurantoin Tablets B.P.	50 mg	Oral	25	1	NW
	100 mg	Oral	25	1	NW
Norethisterone Acetate B.P.	Tablet, 10 mg	Oral	100	2	SC
Norethisterone Acetate B.P. with Ethinyloestradiol B.P.	Pack containing 21 tablets, 1 mg-50 micrograms and 7 inert tablets	Oral	4	2	SC
	Tablets, 1 mg-50 micrograms, 21	Oral	4	2	SC
Norethisterone B.P. with Ethinyloestradiol B.P.	Pack containing 21 tablets, 500 micrograms-35 micrograms and 7 inert tablets	Oral	4	2	SD
	Pack containing 21 tablets, 1 mg-35 micrograms and 7 inert tablets	Oral	4	2	SD
	Pack containing 12 tablets, 500 micrograms-35 micrograms, 9 tablets, 1 mg-35 micrograms and 7 inert tablets	Oral	4	2	SD
	Tablets, 500 micrograms-35 micrograms, 21	Oral	4	2	CL, SD
	Tablets, 1 mg-35 micrograms, 21	Oral	4	2	SD
Norethisterone B.P. with Mestranol B.P.	Pack containing 21 tablets, 1 mg-50 micrograms and 7 inert tablets	Oral	4	2	SD
	Tablets, 1 mg-50 micrograms, 21	Oral	4	2	CL, SD
Norethisterone Tablets B.P.	350 micrograms, 28	Oral	4	2	CL, SD
	5 mg	Oral	30	5	SC
Norfloxacin	Tablet, 400 mg	Oral	14	1	MK
Norgestrel with Ethinyloestradiol B.P.	Tablets, 500 micrograms-50 micrograms, 20	Oral	4	2	SC
Nortriptyline Hydrochloride B.P.	Elixir, 10 mg per 5 mL, 100 mL	Oral	1	4	DL
Nortriptyline Tablets B.P.	10 mg	Oral	50	2	DL, SQ
	25 mg	Oral	50	2	DL, SQ
"Nutramigen"	Powder, 1 kg	Oral	1	20	MJ
Nystatin B.P.	Capsule, 500,000 units	Oral	50	..	SQ
	Cream, 100,000 units per g, 15 g	Application	1	1	LE, SQ

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
	Gel, 100,000 units per g, 15 g	Application	1	1	SQ
	Lozenge, 100,000 units	Oral	20	1	LE
	Tablet, 500,000 units	Oral	50	..	LE
	Vaginal cream, 100,000 units per 4 g, 75 g		1	1	SQ
	Vaginal cream, 100,000 units per 5 g, 75 g		1	1	LE
Nystatin Mixture B.P.	100,000 units per mL, 24 mL	Oral	1	1	LE, SQ
Nystatin Ointment B.P.	100,000 units per g, 15 g	Application	1	1	LE, SQ
Nystatin Pessaries B.P.	100,000 units, 15		1	1	LE, SQ
	100,000 units (cream base), 15		1	1	LE
Nystatin Tablets B.P.	500,000 units	Oral	50	..	GP, SQ
"Odortrol"	Liquid, 15 mL		1	..	LA
Oestradiol Valerate	Injection, 10 mg in 1 mL amp.	Injection	3	..	SC
	Tablet, 1 mg	Oral	28	5	SC
	Tablet, 2 mg	Oral	28	5	SC
Oestrogens—Conjugated	Tablet, 300 micrograms	Oral	28	5	AY
	Tablet, 625 micrograms	Oral	28	5	AY
Oestrone B.P.C. 1954	Pessaries, 0.1 mg, 12		1	1	OR
	Pessaries, 1 mg, 12		1	1	OR
Ornidazole	Tablet, 500 mg	Oral	3	..	RO
Orphenadrine Hydrochloride Tablets B.P.	50 mg	Oral	100	5	RK
Oxazepam Tablets B.P.	15 mg	Oral	25	..	AF, AY, PT, WY
	30 mg	Oral	25	..	AF, AY, PT, WY
Oxprenolol Hydrochloride B.P. with any determined brand of Water for Injections or other solvent	Injection, 2 mg (with required solvent)	Injection	5	..	CG
Oxprenolol Tablets B.P.	20 mg	Oral	100	5	AF, CG
	40 mg	Oral	100	5	AF, CG
Oxycodone Hydrochloride	Tablet, 5 mg	Oral	20	..	BT
Oxycodone Pectinate	Suppositories, 30 mg (base), 12		1	..	BT
Oxymetholone Tablets B.P.	50 mg	Oral	100	..	SD
	100 mg	Oral	100	..	PD
Oxytetracycline Hydrochloride B.P.	Ointment, 30 mg per g, 15 g	Application	1	..	PF
Oxytocin Injection B.P.	Ampoule, 2 units in 2 mL	Injection	5	..	SZ
	Ampoule, 5 units in 1 mL	Injection	5	..	SZ
	Ampoule, 10 units in 1 mL	Injection	5	..	SZ
Pancreatin B.P.	Capsule, providing not less than 6,500 B.P. units of lipase activity	Oral	500	4	RS
	Tablet, providing not less than 6,500 B.P. units of lipase activity	Oral	500	4	RS
Pancrelipase	Capsule, providing not less than 5,000 B.P. units of lipase activity	Oral	250	10	CL
	Capsule, providing not less than 10,000 B.P. units of lipase activity	Oral	250	10	OR
Papaveretum B.P.C. 1973	Injection, 20 mg in 1 mL amp.	Injection	5	..	RO
Papaveretum B.P.C. 1973 with Hyoscine Hydrobromide B.P.	Injection, 20 mg-400 micrograms in 1 mL amp.	Injection	5	..	RO
Paracetamol B.P.	Mixture, 120 mg per 5 mL, 100 mL	Oral	1	2	BW, US, WL

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Paracetamol Tablets B.P.	500 mg	Oral	100	1	BW, DH, FM, PR, WL
Paraffin, Soft White B.P.	Cream, compound, 85 g	Application	1	..	DY
	Ointment, compound, 70 g	Application	1	..	DY
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Paraffin, Soft White B.P. with Liquid Paraffin B.P.	Eye ointment, compound, 3.5 g	Application to the eye	1	6	AQ
	Eye ointment, compound, 7 g	Application to the eye	1	6	AG
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Penicillamine B.P.	Tablet, 125 mg	Oral	100	1	KN
	Tablet, 250 mg	Oral	100	1	KN
Penicillamine Tablets B.P.	125 mg	Oral	100	1	DL
	250 mg	Oral	100	1	DL
Perhexiline Maleate	Tablet, 100 mg	Oral	100	..	ML
Pericyazine	Mixture, 2.5 mg per 5 mL, 100 mL	Oral	1	4	MB
	Tablet, 2.5 mg	Oral	100	1	MB
	Tablet, 10 mg	Oral	100	1	MB
Pethidine Injection B.P.	Ampoule, 50 mg in 1 mL	Injection	5	..	BL, BT, SI
	Ampoule, 100 mg in 2 mL	Injection	5	..	BL, BT, SI
Pethidine Tablets B.P.	50 mg	Oral	20	..	SI
Phenelzine Tablets B.P.	15 mg	Oral	50	2	WW
Phenethicillin Capsules B.P.	250 mg	Oral	25	1	SI
	500 mg	Oral	25	1	SI
Phenethicillin Potassium B.P. with Purified Water B.P.	Powder for syrup, 125 mg (Phenethicillin) per 5 mL, 100 mL	Oral	1	1	SI
	Powder for syrup, 250 mg (Phenethicillin) per 5 mL, 100 mL	Oral	1	..	SI
Phenethicillin Tablets B.P.	250 mg	Oral	25	1	SI
Phenindione Tablets B.P.	10 mg	Oral	100	2	GL
	50 mg	Oral	100	2	GL
Phenobarbitone Injection B.P.	Ampoule, 200 mg in 1 mL	Injection	5	..	FM
Phenobarbitone Tablets B.P.	30 mg	Oral	200	4	DH, FM, SI
Phenoxybenzamine Capsules B.P.	10 mg	Oral	100	..	SK
Phenoxymethylpenicillin (Benzathine Salt)	Suspension, 125 mg per 5 mL, 100 mL	Oral	1	1	CS, SI
	Suspension, 250 mg per 5 mL, 100 mL	Oral	1	1	CS, SI
Phenoxymethylpenicillin (Hydrabamine Salt)	Suspension, 125 mg per 5 mL, 100 mL	Oral	1	1	AB
	Suspension, 250 mg per 5 mL, 100 mL	Oral	1	1	AB
	Tablet, 125 mg	Oral	25	1	AB
Phenoxymethylpenicillin Potassium Capsules B.P.	250 mg	Oral	25	1	AB, CS, FM, LY, SI
	500 mg	Oral	25	1	CS, FM, SI
Phenoxymethylpenicillin Potassium Tablets B.P.	250 mg	Oral	25	1	AB, CS, FM, LY, SI
	500 mg	Oral	25	1	AB, CS, FM, LY
Phensuximide B.P.C. 1973	Capsule, 500 mg	Oral	200	2	PD
Phenylephrine Hydrochloride B.P.	Eye drops, 1.2 mg per mL, 15 mL	Application to the eye	1	2	AG, AQ
	Eye drops, 100 mg per mL, 5 mL	Application to the eye	1	..	WL
	Ointment, compound, 60 g		1	1	WL
	Suppositories, compound, 12		1	1	WL

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Phenytoin B.P.	Tablets, 50 mg, 200	Oral	1	2	PD
Phenytoin Capsules B.P.	30 mg, 200	Oral	1	2	PD
	100 mg, 200	Oral	1	2	PD
Phenytoin Injection B.P.	Ampoule, 100 mg in 2 mL	Injection	1	..	PD
	Ampoule, 250 mg in 5 mL	Injection	1	..	PD
Phenytoin Mixture B.P.	30 mg per 5 mL, 500mL	Oral	1	3	PD
Phytomenadione Injection B.P.	Ampoule, 1 mg	Injection	5	..	RO
	Ampoule, 10 mg	Injection	5	..	RO
Pilocarpine	Eye disc, 5 mg (releasing 20 micrograms per hour)	Application to the eye	8	..	PT
	Eye disc, 11 mg (releasing 40 micrograms per hour)	Application to the eye	8	..	PT
Pilocarpine Hydrochloride B.P.	Eye drops, 5 mg per mL, 15 mL	Application to the eye	1	6	AG, AQ, IQ, SI
	Eye drops, 10 mg per mL, 15 mL	Application to the eye	1	6	AG, AQ, IQ, SI
	Eye drops, 20 mg per mL, 15 mL	Application to the eye	1	6	AG, AQ, IQ, SI
	Eye drops, 30 mg per mL, 15 mL	Application to the eye	1	6	AG, AQ, IQ, SI
	Eye drops, 40 mg per mL, 15 mL	Application to the eye	1	6	AG, AQ, IQ, SI
	Eye drops, 60 mg per mL, 15 mL	Application to the eye	1	6	AG, AQ, SI
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Pindolol B.P.	Injection, 400 micrograms in 2 mL amp.	Injection	5	..	SZ
Pindolol Tablets B.P.	5 mg	Oral	100	5	AF, SZ
	15 mg	Oral	50	5	AF, SZ
Piroxicam	Capsule, 10 mg	Oral	50	3	PF
Pizotifen Malate	Tablet, 500 micrograms (base)	Oral	100	2	SZ
"PK AID I"	Powder, 250 g	Oral	2	5	SJ
"PK AID II"	Powder, 250 g	Oral	2	5	SJ
Plague Vaccine B.P. 1973	Injection, 3,000 M. per mL, 0.5 mL amp.	Injection	2	..	CS
Pneumococcal Vaccine, Polyvalent	Injection, 0.5 mL in disposable syringe (17 valent)	Injection	1	..	SK
	Injection, 0.5 mL vial (23 valent)	Injection	1	..	CS
Polygeline	Intravenous infusion, 17.5 g per 500 mL with Na^+ 145 mmol per L, K^+ 5.1 mmol per L, Ca^{2+} 6.25 mmol per L and Cl^- 145 mmol per L; 500 mL	Injection	3	..	HP
Polyisobutylene	Wafers, compound adhesive, pack of 5	Topical	1	5	HO
	Wafers, compound adhesive with discs, pack of 5	Topical	1	5	BH, SQ
Polymyxin B Sulphate B.P. with Bacitracin B.P. 1968 and Neomycin Sulphate B.P.	Eye ointment, 5,000 units-400 units-5 mg per g, 4 g	Application to the eye	1	..	UP
Polymyxin B Sulphate B.P. with Bacitracin Zinc B.P. and Neomycin Sulphate B.P.	Ear drops, 10,000 units-500 units-3.5 mg (base) per mL, 15 mL	Application to the ear	1	..	CL
	Eye ointment, 5,000 units-400 units-5 mg per g, 4 g	Application to the eye	1	..	BW
Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin	Eye drops, 5,000 units-2.5 mg-25 micrograms per mL, 10 mL	Application to the eye	1	2	BW
Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P.	Ear drops, 10,000 units-5 mg-10 mg per mL, 7 mL	Application to the ear	1	2	BW

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Polyvinyl Alcohol	Eye drops, 14 mg per mL, 15 mL	Application to the eye	1	6	AG
	Eye drops, 30 mg per mL, 15 mL	Application to the eye	1	6	AG
Polyvinyl Alcohol with Povidone B.P.	Eye drops, 14 mg-6 mg per mL, 15 mL	Application to the eye	1	6	AG
Polyvinylpyrrolidone and Vinyl Acetate Copolymer	Spray, aerosol, 60 mg per mL, 121 mL	Application	1	..	EG
"Portagen"	Powder, 450 g	Oral	2	20	MJ
Potassium Chloride B.P.	Elixir, 1.5 g per 15 mL, 500 mL	Oral	1	2	SC
	Tablet, 600 mg (sustained release)	Oral	100	2	AF, CG, PR, PT
Potassium Chloride B.P. with Potassium Bicarbonate Effervescent Tablets	14 mmol K^+ and 8 mmol Cl^-	Oral	30	2	PT
Pralidoxime Iodide	Injection, 500 mg	Injection	5	..	AB
Prazosin Hydrochloride	Tablet, 1 mg (base)	Oral	100	5	PF
	Tablet, 2 mg (base)	Oral	100	5	PF
	Tablet, 5 mg (base)	Oral	100	5	PF
Prednisolone Acetate	Eye drops, 5 mg per mL, 5 mL	Application to the eye	1	6	AQ
	Injection, 10 mg in 1 mL amp.	Intra-articular injection	5	..	SC
Prednisolone Acetate with Phenylephrine Hydrochloride B.P.	Eye drops, 10 mg-1.2 mg per mL, 10 mL	Application to the eye	1	2	AG
Prednisolone B.P.	Eye ointment, 5 mg per g, 4 g	Application to the eye	1	..	UP
Prednisolone Sodium Phosphate B.P.	Enema, retention, 20 mg per 100 mL	Enema	28	1	GL
	Eye/ear drops, 5 mg per mL, 5 mL	Application to the eye/ear	1	6	GL
	Suppositories, 5 mg (base), 10		3	1	GL
Prednisolone Stearoylglycolate	Tablet, 6.65 mg	Oral	30	2	FE
Prednisolone Tablets B.P.	1 mg	Oral	100	4	PT
	5 mg	Oral	60	4	FM, NN, PR, PT, UP, US
	25 mg	Oral	30	4	FM, PT
Prednisone Tablets B.P.	1 mg	Oral	100	4	PT
	5 mg	Oral	60	4	DH, FM, NN, PR, PT, US
	25 mg	Oral	30	4	FM, PT
"Pregestimil"	Powder, 454 g	Oral	2	20	MJ
Primaquine Tablets B.P.	Tablet, equivalent to 7.5 mg Primaquine base	Oral	42	..	IC
Primidone Tablets B.P.	250 mg	Oral	200	2	IC, PT
Probenecid Tablets B.P.	500 mg	Oral	100	5	FR, PT
Probucol	Tablet, 250 mg	Oral	112	5	ML
Procainamide Hydrochloride B.P.	Capsule, 250 mg	Oral	100	2	SQ
	Capsule, 375 mg	Oral	100	2	SQ
Procainamide Injection B.P.	Vial, 100 mg per mL, 10 mL	Injection	2	..	SQ
Procaine Penicillin Injection B.P.	Syringe, disposable, 1 g	Injection	5	..	SI
	Syringe, disposable, 1.5 g	Injection	5	..	SI
Procarbazine Hydrochloride	Capsule, 50 mg	Oral	100	2	RO
Prochlorperazine	Suppositories, 3 mg, equivalent to 5 mg Prochlorperazine Maleate, 5		1	2	MB
	Suppositories, 15 mg, equivalent to 25 mg Prochlorperazine Maleate, 5		1	2	MB
Prochlorperazine Edisylate	Injection, 12.5 mg in 1 mL	Injection	10	..	SK
Prochlorperazine Injection B.P.	Ampoule, 12.5 mg in 1 mL	Injection	10	..	MB

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Prochlorperazine Tablets B.P.	5 mg	Oral	25	..	MB, PT, SK
Procyclidine Tablets B.P.	5 mg	Oral	100	5	BW
Promethazine Hydrochloride Injection B.P.	Ampoule, 50 mg in 2 mL	Injection	10	..	BL
Promethazine Theoclate Tablets B.P.	25 mg	Oral	30	1	MB
Propantheline Tablets B.P.	15 mg	Oral	100	5	PT
Propranolol Injection B.P.	1 mg in 1 mL	Injection	5	..	IC
Propranolol Tablets B.P.	10 mg	Oral	100	5	AF, IC, PT
	40 mg	Oral	100	5	AF, IC, PT
	160 mg	Oral	50	5	AF, IC, PT
Propylthiouracil Tablets B.P.	50 mg	Oral	100	4	CL
Protamine Sulphate Injection B.P.	Ampoule, 10 mg per mL, 10 mL	Injection	6	..	BT
Pyrantel Embonate	Tablet, 125 mg (base)	Oral	6	..	AF
	Tablet, 250 mg (base)	Oral	6	..	AF
Pyridostigmine Injection B.P.	Ampoule, 1 mg	Injection	5	1	RO
Pyridostigmine Tablets B.P.	10 mg	Oral	100	2	RO
	60 mg	Oral	100	2	RO
	180 mg (sustained release)	Oral	100	1	RO
Pyridoxine Hydrochloride B.P.	Injection, 50 mg in 1 mL amp.	Injection	5	1	FM
Pyridoxine Hydrochloride Tablets B.P.	25 mg	Oral	100	..	DH, FM, PT
Pyrimethamine B.P. with Dapsone B.P.	Tablet, 12.5 mg-100 mg	Oral	10	..	BW
Pyrimethamine B.P. with Sulfadoxine B.P.	Tablet, 25 mg-500 mg	Oral	12	..	RO
Pyrimethamine Tablets B.P.	25 mg	Oral	50	..	BW
Quinethazone	Tablet, 50 mg	Oral	50	3	LE
Quinidine Bisulphate B.P.	Tablet, 250 mg (sustained release)	Oral	100	5	AP
Quinidine Sulphate B.P.	Tablet, 300 mg (sustained release)	Oral	100	5	RS
Quinidine Sulphate Tablets B.P.	200 mg	Oral	100	5	BW, DH, NN, PR, PT, QE
Quinine Bisulphate Tablets B.P.	300 mg	Oral	50	2	AF, DH, FM, NN, PR, PT, SI, SL, US
Quinine Sulphate Tablets B.P.	300 mg	Oral	50	2	AF, DH, FM, NN, PR, PT, SI, SL, US
Ranitidine Hydrochloride	Tablet, 150 mg (base)	Oral	60	..	GL
Red-back Spider Antivenom	Injection, 500 units amp.	Injection	2	..	CS
Rifampicin B.P.	Capsule, 150 mg	Oral	10	..	AF
	Capsule, 300 mg	Oral	10	..	AF
Rolitetracycline	Injection, 275 mg amp. and 10 mL solvent	I.V. injection	5	..	HP
	Injection, 350 mg amp. and 2 mL solvent	I.M. injection	5	..	HP
Salbutamol B.P.	Spray, metered aerosol, 20 mg in 17 g	Inhalation	1	5	GL, RK

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Salbutamol Sulphate B.P.	Capsule, 200 micrograms (base)	Inhalation by mouth	100	5	GL
	Solution, 5 mg (base) per mL, 30 mL	Inhalation	1	5	GL, RK
	Syrup, 2 mg (base) per 5 mL, 300 mL	Oral	1	5	GL, RK
Salbutamol Tablets B.P.	4 mg	Oral	100	5	GL, RK
Salcatonin Injection B.P.	50 I.U. in 1 mL amp., 5	Injection	6	..	SZ
	80 I.U. in 0.8 mL amp., 5	Injection	3	..	SZ
	100 I.U. in 1 mL amp., 5	Injection	3	..	RG, SZ
	400 I.U. in 2 mL vial	Injection	4	..	RG
Silver Sulphadiazine with Chlorhexidine Gluconate	Cream, 10 mg-2 mg per g, 50 g	Application	1	..	SN
	Cream, 10 mg-2 mg per g, 100 g	Application	1	..	SN
	Cream, 10 mg-2 mg per g, 500 g	Application	1	..	SN
Sodium Acid Citrate B.P.	Mixture, 5.5 g per 20 mL, 500 mL	Oral	1	4	PD
Sodium Acid Phosphate B.P.	Tablet, compound effervescent, equivalent to 500 mg phosphorus	Oral	100	..	SZ
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Sodium Aurothiomalate Injection B.P.	Ampoule, 10 mg	Injection	5	..	MB
	Ampoule, 20 mg	Injection	10	1	MB
	Ampoule, 50 mg	Injection	10	1	MB
Sodium Bicarbonate Intravenous Infusion B.P.	100 mmol in 100 mL	Injection	5	..	AB
Sodium Calciumedetate B.P.	Tablet, 500 mg	Oral	100	2	RK
Sodium Chloride and Glucose Intravenous Infusion B.P.	31 mmol-222 mmol per L, 1 L	Injection	5	1	AB, GF, TV
	31 mmol-239 mmol per L, 1 L	Injection	5	1	AB
	19 mmol-104 mmol per 500 mL, 500 mL	Injection	5	1	AB, TV
	39 mmol-69 mmol per 500 mL, 500 mL	Injection	5	1	AB, TV
	154 mmol-278 mmol per L, 1 L	Injection	2	1	AB, TV
Sodium Chloride B.P. with Potassium Chloride B.P. and Calcium Chloride B.P. in Water for Injections	Sodium Chloride Compound Injection—1 L	Injection	4	1	AB, TV
Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.	Electrolyte Replacement Solution, 5.26 g-3.68 g-5.02 g-370 mg-300 mg per L, 1 L	Injection	2	1	AB, TV
Sodium Chloride Intravenous Infusion B.P.	Ampoule, 9 mg per mL, 2 mL	Injection	5	1	AP, BT
	Ampoule, 9 mg per mL, 5 mL	Injection	5	1	AP, BT
	Ampoule, 9 mg per mL, 10 mL	Injection	5	1	AP, BT
	154 mmol per L, 1 L	Injection	5	1	AB, GF, TV
	513 mmol per L, 1 L	Injection	2	1	AB, TV
Sodium Citro-Tartrate	Granules, effervescent, 100 g	Oral	1	4	AB, PT
Sodium Cromoglycate B.P.	Eye drops, 20 mg per mL, 10 mL	Application to the eye	1	..	FC
	Nebuliser solution, 20 mg per 2 mL, ampoule	Inhalation	120	3	FC
	Spray, metered aerosol, 1 mg per dose, 200 dose, 13.87 g	Inhalation	1	5	FC
Sodium Cromoglycate Insufflation B.P.	Capsule, 20 mg	Inhalation by mouth	100	5	FC
Sodium Fusidate B.P.	Tablet, 250 mg (enteric coated)	Oral	36	..	SK

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Sodium Lactate Compound Intravenous Infusion B.P.	1 L	Injection	5	1	AB, GF, TV
Sodium Lactate Compound Intravenous Infusion B.P. with Anhydrous Glucose B.P.	278 mmol per L, 1 L	Injection	2	1	AB, TV
Sodium Lactate Intravenous Infusion B.P.	1 L	Injection	5	1	VF
Sodium Nitroprusside B.P.	Infusion, 50 mg	Injection	10	..	RO
Sodium Salicylate B.P.	Tablet, 600 mg (enteric coated)	Oral	100	2	AY, PR
Sodium Valproate B.P.	Oral liquid, 200 mg per 5 mL, 200 mL	Oral	3	2	RC
	Tablet, 200 mg (enteric coated)	Oral	200	2	RC
	Tablet, 500 mg (enteric coated)	Oral	200	2	RC
	Tablet, crushable, 100 mg	Oral	200	2	RC
Sodium Valproate Elixir B.P.	200 mg per 5 mL, 200 mL	Oral	3	2	RC
Spectinomycin Hydrochloride B.P.	Injection, 2 g (base) with 3.2 mL diluent	Injection	1	..	UP
	Injection, 4 g (base) with 6.5 mL diluent	Injection	1	..	UP
Spironolactone Tablets B.P.	25 mg	Oral	100	5	PT, SR
Staphylococcus Toxoid B.P. 1968	Injection, 5 mL (diluted 1 in 10)	Injection	1	..	CS
	Injection, 5 mL (undiluted)	Injection	1	..	CS
Sterculia B.P.	Discs, 12		1	5	BH, DY
	Discs, compound, 10		1	5	DY
	Paste, 127.6 g		1	..	HO
	Powder, 71 g		1	..	DY
	Squares, 6		1	5	BH
Sterculia B.P. with Frangula Bark B.P.	Granules, 473 mg-83 mg per g, 250 g	Oral	1	2	SC
Stilboestrol Tablets B.P.	500 micrograms	Oral	100	2	HA
	1 mg	Oral	100	2	HA
	5 mg	Oral	100	2	HA
	10 mg	Oral	100	2	HA
Streptokinase B.P. with any determined brand of Water for Injections or other solvent	Injection, 100,000 I.U. (with required solvent)	Injection	2	..	PS
	Injection, 250,000 I.U. (with required solvent)	Injection	2	..	HP, PS
	Injection, 600,000 I.U. (with required solvent)	Injection	5	..	PS
	Injection, 750,000 I.U. (with required solvent)	Injection	5	..	HP
Sucralfate	Tablet, 1 g	Oral	120	2	BT
Sulindac Tablets B.P.	100 mg	Oral	50	3	FR
Sulphacetamide Sodium B.P.	Eye drops, 100 mg per mL, 15 mL	Application to the eye	1	2	AG, SI
	Eye drops, 200 mg per mL, 15 mL	Application to the eye	1	2	SI
Sulphadimidine Tablets B.P.	500 mg	Oral	40	2	PT
Sulphafurazole B.P.	Eye drops, 40 mg per mL, 10 mL	Application to the eye	1	2	RO
	Eye ointment, 40 mg per g, 5 g	Application to the eye	1	..	RO
Sulphafurazole Tablets B.P.	500 mg	Oral	40	2	RO
Sulphamethizole B.P.	Suspension, paediatric, 100 mg per 5 mL, 100 mL	Oral	1	1	WW
Sulphamethizole Tablets B.P.	250 mg	Oral	40	2	PT
	500 mg	Oral	40	2	PT, WW
	1 g	Oral	20	2	WW
Sulphapyridine Tablets B.P.	500 mg	Oral	100	..	MB

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Sulphasalazine	Tablet, 500 mg	Oral	200	5	AF, PS, PT
	Tablet, 500 mg (enteric coated)	Oral	200	5	PS
Sulphinpyrazone Tablets B.P.	100 mg	Oral	100	5	CG
Sulthiame Tablets B.P.	50 mg	Oral	200	2	BN
	200 mg	Oral	200	2	BN
"Super Banish"	Liquid, 7.5 mL		1	..	DY
Surgical Cement	Skin Bond Adhesive, 118 mL	Application	1	2	DY
Surgical Cement Solvent	227 mL	Application	1	2	DY
	240 mL	Application	1	2	EG
	250 mL	Application	1	2	EG
Tamoxifen Citrate Tablets B.P.	10 mg (base)	Oral	60	5	IC
	20 mg (base)	Oral	60	5	IC
Temazepam	Capsule, 10 mg	Oral	25	..	AF, SI, WY
Terbutaline Sulphate B.P.	Elixir, 300 micrograms per mL, 300 mL	Oral	1	5	AP
	Injection, 100 micrograms in 1 mL amp.	Injection	5	..	AP
	Injection, 500 micrograms in 1 mL amp.	Injection	5	..	AP
	Nebuliser solution, 10 mg per mL, 50 mL	Inhalation	1	5	AP
	Spray, metered aerosol, 250 micrograms per dose, 400 dose, 14 g	Inhalation	1	5	AP
Terbutaline Sulphate Tablets B.P.	5 mg	Oral	100	5	AP
"Teric" N8 with Lauryldimethylbenzyl Ammonium Chloride	Solution, deodorant detergent, 125 g-12.5 g per 500 mL		1	..	EG
Testosterone Enanthate B.P.	Injection, 250 mg in 1 mL amp.	Injection	3	3	SC
Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P. and Testosterone Isocaproate B.P.	Injection, 20 mg-40 mg-40 mg amp.	Injection	3	3	OR
Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.	Injection, 30 mg-60 mg-60 mg-100 mg amp.	Injection	3	3	OR
Testosterone Propionate Injection B.P.	Ampoule, 50 mg in 1 mL	Injection	9	..	SC
Tetanus Vaccine, Adsorbed B.P.	Injection, 0.5 mL amp.	Injection	3	..	CS
Tetrabenazine	Tablet, 25 mg	Oral	100	2	RO
Tetracosactrin Zinc Injection B.P.	Ampoule, 500 micrograms in 1 mL	Injection	5	..	CG
	Ampoule, 1 mg in 1 mL	Injection	5	..	CG
Tetracycline B.P. with a buffering agent	Capsule, 250 mg	Oral	25	1	AP, CS, FM, HP, LE, SQ
Tetracycline B.P. with a buffering agent and Nystatin B.P.	Capsule, 250 mg-250,000 units	Oral	25	1	SQ
Tetracycline Capsules B.P.	250 mg	Oral	25	1	BZ, LE, UP
Tetracycline Hydrochloride B.P. with Nystatin B.P.	Capsule, 250 mg-250,000 units	Oral	25	1	AP, LE
Theophylline B.P.	Capsule, 100 mg (controlled release)	Oral	100	5	FC
	Capsule, 200 mg	Oral	100	5	SC
	Capsule, 250 mg (controlled release)	Oral	100	5	FC
	Elixir, 80 mg per 15 mL, 500 mL	Oral	1	5	SC

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
	Syrup, 80 mg per 15 mL, 500 mL	Oral	1	5	RK
	Tablet, 50 mg	Oral	100	5	RK
	Tablet, 125 mg	Oral	100	5	RK
	Tablet, 200 mg	Oral	100	5	RK
	Tablet, 200 mg (sustained release)	Oral	100	5	AP
	Tablet, 250 mg (sustained release)	Oral	100	5	RK
	Tablet, 300 mg (sustained release)	Oral	100	5	AP
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Thiabendazole Tablets B.P.	500 mg	Oral	16	..	MK
Thiamine Hydrochloride Injection B.P.	Ampoule, 100 mg in 1 mL	Injection	5	1	FM
Thiamine Hydrochloride Tablets B.P.	100 mg	Oral	100	2	FM, NN, PR, PT, QE, US
Thiethylperazine Malate	Injection, 6.5 mg (base) in 1 mL amp.	Injection	10	..	SZ
Thiethylperazine Maleate	Tablet, 6.5 mg (base)	Oral	50	..	SZ
	Suppositories, 6.5 mg (base), 6		1	2	SZ
Thioguanine Tablets B.P.	40 mg	Oral	25	1	BW
Thiopropazate Hydrochloride Tablets B.P.	5 mg	Oral	100	1	SR
Thioridazine Hydrochloride B.P.	Injection, 50 mg in 2 mL amp.	Injection	10	..	SZ
	Solution, 30 mg per mL, 30 mL	Oral	1	4	SZ
Thioridazine Tablets B.P.	10 mg	Oral	100	1	AF, SZ
	25 mg	Oral	100	1	AF, SZ
	50 mg	Oral	100	1	AF, SZ
	100 mg	Oral	100	1	AF, SZ
Thiotepa B.P. with any determined brand of Water for Injections or other solvent	Eye drops, set, 15 mg with required solvent	Application to the eye	1	5	LE
	Injection, 15 mg (solvent required)	Injection	2	1	LE
Thyroxine Tablets B.P.	50 micrograms	Oral	100	2	BW
	100 micrograms	Oral	100	2	BW
	200 micrograms	Oral	100	2	BW
Ticarcillin Sodium with any determined brand of Water for Injections or other solvent	Injection, vial containing equivalent 1 g Ticarcillin (with required solvent)	Injection	10	..	BR, CS
	Injection, vial containing equivalent 3 g Ticarcillin (with required solvent)	Injection	10	..	BR, CS
Timolol Maleate Eye Drops B.P.	2.5 mg per mL, 5 mL	Application to the eye	1	6	FR, SI
	5 mg per mL, 5 mL	Application to the eye	1	6	FR, SI
Timolol Maleate Tablets B.P.	5 mg	Oral	100	5	FR
Tinidazole	Tablet, 500 mg	Oral	4	..	PF
Tobramycin B.P.	Eye drops, 3 mg per mL, 5 mL	Application to the eye	1	2	AQ
	Eye ointment, 3 mg per g, 3.5 g	Application to the eye	1	..	AQ
Tobramycin Injection B.P.	40 mg	Injection	5	..	LY
	80 mg	Injection	5	..	LY
Tolazamide Tablets B.P.	250 mg	Oral	100	5	UP
Tolbutamide Tablets B.P.	500 mg	Oral	100	5	HP, PT
	1 g	Oral	100	5	HP
Tranexamic Acid Tablets B.P.	500 mg	Oral	100	2	PS
Tranylcypromine Tablets B.P.	10 mg	Oral	50	2	SK

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Triamcinolone Acetonide B.P.	Injection, 10 mg in 1 mL amp.	Injection	5	..	SQ
Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.	Ear cream, 1 mg-2.5 mg (base)-250 micrograms-100,000 units per g, 5 g	Application to the ear	1	2	SQ
	Ear drops, 1 mg-2.5 mg (base)-250 micrograms-100,000 units per g, 7.5 mL	Application to the ear	1	2	SQ
	Ear ointment, 1 mg-2.5 mg (base)-250 micrograms-100,000 units per g, 5 g	Application to the ear	1	2	SQ
Triamcinolone Acetonide Cream B.P.	200 micrograms per g, 45 g	Application	1	..	SQ
	200 micrograms per g, 100 g	Application	2	..	LE, SQ
	500 micrograms per g, 15 g	Application	1	1	LE, SQ
Triamcinolone Acetonide Ointment B.P.	200 micrograms per g, 45 g	Application	1	..	SQ
	200 micrograms per g, 100 g	Application	2	..	LE, SQ
	500 micrograms per g, 15 g	Application	1	1	LE, SQ
Triamterene B.P.	Tablet, 100 mg	Oral	50	3	SK
Trifluoperazine Hydrochloride B.P.	Injection, 1 mg (base) in 1 mL amp.	Injection	10	..	SK
Trifluoperazine Hydrochloride Tablets B.P.	1 mg	Oral	100	1	PT, SK
	2 mg	Oral	100	1	PT, SK
	5 mg	Oral	100	1	PT, SK
Triglycerides Oil, Medium Chain	1 L	Oral	1	5	KY
Trimetaphan Camsylate B.P. 1968 with Water for Injections	Injection, 250 mg vial with 5 mL amp. water for injections	Injection	3	..	RO
Trimethoprim Tablets B.P.	300 mg	Oral	7	1	AF, BW
Trimipramine	Capsule, 50 mg	Oral	50	2	MB
Trimipramine Tablets B.P.	25 mg (base)	Oral	50	2	MB
Trioxysalen	Tablet, 5 mg	Oral	100	2	PT
Typhoid Vaccine B.P.	1,000 M. S. typhi per mL injection, 0.5 mL amp.	Injection	2	..	CS
Typhus Vaccine B.P.	Injection, 1 mL amp.	Injection	2	..	CS
Urea Cream B.P.	100 mg per g, 100 g	Application	1	2	AG, HA, NW, OL, PS
Vancomycin Hydrochloride B.P. with any determined brand of Water for Injections or other solvent	Injection, 500 mg (with required solvent)		5	..	LY
Vasopressin Tannate	Injection, (oily) 5 units in 1 mL amp.	Injection	10	1	PD
Verapamil Hydrochloride B.P.	Tablet, 40 mg	Oral	100	5	KN, SC
	Tablet, 80 mg	Oral	100	5	KN, SC
Verapamil Hydrochloride Injection B.P.	Ampoule, 5 mg in 2 mL	Injection	5	..	KN, SC
Verapamil Hydrochloride Tablets B.P.	40 mg	Oral	100	5	AF, PT, US
	80 mg	Oral	100	5	AF, PT, US
	120 mg	Oral	100	5	KN, SC, US
	160 mg	Oral	60	5	KN, SC
Vidarabine	Eye ointment, 30 mg per g, 3.5 g	Application to the eye	1	..	PD
Vinblastine Sulphate B.P.	Injection, 10 mg and 10 mL solvent	Injection	2	..	BL
Vinblastine Sulphate B.P. with any determined brand of Water for Injections or other solvent	Injection, 10 mg (with required solvent)	Injection	2	..	LY
Vincristine Sulphate B.P.	Injection, 1 mg and 10 mL solvent	Injection	5	..	BL, LY

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
	Injection, 5 mg and 10 mL solvent	Injection	1	..	BL
Warfarin Tablets B.P.	1 mg	Oral	50	2	BT, GL
	2 mg	Oral	50	2	BT
	2.5 mg	Oral	50	2	BT
	3 mg	Oral	50	2	GL
	5 mg	Oral	50	2	BT, GL
	7.5 mg	Oral	50	2	BT
	10 mg	Oral	50	2	BT
Water for Injections B.P.	Ampoule, 2 mL	Injection	5	3	AP, BT, BZ, SI
	Ampoule, 5 mL	Injection .	5	3	AP, BT, BZ, SI
	Ampoule, 10 mL	Injection	5	3	AP, BT, BZ, SI
Wool Alcohols Ointment B.P.	100 g		1	1	SN
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
"Zerodor"	Liquid, 15 mL		1	..	ZR
Zinc Oxide B.P.	Ointment, compound, 50 g		1	1	WW
	Suppositories, compound, 12		1	1	WW
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Zinc Sulphate B.P. with Phenylephrine Hydrochloride B.P.	Eye drops, 2.5 mg-1.2 mg per mL, 15 mL	Application to the eye	1	2	AG, AQ

FIRST SCHEDULE—PART 2

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Purposes*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Bromocriptine Mesylate Tablets B.P.	2.5 mg (base)	With the written authority of the Secretary: Acromegaly, prior to surgery or radiotherapy or where surgery or radiotherapy is inappropriate Parkinson's disease Pathological hyperprolactinaemia where appropriate surgery or radiotherapy is not indicated or has already been used with incomplete resolution	Oral	60	..	SZ
Codeine Phosphate B.P. with Aspirin B.P.	Tablet, 30 mg-325 mg	With the written authority of the Secretary: Severe disabling pain not responding to non-narcotic analgesics	Oral	40	..	BW
Codeine Phosphate B.P. with Paracetamol B.P.	Tablet, 30 mg-500 mg	With the written authority of the Secretary: Severe disabling pain not responding to non-narcotic analgesics	Oral	40	..	WL
Diazepam B.P.	Syrup, 2 mg per 5 mL, 100 mL	With the written authority of the Secretary: Disabling spasticity Malignant neoplasia (late stage)	Oral	2	..	RO
Diazepam Injection B.P.	10 mg in 2 mL	With the written authority of the Secretary: Disabling spasticity Malignant neoplasia (late stage)	Injection	10	..	BL, RO
Diazepam Tablets B.P.	2 mg	With the written authority of the Secretary: Disabling spasticity Malignant neoplasia (late stage)	Oral	100	..	AF, PT, RO, SU
	5 mg	With the written authority of the Secretary: Disabling spasticity Malignant neoplasia (late stage)	Oral	100	..	AF, PT, RO, SU
Doxycyline Capsules B.P.	100 mg	Urethritis	Oral	21	..	PT
Doxycycline Hydrochloride B.P.	Capsule, 100 mg (base) (containing enteric coated pellets)	Urethritis	Oral	21	..	FA
	Tablet, 100 mg (base)	Urethritis	Oral	21	..	AF, PF
Hydrocortisone Sodium Succinate B.P.	Injection set containing equivalent of 100 mg Hydrocortisone and 2 mL solvent	For use in a hospital	Injection	6	..	NR, UP

Name of Pharmaceutical Benefit	Form (strength, type, size, etc.)	Purposes	Manner of administration	Maximum quantity	Number of repeats	Brand
	Injection set containing equivalent of 250 mg Hydrocortisone and 2 mL solvent	For use in a hospital	Injection	6	..	UP
Medroxyprogesterone Acetate B.P.	Tablet, 10 mg	Endometriosis	Oral	100	2	UP
Methadone Injection B.P.	Ampoule, 10 mg per mL, 1 mL	With the written authority of the Secretary: Severe disabling pain associated with proven malignant neoplasia Severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Injection	10	..	BW
Methadone Tablets B.P.	5 mg	With the written authority of the Secretary: Severe disabling pain associated with proven malignant neoplasia Severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	BW
	10 mg	With the written authority of the Secretary: Severe disabling pain associated with proven malignant neoplasia Severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	BW
Morphine Sulphate Tablets B.P.	30 mg	With the written authority of the Secretary: Severe disabling pain associated with proven malignant neoplasia Severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	FM
Niclosamide Tablets B.P.	500 mg	Hymenolepiasis nana	Oral	16	..	BN
Oxycodone Hydrochloride	Tablet, 5 mg	With the written authority of the Secretary: Severe disabling pain associated with proven malignant neoplasia Severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	BT
Oxycodone Pectinate	Suppositories, 30 mg (base), 12	With the written authority of the Secretary: Severe disabling pain associated with proven malignant neoplasia Severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)		2	..	BT
Pethidine Injection B.P.	Ampoule, 50 mg per mL, 1 mL	With the written authority of the Secretary: Late stage malignant neoplasia	Injection	10	..	BL, BT, SI
	Ampoule, 100 mg in 2 mL	With the written authority of the Secretary: Late stage malignant neoplasia	Injection	10	..	BL, BT, SI

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Purposes*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Phenethicillin Capsules B.P.	250 mg	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	SI
Phenethicillin Tablets B.P.	250 mg	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	SI
Phenoxymethylpenicillin (Hydrabamine Salt)	Tablet, 125 mg	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	AB
Phenoxymethylpenicillin Potassium Capsules B.P.	250 mg	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	AB, CS, FM, LY, SI
Phenoxymethylpenicillin Potassium Tablets B.P.	250 mg	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	AB, CS, FM, LY, SI
Prochlorperazine Tablets B.P.	5 mg	With the written authority of the Secretary: Emesis associated with malignant disease Rotational vertigo	Oral	100	..	MB, PT, SK
Rifampicin B.P.	Capsule, 150 mg	With the written authority of the Secretary: Leprosy in adults	Oral	100	..	AF
	Capsule, 300 mg	With the written authority of the Secretary: Leprosy in adults	Oral	100	..	AF
Tetracycline B.P with a buffering agent	Capsule, 250 mg	Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne	Oral	50	5	AP, CS, FM, HP, LE, SQ
Tetracycline B.P with a buffering agent and Nystatin B.P.	Capsule, 250 mg-250,000 units	Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne	Oral	50	5	SQ
Tetracycline Capsules B.P.	250 mg	Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne	Oral	50	5	BZ, LE, UP
Tetracycline Hydrochloride B.P. with Nystatin B.P.	Capsule, 250 mg-250,000 units	Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne	Oral	50	5	AP, LE

SECOND SCHEDULE

Form of Pharmaceutical Benefit	*Maximum quantity*	*Number of repeats*
Creams	100 g	1
Ear Drops	15 mL	2
Elixirs	100 mL	4
Eye Drops		
Cocaine	15 mL	..
Pilocarpine	15 mL	6
Others	15 mL	6
Eye Lotions	200 mL	1
Gargles	200 mL	4
Glycerins	100 mL	1
Inhalations	50 mL	1
Inhalations, Solid	4 g	1
Linctuses	100 mL	2
Liniments	100 mL	1
Lotions	200 mL	2
Mixtures	200 mL	4
Mixtures for Children	100 mL	4
Mouth Washes	200 mL	1
Nasal Instillations	15 mL	2
Ointments and Waxes	100 g	1
Paints	25 mL	1
Pastes		
Cocaine	25 g	..
Others	100 g	1
Powders, Dusting	100 g	1
Powders for Internal Use	100 g	2
Powders, Irrigation	100 g	1
Soaps	200 mL	1
Solutions	200 mL	2
Syrups	100 mL	4
Tinctures	25 mL	1

THIRD SCHEDULE

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Amoxycillin Capsules B.P.	250 mg (base)	Oral	20	..	AF, BR, CS, PT, SI
	500 mg (base)	Oral	20	..	AF, BR, CS, PT, SI
Amoxycillin Trihydrate B.P.	Tablet, chewable, 250 mg (base)	Oral	20	..	BR, CS
	Tablet, dispersible, 3 g (base)	Oral	1	..	BR, CS
Amoxycillin Trihydrate B.P. with Purified Water B.P.	Powder for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	..	BR, CS, PT, SI
	Powder for syrup, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	BR, CS, PT, SI
Amphotericin B.P.	Tablet, 100 mg	Oral	50	..	SQ
	Lozenge, 10 mg	Oral	20	..	SQ
	Ointment, 30 mg per g, 15 g	Application	1	..	SQ
	Suspension, 100 mg per mL, 24 mL	Oral	1	..	SQ
Ampicillin Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 250 mg (base) vial (with required solvent)	Injection	5	..	CS, PT
	Injection, 500 mg (base) vial (with required solvent)	Injection	5	..	BR, CS, PT
	Injection, 1 g (base) vial (with required solvent)	Injection	5	..	CS, PT
Aspirin Mixture A.P.F. with Codeine Phosphate B.P.	Mixture, 500 mg-30 mg per 10 mL	Oral	200 mL	..	
Benzylpenicillin Potassium B.P. with any determined brand of Water for Injections or other solvent	Injection, 300 mg vial (with required solvent)	Injection	5	..	CS
	Injection, 600 mg vial (with required solvent)	Injection	5	..	CS, GL
	Injection, 3 g vial (with required solvent)	Injection	5	..	CS
Cephalexin B.P. with Purified Water B.P.	Granules for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	..	GL, LY
	Granules for syrup, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	GL, LY
Cephalexin Capsules B.P.	250 mg	Oral	20	..	GL, LY
	500 mg	Oral	20	..	GL, LY
Cephalothin Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 1 g (base) (with required solvent)	Injection	5	..	GL, LY
	Injection, 2 g (base) (with required solvent)	Injection	1	..	LY
	Injection, 4 g (base) (with required solvent)	Injection	1	..	LY
Codeine Phosphate B.P. with Aspirin B.P.	Tablet, 30 mg-325 mg	Oral	20	..	BW
Codeine Phosphate B.P. with Paracetamol B.P.	Tablet, 30 mg-500 mg	Oral	20	..	WL
Co-trimoxazole Mixture, Paediatric B.P.	40 mg-200 mg per 5 mL, 100 mL	Oral	1	..	AF, BW, PT, RO
Co-trimoxazole Tablets B.P.	80 mg-400 mg	Oral	10	..	AF, BW, PT, RO
	160 mg-800 mg	Oral	10	..	AF, BW, PT, RO
Doxycycline Capsules B.P.	100 mg	Oral	7	..	PT
Doxycycline Hydrochloride B.P.	Capsule, 100 mg (base) (containing enteric coated pellets)	Oral	7	..	FA
	Tablet, 100 mg (base)	Oral	7	..	AF, PF
Erythromycin B.P.	Capsule, 125 mg (containing enteric coated pellets)	Oral	25	..	FA
	Capsule, 250 mg (containing enteric coated pellets)	Oral	25	..	FA, LY

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Erythromycin Estolate B.P.	Drops, paediatric, 100 mg (base) per mL, 10 mL	Oral	1	..	LY
	Suspension, 125 mg (base) per 5 mL, 100 mL	Oral	1	..	LY
Erythromycin Ethyl Succinate B.P.	Tablet, chewable, 200 mg (base)	Oral	25	..	AB
Erythromycin Ethyl Succinate B.P. with Purified Water B.P.	Granules for suspension, 200 mg (base) per 5 mL, 100 mL	Oral	1	..	AB
Erythromycin Stearate B.P.	Capsule, 250 mg (base)	Oral	25	..	AB, PT
	Suspension, 125 mg (base) per 5 mL, 100 mL	Oral	1	..	AB
	Suspension, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	AB
Erythromycin Stearate Tablets B.P.	250 mg (base)	Oral	25	..	AB
Erythromycin Tablets B.P.	250 mg	Oral	25	..	UP
Metronidazole Tablets B.P.	200 mg	Oral	21	..	MB, PT, SR
	250 mg	Oral	21	..	CL
Nystatin B.P.	Lozenge, 100,000 units	Oral	20	..	LE
	Tablet, 500,000 units	Oral	25	..	LE
Nystatin Mixture B.P.	100,000 units per mL, 24 mL	Oral	1	..	LE, SQ
Nystatin Tablets B.P.	500,000 units	Oral	25	..	GP, SQ
Paracetamol B.P.	Mixture, 120 mg per 5 mL, 100 mL	Oral	1	..	BW, US, WL
Phenethicillin Capsules B.P.	250 mg	Oral	25	..	SI
	500 mg	Oral	25	..	SI
Phenethicillin Potassium B.P. with Purified Water B.P.	Powder for syrup, 125 mg (Phenethicillin) per 5 mL, 100 mL	Oral	1	..	SI
	Powder for syrup, 250 mg (Phenethicillin) per 5 mL, 100 mL	Oral	1	..	SI
Phenethicillin Tablets B.P.	250 mg	Oral	25	..	SI
Phenoxymethylpenicillin (Benzathine Salt)	Suspension, 125 mg per 5 mL, 100 mL	Oral	1	..	CS, SI
	Suspension, 250 mg per 5 mL, 100 mL	Oral	1	..	CS, SI
Phenoxymethylpenicillin (Hydrabamine Salt)	Suspension, 125 mg per 5 mL, 100 mL	Oral	1	..	AB
	Suspension, 250 mg per 5 mL, 100 mL	Oral	1	..	AB
	Tablet, 125 mg	Oral	25	..	AB
Phenoxymethylpenicillin Potassium Capsules B.P.	250 mg	Oral	25	..	AB, CS, FM, LY, SI
	500 mg	Oral	25	..	CS, FM, SI
Phenoxymethylpenicillin Potassium Tablets B.P.	250 mg	Oral	25	..	AB, CS, FM, LY, SI
	500 mg	Oral	25	..	AB, CS, FM, LY
Procaine Penicillin Injection B.P.	Syringe, disposable, 1 g	Injection	5	..	SI
	Syringe, disposable, 1.5 g	Injection	5	..	SI
Sulphadimidine Tablets B.P.	500 mg	Oral	40	..	PT
Tetracycline B.P. with a buffering agent	Capsule, 250 mg	Oral	25	..	AP, CS, FM, HP, LE, SQ
Tetracycline Capsules B.P.	250 mg	Oral	25	..	BZ, LE, UP

Name of Pharmaceutical Benefit	*Form (strength, type, size, etc.)*	*Manner of administration*	*Maximum quantity*	*Number of repeats*	*Brand*
Water for Injections B.P.	Ampoule, 2 mL	Injection	5	..	AP, BT, BZ, SI
	Ampoule, 5 mL	Injection	5	..	AP, BT, BZ, SI
	Ampoule, 10 mL	Injection	5	..	AP, BT, BZ, SI

Dated this 1st day of December 1987.

J. S. DEEBLE
Acting First Assistant Secretary
Health Benefits Division
Delegate of the Minister of State for Community Services and Health

N.N.—8714828A

Employment, Education and Training

NOTIFICATION OF NON-GOVERNMENT SCHOOLS SEEKING ELIGIBILITY FOR COMMONWEALTH FINANCIAL ASSISTANCE

The following schools have notified their intention to seek eligibility for Commonwealth financial assistance in respect of their proposed commencement or, in the case of existing non-government schools, their proposed change in operation.

Interested parties have the opportunity to make submissions about particular proposals. They should be made no later than four weeks following publication of details of the particular proposal in the *Gazette*. Such submissions will be brought to the attention of New Schools Committees for their consideration when recommending a priority funding category. They will also be made available to proponents of the new schools or schools changing operations.

Submissions should be directed to:

The Secretary
Commonwealth Department of Employment, Education and Training
P.O. Box 826
Woden, A.C.T. 2606

Attention: New Schools Section

The following abbreviations are used:

JS: Junior secondary

P: Primary

S: Secondary (junior and senior)

SS: Senior Secondary

W: Whole

P: Partial

A: Additional Annex

Projected enrolments for the year in which funding is sought and maximum projected enrolments at each level are included.

Commencing school

NEW SOUTH WALES

1989

School name:	Cape Byron Rudolf Steiner School
School town/suburb:	Byron Bay
School state:	N.S.W.
Funding year:	89
Sponsoring organistn:	
Proposed change:	Commencement
Projected enroll yrl:	89
Proj enroll primaryl:	30
Proj enroll juniorl:	0
Proj enroll seniorl:	0
Max enroll primary:	125
Max enroll junior:	0
Max enroll senior:	0

SOUTH AUSTRALIA

1989

School name:	Southern Montessori Junior Primary School
School town/suburb:	Morphett Vale
School state:	
Funding year:	89
Sponsoring organistn:	
Proposed change:	Commencement
Projected enroll yrl:	89
Proj enroll primaryl:	25
Proj enroll juniorl:	0
Proj enroll seniorl:	0
Max enroll primary:	45
Max enroll junior:	0
Max enroll senior:	0

N.N.—8741748

Industrial Relations

Freedom of Information Act 1982

Section 19 notice

INDUSTRIAL RELATIONS PORTFOLIO

Notice is hereby given that Parliament House, Canberra, A.C.T. is an address of the Minister of State for Industrial Relations to which requests for access to documents made in pursuance of the *Freedom of Information Act 1982* may be sent or delivered in accordance with section 19 of the Act.

Dated this 18th day of November 1987.

RALPH WILLIS

Minister of State for Industrial Relations

Notice is hereby given that, for the purposes of section 19 of the *Freedom of Information Act 1982*, an address specified in Column 2 or Column 3 of the Schedule being the address of the agency or each of the agencies specified in column 1 of the Schedule, is an address of that agency to which requests for access to documents made to the agency in pursuance of that Act may be sent or delivered in accordance with that section.

SCHEDULE

Addresses of agency to which requests may be sent or delivered

Column 1 *Agency*	*Column 2* *Address*	*Column 3* *Address*
Industrial Relations, Department of	G.P.O. Box 9879, Canberra, A.C.T. 2601	1 Farrell Place, Canberra City, A.C.T. 10-16 Queen Street, Melbourne, Vic. Trans-City House, 15 Castlereagh Street, Sydney, N.S.W. 167 Eagle Street, Brisbane, Qld St Martin's Tower, 44 St George's Terrace, Perth, W.A. Da Costa Building, 68 Grenfell Street, Adelaide, S.A.

Column 1 *Agency*	*Column 2* *Address*	*Column 3* *Address*
		T & G Building, 115 Collins Street, Hobart, Tas. Kriewaldt Chambers, 6 Searcy Street, Darwin, N.T.
Central (Blacksmithing Trades) Committee Central (Boilermaking Trades) Committee Central (Boot Trades) Committee Central (Electrical Trades) Committee Central (Engineering Trades) Committee Central (Sheetmetal Trades) Committee	G.P.O. Box 9879, Canberra, A.C.T. 2601	1 Farrell Place, Canberra City, A.C.T.
Local (Blacksmithing (Trades) Committee (N.S.W.) Local (Boilermaking Trades) Committee (N.S.W.) Local (Boot Trades) Committee (N.S.W.) Local (Electrical Trades) Committee (N.S.W.) Local (Sheetmetal Trades) Committee (N.S.W.)	G.P.O. Box 9879, Sydney, N.S.W. 2001	Trans-City House, 15 Castlereagh Street, Sydney, N.S.W.
Local (Blacksmithing Trades) Committee (Qld) Local (Boilermaking Trades) Committee (Qld) Local (Boot Trades) Committee (Qld) Local (Electrical Trades) Committee (Qld) Local (Engineering Trades) Committee (Qld) Local (Sheetmetal Trades) Committee (Qld)	G.P.O. Box 9879 Brisbane, Qld 4001	167 Eagle Street, Brisbane, Qld
Local (Blacksmithing Trades) Committee (S.A.) Local (Boilermaking Trades) Committee (S.A.) Local (Boot Trades) Committee (S.A.) Local (Electrical Trades) Committee (S.A.) Local (Engineering Trades) Committee (S.A.) Local (Sheetmetal Trades) Committee (S.A.)	G.P.O. Box 9879 Adelaide, S.A. 5001	Da Costa Building, 68 Grenfell Street, Adelaide, S.A.
Local (Blacksmithing Trades) Committee (Tas.) Local (Boilermaking Trades) Committee (Tas.) Local (Boot Trades) Committee (Tas.) Local (Electrical Trades) Committee (Tas.) Local (Engineering Trades) Committee (Tas.) Local (Sheetmetal Trades) Committee (Tas.)	G.P.O. Box 9879, Hobart, Tas. 7001	Commonwealth Bank Building, 45 Murray Street, Hobart, Tas.
Local (Blacksmithing Trades) Committee (Vic.) Local (Boilermaking Trades) Committee (Vic.) Local (Boot Trades) Committee (Vic.) Local (Electrical Trades) Committee (Vic.) Local (Engineering Trades) Committee (Vic.) Local (Sheetmetal Trades) Committee (Vic.)	G.P.O. Box 9879, Melbourne, Vic. 3001	9th Floor, 10-16 Queen Street, Melbourne, Vic.
Local (Blacksmithing Trades) Committee (W.A.) Local (Boilermaking Trades) Committee (W.A.) Local (Boot Trades) Committee (W.A.)	G.P.O. Box 9879, Perth, W.A. 6001	St Martin's Tower, 44 St George's Terrace, Perth, W.A.

Column 1 *Agency*	*Column 2* *Address*	*Column 3* *Address*
Local (Electrical Trades) Committee (W.A.)		
Local (Engineering Trades) Committee (W.A.)		
Local (Sheetmetal Trades) Committee (W.A.)		
Academic Salaries Tribunal	P.O. Box 281, Civic Square, A.C.T. 2608	Mining Industry House, 216 Northbourne Avenue, Braddon, A.C.T.
Affirmative Action Agency	P.O. Box 974, North Sydney, N.S.W. 2059	The Denison, 65 Berry Street, North Sydney, N.S.W.
Australian Conciliation and Arbitration Commission	Level 35, Nauru House, 80 Collins Street, Melbourne, Vic. 3000	Level 35, Nauru House, 80 Collins Street, Melbourne, Vic.
Australian Trade Union Training Authority	P.O. Box 6115, St Kilda Road Central, Vic. 3004	8th Floor, 499 St Kilda Road, Melbourne, Vic.
	P.O. Box 281, Carlton South, Vic. 3053	2 Drummound Street, Carlton South, Vic.
	P.O. Box K722, Haymarket, N.S.W. 2000	8th Floor, Roden Cutler House, 24-28 Campbell Street, Sydney, N.S.W.
	P.O. Box 510, Wodonga, Vic. 3690	Clyde Cameron College, Nordsvan Drive, Wodonga, Vic.
	316 Lord Street, East Perth, W.A. 6000	316 Lord Street, East Perth, W.A.
	G.P.O. Box 752, Brisbane, Qld 4001	2nd Floor, 141 Queen Street, Brisbane, Qld
	46 Greenhill Road, Wayville, S.A. 5034	46 Greenhill Road, Wayville, S.A.
	18 Watchorn Street, Hobart, Tas. 7000	18 Watchorn Street, Hobart, Tas.
	G.P.O. Box 441, Canberra, A.C.T. 2601	3rd Floor, 496 Northbourne Avenue, Dickson, A.C.T.
	G.P.O. Box 114, Wollongong, N.S.W. 2500	Technology Centre Building, Northfield Avenue, Wollongong, N.S.W.
	P.O. Box 5218c, Newcastle West, N.S.W. 2300	1st Floor, Tonella Centre, Revenshaw Street, Newcastle, N.S.W.
Coal Industry Tribunal	La Salle Building, 70 Castlereagh Street, Sydney, N.S.W. 2000	La Salle Building, 70 Castlereagh Street, Sydney, N.S.W.
Defence Force Remuneration Tribunal	P.O. Box 537, Manuka, A.C.T. 2603	ANZ Bank Building, 33 Bougainville Street, Manuka, A.C.T.
Federal Police Arbitral Tribunal	G.P.O. Box 1994s, Melbourne, Vic. 3001	Level 35, Nauru House, 80 Collins Street, Melbourne, Vic.
Flight Crew Officers Industrial Tribunal	G.P.O. Box 1994s, Melbourne, Vic. 3001	Level 35, Nauru House, 80 Collins Street, Melbourne, Vic.
Industrial Registrar and Deputy Industrial Registrars	G.P.O. Box 1994s, Melbourne, Vic. 3001	Level 35, Nauru House, 80 Collins Street, Melbourne, Vic.
	Level 8, 80 William Street, East Sydney, N.S.W. 2011	Level 8, 80 William Street, East Sydney, N.S.W.
	Level 6, Commonwealth Courts Building, 294 Adelaide Street, Brisbane, Qld 4000	Level 6, Commonwealth Courts Building, 294 Adelaide Street, Brisbane, Qld
	G.P.O. Box X2206, Perth, W.A. 6001	2nd Floor, National Westminster House, 251 Adelaide Terrace, Perth, W.A.
	G.P.O. Box 1232M, Hobart, Tas. 7001	1st Floor, Commonwealth Law Courts, 39-41 Davey Street, Hobart, Tas.
	G.P.O. Box 969, Darwin, N.T. 5794	Construction House, 1 Briggs Street, Darwin, N.T.
	G.P.O. Box 539, Canberra, A.C.T. 2601	4th Floor, CML Building, cnr Marcus Clarke Street and University Avenue, Canberra, A.C.T.
National Occupational Health and Safety Commission (Worksafe Australia)	G.P.O. Box 58, Sydney, N.S.W. 2001	St Martin's Tower, 31 Market Street, Sydney, N.S.W.
	G.P.O. Box 9, Canberra, A.C.T. 2601	10 Moore Street, Canberra City, A.C.T.

Column 1 *Agency*	*Column 2* *Address*	*Column 3* *Address*
Remuneration Tribunal	P.O. Box 281, Civic Square, A.C.T. 2608	Mining Industry House, 216 Northbourne Avenue, Braddon, A.C.T.
Stevedoring Industry Finance Committee	P.O. Box Q296, Queen Victoria Building, Sydney, N.S.W. 2000	131-137 York Street, Sydney, N.S.W.

Dated this 18th day of November 1987.

RALPH WILLIS
Minister of State for Industrial Relations

CA03I058 CR$ N.N.—8741749

AUSTRALIAN CONCILIATION AND ARBITRATION COMMISSION

Conciliation and Arbitration Act 1904

COMMON RULE

1. Application has been made that the following award shall be declared common rule in the A.C.T. in the industry in connection with which the dispute arose which led to the making of the award. The said industry is described in the said award.
2. It is proposed to declare the said award a common rule.
   The award is: Chemists (Australian Capital Territory) Award 1983
3. A copy of the award may be inspected free of charge at the office of the Registrar at the address shown in item 4.
4. The application will be heard at 11.30 a.m. on Wednesday, 16 December 1987 at 4th Floor, CML Building, University Avenue, Canberra City, A.C.T.
5. All persons and organisations interested and desiring to be heard may appear or be represented before the Commission and shall be heard.
6. Persons and organisations not so appearing or represented will be bound by any declaration made by the Commission in the matter which is applicable to them.
7. Compliance with regulation 35 is not required.

Dated this 1st day of December 1987.

BERNARD O'DONNELL
Registrar

CA03I048 CRACTOIR$ N.N.—8741750

AUSTRALIAN CONCILIATION AND ARBITRATION COMMISSION

Conciliation and Arbitration Act 1904

COMMON RULE

1. Application has been made that the following award shall be declared common rule in the A.C.T. in the industry in connection with which the dispute arose which led to the making of the award. The said industry is described in the said award.
2. It is proposed to declare the said award a common rule.
   The award is: Retail and Wholesale Shop Employees (Australian Capital Territory) Award 1983
3. A copy of the award may be inspected free of charge at the office of the Registrar at the address shown in item 4.
4. The application will be heard at 11.30 a.m. on Wednesday, 16 December 1987 at 4th Floor, CML Building, University Avenue, Canberra City, A.C.T.
5. All persons and organisations interested and desiring to be heard may appear or be represented before the Commission and shall be heard.
6. Persons and organisations not so appearing or represented will be bound by any declaration made by the Commission in the matter which is applicable to them.
7. Compliance with regulation 35 is not required.

Dated this 1st day of December 1987.

BERNARD O'DONNELL
Registrar

N.N.—8741751

IN THE AUSTRALIAN CONCILIATION AND ARBITRATION COMMISSION

Conciliation and Arbitration Act 1904

NOTICE UNDER SUB-SECTION 49A (3) IN RELATION TO VARIATION OF A COMMON RULE

In the matter of the CLOTHING TRADES AWARD 1982

C No. 5084 of 1987

And in the matter of the variation of the award dated 1 February 1983 in the above matter.

Notice is hereby given:

(a) that on 26 November 1987, the Commission varied the terms of the above mentioned award referred to in the Schedule as set out in the Schedule;

(b) that the variation will be a common rule in the Australian Capital Territory in the industry in respect of which the dispute arose with effect from the first pay period to commence on or after 13 November 1987; and

(c) that any person or organisation having an objection to the variation binding that person or organisation and desiring to be heard on relation to that objection is invited to lodge with the Commission a notice of that objection within 28 days after the date specified in paragraph (a).

A copy of the award may be inspected at the office of the Registrar. Objections should be lodged with the Registrar at 4th Floor, CML Building, University Avenue, Canberra, by 4.30 p.m. on 24 December 1987.

SCHEDULE

TERMS VARIED

Clause No.	*Subject*	*Substance of variation*
	PRINT NO. H0106	
Schedule of respondents	Wages and conditions	Respondency

Dated this 3rd day of December 1987.

BERNARD O'DONNELL
Deputy Industrial Registrar

N.N.—8741752

Industry, Technology and Commerce

COMMONWEALTH OF AUSTRALIA

Patent Attorneys Regulations

APPOINTMENT OF PATENT ATTORNEYS DISCIPLINARY TRIBUNAL

Whereas regulations 25 and 26 of the Patent Attorneys Regulations provide that there shall be a Tribunal to be known as the Patent Attorneys Disciplinary Tribunal, which shall be constituted by a person appointed by instrument signed by the Minister:

Now therefore I, BARRY OWEN JONES, the Minister of State for Science and Small Business, do hereby appoint Alan Kingsley Cornell to be the Patent Attorneys Disciplinary Tribunal to hold office until 30 November 1990.

Dated this 19th day of November 1987.

BARRY O. JONES
Minister of State
for Science and Small Business

N.N.—8741753

COMMONWEALTH OF AUSTRALIA
CUSTOMS ACT 1901

NOTICE OF FAIR RATES OF EXCHANGE

I, BRYAN GEOFFREY GILL, delegate of the Comptroller-General of Customs, hereby specify, pursuant to paragraph (a) of sub-section 161B(2) of the *Customs Act 1901* that the rates of exchange specified in Columns 3 to 7 of the Schedule hereunder are fair rates of exchange for the conversion of the foreign currencies of countries specified opposite in Columns 1 and 2 into Australian dollars on the dates under which the specified rates of exchange appear for the purposes of Division 2 of Part VIII of the *Customs Act 1901*.

SCHEDULE

Column 1 Country	Column 2 Foreign Currency	(Foreign Currency = AUS $1) Column 3 Date 18/11/87	Column 4 Date 19/11/87	Column 5 Date 20-22/11	Column 6 Date 23/11/87	Column 7 Date 24/11/87
AUSTRIA	Schillings	8.2585	8.2000	8.1861	8.0789	8.0493
BELGIUM/LUX	Francs	24.5800	24.4200	24.4200	24.1200	24.0000
BRAZIL	Cruzado	40.1200	40.5800	40.5200	41.2000	41.3540
CANADA	Dollars	0.9134	0.9115	0.9088	0.9008	0.8985
CHINA	New Yuan	2.5755	2.5777	2.5740	2.5484	2.5428
DENMARK	Kroner	4.5262	4.4932	4.4939	4.4352	4.4199
FIJI	Dollars	1.0390	1.0374	1.0359	1.0250	1.0132
FINLAND	Marks	2.8749	2.8605	2.8554	2.8206	2.8084
FRANCE	Francs	3.9817	3.9513	3.9548	3.9036	3.8948
GERMANY F.R.	Deutschmarks	1.1756	1.1653	1.1665	1.1497	1.1466
GREECE	Drachmas	92.0200	91.4100	91.3700	90.0900	89.8500
HONG KONG	Dollars	5.4114	5.4128	5.3977	5.3364	5.3311
INDIA	Rupees	9.0601	9.0302	9.0074	8.8958	8.8867
INDONESIA	Rupiahs	1142.0000	1143.0000	1141.0000	1131.0000	1129.0000
IRELAND	Pounds	0.4410	0.4385	0.4377	0.4307	0.4312
ISRAEL	Shekel	1.1071	1.1081	1.1065	1.0955	1.0931
ITALY	Lire	862.4800	857.8100	857.2100	846.0000	843.4500
JAPAN	Yen	94.1500	93.6500	93.9100	92.7400	92.3500
KOREA	Won	551.7500	551.8800	550.9700	545.2100	543.8800
MALAYSIA	Dollars	1.7368	1.7353	1.7296	1.7113	1.7073
NETHERLANDS	Guilders	1.3242	1.3114	1.3118	1.2954	1.2902
NEW ZEALAND	Dollars	1.1205	1.1225	1.1201	1.1109	1.1016
NORWAY	Kroner	4.4637	4.4421	4.4442	4.4087	4.4151
PAKISTAN	Rupees	11.8400	11.8500	11.8300	11.7100	11.6900
PNG	Kina	0.6186	0.6188	0.6179	0.6138	0.6131
PHILIPPINES	Pesos	14.3400	14.3600	14.3300	14.1900	14.1500
PORTUGAL	Escudos	94.7500	94.1700	94.1400	92.9400	92.9300
SINGAPORE	Dollars	1.4183	1.4144	1.4086	1.3936	1.3900
SOLOMON IS.	Dollars	1.3764	1.3654	1.3648	1.3485	1.3482
SOUTH AFRICA	Rand	1.3875	1.3857	1.3784	1.3647	1.3495
SPAIN	Pesetas	79.0400	78.6300	78.3900	77.2800	77.3300
SRI LANKA	Rupees	21.1200	21.0800	21.1100	20.9000	20.8600
SWEDEN	Kroner	4.2319	4.2026	4.2030	4.1595	4.1462
SWITZERLAND	Francs	0.9633	0.9557	0.9565	0.9436	0.9397
TAIWAN	Dollars	20.6100	20.6100	20.5600	20.3200	20.2600
THAILAND	Bahts	17.5600	17.6000	17.5300	17.3500	17.3200
UK	Pounds	0.3941	0.3899	0.3904	0.3845	0.3840
USA	Dollars	0.6937	0.6943	0.6933	0.6864	0.6849

B.G.GILL
Delegate of the
Comptroller-General of Customs
CANBERRA A.C.T.
25/11/87

N.N.—8740348

COMMONWEALTH OF AUSTRALIA
CUSTOMS ACT 1901

NOTICE OF FAIR RATES OF EXCHANGE

I, BRYAN GEOFFREY GILL, delegate of the Comptroller-General of Customs, hereby specify, pursuant to paragraph (a) of sub-section 161B(2) of the *Customs Act 1901* that the rates of exchange specified in Columns 3 to 7 of the Schedule hereunder are fair rates of exchange for the conversion of the foreign currencies of countries specified opposite in Columns 1 and 2 into Australian dollars on the dates under which the specified rates of exchange appear for the purposes of Division 2 of Part VIII of the *Customs Act 1901*.

SCHEDULE

Column 1 Country	Column 2 Foreign Currency	(Foreign Currency = AUS $1) Column 3 Date 25/11/87	Column 4 Date 26/11/87	Column 5 Date 27-29/11	Column 6 Date 30/11/87	Column 7 Date 1/12/87
AUSTRIA	Schillings	8.1082	8.1300	8.1070	8.1448	8.1123
BELGIUM/LUX	Francs	24.1100	24.1600	24.0900	24.1900	24.1900
BRAZIL	Cruzado	41.7000	42.4200	42.4100	43.6900	43.7800
CANADA	Dollars	0.9059	0.9081	0.9071	0.9196	0.9229
CHINA	New Yuan	2.5640	2.5748	2.5740	2.6108	2.6160
DENMARK	Kroner	4.4360	4.4575	4.4331	4.4654	4.4653
FIJI	Dollars	1.0236	1.0246	1.0364	1.0341	1.0339
FINLAND	Marks	2.8272	2.8339	2.8223	2.8500	2.8451
FRANCE	Francs	3.9088	3.9246	3.9015	3.9444	3.9306
GERMANY F.R.	Deutschmarks	1.1503	1.1575	1.1488	1.1556	1.1551
GREECE	Drachmas	90.7100	90.8300	90.5000	90.0800	91.0200
HONG KONG	Dollars	5.3813	5.3984	5.3897	5.4646	5.4730
INDIA	Rupees	8.9782	9.0131	9.0021	9.0986	9.1018
INDONESIA	Rupiahs	1137.0000	1142.0000	1142.6000	1157.4700	1159.7700
IRELAND	Pounds	0.4323	0.4344	0.4338	0.4354	0.4343
ISRAEL	Shekel	1.1022	1.1068	1.1065	1.1223	1.1245
ITALY	Lire	846.2400	851.0400	846.0600	854.3900	853.2700
JAPAN	Yen	92.9300	93.4600	92.9400	93.3300	93.1800
KOREA	Won	548.3800	550.5700	550.2000	557.7800	558.7500
MALAYSIA	Dollars	1.7216	1.7294	1.7306	1.7521	1.7521
NETHERLANDS	Guilders	1.2954	1.3023	1.2941	1.3032	1.2996
NEW ZEALAND	Dollars	1.1010	1.0996	1.0835	1.0853	1.0856
NORWAY	Kroner	4.4290	4.4470	4.4429	4.4923	4.5012
PAKISTAN	Rupees	11.7900	11.8400	11.8300	12.0000	12.0300
PNG	Kina	0.6151	0.6168	0.6209	0.6179	0.6184
PHILIPPINES	Pesos	14.2700	14.3300	14.3300	14.5300	14.5600
PORTUGAL	Escudos	93.5200	93.7300	93.7600	94.3500	94.2800
SINGAPORE	Dollars	1.4021	1.4109	1.4114	1.4295	1.4254
SOLOMON IS.	Dollars	1.3581	1.3638	1.3634	1.3829	1.3843
SOUTH AFRICA	Rand	1.3568	1.3554	1.3585	1.3638	1.3620
SPAIN	Pesetas	77.6600	77.6300	77.4600	77.8700	77.6600
SRI LANKA	Rupees	21.0400	21.1300	21.1200	21.4200	21.4600
SWEDEN	Kroner	4.1620	4.1774	4.1642	4.2054	4.1973
SWITZERLAND	Francs	0.9438	0.9502	0.9442	0.9488	0.9477
TAIWAN	Dollars	20.4100	20.4600	20.4300	20.6900	20.7100
THAILAND	Bahts	17.5700	17.6400	17.5300	17.7400	17.7500
UK	Pounds	0.3848	0.3866	0.3846	0.3859	0.3856
USA	Dollars	0.6906	0.6935	0.6933	0.7032	0.7046

B.G.GILL
Delegate of the
Comptroller-General of Customs
CANBERRA A.C.T.
2/12/87

N.N.—8741754

Primary Industries and Energy

COMMONWEALTH OF AUSTRALIA

Quarantine Act 1908

NOTICE UNDER PARAGRAPH 14A (1) (c)

I, PETER MORRIS, the Minister of State for Resources in pursuance of paragraph 14A (1) (c) of the *Quarantine Act 1908*, hereby revoke the determination made by the Minister of State for Primary Industry, John Kerin, on the thirtieth day of January 1985 in pursuance of paragraph 14A (1) (c) of the *Quarantine Act 1908* and published in the *Commonwealth of Australia Gazette* No. S 41, 14 February 1985 pp. 5-6, and determine that:

(a) the goods specified in the Schedule shall, when carried for traditional trading only and not in commercial quantities, be exempted from the prohibitions and restrictions contained in and under the *Quarantine Act 1908*; and

(b) the entry of ornamental feathers from Papua New Guinea into the Protected Zone, shall be restricted to those feathers which are incorporated in traditional head-dress and other traditional ornaments for use during ceremonial occasions and must be returned to Papua New Guinea following such ceremonial use.

Dated this 19th day of October 1987.

PETER MORRIS
Minister of State for Resources

SCHEDULE

Kundu drums made of goanna, lizard or snake skins and soft wood

Pandan mats and skirts of coconut leaf

Baskets of palm and pandan leaf

Bows of black palm or bamboo

Spears of bamboo, mangrove or wongai wood with steel prong

Beads made of seeds

Wood carvings

Arm band of woven palm/pandan leaf

Head dress consisting of bamboo frame and feathers subject to paragraph (b)

Woven fibre belts

Sea-shells

Ornamental feathers subject to paragraph (b) or goanna skins

Fish, crab, dugong or turtle meat, yams, sago or de-husked coconuts

N.N.—8741755

Transport and Communications

COMMONWEALTH OF AUSTRALIA

Telecommunications Act 1975

DETERMINATION OF RENTALS AND CHARGES

I, LEO ANTHONY TYRRELL, the General Manager, Commercial Services of the Australian Telecommunications Commission, being a person to whom the Commission has by instrument in writing under section 33 of the *Telecommunications Act 1975*, delegated its powers and functions under the Act, in pursuance of section 11 of the Act, hereby make the following determination:

1. The determination of rentals and charges made by the Commission on 21 August 1975*, as varied to date†, is further varied by adding after Item 16E of Schedule 2 the following:

'ITEM 16F CHARGES FOR ELECTRONIC WHITE PAGES

The charges payable in respect of the Electronic White Pages service shall be as follows:

	$
(a) A charge for subscription to the service	100.00
(b) Usage charges as follows:	
(i) A charge per request and	0.10
(ii) An access charge per minute	0.30'

2. This determination shall take effect on and from 11 November 1987.

Dated this 28th day of October 1987.

L. A. TYRRELL
Delegate of the Australian Telecommunications Commission

* Notified in *Gazette* No. S 170 of 29.8.75

† For previous amendment see footnote † appearing on pages 1276-1278 of *Gazette* GN 21 of 23.9.87.

Note: In lieu of notification on 18.11.87.

TIME STEP IN TELECOM AUSTRALIA TIME SCALES

In accordance with international agreement, all Australian Telecommunication Commission time services will be retarded precisely one second by the insertion of a leap second preceding 1100 hours Australian Eastern Summer Time on Friday, 1 January 1988. This means that the last minute prior to the abovementioned time will be 61 seconds long. The leap second, which will occur simultaneously throughout the world, finishes at 0000 hours Co-ordinated Universal Time (UTC) on 1 January 1988, which corresponds to the following Australian zone times:

0800 hours Western Standard Time in West Australia

0930 hours Central Standard Time in Northern Territory

1000 hours Eastern Standard Time in Queensland

1030 hours Central Summer Time in South Australia

1100 hours Eastern Summer Time in New South Wales, Victoria and Tasmania on Friday, 1 January 1988.

Hourly radio time signals generated by the Commission will be retarded by one second just prior to the sequence marking 1100 hours Eastern Summer time (and the above equivalent times) on 1 January 1988.

Telephone time-of-day services (speaking clocks) operated by the Commission will be retarded by one second after the signal for 10 h. 59 m. 50 s. Eastern Summer Time (and other equivalent times) on 1 January 1988.

Civil time serial code generated by the Commission will be retarded by one second just prior to 1100 hours Australian Eastern Summer Time (and other equivalent times) on 1 January 1988.

For the purposes of dating events, and using Australian Eastern Summer Time as an example, the leap second is deemed to commence at 10 h. 59 m. 60 s. (i.e. one second after 10 h. 59 m. 59 s.) and finishes at 11 h. 00 m.00 s. on 1 January 1988.

Further details may be obtained from the Section Head, Reference Measurements Section, Telecom Australia Research Laboratories, Box 249, Clayton, Victoria 3168.

N.N.—8741756

COMMONWEALTH OF AUSTRALIA

Telecommunications Act 1975

DETERMINATION OF RENTALS AND CHARGES

The Australian Telecommunications Commission, in pursuance of the powers conferred upon it by the *Telecommunications Act 1975*, hereby makes the following determination:

1. The determination of rentals and charges made by the Commission on the 21st August 1975*, as varied to date†, is further varied as follows:

(a) Item 1 of Schedule 1 is amended by omitting the table from paragraph (a) and substituting the following table:

'TABLE:

Class and type of telephone service	*Exclusive service*	*Each telephone forming part of a party line service connecting two subscribers*	*Each telephone forming part of a party line service connecting more than two subscribers*
	$	$	$
Class I Business Service	234.00	222.00	210.00
Class I Non-business Service	135.72	129.72	123.72
Class I Pensioner Service			
—Business	186.00	174.00	162.00
—Non-business	87.72	81.72	75.72
Class II Business Service	110.40	103.56	96.84
Class II Non-business Service	70.56	64.92	59.28
Class II Pensioner Service			
—Business	62.40	55.56	48.84
—Non-business	22.56	16.92	11.28'

(b) Sub-paragraph (b) (i) of Item 1D of Schedule 1 is amended by omitting from the table the figures '234.00', '138.00', '186.00', '90.00', '110.40', '71.76', '62.40' and '23.76' and substituting the figures '234.00', '135.72', '186.00', '87.72', '110.40', '70.56', '62.40' and '22.56' respectively.

(c) Paragraph (b) of Item 2A of Schedule 1 is amended by omitting sub-paragraphs (b) (i) and (b) (ii) and substituting the following:

'(b) (i) in the case of a call made between 8.00 a.m. and 10.00 p.m. Monday to Friday, and between 8.00 a.m. and 6.00 p.m. Saturday—180 seconds; and

(b) (ii) in the case of a call made between 10.00 p.m. and 8.00 a.m. daily, between 6.00 p.m. and 10.00 p.m. Saturday, and between 8.00 a.m. and 10.00 p.m. Sunday—267 seconds.'

(d) Item 3 of Schedule 1 is amended by omitting paragraph (i) and substituting the following:

'(i) For the purposes of this Item, but subject to paragraph (j):

"Automatic trunk call" means a call the connection of which to the service to which the call is made is effected without the assistance of a telephonist at an exchange, not being the receiving exchange.

"Day rate" means the rate applicable for a call made between the hours of 8.00 a.m. and 6.00 p.m. on each day other than a Sunday.

"Economy rate" means the rate applicable for a call made between the hours of 10.00 p.m. and 8.00 a.m. daily, between the hours of 6.00 p.m. and 10.00 p.m. on a Saturday, and between the hours of 8.00 a.m. and 10.00 p.m. on a Sunday.

"Manual trunk call" means a trunk call other than an automatic trunk call.

"Night rate" means the rate applicable for a call made between the hours of 6.00 p.m. and 10.00 p.m. Monday to Friday.'

2. This determination shall take effect on and from 1 December 1987.

Dated this ninth day of November 1987.

(C.S.) The Common Seal of the Australian Telecommunications Commission hereunto affixed by order of the Commission in the presence of:

R. W. BRACK
Chairman
M. K. WARD
Managing Director

* Notified in *Gazette* No. S 170 of 27.8.75.

† For previous amendment see footnote † to the amendment appearing at p. 1215 of *Gazette* No. GN 20 of 16.9.87.

N.N.—8741757

AUSTRALIAN BROADCASTING TRIBUNAL

LICENCE RENEWALS

COMMERCIAL RADIO STATION 7QT QUEENSTOWN AND COMMERCIAL RADIO TRANSLATOR STATION 7QT ROSEBERY

The Australian Broadcasting Tribunal has commenced an inquiry into the renewal of the licences for the above stations which are due to expire on 31 March 1988.

Applications for the renewals of the licences have been lodged by 7QT Pty Ltd.

The issue to be considered in the inquiries is whether the Tribunal should refuse to renew the licences for any of the reasons set out in s. 86 (1IB) of the *Broadcasting and Television Act 1942*, and in particular:

(a) whether the licensee has complied with its undertakings to provide an adequate and comprehensive service pursuant to the licences, and to use and encourage the use of Australian creative resources;

(b) whether the licensee is no longer a fit and proper person to hold the licences;

(c) whether the licensee has the necessary financial, technical and management capabilities;

(d) whether conditions of the licences have not been complied with;

(e) whether the services are commercially viable.

If you wish to make a submission to the inquiries on any of these matters, you should lodge it with the Tribunal's North Sydney Office by 5.00 p.m. on 22 January 1988.

Before lodging a submission, you should inspect the inquiry file (containing the applications and other useful background information) and read the Tribunal's Guide for submitters (copies are available from the Tribunal and are attached to the inquiry file).

The inquiry file can be inspected during business hours at the Tribunal's North Sydney office at Tandem House, 76 Berry Street, North Sydney (contact officer: Ian Laird) and at:

Queenstown Branch (Robert Sticht Memorial Library)
West Coast Community College
Driffield Street
Queenstown, Tas. 7467

Monday, Wednesday and Friday: 9.00 a.m. to 5.00 p.m.
Tuesday and Thursday: 9.00 a.m. to 9.00 p.m.

(Inquiries to be made with the Librarian).

N.N.—8741758

AUSTRALIAN BROADCASTING TRIBUNAL

LICENCE RENEWALS

COMMERCIAL RADIO STATION 7HO HOBART AND PUBLIC RADIO STATION 7HEC NEW TOWN TASMANIA

The Australian Broadcasting Tribunal has commenced inquiries into the renewals of the licences for the above stations which are due to expire on 31 March 1988.

Applications for the renewals of the licences have been lodged by Commercial Broadcasters Pty Ltd (Licensee of 7HO Hobart) and Hope Foundation Communications Inc. (licensee of 7HFC New Town).

The issue to be considered in the inquiries is whether the Tribunal should refuse to renew the licences for any of the reasons set out in s. 86 (1IB) of the *Broadcasting and Television Act 1942*, and in particular:

(a) whether the licensee has complied with its undertakings to provide an adequate and comprehensive service pursuant to the licences, and to use and encourage the use of Australian creative resources;

(b) whether the licensee is no longer a fit and proper person to hold the licences;

(c) whether the licensee has the necessary financial, technical and management capabilities;

(d) whether conditions of the licences have not been complied with;

(e) whether the services are commercially viable.

If you wish to make a submission to the inquiries on any of these matters, you should lodge it with the Tribunal's North Sydney Office by 5.00 p.m. on 22 January 1988.

Before lodging a submission, you should inspect the inquiry files (containing the applications and other useful background information) and read the Tribunal's Guide for submitters (copies are available from the Tribunal and are attached to the inquiry files).

The inquiry files can be inspected during business hours at the Tribunal's North Sydney office at Tandem House, 76 Berry Street, North Sydney (contact officer: Ian Laird) and at:

State Library of Tasmania
Reference and Information Section
91 Murray Street
Hobart, Tas. 7000

Monday-Friday: 9.00 a.m. to 5.00 p.m.
Saturday: 10.00 a.m. to 12.00 noon

(Inquiries to be made with the Director).

N.N.—8741759

AUSTRALIAN BROADCASTING TRIBUNAL

GRANT OF SUPPLEMENTARY RADIO LICENCE

MOREE N.S.W.

An application under sub-section 82A (1) of the *Broadcasting and Television Act 1942* (the Act) for the grant of a supplementary radio licence was lodged with the then Minister for Communications by the licensee of commercial radio station 2VM Moree.

Moree Broadcasting and Development Co. Limited
87-89 Balo Street
Moree, N.S.W. 2400

The then Minister referred the application to the Australian Broadcasting Tribunal which has commenced an inquiry into the grant of the licence.

SERVICE AREA

The Minister has determined that the area to be served by the supplementary licence, if granted shall be identical to the area served by commercial radio station 2VM.

The specifications to which it is proposed a supplementary radio licence, if granted to Moree Broadcasting and Development Co. Limited be subject to are:

(a) the area determined to be served by the supplementary radio licence in terms of areas defined by the Australian Bureau of Statistics at Census of 30 June 1981 shall be the local government area of Moree Plains and parts of the local government areas of Narrabri, Walgett and Yallaroi in New South Wales; the local government area of Goondiwindi and parts of the local government areas of Balonne and Waggamba in Queensland.

(b) the licensee shall operate within the proposed technical conditions specified in Attachment Serial No. 1051 which formed part of the Minister's notice to the Tribunal under sub-section 82A (4) of the Act.

Full details of the proposed service area and the technical specifications are included in the Minister's notice, a copy of which is attached to the inquiry file (see below).

ISSUES

The issues to be considered in the inquiry are whether the Tribunal should refuse to grant the license for any reason set out in s. 83 (6) of the Act and in particular:

(a) whether the applicant is a fit and proper person to hold the licence;

(b) whether the applicant has the necessary financial, technical and management capabilities;

(c) the need for the commercial viability of existing radio and television services in the proposed service area;

(d) whether applications for an independent radio licence to serve the proposed service area should be invited having regard to those matters specified in s. 83 (6) (e) of the Act including:

(i) whether an additional independent radio service in the area is reasonably likely to be commercially viable

(ii) the need for an adequate and comprehensive service to be provided by any such proposed commercial radio service; and

(iii) any undue concentration of the ownership or control, direct and indirect, of the media (including print media) in the proposed service area.

SUBMISSIONS

If you wish to make a submission to the inquiry on any of these matters, you should lodge it with the Tribunal's North Sydney office by 5.00 p.m. on 22 January 1988.

Before lodging a submission, you should inspect the relevant inquiry file (containing the application and other useful background information) and read the Tribunal's Guide for submitters (copies are available from the Tribunal and are attached to the inquiry file).

The inquiry file can be inspected during business hours at the Tribunal's North Sydney office at Tandem House, 76 Berry Street, North Sydney (contact officer: Lyn Rochfort) and at:

Moree Regional Library
Balo Street
Moree, N.S.W. 2400

Monday-Friday 8.30 a.m.-5.30 p.m.
Saturday 9.00 a.m.-12 noon

(Inquiries to be made with the Librarian).

N.N.—8741760

Treasurer

AUSTRALIA

Foreign Takeovers Act 1975

INTERIM ORDER

WHEREAS:

(A) Western Biotechnology Limited ('Western Biotechnology') a corporation incorporated in Western Australia and having its registered office at 2-6 Railway Parade, Bayswater, in that State, is a prescribed corporation that carries on an Australian business;

(B) Roche Products Pty Limited ('Roche') a company incorporated in New South Wales and having its registered office at 4-10 Inman Road, Dee Why, in that State, is a foreign person, being a wholly owned subsidiary of Sapac Corporation Limited, a company incorporated in New Brunswick, Canada;

(C) I, ALLAN CLYDE HOLDING, Minister of State for Employment Services and Youth Affairs, acting for and on behalf of the Treasurer, am satisfied that Roche proposes to acquire all the issued shares, and all the issued options to acquire shares, of Western Biotechnology;

NOW THEREFORE, for the purpose of enabling consideration to be given to whether an order should be made under sub-section 18 (2) of the Act, I prohibit the proposed acquisition for a period of ninety days after this order comes into operation.

Dated this 2nd day of December 1987.

CLYDE HOLDING
Minister of State for Employment Services
and Youth Affairs
for and on behalf of the Treasurer

Printed by C. J. THOMPSON, Commonwealth Government Printer, Canberra

Commonwealth of Australia Gazette

No. S 323, Friday, 27 November 1987

Published by the Australian Government Publishing Service, Canberra

SPECIAL

COMMONWEALTH OF AUSTRALIA

Excise Tariff Act 1921

DETERMINATION UNDER SUB-SECTION 6B (11)

I, JOHN CHARLES KERIN, Minister of State for Primary Industries and Energy, having regard to:

(a) the price, or prices, at which imported stabilised crude oil is sold in Australia; and

(b) the cost of transporting relevant oil within Australia,

by this instrument published in the *Gazette*, in pursuance of sub-section 6B (11) of the *Excise Tariff Act 1921*, determine that $177.98 per kilolitre is to be, from 1 December 1987, the Import Parity Price of Bass Strait stabilised crude petroleum oil for the purposes of section 6B of that Act.

Dated 25 November 1987.

JOHN KERIN

Minister of State for Primary Industries and Energy

COMMONWEALTH OF AUSTRALIA

PRICES FOR STABILISED CRUDE (OTHER THAN STABILISED CRUDE FROM BASS STRAIT)

It is hereby notified, for public information, that if the method used to calculate the Import Parity Price specified in the Determination under sub-section 6B (11) of the *Excise Tariff Act 1921* published in the *Gazette* today were the method for determining the price of stabilised crude petroleum oil specified in Column 2 of the following table in an item, the amount specified in Column 3 of the table in that item would be the price of that oil:

TABLE

Column 1	*Column 2*	*Column 3*
Item	*Stabilised crude petroleum oil*	*Amount per kilolitre*
		$
1	Stabilised crude petroleum oil entered for home consumption on or after 1 December 1987 produced from petroleum obtained from an oil production area at Barrow Island and delivered to the port of Kwinana in Western Australia.	177.49
2	Stabilised crude petroleum oil entered for home consumption on or after 1 December 1987 produced from petroleum obtained from the Bodalla South area in the Eromanga Basin and from an oil production area in the Bowen-Surat Basins and delivered to the port of Brisbane in Queensland.	182.82
3	Stabilised crude petroleum oil entered for home consumption on or after 1 December 1987 produced from petroleum obtained from the Dongara and Yardarino areas in the Perth Basin and delivered to the port of Kwinana in Western Australia.	172.04
4	Stabilised crude petroleum oil entered for home consumption on or after 1 December 1987 produced from petroleum obtained from an oil production area in the Cooper-Eromanga Basins (excluding the Jackson, Bodalla South and Tintaburra areas) and delivered to the port of Port Stanvac in South Australia.	178.95
5	Stabilised crude petroleum oil entered for home consumption on or after 1 December 1987 produced from petroleum obtained from the Jackson and Tintaburra areas and delivered to the port of Brisbane in Queensland.	182.93
6	Stabilised crude petroleum oil entered for home consumption on or after 1 December 1987 produced from petroleum obtained from an oil production area in the Canning Basin and delivered to the port of Kwinana in Western Australia.	173.59
7	Stabilised crude petroleum oil entered for home consumption on or after 1 December 1987 produced from petroleum obtained from the Mereenie area in the Amadeus Basin and delivered to the port of Port Stanvac in South Australia.	175.94
8	Stabilised crude petroleum oil entered for home consumption on or after 1 December 1987 produced from petroleum obtained from the Mount Horner area in the Perth Basin and delivered to the port of Kwinana in Western Australia.	167.52
9	Stabilised crude petroleum oil entered for home consumption on or after 1 December 1987 produced from petroleum obtained from the Varanus area and delivered to the port of Kwinana in Western Australia.	180.05

Printed by C. J. THOMPSON,
Commonwealth Government Printer, Canberra

15859/87 Cat. No. 87 6200 2

Commonwealth of Australia Gazette

No. S 324, Monday, 30 November 1987

Published by the Australian Government Publishing Service, Canberra

SPECIAL

NOTIFICATION OF THE MAKING OF STATUTORY RULES

NOTICE is hereby given that the undermentioned Statutory Rules have been made. Copies of the Statutory Rules may be purchased at the Commonwealth Government Bookshop, 70 Alinga Street, Canberra City, Australian Capital Territory.

Act under which the Statutory Rules were made	*Description of the Statutory Rules*	*Number and year of the Statutory Rules*
Radiocommunications Act 1983	Radiocommunications (Licensing and General) Regulations (Amendment)	No. 272, 1987
Radiocommunications (Transmitter Licence Tax) Act 1983	Radiocommunications (Transmitter Licence Tax) Regulations (Amendment)	No. 273, 1987
Radiocommunications (Frequency Reservation Certificate Tax) Act 1983	Radiocommunications (Frequency Reservation Certificate Tax) Regulations (Amendment)	No. 274, 1987
Radiocommunications (Temporary Permit Tax) Act 1983	Radiocommunications (Temporary Permit Tax) Regulations (Amendment)	No. 275, 1987
Radiocommunications (Receiver Licence Tax) Act 1983	Radiocommunications (Receiver Licence Tax) Regulations (Amendment)	No. 276, 1987
Radiocommunications (Test Permit Tax) Act 1983	Radiocommunications (Test Permit Tax) Regulations (Amendment)	No. 277, 1987
Air Navigation Act 1920	Air Navigation Regulations (Amendment)	No. 278, 1987
National Health Act 1953	National Health (Pharmaceutical Benefits) Regulations (Amendment)	No. 279, 1987

Printed by C. J. THOMPSON,
Commonwealth Government Printer, Canberra

15871/87 Cat. No. 87 6272 8

Commonwealth of Australia Gazette

No. S 325, Monday, 30 November 1987

Published by the Australian Government Publishing Service, Canberra

SPECIAL

Fisheries Act 1952

Fisheries Notice No. 200

PROHIBITION RELATING TO THE TAKING OF PRAWNS OFF NORTHERN AUSTRALIA

I, PETER FREDERICK MORRIS, the Minister of State for Resources, hereby:

(a) pursuant to paragraph 8 (1) (a) of the *Fisheries Act 1952*, prohibit the taking of prawns (family Penaeidae) in the area of proclaimed waters

(i) that is specified in Schedule 1 and lies east of 138°00'East, during the period commencing at 2200 hours Greenwich mean time on 30 November 1987 and terminating at 0200 hours Greenwich mean time on 15 April 1988, and

(ii) that is specified in Schedule 1 and lies west of 138°00'East, during the period commencing at 2230 hours Greenwich mean time on 30 November 1987 and terminating at 0200 hours Greenwich mean time on 15 April 1988;

(b) pursuant to paragraph 8 (1) (e) of the *Fisheries Act 1952* and subject to paragraphs (c), (d) and (e) prohibit persons from having in their possession or charge, in a boat in the area of proclaimed waters specified in Schedule 1 during the period specified in paragraph (a), equipment for taking fish, being equipment of a kind specified in Schedule 2 unless that equipment is carried by the boat in the manner specified in Schedule 3;

(c) pursuant to subsection 8 (2) of the *Fisheries Act 1952*, exempt from the prohibitions in paragraphs (a) and (b) the taking of prawns by the use of a boat to which the applicable number of Class A units and a Class B unit or a Class C unit have been assigned under the Northern Prawn Fishery Management Plan in force under subsection 7B (1) of that Act, if the master, being the holder of the licence in respect of the boat in force under subsection 9 (2) of that Act or a person acting on behalf of that licence-holder

(i) produces to the secretary to the Northern Territory Department of Industries and Development (in this paragraph referred to as the Secretary) evidence to the satisfaction of the Secretary that a company, licensed under a law of the Northern Territory to carry out activities by way of aquaculture of prawns in the Northern Territory using gravid prawns taken from wild stock as the source of broodstock for that aquaculture, has entered into a contract with the licence-holder to use that boat to take prawns for the purpose of providing the company with gravid prawns alive for use in those activities;

(ii) on request by the Secretary or an officer of the Northern Territory Department of Industries and Development nominated by the Secretary for that purpose, embarks an officer in the boat before proceeding to sea to take gravid prawns and returns that officer to the place of embarkation after completing that taking;

(iii) if not requested to embark an officer during the taking of gravid prawns, notifies a person specified in sub-paragraph (ii) of the expected time at which the boat will reach port after that taking is completed and there submits the boat to inspection by an officer; and

(iv) causes all fish, other than the gravid prawns, taken in the equipment during the undertaking to be returned to the sea;

(d) pursuant to subsection 8 (2) of the *Fisheries Act 1952*, exempt from the prohibitions in paragraph (b), during the period commencing at 2000 hours Greenwich mean time on 30 March 1988 and ending at 1000 hours Greenwich mean time on 12 April 1988 in the areas of proclaimed water specified in Schedule 4, the master of a boat to which the applicable number of Class A units and a Class B unit or a Class C unit have been assigned under the Northern Prawn Fishery Management Plan in force under subsection 7B (1) of that Act, who conducts fishing gear trials and who:

(i) conducts the trials in such a way as to avoid the taking of fish, crustaceans or molluscs;

(ii) causes all fish, crustaceans and molluscs taken in the equipment during the trials not to be brought on board the boat; and

(iii) when conducting the trials;

(1) in an area of proclaimed waters specified in Division A or B of Schedule 4, notifies the Queensland Boating and Fisheries Patrol at Karumba that the master intends to undertake fishing gear trials with the use of the boat in that area specified not less than 24 hours before undertaking the trials; or

(2) in an area of proclaimed waters specified in Division C or D of Schedule 4, notifies the Northern Territory Director of Fisheries that the master intends to undertake fishing gear trials with the use of the boat in that area not less than 24 hours before undertaking the trials; and

(e) in pursuance of paragraph 8 (4D) (b)of the *Fisheries Act 1952*, declare that the activities prohibited by paragraph (b) are activities in respect of which an endorsement may be made under subsection 9 (4) of that Act.

SCHEDULE 1

Area of proclaimed waters referred to in paragraph (a)

The area of proclaimed waters contained within the area bounded by a line:

(1) commencing at the intersection of the north-western shore of Australia with a meridian of Longitude 123°45'East;

(2) running thence north along the meridian to its intersection by the line, every point on which is 12 nautical miles seaward of the nearest point on the baseline from which the breadth of the territorial sea of Australia is measured;

16434/87 Cat No. 87 6290 3

(3) thence generally northerly and easterly along that line to its intersection north of Australia with the meridian of Longitude 127°00'East;

(4) thence easterly along the geodesic to the point of Latitude 13°21'South, Longitude 129°40'East;

(5) thence north along the meridian of Longitude 129°40'East to its intersection with the parallel of Latitude 10°30'South;

(6) thence east along that parallel to its intersection with the meridian of Longitude 133°16'East;

(7) thence south along that meridian to its intersection with the parallel of Latitude 11°00'South;

(8) thence south-easterly along the geodesic to the point of Latitude 11°25'South, Longitude 134°15'East;

(9) thence east along the parallel of Latitude 11°25'South to its intersection with the meridian of Longitude 135°35'East;

(10) thence north-easterly along the geodesic to the point of Latitude 11°05'South, Longitude 136°10'East;

(11) thence north-easterly along the geodesic to the point of Latitude 10°30'South, Longitude 136°40'East;

(12) thence south-easterly along the geodesic to the point of Latitude 11°00'South, Longitude 137°05'East;

(13) thence south along the meridian of Longitude 137°05'East to its intersection with the parallel of Latitude 11°47'South;

(14) thence in an easterly direction along the geodesic to the intersection of the parallel of Latitude 12°00'South, with the eastern shore of the Gulf of Carpentaria;

(15) thence following the northern shore of Australia to the point of commencement.

SCHEDULE 2

Equipment referred to in paragraph (b)

(1) Otter trawl nets and boards;

(2) Beams and beam trawl nets;

(3) Otter try nets and boards.

SCHEDULE 3

Manner of carrying equipment referred to in paragraph (b)

An otter trawl net, a beam trawl or an otter try net is carried in the specified manner when the net, together with the otter boards or the beam, as the case may be, is suspended from a mast or boom so that no part of the equipment is over or in the water.

SCHEDULE 4

Areas of proclaimed waters referred to in paragraph (d)

Division A

The area of proclaimed waters contained within the area bounded by a line:

(1) commencing at the point of Latitude 17°20'South, Longitude 140°35'East;

(2) running thence north along the meridian of 140°35' East to its intersection with the parallel of Latitude 17°15' South;

(3) thence east along that parallel to its intersection with the meridian of Longitude 140°45' East;

(4) thence south along that meridian to its intersection with the parallel of Latitude 17°20' South;

(5) thence west along that parallel to the point of commencement.

Division B

The area of proclaimed waters contained within the area bounded by a line:

(1) commencing at the point of Latitude 16°35' South, Longitude 140°25' East;

(2) running thence north along the meridian of 140°25' East to its intersection with the parallel of Latitude 16°30' South;

(3) thence east along that parallel to its intersection with the meridian of Longitude 140°30' East;

(4) thence south along that meridian to its intersection with the parallel of Latitude 16°35' South;

(5) thence west along that parallel to the point of commencement.

Division C

The area of proclaimed waters bounded by a line:

(1) commencing at the point of Latitude 12°24' South, Longitude 130°38' East, (near Charles Point);

(2) running thence north along the meridian of Longitude 130°3' East to its intersection with the parallel of Latitude 12°20' South;

(3) thence east along that parallel to its intersection with the meridian of Longitude 130°41'50' East;

(4) thence south-easterly along the geodesic to its intersection with the meridian of Longitude 12°24'36' (near No. 7 buoy);

(5) thence south along the meridian to its intersection with the northern shore in the vicinity of Cox Peninsula;

(6) thence westerly along that shore to the point of commencement;

Division D

The area of proclaimed waters bounded by a line:

(1) commencing at the intersection of the northern shore of Groote Eylandt with the meridian of Longitude 136°25' East;

(2) running thence north along the meridian to its intersection with the parallel of Latitude 13°45' South;

(3) thence east along that parallel to its intersection with the meridian of Longitude 136°30' East;

(4) thence south along that meridian to its intersection with the parallel of Latitude 13°50' South;

(5) thence west along that parallel to the point of commencement.

Dated this 24th day of November 1987.

PETER MORRIS
Minister of State for Resources

Printed by C. J. THOMPSON, Commonwealth Government Printer, Canberra

Commonwealth of Australia Gazette

No. S 326, Monday, 30 November 1987

Published by the Australian Government Publishing Service, Canberra

SPECIAL

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

DETERMINATION OF FEES

I, WILLIAM JOHN HARRIS, delegate of the Minister of State for The Arts, Sport, the Environment, Tourism and Territories, acting under section 37B of the *City Area Leases Ordinance 1936* ('the Ordinance') determine that the fee payable for the purposes of section 10 of the Ordinance shall be the amount set out in Column 2 of the Schedule opposite and in relation to the matter set out in Column 1 of the Schedule.

Dated this 30th day of November 1987.

W. J. HARRIS

Delegate of the Minister of State for The Arts, Sport the Environment, Tourism and Territories

SCHEDULE

Column 1	*Column 2*
Matter	*Amount $*
Application for approval to conduct a profession, occupation, trade or calling from a residential block:	
(i) When an application is made by a lessee and, at the time of the application, the lessee is conducting his or her profession, occupation trade or calling under an approval granted by the Minister—	100.00
(ii) In any other case—	200.00

AUSTRALIAN CAPITAL TERRITORY

Liquor Ordinance 1975

DETERMINATION OF FEES

I, WILLIAM JOHN HARRIS, Delegate of the Minister of State for The Arts, Sport, the Environment, Tourism and Territories, acting under section 105A of the *Liquor Ordinance 1975* ('the Ordinance') determine that, notwithstanding the determination of fees made under section 105A of the Ordinance made by instrument published in the *Commonwealth of Australia Gazette* No. S 412 on 20 August 1986, the fee payable for the purposes of sections 94 (2) (a) or 94 (2) (b) of the Ordinance for the renewal of an Off Licence by a licensee listed in the Schedule to this instrument shall be $1 000.00.

Dated this 30th day of November 1987.

W. J. HARRIS

Delegate of the Minister of State for The Arts, Sport, the Environment, Tourism and Territories

SCHEDULE

Licensees subject to this determination:

Matteo Bortolussi
C.B.A.A.S. Investments Pty Ltd
Campbells Cash and Carry Pty Ltd
Liquor Distributors Pty Ltd
Harry Williams and Co. Pty Ltd
Dorina Lazzarini & Enzo D'Annibale
G & L Warehouse Pty Limited
Oak Barrel.Winery Pty Ltd & Gida Pty Ltd
Canberra Wine Supplies Pty Ltd
(licence No. 140 only)
Swift & Moore Pty Ltd
Carlton Wines & Spirits (Aust.) Pty Ltd
Cantarella (Canberra) Pty Ltd

Printed by C. J. THOMPSON,
Commonwealth Government Printer, Canberra

16435/87 Cat. No. 87 6302 9

Commonwealth of Australia Gazette

No. S 327, Tuesday, 1 December 1987

Published by the Australian Government Publishing Service, Canberra

SPECIAL

Lands Acquisition Act 1955

NOTICE OF THE ACQUISITION OF LAND BY THE COMMONWEALTH

It is hereby notified that His Excellency the Governor-General acting with the advice of the Federal Executive Council has authorized pursuant to the provisions of the *Lands Acquisition Act 1955*, the acquisition by compulsory process of the land hereunder described, and I hereby declare that the said land is acquired by The Commonwealth of Australia under the said Act for the following public purpose approved by the Governor-General:

National Park

Dated this twenty-fifth day of November One thousand nine hundred and eighty-seven.

(File No. 84/171)

STEWART WEST

Minister of State for Administrative Services

Description of Land

Pastoral Lease No. 668—known as Gimbat Station containing approximately 2995 square kilometres more particularly described as N.T. Portion 698 in the Northern Territory Crown Lands Lease Register Book—Volume 46 Folio 61.

COMMONWEALTH OF AUSTRALIA

Lands Acquisition Act 1955

NOTICE OF THE ACQUISITION OF LAND BY THE COMMONWEALTH

1. It is hereby notified that His Excellency the Governor-General, acting with the advice of the Federal Executive Council, has authorized pursuant to the provisions of the *Lands Acquisition Act 1955* and the *Pipeline Authority Act 1973* (hereinafter called 'the Act') the acquisition by compulsory process of the land hereunder described.

2. I hereby declare that the said land is acquired for the following public purpose approved by the Governor-General, namely; for the purposes of the Authority, such purposes being the construction, maintenance and operation of pipelines or parts thereof under and in accordance with the Act.

Dated this twenty-fifth day of November One thousand nine hundred and eighty-seven.

75/629 (2)

STEWART WEST

Minister of State for Administrative Services

Description of Land

So much and such parts as lie above a depth of 30.48 metres below the surface of all that piece of land situate at Cobar in the Shire of Cobar containing an area of 1.453 hectares more or less being Lots 5 to 11 inclusive in Section 7 and Lots 1 to 5 inclusive Lots 14 and 15 in Section 8 of Deposited Plan 2780 and a Closed Road Parish of Cobar County of Robinson in the Western Division of the State of New South Wales and being Lot 2 on plan catalogued in the New South Wales Branch of the Surveying and Land Information Group as Negative No. 24068 N.S.W.: commencing on a southern side of First Street at the north western corner of Lot 1 in plan registered at the New South Wales Land Titles Office as Deposited Plan 600916 and bounded thence on the east by the western boundary of the aforesaid Lot 1 in Deposited Plan 600916 bearing 180 degrees 129.1 metres thence on the south by part of the northern side of Railway Parade bearing 278 degrees 11 minutes 121.94 metres thence on the west by the eastern boundaries of Lots 12, 2, 3, and 4 in Section 7 Deposited Plan 2780 bearing 0 degrees 111.73 metres thence on the north by part of the southern side of First Street bearing 89 degrees 59 minutes 40 seconds 120.7 metres to the point of commencement.

Printed by C. J. THOMPSON,
Commonwealth Government Printer, Canberra

16436/87 Cat. No. 87 6308 X

Commonwealth of Australia Gazette

No S 328, Tuesday, 1 December 1987
Published by the Australian Government Publishing Service, Canberra

SPECIAL

AUSTRALIAN NATIONAL RAILWAYS COMMISSION

NOTIFICATION OF THE MAKING OF BY-LAWS

NOTICE is hereby given that the Australian National Railways Commission has made the undermentioned By-laws on 30 October and 16 November 1987. Copies can be obtained from the Chairman, Australian National Railways Commission, Richmond Road, Keswich, SA 5025

Act under which by-laws were made	*Description of by-laws*
Australian National Railways Commission Act 1983	*General By-laws-Amendment No. 1*

Printed by C. J. THOMPSON,
Commonwealth Government Printer, Canberra
16437/87 Cat. No. 87 6296 4

Commonwealth of Australia Gazette

No. S 329, Tuesday, 1 December 1987

Published by the Australian Government Publishing Service, Canberra

SPECIAL

AUSTRALIAN CAPITAL TERRITORY

MOTOR TRAFFIC ORDINANCE 1936

DETERMINATION OF FEES

I, **WILLIAM JOHN HARRIS**, Delegate of the Minister of State for the Arts, Sport, the Environment, Tourism and Territories, pursuant to section 217A of the Motor Traffic Ordinance 1936 ("the Ordinance") **REVOKE**, with effect from 1 December 1987, the determination of fees and charges for the purposes of the Ordinance which was made by instrument published in Gazette No. S235 on 16 September 1987 and **DETERMINE**, with effect from 1 December 1987, that:

(1) the fees for the purposes of those sections of the Ordinance or regulations of the Motor Traffic Regulations specified in Column 1 of Schedule 1 for the matters set out in Column 2 of Schedule 1 in relation to each section or regulation, shall be the amount set out in, or calculated in accordance with the formula set out in Column 3 of Schedule 1 in relation to that matter and section or regulation;

(2) notwithstanding (1), the fees for the purposes of section 8 or 14 of the Ordinance for the registration or renewal of registration of a motor vehicle or trailer of a kind set out in Column 1 of Schedule 2, being a motor vehicle or trailer which has been produced for examination or inspection by an inspector under section 17 of the Ordinance between 16 September 1987 and 30 November 1987 and which is to be registered or the registration of which is to be renewed before 1 January 1988 shall be the amount set out in Column 2 of Schedule 2 in relation to that kind of motor vehicle or trailer; and

(3) for the purposes of this determination:

(a) the expression "for original registration" means the registration of a motor vehicle or trailer when the vehicle has not been registered previously in a State or Territory of Australia;

(b) "Historic vehicle" means a vehicle falling into the classification of vehicles made by paragraph (o) of the Motor Vehicle (Third Party Insurance) Regulations.

Dated this 1st day of December 1987

W. J. Harris.

Delegate of the Minister of State for the Arts, Sport, the Environment, Tourism and Territories

16439/87 Cat. No. 87 6314 7

This is page 1 of schedule 1 to the instrument of determination of fees made by the Delegate of the Minister for the Arts, Sport, the Environment, Tourism and Territories pursuant to the Motor Traffic Ordinance 1936 made on the day of 1987.

COLUMN 1 Section of Motor Traffic Ordinance 1936 or Regulation of Motor Traffic Regulations	COLUMN 2 Matter	COLUMN 3 Amount ($) or formula
	1. REGISTRATION OF VEHICLES	
	Fee payable before registration or renewal of registration under section 14, or section 8(1):	
Section 14	(a) for passenger carrying vehicles:	
	(i)where the vehicle weighs 2000 kg or less	$91.00 plus $27.00 for original registration
	(ii)where the vehicle weighs more than 2000 kg but not more than 4000 kg	$91.00 plus $33.00 for each 250 kg or part of 250kg by which the vehicle's weight exceeds 2000kg plus $27.00 for original registration
	(iii)where the vehicle weighs more than 4000 kg	$344.00 plus $20.00 for each 250kg or part of 250kg by which the vehicle's weight exceeds 4000kg plus $27.00 for original registration
Section 14	(b)for Goods carrying vehicles:	

.....
.....
Delegate's Initials

This is page 2 of Schedule 1 to the instrument of determination of fees made by the Delegate of the Minister for the Arts, Sport, the Environment, Tourism and Territories pursuant to the Motor Traffic Ordinance 1936 made on the ..... day of ..... 1987.

COLUMN 1 Section of Motor Traffic Ordinance 1936 or Regulation of Motor Traffic Regulations	COLUMN 2 Matter	COLUMN 3 Amount ($) or formula
	(i)where the vehicle weighs 1000 kg or less	$98.00 plus $27.00 for original registration
	(ii)where the vehicle weighs more than 1000 kg but not more than 3000 kg	$98.00 plus $36.00 per 250 kg or part of 250 kg by which the vehicle's weight exceeds 1000 kg plus $27.00 for original registration
	(iii)where the vehicle weighs more than 3000 kg	$392.00 plus $41.00 per 250kg or part of 250kg by which the vehicle's weight exceeds 3000kg plus $27.00 for original registration
Section 14	(c)Fixed load (equipment) lorry, motor implement, motor tractor	
	(i)where the vehicle weighs 2000kg or less	$33.00 plus $27.00 for original registration
	(ii)where the vehicle weighs more than 2000kg but not more than 4000 kg	$63.00 plus $27.00 for original registration

.....
.....
Delegate's Initials

This is page 3 of Schedule 1 to the instrument of determination of fees made by the Delegate of the Minister for the Arts, Sport, the Environment, Tourism and Territories pursuant to the Motor Traffic Ordinance 1936 made on the day of 1987.

COLUMN 1 Section of Motor Traffic Ordinance 1936 or Regulation of Motor Traffic Regulations	COLUMN 2 Matter	COLUMN 3 Amount ($) or formula
	(iii)where the vehicle weighs more than 4000kg	$143.00 plus $27.00 for original registration
Section 8(1)	(d)Goods trailer	
	(i)where the vehicle weighs 250 kg or less	$25.00 plus $17.00 for original registration
	(ii)where the vehicle weighs more than 250 kg but not more than 500 kg	$50.00 plus $17.00 for original registration
	(iii)where the vehicle weighs more than 500 kg but not more than 1000 kg	$50.00 plus $19.00 per 250kg or part of 250kg by which the vehicle's weight exceeds 500 kg plus $17.00 for original registration
	(iv)where the vehicle weighs more than 1000 kg	$87.00 plus $49.00 per 250kg or part of 250kg by which the vehicle's weight exceeds 1000kg plus $17.00 for original registration
Section 8(1)	(e)Fixed load (equipment) trailer	

.....
.....
Delegate's Initials

This is page 4 of Schedule 1 to the instrument of determination of fees made by the Delegate of the Minister for the Arts, Sport, the Environment, Tourism and Territories pursuant to the Motor Traffic Ordinance 1936 made on the ..... day of ..... 1987.

COLUMN 1 Section of Motor Traffic Ordinance 1936 or Regulation of Motor Traffic Regulations	COLUMN 2 Matter	COLUMN 3 Amount ($) or formula
	(i)where the vehicle weighs 400 kg or less	$37.00 plus $17.00 for the original registration
	(ii)where the vehicle weighs more than 400 kg but not more than 2000 kg	$85.00 plus $17.00 for the original registration
	(iii)where the vehicle weighs more than 2000 kg	$85.00 plus $20.00 per 250kg or part of 250kg by which the vehicle's weight exceeds 2000kg plus $17.00 for the original registration
Section 14	(f)for historic vehicles	
	(i) where an inspection is carried out at a Motor Vehicle Registry	$27.00 plus $27.00 for the original registration
	(ii)where an inspection is carried out other than at a Motor Vehicle Registry	$13.00 plus $27.00 for the original registration
Section 14	(g)for motorcycles	$22.00 plus $17.00 for the original registration
Section 105(4)	(h)fee on grant or renewal of registration or a licence for a period of less than 12 months	12.00

.....
.....
Delegate's Initials

This is page 5 of Schedule 1 to the instrument of determination of fees made by the Delegate of the Minister for the Arts, Sport, the Environment, Tourism and Territories pursuant to the Motor Traffic Ordinance 1936 made on the day of 1987.

COLUMN 1	COLUMN 2	COLUMN 3
Section of Motor Traffic Ordinance 1936 or Regulation of Motor Traffic Regulations	Matter	Amount ($) or formula
	2 Inspection of vehicles	
	Fee payable before the examination or inspection of a vehicle pursuant to section 17 of the Ordinance.	
Section 14	**(a) for passenger carrying vehicles**	
	where the vehicle weighs 2000 kg or less	14.00
	where the vehicle weighs more than 2000 kg but not more than 4000 kg	14.00
	where the vehicle weighs more than 4000 kg	27.00
Section 14	**(b) for goods carrying vehicles**	
	where the vehicle weighs 1000 kg or less	14.00
	where the vehicle weighs more than 1000 but not more than 3000 kg	14.00
	where the vehicle weighs more than 3000 kg	30.00

.....
.....
Delegate's Initials

This is page 6 of Schedule 1 to the instrument of determination of fees made by the Delegate of the Minister for the Arts, Sport, the Environment, Tourism and Territories pursuant to the Motor Traffic Ordinance 1936 made on the day of 1987.

COLUMN 1	COLUMN 2	COLUMN 3
Section of Motor Traffic Ordinance 1936 or Regulation of Motor Traffic Regulations	Matter	Amount ($) or formula
Section 14	**(c) for fixed load (equipment) lorry, motor implement, motor tractor**	
	where the vehicle weighs 2000 kg or less	14.00
	where the vehicle weighs more than 2000 kg but not more than than 4000 kg	30.00
	where the vehicle weighs more than 4000 kg	30.00
Section 14	**(d) for goods trailers**	
	where the vehicle weighs 500 kg or less	14.00
	where the vehicle weighs more than 500 kg but not more than 1000 kg	14.00
	where the vehicle weighs more than 1000 kg	14.00
Section 14	**(e) for fixed load (equipment) trailers**	
	where the vehicle weighs 2000 kg or less	14.00
	where the vehicle weighs more than 2000 kg	14.00
Section 14	**(f) motorcycles**	8.00

.....
.....
Delegate's Initials

This is page 7 of Schedule 1 to the instrument of determination of fees made by the Delegate of the Minister for the Arts, Sport, the Environment, Tourism and Territories pursuant to the Motor Traffic Ordinance 1936 on the day of 1987.

COLUMN 1	COLUMN 2	COLUMN 3
Section of Motor Traffic Ordinance 1936 or Regulation of Motor Traffic Regulations	Matter	Amount ($) or formula
	3. LICENCES AND PERMITS	
Section 14	(a)grant or renewal of driver's licence:	
	for a licence current for one year	24.00
	for a licence current for two years	42.00
	for a licence current for three years	60.00
Section 13A(4)	(b)Issue of a special licence to comply with a Court order	42.00
Section 10(4)	(c)Issue of a conditional licence	42.00
Section 9(2)	(d)Issue of a permit licence current for 3 months	12.00
Section 10(6A)	(e)For a first or subsequent driving test	19.00
Section 14	(f)Grant or renewal of a taxi driver's licence	24.00
Section 14	(g)Grant or renewal of an omnibus driver's licence	24.00
Section 14	(h)Grant or renewal of a private hire car driver's licence	24.00
Section 216(1)	(i)Issue of a licence to move an unregistered vehicle	9.00

.....
.....
Delegate's Initials

This is page 8 of Schedule 1 to the instrument of determination of fees made by the Delegate of the Minister for the Arts, Sport, the Environment, Tourism and Territories pursuant to the Motor Traffic Ordinance 1936 made on the day of 1987.

COLUMN 1 Section of Motor Traffic Ordinance 1936 or Regulation of Motor Traffic Regulations	COLUMN 2 Matter	COLUMN 3 Amount ($) or formula
Section 215(4)	(j)Licence to ply for hire for carriage of goods	15.00
Section 213(6)	(k)Licence to carry workmen to and from their work	15.00
Section 214 (6)	(l)Permit to carry passengers on licenced goods motor vehicles	15.00
Section 27(4)	(m)Renewal of a licence to use a vehicle as a taxi	295.00
Section 27(7)	(n)Transfer of a licence to use a vehicle as a taxi	31.00
Section 33(1)	(o)Grant of a licence to use a vehicle as a motor omnibus	295.00
Section 27(4)	(p)Renewal of a licence to use a vehicle as a motor omnibus	295.00
Section 27(7)	(q)Transfer of a licence to use a vehicle as a motor omnibus	31.00
Section 28(4)	(r)Renewal of a licence to use a vehicle as a private hire car	295.00
Section 28(6)	(s)Transfer of a licence to use a vehicle as a private hire car	31.00
	(t)Licence to conduct a motor omnibus service:	
Section 33(4)	i) for grant	120.00
Section 33(5)	ii) for renewal	60.00

.....
.....
Delegate's Initials

This is page 9 of Schedule 1 to the instrument of determination of fees made by the Delegate of the Minister for the Arts, Sport, the Environment, Tourism and Territories pursuant to the Motor Traffic Ordinance 1936 made on the day of 1987.

COLUMN 1 Section of Motor Traffic Ordinance 1936 or Regulation of Motor Traffic Regulations	COLUMN 2 Matter	COLUMN 3 Amount ($) or formula
Section 33(11)	iii) for transfer	60.00
Section 34(2)	(u)Grant or renewal of a visiting motor omnibus licence	24.00
Section 217(3)	(v)Licence to conduct speed or reliability trial	433.00
Section 190(2)	(w)Permit to carry a wide load	24.00
Section 43(2)	(x)Transfer of trader's licence	49.00
Section 29(5)	(y)Grant or renewal of a licence for the carriage of tourists	24.00
Section 210(1)	(z)Grant of a licence for a visiting motor tractor	12.00
	4. **Number Plates**	
	Fee in respect of number plates for:	
Section 18(4)	(a) Re-issue of number-plates in a new material	13.00
Section 19(2) in relation to Section 19(1)(a)	(b) Replacement of defaced or damaged number plates in respect of a motor vehicle	13.00
Section 20(2)	(c) Replacement of lost or destroyed number plates	13.00
Section 19(2) in relation to Section 19(1)(b)	(d) Replacement of defaced or damaged number plates in respect of a motor cycle	13.00

.....
.....
Delegate's Initials

This is page 10 of Schedule 1 to the instrument of determination of fees made by the Delegate of the Minister for the Arts, Sport, the Environment, Tourism and Territories pursuant to the Motor Traffic Ordinance 1936 made on the ..... day of ..... 1987.

COLUMN 1	COLUMN 2	COLUMN 3
Section of Motor Traffic Ordinance 1936 or Regulation of Motor Traffic Regulations	Matter	Amount ($) or formula
Section 23(2)	(e) Transfer of number plates upon sale or disposal of vehicle	13.00
Section 40(6)	(f) Application for the issue of trader's plates for:	
	i) Motor vehicles	143.00
	ii) Motorcycles or trailers	71.00
Section 26C(3)(b)	(g) Reservation of a registration number	180.00
Section 26E(b)(ii)	(h) Extension of a period of reservation	180.00
	5. RECORDS	
	Fee for inspection, or making available records or documents for:	
Section 98(2)	(a) Certified copy of lost or destroyed certificate or licence	15.00
Section 209(2)(d) and 209(3)	(b) Fee to be deducted on remission or refund of fees	19.00
Section 102(3)	(c) Replacement of a defaced certificate or licence	15.00
Regulation 22	(d) for issue of replacement registration label	8.00

.....
.....
Delegate's Initials

This is page 11 of Schedule 1 to the instrument of determination of fees made by the Delegate of the Minister for the Arts, Sport, the Environment, Tourism and Territories pursuant to the Motor Traffic Ordinance 1936 made on the day of 1987.

COLUMN 1	COLUMN 2	COLUMN 3
Section of Motor Traffic Ordinance 1936 or Regulation of Motor Traffic Regulations	Matter	Amount ($) or formula
	6. AUTHORISED LABELS	
	Fee to accompany an application for the issue of an approved label:	
Section 149A(1)	For vehicles to be used for the carriage of goods in the course of business.	100.00

.....
.....
Delegate's Initials

This is page 1 of Schedule 2 to the instrument of determination of fees made by the Delegate of the Minister for the Arts, Sport, the Environment, Tourism and Territories pursuant to the Motor Traffic Ordinance 1936 made on the ..... day of ..... 1987.

COLUMN 1 Matter	COLUMN 2 Amount ($) or formula
1. **REGISTRATION OF VEHICLES**	
Fee payable before registration or renewal of registration under section 14, or section 8(1):	
(a) **for passenger carrying vehicles:**	
(i)where the vehicle weighs 2000 kg or less	$105.00 plus $27.00 for original registration
(ii)where the vehicle weighs more than 2000 kg but not more than 4000 kg	$105.00 plus $33.00 for each 250kg or part of 250kg by which the vehicle's weight exceeds 2000kg plus $27.00 for original registration
(iii)where the vehicle weighs more than 4000 kg	$371.00 plus $20.00 for each 250kg or part of 250kg by which the vehicle's weight exceeds 4000kg plus $27.00 for original registration
(b)**for Goods carrying vehicles:**	

.....
.....
Delegate's Initials

This is page 2 of Schedule 2 to the instrument of determination of fees made by the Delegate of the Minister for the Arts, Sport, the Environment, Tourism and Territories pursuant to the Motor Traffic Ordinance 1936 made on the day of 1987.

COLUMN 1 Matter	COLUMN 2 Amount ($) or formula
(i)where the vehicle weighs 1000 kg or less	$112.00 plus $27.00 for original registration
(ii)where the vehicle weighs more than 1000 kg but not more than 3000 kg	$112.00 plus $36.00 per 250 kg or part of 250 kg by which the vehicle's weight exceeds 1000 kg plus $27.00 for original registration
(iii)where the vehicle weighs more than 3000 kg	$422.00 plus $41.00 per 250kg or part of 250kg by which the vehicle's weight exceeds 3000kg plus $27.00 for original registration
(c)Fixed load (equipment) lorry, motor implement, motor tractor	
(i)where the vehicle weighs 2000kg or less	$47.00 plus $27.00 for original registration
(ii)where the vehicle weighs more than 2000kg but not more than 4000 kg	$93.00 plus $27.00 for original registration

.....
.....
Delegate's Initials

This is page 3 of Schedule 2 to the instrument of determination of fees made by the Delegate of the Minister for the Arts, Sport, the Environment, Tourism and Territories pursuant to the Motor Traffic Ordinance 1936 made on the ..... day of ..... 1987.

COLUMN 1 Matter	COLUMN 2 Amount ($) or formula
(iii)where the vehicle weighs more than 4000kg	$173.00 plus $27.00 for original registration
(d)Goods trailer	
(i)where the vehicle weighs 250 kg or less	$25.00 plus $17.00 for original registration
(ii)where the vehicle weighs more than 250 kg but not more than 500 kg	$64.00 plus $17.00 for original registration
(iii)where the vehicle weighs more than 500 kg but not more than 1000 kg	$64.00 plus $19.00 per 250kg or part of 250kg by which the vehicle's weight exceeds 500 kg plus $17.00 for original registration
(iv)where the vehicle weighs more than 1000 kg	$101.00 plus $49.00 per 250kg or part of 250kg by which the vehicle's weight exceeds 1000kg plus $17.00 for original registration
(e)Fixed load (equipment) trailer	

.....
.....
Delegate's Initials

This is page 4 of Schedule 2 to the instrument of determination of fees made by the Delegate of the Minister for the Arts, Sport, the Environment, Tourism and Territories pursuant to the Motor Traffic Ordinance 1936 made on the day of 1987.

COLUMN 1 Matter	COLUMN 2 Amount ($) or formula
(i)where the vehicle weighs 400 kg or less	$37.00 plus $17.00 for the original registration
(ii)where the vehicle weighs more than 400 kg but not more than 2000 kg	$99.00 plus $17.00 for the original registration
(iii)where the vehicle weighs more than 2000 kg	$99.00 plus $20.00 per 250kg or part of 250kg by which the vehicle's weight exceeds 2000kg plus $17.00 for the original registration
(f)for historic vehicles	
(i) where an inspection is carried out at a Motor Vehicle Registry	$27.00 plus $27.00 for the original registration
(ii)where an inspection is carried out other than at a Motor Vehicle Registry	$13.00 plus $27.00 for the original registration
(g)for motorcycles	$30.00 plus $17.00 for the original registration

Printed by C. J. Thompson, Commonwealth Government Printer, Canberra

Commonwealth of Australia Gazette

No. S 330, Wednesday, 2 December 1987

Published by the Australian Government Publishing Service, Canberra

SPECIAL

Lands Acquisition Act 1955

NOTICE OF THE ACQUISITION OF LAND BY THE COMMONWEALTH.

It is hereby notified that His Excellency the Governor-General acting with the advice of the Federal Executive Council has authorized pursuant to the provisions of the *Lands Acquisition Act 1955*, the acquisition by compulsory process of the land hereunder described, and I hereby declare that the said land is acquired by The Commonwealth of Australia under the said Act for the following public purpose approved by the Governor-General:—

Defence

Dated this eighteenth day of November One thousand nine hundred and eighty seven

File No. 87/114

STEWART WEST

Minister for Administrative Services

DESCRIPTION OF LAND.

Portion of the properties contained in Certificate of Title Volume 1074 Folio 526, Volume 1685 Folio 302 and Volume 1257 Folio 805 and described as follows:

All that land near Geraldton in the State of Western Australia being portion of Victoria Location 1815 being parts of Lots 5, 6 and 7 on Plan 5981 bounded by lines commencing at the north western corner of Lot 5 of Victoria Location 1815 and proceeding 89 degrees 31 minutes 430.64 metres and 89 degrees 10 minutes 1367.16 metres along the southern boundary of Victoria Location 1625, thence 89 degrees 13 minutes 1022.2 metres along the southern boundary of Victoria Location 3415, thence 179 degrees 13 minutes 1230.32 metres, 140 degrees 45 minutes 320.21 metres, 91 degrees 46 minutes 55.56 metres, 93 degrees 31 minutes 44.75 metres, 104 degrees 56 minutes 57.04 metres, 127 degrees 3 minutes 55.17 metres, 140 degrees 27 minutes 64.96 metres, 158 degrees 51 minutes 53.44 metres, 173 degrees 50 minutes 62.56 metres, 177 degrees 14 minutes 80.56 metres, 166 degrees 36 minutes 56.16 metres, 156 degrees 58 minutes 44.88 metres, 142 degrees 57 minutes 43.02 metres, 128 degrees 47 minutes 64.02 metres, 128 degrees 19 minutes 155.72 metres, 152 degrees 34 minutes 251.14 metres through Victoria Location 1815 to an intersection with part of the western boundary of Yanget Road, thence 179 degrees 51 minutes 134.49 metres along the western boundary of Yanget Road, thence 325 degrees 23 minutes 60.81 metres, 291 degrees 33 minutes 30.56 metres, 321 degrees 23 minutes 36.48 metres, 348 degrees 56 minutes 30.12 metres, 355 degrees 29 minutes 101.83 metres, 350 degrees 21 minutes 47.4 metres, 338 degrees 27 minutes 36.74 metres, 327 degrees 1 minute 36.94 metres, 314 degrees 19 minutes 46.5 metres, 303 degrees 9 minutes 119.46 metres, 310 degrees 55.59 metres, 322 degrees 57 minutes 52.58 metres, 336 degrees 58 minutes 54.86 metres, 351 degrees 31 minutes 64.24 metres, 357 degrees 14 minutes 80.93 metres, 354 degrees 1 minute 56.39 metres, 338 degrees 51 minutes 43.33 metres, 320 degrees 27 minutes 52.67 metres, 301 degrees 54 minutes 43.96 metres, 284 degrees 51 minutes 45.54 metres, 273 degrees 27 minutes 41.14 metres, 272 degrees 35 minutes 177.62 metres, 314 degrees 11 minutes 106.9 metres, 179 degrees 13 minutes 162.51 metres, 269 degrees 13 minutes 2566.61 metres, 358 degrees 527.79 metres to a point on a southern boundary of Lot 5 of Victoria Location 1815, thence 264 degrees 30 minutes 220.30 metres, 358 degrees 1091.76 metres along boundaries of Lot 5 of Victoria Location 1815 to the starting point. All bearings are true or thereabouts and distances are more or less. Subject to survey.

Printed by C. J. THOMPSON,
Commonwealth Government Printer, Canberra

16440/87 Cat. No. 87 6320 4

Commonwealth of Australia Gazette

No S 331, Thursday, 3 December 1987

Published by the Australian Government Publishing Service, Canberra

SPECIAL

AUSTRALIAN CAPITAL TERRITORY

Remand Centres Ordinance 1976

DECLARATION OF TEMPORARY REMAND CENTRE

Whereas, in pursuance of section 5 (1) of the *Remand Centres Ordinance 1976* ('the Ordinance'), the Administrator appointed under the Ordinance has informed me:

(a) that the number of detainees in the remand centre declared by instrument published, pursuant to section 4 of the Ordinance, in the *Commonwealth of Australia gazette* No. S 169 of 27 September 1976 is likely to be greater than the number that can be held conveniently in the centre; and

(b) that it is not convenient to transfer some detainees to another institution within or outside the Territory;

Now therefore, I, LINDA MAY WEBB, the person for the time being holding or performing the duties of First Assistant Secretary, Position No. 4292, Department of The Arts, Sport, the Environment, Tourism and Territories, delegate of the Minister of State for The Arts, Sport, the Environment, Tourism and Territories, in pursuance of section 5 (3) of the Ordinance hereby declare the area of land on which is located that portion of the Belconnen Police Station known as Cells 1, 2, 3, 4, 5 and 6, and the washroom and exercise yard (male) appurtenant thereto and, Cells 7 and 8 and the washroom and exercise yard (female) appurtenant thereto, being part of Section 23 Belconnen to be a temporary remand centre for the period of one month commencing on the date that this instrument is published in the *Commonwealth of Australia gazette.*

Dated this first day of December 1987.

L. WEBB

Delegate of the Minister of State for The Arts, Sport, the Environment, Tourism and Territories

Printed by C. J. THOMPSON,
Commonwealth Government Printer, Canberra

16441/87 Cat. No. 87 6326 5

Commonwealth of Australia Gazette

No. S 332, Friday, 4 December 1987

Published by the Australian Government Publishing Service, Canberra

SPECIAL

Lemonthyme and Southern Forests (Commission of Inquiry) Act 1987

I, GRAHAM FREDERICK RICHARDSON, the Minister of State for the Environment and the Arts, specify in accordance with subparagraph 20 (a) (i) of the Act that the areas identified by the Commission of Inquiry in its interim report of 20 November 1987 as definitely not qualifying areas are those areas described in the Schedule and depicted in the maps reproduced on the following pages and numbered in accordance with the report.

SCHEDULE

Area	*Maps*
Coupe LA45	5
Coupe GA120B	5
Coupe JB4	7
That portion of Coupe DNIOC that lies within the boundary of the Southern Forests area	8

Dated this 29th day of November 1987.

GRAHAM RICHARDSON
Minister of State for the
Environment and the Arts

Printed by C. J. THOMPSON,
Commonwealth Government Printer, Canberra

16438/87 Cat. No. 87 6284 6

MAP 5

LEMONTHYME PROTECTED AREA COUPES LA45, LA49 AND GA120B

CRADLE MOUNTAIN – LAKE ST CLAIR NATIONAL PARK

CROWN LAND

STATE FOREST

GA 120B

LA 45

LA 49

LEMONTHYME Protected Area

Proposed Road

Prepared for the Commission of Inquiry into the Lemonthyme and Southern Forests.

SOUTHERN FORESTS PROTECTED AREA COUPES JB4 AND SN21



SOUTHERN FORESTS
Protected Area

1000 750 500 0 1 2 3 4
SCALE 1:25 000
1 centimetre on this map represents 25 metres on the ground

Prepared for the Commission of Inquiry into the Lemonthyme and Southern Forests.

SOUTHERN FORESTS PROTECTED AREA COUPE DN10C